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Trypanosoma cruzi, an important zoonotic protozoan that causes Chagas disease, affects 
at least 8 million people in Latin America. Chagas disease is an important life-long 
infection in humans that can be divided into distinct clinical stages: the acute phase, 
where patient symptoms can vary from asymptomatic to severe; the indeterminate 
form, which is usually asymptomatic; and the chronic phase, where cardiomyopathy 
and/or digestive megasyndromes appear. In addition to its medical importance, T. cruzi 
is an interesting biological model for studying processes such as: (1) cell differentiation, 
where a non-infective stage transforms into an infective one; (2) cell invasion, where the 
infective stages are able to penetrate into a mammalian host cell, where they multiply 
several times and thus amplify the infection; and (3) evasion from the immune system, 
using several mechanisms.
This book, with 13 chapters, has been organized in four major sections: 1. “Basic Biology,” 
2. “Biochemistry and Molecular Biology,” 3. “Parasite–Host Cell Interaction,” and 4 
“Chemotherapy.” The chapters include basic biological information on the protozoan 
lifecycle, including new information on parasite genomics and proteomics. In addition, 
they analyze the interaction with host cells as well the immune response and evasion, 
ending with information on experimental chemotherapy against Chagas disease.
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Preface
Chagas disease is an important life-long infection in humans that can be divided 
into distinct clinical stages: the acute phase, where patient symptoms can vary from
asymptomatic to severe; the indeterminate form, which is usually asymptomatic; 
and the chronic phase, where cardiomyopathy and/or digestive megasyndromes
appear. It is caused by the intracellular parasitic protozoan Trypanosoma cruzi, 
the major focus of this book. There are two major reasons for significant interest
in the study of this protozoan and the disease it causes. First, in Latin America, at
least 8 million people are infected with T. cruzi and 13,000 die each year. In addi-
tion, migration patterns are driving the globalization of the disease and there are
around 300,000 and 120,000 people infected in the USA and Europe, respectively. 
Second, T. cruzi is an interesting biological model for studying processes such as: 
(1) cell differentiation, where a non-infective stage transforms into an infective
one; (2) cell invasion, where the infective stages are able to penetrate into a mam-
malian host cell, where they multiply several times and thus amplify the infection; 
and (3) evasion from the immune system, using several mechanisms.
Taking into consideration the importance of and interest in T. cruzi and Chagas
disease, this book is organized in four sections. Section 1 deals with the basic aspects
of the protozoan biology with an overview of the lifecycle of the parasite in inver-
tebrate and vertebrate hosts, as well as the various developmental states of T. cruzi
maintained in the laboratory. Available information on the reservoir host of T. cruzi
in the Amazon rainforest is also discussed. Section 2 deals with basic biochemical
data on the parasite, including proteomic and genomic data presently available for
various T. cruzi developmental stages. Section 3 deals with the interaction of the
parasite with the host, covering topics such as entry of the parasite into host cells
and mechanisms involved in evasion of the immune response. Section 4 comprises
data on experimental chemotherapy.
Wanderley de Souza MD, PhD
Professor of Cell Biology and Parasitology
at the Instituto de Biofísica Carlos Chagas Filho,
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Introductory Chapter:  
Biology of Trypanosoma cruzi
Wanderley de Souza
1. Introduction
Trypanosoma cruzi, an important zoonotic protozoan that causes Chagas 
disease, is the focus of this book. There are two major reasons for the significant 
interest in the study of this protozoan and the disease it causes. First, Chagas 
disease is an important life-long infection in humans that can be divided into 
distinct clinical stages: the acute phase, where patient symptoms can vary from 
asymptomatic to severe; the indeterminate form, which is usually asymptomatic; 
and the chronic phase, where cardiomyopathy and/or digestive mega syndromes 
appear. In Latin America, at least 8 million people are infected with T. cruzi and 
13,000 die each year. In addition, migration patterns are driving the globalization 
of the disease and there are around 300,000 and 120,000 people infected in the 
USA and Europe, respectively. Second, T. cruzi is an interesting biological model 
for studying processes such as: (a) cell differentiation, where a non-infective stage 
transforms into an infective one; (b) cell invasion, where the infective stages are 
able to penetrate into a mammalian host cell, where they multiply several times 
and thus amplify the infection; and (c) evasion from the immune system, using 
several mechanisms.
To better understand the information presented in various chapters of this book, 
let us review some basic information about T. cruzi infection [1]. Figure 1 shows a 
general view of the life cycle of T. cruzi in both vertebrate and invertebrate hosts 
[2]. The three basic developmental stages (trypomastigote, amastigote, and epimas-
tigote) are schematically shown in Figure 2a–c, based on images obtained using 
transmission electron microscopy [2]. The various structures and organelles found 
in the protozoan are indicated. Figure 3 shows a scheme, where the various phases 
of the interaction of the trypomastigote form of T. cruzi with a host cell are indi-
cated [1, 2]. The process starts with adhesion of the infective stage to the host cell 
surface followed by parasite internalization with formation of a parasitophorous 
vacuole (PV), lysis of the PV membrane, division of amastigotes in the cytoplasm 
of the host cell, and transformation of amastigotes into trypomastigotes that are 
then released into the intercellular space.
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Figure 2. 
Schematic representations of T. cruzi (trypomastigote, amastigote, and epimastigote) organelles with 2D 
models. These images were made based on micrographs of light microscopy as well as scanning and transmission 
electron microscopy (from [2]).
Figure 1. 
The life cycle of T. cruzi. 1—The insect vector (female or male) bites a mammalian host and ingests 
trypomastigotes located in the blood. 2—Metacyclic trypomastigotes. 3—Trypomastigotes transform into 
epimastigotes and some spheromastigotes. 4—Epimastigotes multiply in the midgut. 5—Epimastigotes transform 
into metacyclic trypomastigotes in the hindgut. 6—The insect vector passes the metacyclic trypomastigotes in 
feces near a bite site after feeding on a mammalian host. 7—Metacyclic trypomastigotes form. 8—Metacyclic 
trypomastigote infects macrophages. 9—Metacyclic trypomastigote transforms into amastigote. 10—Amastigote 
is released from the parasitophorous vacuole. 11—Amastigotes multiply in the cytoplasm. 12—Amastigotes 
transform into trypomastigotes. 13—Trypomastigotes burst out of the cell. 14—Amastigotes and trypomastigotes 
form. 15—(a) Trypomastigotes and (b) amastigotes infect macrophages. In the central portion of the figure, we 
added the most important animal reservoirs involved in the maintenance of the parasite in the domestic and 
peridomestic environment (from [2]).
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Figure 3. 
Schematic representation of the interaction of trypomastigotes with the host cell. The various steps of the 
interaction are shown with attachment (A, B), internalization with formation of a parasitophorous (PV) (C), 
lysis of the PV membrane (D), successive division of amastigotes in the cytoplasm (E, F), transformation of 
amastigotes into trypomastigotes (G) and rupture of the cell releasing a large number of trypomastigotes (H) 
(from [2]).
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Trypanosoma cruzi (T. cruzi) is a protozoan parasite that causes Chagas disease, 
a zoonotic disease that can be transmitted to humans by blood-sucking triatomine 
bugs. T. cruzi is a single-celled eukaryote with a complex life cycle alternating 
between reduviid bug invertebrate vectors and vertebrate hosts. This article will 
look at the developmental stages of T. cruzi in the invertebrate vector and the 
vertebrate hosts, the different surface membrane proteins involved in different life 
cycle stages of T. cruzi, roles of different amino acids in the life cycle, carbon and 
energy sources and gene expression in the life cycle of T. cruzi. The author will also 
look at extracellular vesicles (EV) and its role in the dissemination and survival of 
T. cruzi in mammalian host.
Keywords: Trypanosoma cruzi, metacyclogenesis, trypanosomatid, epimastigote, 
metacyclic trypomastigotes, extracellular vesicles
1. Introduction
The genus Trypanosoma has many species of protozoans but only Trypanosoma 
cruzi, Trypanosoma brucei gambiense and Trypanosoma brucei rhodesiense cause 
disease in humans. Trypanosoma cruzi, a protozoan parasite hemoflagellate is the 
etiologic agent of Chagas disease [1] while Trypanosoma brucei gambiense and 
Trypanosoma brucei rhodesiense causes African trypanosomiasis. Chagas disease 
also known as American trypanosomiasis affects millions of people throughout the 
Americas [2]. In 1909, Carlos Chagas first described this disease when he discovered 
the parasite in the blood of a Brazilian child with lymphadenopathy, anemia and 
fever [3, 4].
T. cruzi is a member of the family trypanosomatidae in the order Kinetoplastida 
and belongs to a subspecie called stercoraria (Figure 1). The development of 
stercoraria parasites takes place in the intestinal track of the invertebrate vector 
and the infection to the vertebrate occur through the feces. T. cruzi is carried in the 
guts of hematophagous triatomine bugs (kissing bugs) and transmission occurs 
when infected bug feces contaminate the bite site or intact mucous membranes. 
During feeding, the infected triatomine insect receives a significant amount of 
blood in its digestive system which forces the elimination of the bulk of accumu-
lated excreta (consisting of feces and urine) which is normally deposited on the 
skin surface. The released feces contain the metacyclic trypomastigotes, which by 
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also known as American trypanosomiasis affects millions of people throughout the 
Americas [2]. In 1909, Carlos Chagas first described this disease when he discovered 
the parasite in the blood of a Brazilian child with lymphadenopathy, anemia and 
fever [3, 4].
T. cruzi is a member of the family trypanosomatidae in the order Kinetoplastida 
and belongs to a subspecie called stercoraria (Figure 1). The development of 
stercoraria parasites takes place in the intestinal track of the invertebrate vector 
and the infection to the vertebrate occur through the feces. T. cruzi is carried in the 
guts of hematophagous triatomine bugs (kissing bugs) and transmission occurs 
when infected bug feces contaminate the bite site or intact mucous membranes. 
During feeding, the infected triatomine insect receives a significant amount of 
blood in its digestive system which forces the elimination of the bulk of accumu-
lated excreta (consisting of feces and urine) which is normally deposited on the 
skin surface. The released feces contain the metacyclic trypomastigotes, which by 
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active movement and release of histolytic enzymes, actively penetrate the skin. 
Other modes of T. cruzi transmission includes through organ transplant, through 
transfusion and congenitally [5]. The mechanism of transmission of T. cruzi 
contrasts with that of the three subspecies of African trypanosomes that causes 
human and animal African trypanosomiasis disease, Trypanosoma brucei gam-
biense, Trypanosoma brucei rhodesiense and Trypanosoma brucei brucei, which are 
transmitted via the saliva of their vectors (salivarian) and with the mechanism by 
which the nonpathogenic trypanosome found in the Americas Trypanosoma rangeli 
is transmitted to its mammalian hosts. In addition to colonizing the stomach of 
their invertebrate vector, salivarian parasites migrate towards the salivary gland of 
the vector where the infectious form for the vertebrate develops but never pass to 
the intestinal track. In the process of obtaining a blood meal by the vector, infec-
tion of the vertebrate occurs through saliva. Like tsetse fly (the vector of human 
and animal African trypanosomiasis), the triatomine vector ingests circulating try-
pomastigotes when it takes a blood meal from an infected mammalian host. T. cruzi 
infects vertebrate and invertebrate hosts during defined stages in its life cycle [6].
2. The life cycle of Trypanosoma cruzi
The life cycle of Trypanosoma cruzi involves two intermediate hosts: the inver-
tebrate vector (triatomine insects) and the vertebrate host (humans) and has three 
developmental stages namely, trypomastigotes, amastigotes and epimastigotes [8].
The general view of the life cycle of Trypanosoma cruzi is as shown in Figure 2. 
The cycle started with the insect sucking of bloodstream trypomastigotes of the 
infected vertebrates. Most of the ingested trypomastigotes are broken down in the 
stomach of the insect while the surviving trypomastigotes transform into either 
spheromastigotes (spherical stage) or into epimastigote stage few days later [9]. 
Epimastigotes move to the intestine where they divide intensely and attach to the 
perimicrovillar membranes which are secreted by intestinal cells of posterior mid-
gut [10, 11]. Attachment to perimicrovillar membranes (PMM) in the insect midgut 
is an essential step for parasite division and is important in the process of metacy-
clogenesis which involves the transformation of the non-infective epimastigotes 
into highly infective trypomastigotes known as metacyclic trypomastigotes [12].
Metacyclic parasite forms express a set of surface glycoproteins that interact 
with mammalian cells [13, 14]. One of the glycoproteins, a metacyclic-stage-specific 
82-kDa glycoprotein (gp82), has been implicated in host cell invasion [15]. The 
gp82 glycoprotein is an adhesion molecule that binds to host cells in a receptor-
mediated manner and triggers Ca2+ mobilization [16] which is essential for parasite 
Figure 1. 
Classification of trypanosomes. Source: Baral [7].
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penetration [17–20]. The gp82 also induces the activation of metacyclic trypomas-
tigote protein tyrosine kinase [21] and an increase in the parasite intracellular Ca2+ 
concentration [22]. Other glycoproteins which are expressed in bloodstream or 
tissue-culture derived trypomastigotes and which are implicated in mammalian 
cell adhesion/invasion are gp83 [23], gp85 [24], and Tc-85 [25]. The gp83 has been 
reported to signal through the mitogen-activated protein kinase pathway to up 
regulate T. cruzi entry in macrophages [26]. Also, surface glycoinositolphospho-
lipids (GIPLs) of the parasite have been shown to be involved in the attachment 
process [10].
3. Metacyclogenesis
Metacyclogenesis is the fundamental step in the life cycle of T. cruzi which 
involves the differentiation of epimastigotes into metacyclic trypomastigotes and 
occurs in the midgut of triatomine vector. During metacyclogenesis, bloodstream 
trypomastigotes differentiate into replicative epimastigotes in the triatomine 
insect’s stomach, which divide in the midgut, migrate to the rectum and adheres to 
the epithelium through a flagellum prior to differentiation into a non-replicative, 
infective metacyclic trypomastigote form which are then released into the excreta 
of the triatomine insect while taking a blood meal on the vertebrate [27, 28]. The 
factors that trigger metacyclogenesis are still unknown, but might be stimulated 
by nutritional starvation, cyclic AMP and adenylate cyclase [29]. For instance, 
while in the midgut of triatomine vector, T. cruzi epimastigotes multiply in the 
nutrient rich environment after obtaining blood meal and as the meal is digested, 
the parasite density increases, the environment becomes nutrient poor making 
the epimastigotes become more elongate. On the epimastigotes reaching the insect 
Figure 2. 
Life cycle of T. cruzi showing the various forms of the protozoan in the invertebrate (triatomines) and 
vertebrate (mammals) hosts. Adapted from the Center of Control Diseases homepage.
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penetration [17–20]. The gp82 also induces the activation of metacyclic trypomas-
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tissue-culture derived trypomastigotes and which are implicated in mammalian 
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reported to signal through the mitogen-activated protein kinase pathway to up 
regulate T. cruzi entry in macrophages [26]. Also, surface glycoinositolphospho-
lipids (GIPLs) of the parasite have been shown to be involved in the attachment 
process [10].
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involves the differentiation of epimastigotes into metacyclic trypomastigotes and 
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infective metacyclic trypomastigote form which are then released into the excreta 
of the triatomine insect while taking a blood meal on the vertebrate [27, 28]. The 
factors that trigger metacyclogenesis are still unknown, but might be stimulated 
by nutritional starvation, cyclic AMP and adenylate cyclase [29]. For instance, 
while in the midgut of triatomine vector, T. cruzi epimastigotes multiply in the 
nutrient rich environment after obtaining blood meal and as the meal is digested, 
the parasite density increases, the environment becomes nutrient poor making 
the epimastigotes become more elongate. On the epimastigotes reaching the insect 
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Figure 3. 
Developmental stages of T. cruzi in vertebrate and invertebrate. Adapted from: Jimenez [96].
rectum, it undergoes metacyclogenesis into human infective trypomastigote forms. 
Metacyclogenesis occurs when epimastigotes from the nutrient poor hindgut attach 
to the waxy cuticle of the triatomine vector rectum, initiating a dramatic morpho-
logical change. Once formed, metacyclics detach from the waxy cuticle and are 
excreted. Contamination of the triatomine vector bite wound of the mammalian 
host with these excreta leads to infection, completing the life cycle.
Description of metacyclogenesis can be in two parts, the first leading to the 
second. Firstly, the trypanosome senses loss of sugars from its environment and 
responds by elongating its cell body and flagellum and by activating its mitochon-
drion which leads to the lengthening of the trypanosome flagellar membrane that 
is rich in sterol and more hydrophobic than the somatic membrane. Secondly, the 
lengthening of the flagellar permits the trypanosomes to adhere to a hydrophobic 
surface and it is this interaction that triggers metacyclogenesis. This trigger for 
metacyclogenesis is cyclic adenosine monophosphate (cAMP) mediated.
Cyclic AMP plays an important role in the control of lower eukaryotes differ-
entiation [30–32]. The relative amounts of cyclic AMP can change according to the 
surrounding environment, enabling the organisms to adapt quickly to new condi-
tions. The differential balance of cAMP may result in activation of protein kinases 
[33, 34], transcription of specific genes [35–37] and changes in the cytoskeleton 
structure [38], which ultimately lead to morphogenetic cell alterations. Cyclic AMP 
balance could vary as a response to a changing environment leading to differential 
gene expression and morphological changes allowing the parasite to go through 
its life cycle. Calmodulin is known to play a direct role in controlling the levels 
of cAMP in eukaryotic cells [39] and in the case of T. cruzi, it has been shown to 
activate the cAMP phosphodiesterase [40].
4. The developmental stages of T. cruzi in vertebrate and invertebrate
The T. cruzi developmental stages alternates between infective and noninfective 
forms. Amastigote and epimastigote are noninfective but replicative stages inside 
the mammalian host (vertebrate) and in the gut of the insect vector (invertebrate) 
respectively (Figure 3). The bloodstream trypomastigotes found in the blood of the 
13
Life Cycle of Trypanosoma cruzi in the Invertebrate and the Vertebrate Hosts
DOI: http://dx.doi.org/10.5772/intechopen.84639
vertebrate host and the metacyclic trypomastigotes found in the rectum of the insect 
invertebrate vector are considered as the two different trypomastigote infective but 
nonreplicative developmental stages. The sucking of the blood of vertebrate mam-
malian host infected with the bloodstream trypomastigotes by the insect started the 
cycle and inside the stomach of the insect, the ingested trypomastigotes transform 
into epimastigotes which replicates intensely in the midgut. The epimastigotes 
transform into metacyclic trypomastigotes in the hindgut of the insect host which 
are eliminated through feces when the insect vector takes a blood meal from an unin-
fected host. The excreted metacyclic trypomastigote in the lesioned skin caused by 
the insect bite leads to T. cruzi infection. Once the metacyclic trypomastigote is inside 
the mammalian host, it invades the host cells at the inoculation site and transform 
into the replicative amastigote form which transform back into bloodstream trypo-
mastigote form upon completion of a replicative cycle as intracellular amastigotes.
5. Surface membrane proteins
Membrane proteins play an important role in the biology of T. cruzi, including 
the interaction between parasite and host [41–45]. Two thousand seven hundred 
and eighty four (2784) proteins belonging to 1168 protein groups were identified 
in the proteomic analyses of different stages in the life cycle of T. cruzi. The T. cruzi 
proteins is in relative abundance throughout its life cycle since about 30% of the 
identified proteins were found at all life cycle stages and at least 248 proteins were 
only expressed at one stage of the life cycle. The families of surface membrane pro-
teins from T. cruzi which are the most abundant and/or relevant during its life cycle 
are: mucin, trans-sialidase, TcGP63, amastin, TcTASV, mucin-associated surface 
proteins (MASP) and cruzipain.
5.1 The mucins family
Trypanosoma cruzi is covered by a dense layer of mucin-type molecules which are 
the major T. cruzi surface glycoproteins [46]. These proteins are widely distributed 
over the cell body, flagellar pocket and flagellum of the different developmental 
forms [47] and play a key role in the parasite protection as well as in the infectivity 
and modulation of the host immune response throughout the life cycle of T. cruzi 
[48–51]. The mucins of trypanosoma cruzi is divided into two gene families, namely 
TcMUC and TcSMUG [48, 52] and these proteins are divided into groups based on 
their central domains: TcMUC is divided into TcMUC I, TcMUC II and TcMUC III 
[52, 53] . TcMUC I protein is distributed on the amastigote and the bloodstream try-
pomastigote surface and is the major component in the amastigote form. This protein 
show internal tandem repeats on their structure with a T8KP2 amino acid consensus 
sequence which are suitable targets for the O-glycosylation pathway in T. cruzi, 
flanked by an N-terminal signal peptide and a C-terminal glycosylphosphatidylinosi-
tol anchor signal [48, 55]. TcMUC II protein is also distributed on the amastigote and 
the bloodstream trypomastigote surface and is found more in membrane lipid rafts 
of the trypomastigote stage [54]. Like TcMUC I, TcMUC II genes encode proteins 
that share similar N- and C-terminal but without the T8KP2 motifs [56, 57]. The 
single gene product of the TcMUC III group is termed trypomastigote small surface 
antigen (TSSA) and has been identified as a mucin-like glycoprotein [58]. TSSA are 
displayed on the surface of the trypomastigote forms of Trypanosoma cruzi and are 
expressed in vivo as a 20-kDa protein during the mammal-derived stages [59–61].
The second mucin protein family TcSMUG family is divided into two groups: 
TcSMUG S (small) and TcSMUG L (large) according to their encoded mRNA size 
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vertebrate host and the metacyclic trypomastigotes found in the rectum of the insect 
invertebrate vector are considered as the two different trypomastigote infective but 
nonreplicative developmental stages. The sucking of the blood of vertebrate mam-
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into the replicative amastigote form which transform back into bloodstream trypo-
mastigote form upon completion of a replicative cycle as intracellular amastigotes.
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and eighty four (2784) proteins belonging to 1168 protein groups were identified 
in the proteomic analyses of different stages in the life cycle of T. cruzi. The T. cruzi 
proteins is in relative abundance throughout its life cycle since about 30% of the 
identified proteins were found at all life cycle stages and at least 248 proteins were 
only expressed at one stage of the life cycle. The families of surface membrane pro-
teins from T. cruzi which are the most abundant and/or relevant during its life cycle 
are: mucin, trans-sialidase, TcGP63, amastin, TcTASV, mucin-associated surface 
proteins (MASP) and cruzipain.
5.1 The mucins family
Trypanosoma cruzi is covered by a dense layer of mucin-type molecules which are 
the major T. cruzi surface glycoproteins [46]. These proteins are widely distributed 
over the cell body, flagellar pocket and flagellum of the different developmental 
forms [47] and play a key role in the parasite protection as well as in the infectivity 
and modulation of the host immune response throughout the life cycle of T. cruzi 
[48–51]. The mucins of trypanosoma cruzi is divided into two gene families, namely 
TcMUC and TcSMUG [48, 52] and these proteins are divided into groups based on 
their central domains: TcMUC is divided into TcMUC I, TcMUC II and TcMUC III 
[52, 53] . TcMUC I protein is distributed on the amastigote and the bloodstream try-
pomastigote surface and is the major component in the amastigote form. This protein 
show internal tandem repeats on their structure with a T8KP2 amino acid consensus 
sequence which are suitable targets for the O-glycosylation pathway in T. cruzi, 
flanked by an N-terminal signal peptide and a C-terminal glycosylphosphatidylinosi-
tol anchor signal [48, 55]. TcMUC II protein is also distributed on the amastigote and 
the bloodstream trypomastigote surface and is found more in membrane lipid rafts 
of the trypomastigote stage [54]. Like TcMUC I, TcMUC II genes encode proteins 
that share similar N- and C-terminal but without the T8KP2 motifs [56, 57]. The 
single gene product of the TcMUC III group is termed trypomastigote small surface 
antigen (TSSA) and has been identified as a mucin-like glycoprotein [58]. TSSA are 
displayed on the surface of the trypomastigote forms of Trypanosoma cruzi and are 
expressed in vivo as a 20-kDa protein during the mammal-derived stages [59–61].
The second mucin protein family TcSMUG family is divided into two groups: 
TcSMUG S (small) and TcSMUG L (large) according to their encoded mRNA size 
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[58, 62] and encodes for very small open reading frame containing a putative signal 
peptide at the N-terminus and a GPI-anchor signal in the C-terminus. The TcSMUG 
S group is found in the epimastigote and metacyclic trypomastigote forms and 
encodes for 35–50 kDa mucins N-glycosylated (Gp35/50 mucins) and they are the 
major acceptors of sialic acid on the parasite surface by parasite trans-sialidases 
in T. cruzi [63, 64]. In contrast, TcSMUG L group encodes for mucin-type glyco-
conjugates which are not sialic acid acceptors and only present in the surface of 
the epimastigote stage [65, 66] and contains one or two additional N-glycosylation 
signals between the N-terminal region and the threonine-rich region depending on 
the origin of the encoding allele [65].
5.2 The trans-sialidases (TS) protein family
The trans-sialidases (TS) protein family of trypanosoma cruzi are a large 
superfamily, which includes 1430 gene members, including 693 pseudogenes [67]. 
Trans-sialidase shares certain characteristics with mucin protein family as they are 
distributed along the cell body, flagellum, and flagellar pocket of T. cruzi [68]. The 
trans-sialidase superfamily is classified into four groups based on their sequence 
similarity and functional properties namely: TS 1, TS II, TS III and TS IV [69]. The 
TS activity involves the transfer of sialic acid from host glycoconjugates to mainly 
the parasite mucins present in the plasma membrane of trypomastigotes [70, 71]. 
Trypanosomes are unable to synthesize the monosaccharide sialic acid; therefore 
they need to scavenge it from the infected host using these TS activities. The 
sialylation process in T. cruzi is crucial for its viability and propagation into the host 
[72, 73].
The TS I comprises of proteins with trans-sialidase (TS) and/or neuraminidase 
activities [74]. Neuraminidase activity occurs when nonsuitable acceptor mol-
ecules for sialic acid are present and then sialic acid is transferred to water [75]. 
Neuraminidase activity is involved in the removal of sialic acid from parasites and/
or host-cell molecules which is required for parasite internalization [76]. The TS I 
members incudes: TCNA (neuraminidase), SAPA (shed acute-phase antigen), and 
TS-epi. SAPA and TCNA proteins are closely related with 84% homology at the 
amino acid level and have active trans-sialidase and neuraminidase activities and 
are expressed during bloodstream trypomastigote stage [77]. SAPA and TCNA have 
two main regions: an N-terminal catalytic region and a C terminal extension, which 
repeats 12 amino acids (SAPA repeats) in tandem with the consensus sequence. 
SAPA has only 14 tandem repeats compared to 44 for TCNA and the presence of 
SAPA repeats increases the half-life of the protein in the blood [78]. Both proteins 
are attached by glycosylphosphatidylinositol to the parasite plasma membrane and 
can be found in the serum of deeply infected mammals.
TS-epi, the third member of group TS I is an active trans-sialidase expressed in 
the insect dwelling epimastigote form at the stationary phase and is different from 
the trans-sialidase expressed of the blood trypomastigotes. Unlike other members 
of the group, TS-epi lacks SAPA repeats and is not attached to the membrane by 
glycosylphosphatidylinositol.
Members of TS group II includes: ASP-1, ASP-2, TSA-1, Tc85, SA85, GP82, and 
GP90 and they all have been implicated in host-cell attachment and invasion. 
ASP-1, ASP-2 (both are amastigote surface proteins) and TSA-1 (trypomastigote 
surface antigen) are targets of T. cruzi-specific CD8+ cytotoxic T lymphocytes and 
they induce strong antibody responses in infected mice and humans. The SA85 
glycoproteins are expressed by amastigote and bloodstream trypomastigote forms 
but only the amastigote form expresses the mannose-binding protein ligand which 
seems to be involved in the opsonization of the parasite enhancing its infection 
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capability. The Tc85 molecule is an 85 kDa glycoprotein which is found abundantly 
in bloodstream trypomastigotes and is identified as a ligand capable of binding to 
different host receptor molecules located on the cell surface of either monocytes, 
neutrophils, or fibroblasts. The GP82 and GP90 members of TSII are glycopro-
teins expressed on the surface of the metacyclic trypomastigote form and they 
are mainly found at the plasma membrane with opposite roles in mammalian cell 
invasion. GP82 is able to activate a Ca2+ signaling pathway in host cells following 
parasite adhesion, which is required for T. cruzi internalization and is also the 
signaling receptor that mediates protein tyrosine phosphorylation, which is neces-
sary for host-cell invasion. As defined by its reactivity with monoclonal antibodies, 
GP90 is a metacyclic stage-specific glycoprotein and expressed by metacyclic 
forms but lacks any enzymatic activity. GP90 is present in the mammalian stages 
of T. cruzi life cycle and has the antiphagocytic effect mediated by the removal of 
sugar residues necessary for parasite internalization.
TS Group III which is formed by surface proteins present in mammal blood-
stream trypomastigotes includes: complement regulatory protein (CRP), surface 
flagellar protein (FL-160), chronic exoantigen (CEA), and trypomastigote excre-
tory-secretory antigens (TESA) [79]. These surface proteins are recognized by sera 
from patients infected with Chagas’ disease and they are able to inhibit the classical 
and the alternative pathways of complement activation, which could be a protection 
from lysis by the host in the trypomastigote form [80, 81]. TESA is distributed on 
the cell surface membrane of T. cruzi [80] whereas CRP, FL160, and CEA are flagel-
lum associated membrane proteins [80, 82, 83].
The TS Group IV is included in the trans-sialidase superfamily because it 
contains the conserved motif VTVxNVxLYNR, which is shared by all known TS 
members and is composed of genes encoding trypomastigote surface antigens 
whose biological function is still unknown [84, 85]. The TsTc13 protein, a member 
of TS Group IV has been shown to be highly antigenic and is present in the infective 
metacyclic trypomastigote form [86].
5.3 TcGP63 family
This protein is expressed by trypanosomes and Leishmania species and is a 
family of cell surface-localized, zinc-dependent metalloproteases also known 
as GP63 proteins, major surface proteases or leishmanolysins. They serve as 
ligands for host cell attachment and protect the parasite from intraphagolyso-
somal degradation in Leishmania while they function to release variant surface 
glycoproteins from the cell surface during antigenic variation in the bloodstream 
form of the African trypanosome (Trypanosoma brucei). Trypanosoma cruzi 
possesses GP63-like genes (TcGP63) which are differentially regulated, suggest-
ing its functional importance at multiple stages in the parasite life cycle [87]. 
The TcGP63 family is made up of two groups of proteins namely: TcGP63-I and 
TcGP63-II [88]. The TcGP63-I has low gene copies of 5–10, whereas TcGP63-II has 
62 gene copies [87]. The TcGP63-I group is present in all the life-stages/cycles of 
T. cruzi and possess metallopeptidase activity and are bound to the protozoan’s 
membrane by a C-terminal glycosylphosphatidylinositol- (GPI-) anchor signal. 
In T. cruzi, TcGP63-I exist in two isoforms: the glycosylated and the nonglycosyl-
ated isoforms. The 61 kDa glycosylated isoform is present in similar levels in both 
epimastigote and amastigote forms and is irregularly expressed on the surface 
membranes of the epimastigote while the 55 kDa nonglycosylated isoform is 
present in the metacyclic trypomastigote and is located intracellularly near the 
kinetoplast and the flagellar pocket [88]. Members of TcGP63-II are two tran-
scripts of 2.6 and 2.8 kb protein.
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[58, 62] and encodes for very small open reading frame containing a putative signal 
peptide at the N-terminus and a GPI-anchor signal in the C-terminus. The TcSMUG 
S group is found in the epimastigote and metacyclic trypomastigote forms and 
encodes for 35–50 kDa mucins N-glycosylated (Gp35/50 mucins) and they are the 
major acceptors of sialic acid on the parasite surface by parasite trans-sialidases 
in T. cruzi [63, 64]. In contrast, TcSMUG L group encodes for mucin-type glyco-
conjugates which are not sialic acid acceptors and only present in the surface of 
the epimastigote stage [65, 66] and contains one or two additional N-glycosylation 
signals between the N-terminal region and the threonine-rich region depending on 
the origin of the encoding allele [65].
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Trans-sialidase shares certain characteristics with mucin protein family as they are 
distributed along the cell body, flagellum, and flagellar pocket of T. cruzi [68]. The 
trans-sialidase superfamily is classified into four groups based on their sequence 
similarity and functional properties namely: TS 1, TS II, TS III and TS IV [69]. The 
TS activity involves the transfer of sialic acid from host glycoconjugates to mainly 
the parasite mucins present in the plasma membrane of trypomastigotes [70, 71]. 
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[72, 73].
The TS I comprises of proteins with trans-sialidase (TS) and/or neuraminidase 
activities [74]. Neuraminidase activity occurs when nonsuitable acceptor mol-
ecules for sialic acid are present and then sialic acid is transferred to water [75]. 
Neuraminidase activity is involved in the removal of sialic acid from parasites and/
or host-cell molecules which is required for parasite internalization [76]. The TS I 
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are attached by glycosylphosphatidylinositol to the parasite plasma membrane and 
can be found in the serum of deeply infected mammals.
TS-epi, the third member of group TS I is an active trans-sialidase expressed in 
the insect dwelling epimastigote form at the stationary phase and is different from 
the trans-sialidase expressed of the blood trypomastigotes. Unlike other members 
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Members of TS group II includes: ASP-1, ASP-2, TSA-1, Tc85, SA85, GP82, and 
GP90 and they all have been implicated in host-cell attachment and invasion. 
ASP-1, ASP-2 (both are amastigote surface proteins) and TSA-1 (trypomastigote 
surface antigen) are targets of T. cruzi-specific CD8+ cytotoxic T lymphocytes and 
they induce strong antibody responses in infected mice and humans. The SA85 
glycoproteins are expressed by amastigote and bloodstream trypomastigote forms 
but only the amastigote form expresses the mannose-binding protein ligand which 
seems to be involved in the opsonization of the parasite enhancing its infection 
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capability. The Tc85 molecule is an 85 kDa glycoprotein which is found abundantly 
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scripts of 2.6 and 2.8 kb protein.
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5.4 Amastin family
The amastin family which is a group of transmembrane glycoproteins consists 
of small proteins of about 180 amino acids. The genome of trypanosoma cruzi has 
two groups of amastin family: the 𝛽𝛽-amastin and the 𝛿𝛿-amastins. The 𝛽𝛽-amastin 
group has two members namely: 𝛽𝛽1-amastin and 𝛽𝛽2-amastin. Genes encoding for 
the 𝛽𝛽1-amastin and 𝛽𝛽2-amastin are localized in the chromosome 32 of T. cruzi. 
The 𝛿𝛿-amastins group has 𝛿𝛿-amastin and 𝛿𝛿-ama40/50 as members and are found 
on chromosomes 34 and 26, respectively. 𝛽𝛽1-amastin and 𝛿𝛿-amastins are located 
at the cell surface. In addition to their surface localization, 𝛽𝛽2 amastin shows a 
disperse distribution within the cytoplasm [89]. Even though the exact biologi-
cal function of amastin is still unknown, as a transmembrane proteins, amastins 
could play a role in proton or ion traffic across the membrane [90]. The 𝛽𝛽-amastin 
transcripts are more abundant in epimastigotes than in amastigotes or trypomas-
tigotes while transcript levels of 𝛿𝛿-amastins are upregulated in amastigotes from 
different T. cruzi strains and 𝛽𝛽-amastins may be involved in the parasite adaptation 
to the insect vector [91].
5.5 T. cruzi trypomastigote alanine, serine and valine (TcTASV) family
The TcTASV protein family is conserved among all the T. cruzi lineages 
analyzed so far and has no orthologues in other species, including the closely-
related trypanosomatids T. brucei, T. rangeli and Leishmania sp and belong to 
a medium-size multigene family of ~40 members that was identified from a 
library of trypomastigote-enriched mRNAs [92]. TcTASV proteins are expressed 
mainly in the trypomastigote stage and its function is still unknown. In TcTASV 
proteins, the N- and C-terminal regions respectively possess a signal peptide 
and a consensus for a glycosylphosphatidylinositol (GPI) anchor addition, and 
display the highest level of conservation, while the central region presents more 
variability. The TcTASV protein family is divided into 4 groups: TcTASV-A, 
TcTASV-B, TcTASV-C and TcTASV-W, with each group defined by the primary 
amino acid sequence and length of polypeptides. TcTASV protein family can 
be distinguished by the common amino acid motif tasv_all that starts approxi-
mately at amino acid 42 (Vx1x2x3[CES]x4x5TDGx6Lx7Wx8x9x10x11Ex12x13Wx14x-
15Cx16x17x18P). Each group has certain amino acid in-between the tasv_all motif. 
The TcTASV-B contains serine and arginine, and TcTASV-W has alanine at X4 and 
glutamic acid at X5 while TcTASV-C and TcTASV-A both have proline and glycine 
at positions X4 and X5.
5.6 Mucin-associated surface proteins (MASPs) family
The MASP family is characterized by having highly conserved N and 
C-terminal domains and a variable and repetitive central region, with a maximum 
expression in the human infective stages of the parasite. MASP are expressed 
simultaneously in bloodstream trypomastigotes as well as in amastigotes and 
epimastigotes and MASP molecules are the most abundant antigens found on the 
surface of the infective trypomastigote stage of T. cruzi. MASP family plays an 
important role in the invasion of the mammalian host cell, but could also be crucial 
for the survival and the establishment of the parasite in the invertebrate host. The 
overexpression of MASPs in the intracellular parasites prior to the division of the 
amastigotes located in the plasma membrane suggests that some of the proteins of 
this extensive family play a major biological role in the survival and multiplication 
of intracellular amastigotes.
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5.7 Cruzipain family
This glycoprotein is synthesized as a zymogen that is activated by cleavage of the 
N-terminal pro-domain to generate the mature protease and belongs to the mam-
malian papain superfamily but contains, as other cysteine proteases (CPs) from 
trypanosomatids, an unusual C-terminal extension. Cruzipain family has many 
groups which include: native-cruzipain (N-cruzipain), recombinant-cruzipain 
1 (R-cruzipain 1) and recombinant cruzipain 2 (R-cruzipain 2). Cruzipains are 
expressed on all the body surface of epimastigotes and amastigotes forms while in 
the trypomastigote form, cruzipain is expressed only in the flagellar pocket region. 
Cruzipain plays a role in the process of T. cruzi internalization into mammalian 
cells. Cruzipain is not only essential for parasite survival but also generates a strong 
immune response in infected individuals.
6. Extracellular vesicles in the life cycle of T. cruzi
Extracellular vesicles (EVs) typically consist of a lipid bilayer membrane contain-
ing integral membrane proteins and a luminal cavity that is loaded with a variety of 
soluble proteins and nucleic acids. T. cruzi parasites, like many other cells, release 
extracellular vesicles (EV) that are involved in cell-cell communication or in the modu-
lation of the host immune responses to promote the establishment of an infection 
[93]. In T. cruzi parasites, two classes of extracellular vesicles have been characterized 
based on size. These include exovesicles also referred to as ectosomes and exosomes. 
Ectosomes which bud directly from the plasma membrane have a size of 100–1000 nm 
while exosomes which are vesicles that are secreted into the extracellular environment 
following the fusion of multivesicular endosomes with the plasma membrane, typi-
cally occurring at the flagellar pocket membrane have a size of 30–100 nm. Analysis of 
extracellular vesicles released by epimastigotes and metacyclic trypomastigotes in cul-
ture demonstrated the presence of two populations of extracellular vesicles containing 
plasma membrane and intracellular proteins, and also nucleic acids. The T. cruzi small 
membrane proteins (TcSMP), a family of proteins or phosphatases detected on T. cruzi 
EVs has been shown to trigger Ca2+ signaling and lysosome mobilization/exocytosis, 
events that promote formation of parasitophorous vacuoles and parasite invasion. In 
the early stages of T. cruzi infection, parasites promote the release of plasma membrane 
vesicles from the host cell, which may contribute to parasite survival in the circulatory 
system, an event thought to help mediate host cell invasion.
Immune cells are one of the main targets of extracellular vesicles. Extracellular 
vesicles secreted during acute and/or chronic T. cruzi infection should play a role 
in the dissemination and survival of this parasite in the vertebrate mammalian 
host since the released extracellular vesicles from virus-infected cells, bacteria, 
fungi or parasites have been demonstrated to play a pivotal role in the modulation 
of the immune system. Several types of extracellular vesicles are promoters of the 
innate and acquired immune response and defined as types of pathogen-associated 
molecular patterns (PAMPs) which could be formed by a wide range of macro-mol-
ecules such as lipids, proteins, carbohydrates, or nucleic acids and are recognized 
by pattern recognition receptors (PPRs) such as toll-like receptors (TLRs) present 
in leukocytes and various non-immune cells, which will in turn initiate a signaling 
cascade that leads to the activation of an immune response against the pathogen 
[94]. In T. cruzi, several PAMPs have already been described, for instance, parasite 
cytidine-phosphate-guanosine (CpG)-DNA released from lysed intracellular para-
sites stimulates TLR7 and TLR9 activation and production of T helper type 1 (Th1) 
proinflammatory cytokines or parasite α-Gal-containing glycoconjugates such as 
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N-terminal pro-domain to generate the mature protease and belongs to the mam-
malian papain superfamily but contains, as other cysteine proteases (CPs) from 
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ecules such as lipids, proteins, carbohydrates, or nucleic acids and are recognized 
by pattern recognition receptors (PPRs) such as toll-like receptors (TLRs) present 
in leukocytes and various non-immune cells, which will in turn initiate a signaling 
cascade that leads to the activation of an immune response against the pathogen 
[94]. In T. cruzi, several PAMPs have already been described, for instance, parasite 
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sites stimulates TLR7 and TLR9 activation and production of T helper type 1 (Th1) 
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mucins or gp85/trans-sialidase recognized by TLR2/6 leading to tumor necrosis 
factor (TNF-α) production in macrophages and inhibition of IL-12 in dendritic 
cells. Studies on T. cruzi extracellular vesicles have shown that these vesicles could 
act as an agonist of TLR2 signaling, which leads to the secretion of proinflamma-
tory cytokines (TNF-α and IL-6) and nitric oxide which could be explained by the 
presence of GPI-anchored molecules like mucins, mucin-associated surface proteins 
(MASPs), or trans-sialidases (TSs) on the extracellular vesicles surface.
7. Carbon and energy sources in T. cruzi life cycle
The life cycle of T. cruzi alternates between glucose-rich and glucose-poor 
environments having to adapt to different sources of energy and carbon. The differ-
entiation of epimastigotes, the non-infective dividing forms found in the digestive 
tract of the invertebrate host into metacyclic trypomastigotes (metacyclogenesis) 
occur in an amino-acid-rich and carbohydrate-poor medium. In vertebrate, the 
trypomastigotes differentiate into the dividing forms called amastigotes occur in a 
medium poor in free glucose.
Trypanosomatids can use either glucose or amino acids as main carbon 
and energy source, although one cannot rule out the use of fatty acids as well. 
Amino acids, especially l-proline and l-glutamine which are abundant in the 
hemolymph and tissue fluids of the blood sucking vector are the main source of 
carbon and energy in the insect stages. l-Proline seems to be involved in several 
mechanisms of resistance to oxidative, nutritional and thermal stress and is 
important in metacyclogenesis for the differentiation of intracellular epimasti-
gotes to trypomastigotes in T. cruzi. Several amino acids such as proline, aspartate 
and glutamate are actively transported and oxidized by T. cruzi. The catabolism 
of aromatic amino acids appears to be related to the cytosolic NADH+ reoxida-
tion. Also, the presence of at least 60 genes belonging to a single family of amino 
acid transporter in T. cruzi further reinforces the relevance of amino acids in the 
biology of these organisms. While some trypanosomatids metabolically prefer 
glucose to amino acid when grown in a medium rich in glucose and amino acid, 
as seen in proline and glucose metabolism in T. brucei, other trypanosomatids 
like Crithidia deanei, a monoxenic and non-pathogenic trypanosomatid living in 
the insect gut preferentially metabolize amino acids irrespective of the glucose 
content of the culture medium [95].
Amino acids are crucial nutrients during the T. cruzi life cycle; apart from their 
use as carbon and energy sources, they participate in several biological processes 
that help the parasite adjust to their changing environment. Arginine metabolism 
is linked to T. cruzi growth and is involved in the management of cell energy under 
nutritional stress condition. Certain amino acids such as proline, glutamate, and 
aspartate are essentials in the process of metacyclogenesis. Apart from being 
involved in the process of metacyclogenesis, proline and glutamate seems to have 
a broad variety of functions. While proline is involved in fulfilling the energy 
requirements for host cell invasion, differentiation from the intracellular transient 
epimastigote-like stage to trypomastigote forms and resistance to oxidative stress, 
glutamate is directly involved in osmoregulation and cell volume control.
8. Changes in gene expression during the life cycle of T. cruzi
As a result of changing environments during the life cycle, T. cruzi undergoes 
rapid and significant changes in gene expression, which are achieved essentially 
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at the post-transcriptional level through modulation of messenger RNA (mRNA) 
stability and translational control mechanisms. In order to adapt to the different 
environment they find within one or the other host species, T. cruzi also undergoes 
drastic morphological and biochemical changes and are also able to differentiate 
from proliferative to nonproliferative cells within the same host. All these changes 
are orchestrated by the differential expression of stage-specific genes.
Cellular differentiation is controlled at multiple levels including, for most eukary-
otic cells, initiation of gene transcription. The discriminatory mechanisms for the 
initiation of transcription at individual loci is largely absent in trypanosomatids and 
most protein-coding genes lack promoters and are transcribed as long polycistronic 
units that are processed into individual mRNAs. Consequently, trypanosomes rely on 
post-transcriptional processes such as translational efficiency, mRNA stability and 
post-translational modification to coordinate developmental transitions and other 
adaptive responses encountered throughout their complex life cycles.
In eukaryotes, protein-coding genes are transcribed into monocistronic 
pre-mRNA transcripts containing coding sequences (exons) and non-coding 
sequences (introns) that are processed into mature mRNAs through cis-splicing 
reactions. RNA polymerase II is the enzyme responsible for the transcription of 
protein-coding genes while RNA polymerase I transcribes ribosomal RNA. In 
trypanosomatids, however, transcription is polycistronic, there are no introns 
and, therefore, no cis-splicing reactions. Processing of pre-mRNA into single 
gene units is effected by trans-splicing reactions, a process that has been found to 
operate only in trypanosomatids and other organisms like Euglena, nematode and 
trematode worms.
Granules of mRNA such as processing bodies (P bodies) and stress granules 
(SGs) are involved in post-transcriptional regulation of gene expression. P bodies 
are constitutively present in the cell and can grow in size and number when cells 
are perturbed while SGs only arise under cellular stress. P bodies contain mRNA 
and proteins involved in translational repression, mRNA decapping, 5′ → 3′ mRNA 
decay, nonsense-mediated decay (NMD) and the miRNA (microRNA) pathway. 
P bodies were initially thought to be the place where mRNA was recruited to be 
degraded and recently, a function as mRNA storage depots has been assigned to P 
bodies. By contrast, SGs are stalled 43S translation pre-initiation complexes, mainly 
composed of mRNA, translation initiation factors and 40S ribosomal proteins. SGs 
are thought to function as mRNA triage centers during stress.
9. Conclusion
Trypanosoma cruzi, the parasite responsible of Chagas disease has a complex 
life cycle including intracellular and extracellular forms, which alternate between 
invertebrate insect vectors and vertebrate mammalian hosts. T. cruzi replicate extra-
cellularly within the insect, but have to infect cells to multiply within the mammal 
which contrasts with the African trypanosome which is extracellular in both hosts. 
During their life cycles, they alternate between a mammalian host and an insect 
vector and undergo profound biochemical and morphological transformations in 
order to adapt to the different environments changes orchestrated by precise gene 
regulation programs.
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mucins or gp85/trans-sialidase recognized by TLR2/6 leading to tumor necrosis 
factor (TNF-α) production in macrophages and inhibition of IL-12 in dendritic 
cells. Studies on T. cruzi extracellular vesicles have shown that these vesicles could 
act as an agonist of TLR2 signaling, which leads to the secretion of proinflamma-
tory cytokines (TNF-α and IL-6) and nitric oxide which could be explained by the 
presence of GPI-anchored molecules like mucins, mucin-associated surface proteins 
(MASPs), or trans-sialidases (TSs) on the extracellular vesicles surface.
7. Carbon and energy sources in T. cruzi life cycle
The life cycle of T. cruzi alternates between glucose-rich and glucose-poor 
environments having to adapt to different sources of energy and carbon. The differ-
entiation of epimastigotes, the non-infective dividing forms found in the digestive 
tract of the invertebrate host into metacyclic trypomastigotes (metacyclogenesis) 
occur in an amino-acid-rich and carbohydrate-poor medium. In vertebrate, the 
trypomastigotes differentiate into the dividing forms called amastigotes occur in a 
medium poor in free glucose.
Trypanosomatids can use either glucose or amino acids as main carbon 
and energy source, although one cannot rule out the use of fatty acids as well. 
Amino acids, especially l-proline and l-glutamine which are abundant in the 
hemolymph and tissue fluids of the blood sucking vector are the main source of 
carbon and energy in the insect stages. l-Proline seems to be involved in several 
mechanisms of resistance to oxidative, nutritional and thermal stress and is 
important in metacyclogenesis for the differentiation of intracellular epimasti-
gotes to trypomastigotes in T. cruzi. Several amino acids such as proline, aspartate 
and glutamate are actively transported and oxidized by T. cruzi. The catabolism 
of aromatic amino acids appears to be related to the cytosolic NADH+ reoxida-
tion. Also, the presence of at least 60 genes belonging to a single family of amino 
acid transporter in T. cruzi further reinforces the relevance of amino acids in the 
biology of these organisms. While some trypanosomatids metabolically prefer 
glucose to amino acid when grown in a medium rich in glucose and amino acid, 
as seen in proline and glucose metabolism in T. brucei, other trypanosomatids 
like Crithidia deanei, a monoxenic and non-pathogenic trypanosomatid living in 
the insect gut preferentially metabolize amino acids irrespective of the glucose 
content of the culture medium [95].
Amino acids are crucial nutrients during the T. cruzi life cycle; apart from their 
use as carbon and energy sources, they participate in several biological processes 
that help the parasite adjust to their changing environment. Arginine metabolism 
is linked to T. cruzi growth and is involved in the management of cell energy under 
nutritional stress condition. Certain amino acids such as proline, glutamate, and 
aspartate are essentials in the process of metacyclogenesis. Apart from being 
involved in the process of metacyclogenesis, proline and glutamate seems to have 
a broad variety of functions. While proline is involved in fulfilling the energy 
requirements for host cell invasion, differentiation from the intracellular transient 
epimastigote-like stage to trypomastigote forms and resistance to oxidative stress, 
glutamate is directly involved in osmoregulation and cell volume control.
8. Changes in gene expression during the life cycle of T. cruzi
As a result of changing environments during the life cycle, T. cruzi undergoes 
rapid and significant changes in gene expression, which are achieved essentially 
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at the post-transcriptional level through modulation of messenger RNA (mRNA) 
stability and translational control mechanisms. In order to adapt to the different 
environment they find within one or the other host species, T. cruzi also undergoes 
drastic morphological and biochemical changes and are also able to differentiate 
from proliferative to nonproliferative cells within the same host. All these changes 
are orchestrated by the differential expression of stage-specific genes.
Cellular differentiation is controlled at multiple levels including, for most eukary-
otic cells, initiation of gene transcription. The discriminatory mechanisms for the 
initiation of transcription at individual loci is largely absent in trypanosomatids and 
most protein-coding genes lack promoters and are transcribed as long polycistronic 
units that are processed into individual mRNAs. Consequently, trypanosomes rely on 
post-transcriptional processes such as translational efficiency, mRNA stability and 
post-translational modification to coordinate developmental transitions and other 
adaptive responses encountered throughout their complex life cycles.
In eukaryotes, protein-coding genes are transcribed into monocistronic 
pre-mRNA transcripts containing coding sequences (exons) and non-coding 
sequences (introns) that are processed into mature mRNAs through cis-splicing 
reactions. RNA polymerase II is the enzyme responsible for the transcription of 
protein-coding genes while RNA polymerase I transcribes ribosomal RNA. In 
trypanosomatids, however, transcription is polycistronic, there are no introns 
and, therefore, no cis-splicing reactions. Processing of pre-mRNA into single 
gene units is effected by trans-splicing reactions, a process that has been found to 
operate only in trypanosomatids and other organisms like Euglena, nematode and 
trematode worms.
Granules of mRNA such as processing bodies (P bodies) and stress granules 
(SGs) are involved in post-transcriptional regulation of gene expression. P bodies 
are constitutively present in the cell and can grow in size and number when cells 
are perturbed while SGs only arise under cellular stress. P bodies contain mRNA 
and proteins involved in translational repression, mRNA decapping, 5′ → 3′ mRNA 
decay, nonsense-mediated decay (NMD) and the miRNA (microRNA) pathway. 
P bodies were initially thought to be the place where mRNA was recruited to be 
degraded and recently, a function as mRNA storage depots has been assigned to P 
bodies. By contrast, SGs are stalled 43S translation pre-initiation complexes, mainly 
composed of mRNA, translation initiation factors and 40S ribosomal proteins. SGs 
are thought to function as mRNA triage centers during stress.
9. Conclusion
Trypanosoma cruzi, the parasite responsible of Chagas disease has a complex 
life cycle including intracellular and extracellular forms, which alternate between 
invertebrate insect vectors and vertebrate mammalian hosts. T. cruzi replicate extra-
cellularly within the insect, but have to infect cells to multiply within the mammal 
which contrasts with the African trypanosome which is extracellular in both hosts. 
During their life cycles, they alternate between a mammalian host and an insect 
vector and undergo profound biochemical and morphological transformations in 
order to adapt to the different environments changes orchestrated by precise gene 
regulation programs.
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Abstract
This chapter aims to present and discuss the main cell culture techniques used 
for the growth and maintenance of the different evolutionary forms of the proto-
zoan Trypanosoma cruzi, the etiologic agent of the Chagas disease. Chagas disease 
is a neglected tropical disease endemic in several Latin American countries. Here, 
we intend to present the main difficulties, advantages, and disadvantages of using 
Trypanosoma cruzi cell culture in parasitic biology. Finally, we present the main 
research opportunities in the context of Trypanosoma cruzi parasitic biology using 
cell culture techniques, such as drug development, characterization of pharmaco-
logical targets, molecular markers for diagnosis, structural biology, and many other 
biomedical applications.
Keywords: Trypanosoma cruzi, Chagas disease, cell culture, in vitro assay, 
metacyclogenesis
1. Introduction
Carlos Chagas described the American trypanosomiasis through micro-
scope observation of hemoflagellate protozoan in the sample blood and named 
Trypanosoma cruzi [1]. The parasite belongs to the Kinetoplastida order and 
Trypanosomatidae family. This family is characterized by the presence of flagel-
lum and only one mitochondrion, which extends throughout the cell body. The 
mitochondrion matrix contains a complex array of DNA fibrils structure called 
kinetoplast (kDNA).
Trypanosoma cruzi (T. cruzi) is a digenetic parasite that develops through a com-
plex life cycle involving an insect vector and a mammalian host. Trypanosomatidae 
family shows, during development stages, several forms, which can be easily identi-
fied by light microscopy in Giemsa-stained preparations. In the case of T. cruzi, three 
main morphogenetic forms are recognized, and the transition between each form 
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involves morphologic modifications in gene expression and cellular cycle (Table 1). 
Therefore, the evolutionary forms, trypomastigote and amastigote, are found in the 
vertebrate host, and epimastigote and metacyclic trypomastigotes are found in the 
invertebrate host [2].
Due to its genetic diversity, the parasite T. cruzi represents one of the best model 
organisms for studies of clonal evolution, with rare events of recombination and/or 
genetic hybridization. Molecular markers, like the mini-exon genes and the ribo-
somal DNA 24S, allow the characterization of T. cruzi lineages and the subdivision 
in seven discrete typing units (DTUs, from TcI to TcVI) [3, 4]. Parasite of T. cruzi 
diversity could be associated with adaptation and survives inside different hosts. 
Therefore, this genotypic variation among the different strains of T. cruzi from 
different geographical regions may explain the frequency of variability in different 
characteristics of parasitism, such as virulence, subclinical infection rate, clinical 
symptoms of infection, and susceptibility to antiparasitic drugs [5].
A century of its discovery, Chagas disease remains a cause of early mortality and 
morbidity in individuals at productive age in endemic areas, generating significant 
socioeconomic impact. The importance of parasite biology studies is undeniable. 
In this context, in vitro studies of T. cruzi offers the opportunity to understand 
the coordination of metabolic and cellular change as a response to environmental 
stimuli in a simple and well-characterized system.
2. How to maintain and cultivate Trypanosoma cruzi?
During life cycle, T. cruzi alternates among different morphological and func-
tional types and different hosts (mammals and triatomine bugs). Epimastigote 
replicative form can result in non-replicative and infective trypomastigote forms. 
Amastigote forms could be achieved by infected mammal cells. The adaptation 
mechanism of T. cruzi to environmental changes and diverse physicochemical 
conditions represents an important means of survival.
Substantial interest in understanding the cell biology of T. cruzi made possible 
its maintenance and growth in in vitro systems. Several methods have already been 
described for obtaining the different stages of the parasite, and these can be cul-
tured in non-defined axenic media, defined axenic media, and in various cell types.
The axenic cultures of T. cruzi were primarily established in different cell types 
and tissues with appropriate conditions that allowed the infection process and 
Evolutionary forms
Epimastigote Trypomastigote metacyclic Trypomastigote Amastigote
Localization Intestine of 
the vector and 
axenic culture
Rectal ampoule 






Inside the cells 
of vertebrate-




Elongate Elongate Elongate Spherical




After the nucleus After the nucleus Near the nucleus
These evolutionary forms are identified by the relative position of the kinetoplast in relation to the nucleus.
Table 1. 
View in optical microscope of the various developmental stages of Trypanosoma cruzi: epimastigote, 
intracellular amastigote, trypomastigote metacyclic, and bloodstream forms.
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its survival [6]. During this period, metacyclogenesis process was observed and 
characterized through detailing all the cellular and/or behavioral transformations 
undergone by the parasite. By observing the biological changes undergone, key 
points during the process became possible to be determined that were later mim-
icked to facilitate the differentiation process [7].
Epimastigote forms are maintained in axenic conditions at 28°C, in the nutritive 
medium liver infusion tryptose (LIT), supplemented with 10% (v/v) heat- 
inactivated fetal bovine serum (FBS) as described by Camargo [8]. Under chemically 
defined conditions and suppression of nutrients, the transformation of epimas-
tigotes into metacyclic trypomastigotes is possible in vitro using a process named 
metacyclogenesis [9].
To obtain intracellular amastigote forms, usually mammal cells, Vero lineage, 
murine peritoneal macrophages, fibroblast (mouse L929), and primary heart or 
skeletal muscles cells are commonly incubated with specific medium supplemented 
with 10% inactivated FBS (v/v) and allowed to adhere usually for 24 h at 37 ± 2°C in 
5% CO2. After this period, adherent cells can infect with trypomastigote metacyclic 
using a 10:1 ratio of parasites per cell and incubated at 37°C in 5% CO2, without 
FBS. Amastigote can be observed in microscope at 4–24 h after infection. Intracellular 
amastigote can release within 72 h trypomastigote metacyclic from culture derived. 
Infected Vero cells can be in continuous cultivation during 6–8 weeks [10].
Infected cells with T. cruzi can spontaneously release amastigote forms into the 
supernatant medium. The viable amastigote forms can be collected and produce 
the axenic amastigote. Firstly, wash cells with phosphate buffer saline (PBS, pH 7.2) 
through centrifugation, collect, and then resuspend in appropriate medium, 
 usually Grace medium supplemented with nicotinamide and ATP. This addition can 
neutralize differentiation of amastigote forms, and the culture can be maintained at 
37°C in a humid atmosphere containing 5% CO2. Every 4 days, the media have to be 
partially removed by centrifugation to remove the supernatant medium and add the 
fresh medium to maintain the amastigote forms [11].
3.  In vitro differentiation of Trypanosoma cruzi epimastigote to 
trypomastigote forms
Metacyclic trypomastigotes (non-replicative) originating from the insect vector 
or trypomastigotes from infected cells, such as culture derived and bloodstream/
tissue, are infective forms of the parasite. Metacyclogenesis is observed in the 
stationary phase of culture, and metacyclic trypomastigotes are largely absent 
during logarithmic growth. However, in vitro differentiation of T. cruzi is possible 
according to biologically active factors and essential nutrient depletion or accu-
mulation of certain metabolites [12]. Generally, metacyclogenesis process can be 
mimicked using chemical differentiation medium or axenic-defined medium and 
nutrient suppression for the differentiation of the epimastigote forms to occur in 
trypomastigotes. The omission of medium supplements, such as glucose, was able to 
lead to flagellar elongation, as observe by Tyler and Engman [13]. The epimastigote-
extending flagellum occurs in order to undergo metacyclogenesis.
By contrast, chemical modification is commonly used for differentiation of epi-
mastigote to trypomastigote forms. Epimastigote forms can be collected from the 
LIT culture, during the stationary phase of the growth curve, and then resuspended 
in artificial triatomine urine (TAU) supplemented with proline (TAUP medium) 
or TAU supplemented with L-proline, L-sodium glutamate, L-sodium aspartate, 
and D-glucose (TAU3AAG medium) [14]. In the first medium, parasite culture 
can differentiate after 10 days and 72–96 h using TAU3AAG medium. Recent study 
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its survival [6]. During this period, metacyclogenesis process was observed and 
characterized through detailing all the cellular and/or behavioral transformations 
undergone by the parasite. By observing the biological changes undergone, key 
points during the process became possible to be determined that were later mim-
icked to facilitate the differentiation process [7].
Epimastigote forms are maintained in axenic conditions at 28°C, in the nutritive 
medium liver infusion tryptose (LIT), supplemented with 10% (v/v) heat- 
inactivated fetal bovine serum (FBS) as described by Camargo [8]. Under chemically 
defined conditions and suppression of nutrients, the transformation of epimas-
tigotes into metacyclic trypomastigotes is possible in vitro using a process named 
metacyclogenesis [9].
To obtain intracellular amastigote forms, usually mammal cells, Vero lineage, 
murine peritoneal macrophages, fibroblast (mouse L929), and primary heart or 
skeletal muscles cells are commonly incubated with specific medium supplemented 
with 10% inactivated FBS (v/v) and allowed to adhere usually for 24 h at 37 ± 2°C in 
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amastigote can release within 72 h trypomastigote metacyclic from culture derived. 
Infected Vero cells can be in continuous cultivation during 6–8 weeks [10].
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supernatant medium. The viable amastigote forms can be collected and produce 
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through centrifugation, collect, and then resuspend in appropriate medium, 
 usually Grace medium supplemented with nicotinamide and ATP. This addition can 
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fresh medium to maintain the amastigote forms [11].
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tissue, are infective forms of the parasite. Metacyclogenesis is observed in the 
stationary phase of culture, and metacyclic trypomastigotes are largely absent 
during logarithmic growth. However, in vitro differentiation of T. cruzi is possible 
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mulation of certain metabolites [12]. Generally, metacyclogenesis process can be 
mimicked using chemical differentiation medium or axenic-defined medium and 
nutrient suppression for the differentiation of the epimastigote forms to occur in 
trypomastigotes. The omission of medium supplements, such as glucose, was able to 
lead to flagellar elongation, as observe by Tyler and Engman [13]. The epimastigote-
extending flagellum occurs in order to undergo metacyclogenesis.
By contrast, chemical modification is commonly used for differentiation of epi-
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LIT culture, during the stationary phase of the growth curve, and then resuspended 
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and D-glucose (TAU3AAG medium) [14]. In the first medium, parasite culture 
can differentiate after 10 days and 72–96 h using TAU3AAG medium. Recent study 
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demonstrated that reductive environment using urate, a salt or ester of uric acid, 
could promote epimastigote differentiation with significant increment of trypo-
mastigotes [15]. In addition, Grace medium supplemented with Triatoma infestans 
intestinal homogenate was used for in vitro metacyclogenesis of T. cruzi [16].
Metacyclic trypomastigotes are essential for the understanding of host-pathogen 
interaction and it is remarkable genetic variability between strains. Although, these 
biological stages in axenic medium are difficult to purify, culture remains with epi-
mastigote stages without showing a high efficiency in the purification of metacyclic 
trypomastigotes [8].
Complement-mediated lysis of epimastigotes followed by separation of the 
trypomastigotes by gradient centrifugation through a dense albumin column 
represents a selective method that exploited to purify viable trypomastigotes from 
cells culture medium. Alternate pathway activation seems capable by itself generat-
ing epimastigote lysis and consequent activation of the classical pathway just in the 
presence of serum [17].
Other several techniques such as density separation with Percoll [18, 19] and 
extensive use of chromatography have permitted purifying metacyclic trypo-
mastigotes for the association of specific molecules expressed on this parasite 
stage membrane separation. Chromatography based on the differential plasma 
membrane charge between epimastigotes and trypomastigotes using ion exchange 
chromatography with resins, such as cellulose-DEAE and sephadex, have been 
developed for the purification of metacyclic trypomastigotes [20, 21]. These 
previous chromatography techniques presented a major disadvantage such as the 
decrease in the infective capacity of the obtained trypomastigote [22].
Recently, a new protocol in LIT medium cultures was implemented using sepharose-
DEAE as a resin during purification process, which could recover metacyclic 
trypomastigotes for two different DTUs (I and II). DTU TcI was the one recovered 
a greater amount of these forms, and parasite infectivity in vitro and in vivo was 
maintained [20]. Metacyclogenesis with different DTUs exhibited significantly 
different morphologies and metacyclogenesis pattern [23].
Still it remains crucial to have easy, fast, and reliable tools to obtain purified 
metacyclic trypomastigote forms of T. cruzi. Thus, results acquired with these puri-
fied parasites should be interpreted with caution in order to validated biological, 
chemical, or immunological studies.
4. Advantages and limitation of in vitro Trypanosoma cruzi culture
The entire T. cruzi cycle can be studied in vitro, and it is one of the easiest to 
keep in the laboratory. A crucial point, which is considered to be a basic require-
ment for all the biological assays in vitro system using T. cruzi is the selection of 
methods and adoption of biosafety procedures, including good laboratory facilities 
and laboratory practices and the use of collective and individual protection tools. 
Therefore, the training of personnel involved in the manipulation and cultivation of 
T. cruzi strains is required, especially on the handling of drug-resistant strains.
Probably, the main advantages of the use of in vitro systems for maintenance 
and cultivation of T. cruzi are related to costs and biosafety. The in vitro system of 
T. cruzi cultivation presents some characteristics that deserve to be highlighted:  
(i) reduction of the number of animals used in experimental models of infection, 
(ii) ethical aspects in animal replacement, (iii) less need for laboratory  
infrastructure, (iv) reduced time of experiments compared to in vivo methods, and 
(iv) lower risk of human infection during culture procedures [15].
33
Cell Culture and Maintenance of the Evolutionary Forms of Trypanosoma cruzi for Studies…
DOI: http://dx.doi.org/10.5772/intechopen.84733
As mentioned above, the use of T. cruzi in in vitro assays allows the researcher to 
access a variety of strains with different biological and genetic profiles, in addi-
tion to the different stages of parasite differentiation. Furthermore, T. cruzi clones 
exhibit a greater rate of multiplication in culture medium.
One of the possibilities of in vitro system is to obtain large amounts of meta-
cyclic trypomastigotes (derived culture or chemical modification medium) with 
biological properties similar to those of the insect-derived forms, which facilitates 
the study of the biology of T. cruzi. On the other hand, there is a controversy that 
the strains are kept in artificial culture media, transformed into true “laboratory 
strains,” with total or partial loss of their original characteristics, despite their mor-
phological similarities. Contreras and colleagues demonstrated that culture-derived 
metacyclic forms of T. cruzi can decrease their capacity to invade cells [16].
The great potential of the in vitro models is the study of the interaction T. cruzi-
host cell throughout amastigote culture. It has been demonstrated the in vitro 
capacity of invasion in all cell types was tested [10, 24]. As yet, in vivo models, 
infected animals, as well as in human, show evidence of a parasite tropism by cells of 
the mononuclear phagocytic system and by muscle and nerve cells, contrary to what 
is observed in vitro as mentioned before. On the other hand, maintained trypomasti-
gote metacyclic in vivo (mice) condition generally increased virulence [14].
However, the in vitro assay does not provide full information on the behavior 
and characteristics about T. cruzi. The complexity of in vivo system is bigger than 
in parasite cultivation system. The mechanisms of parasite-host interaction are 
controlled by cells and innumerable proteins that trigger numerous genetic and 
physiological signals in the parasite. These interactions cannot be accurately evalu-
ated in in vitro systems.
5. Applications in the cell culture of Trypanosoma cruzi
Despite decades of research in T. cruzi biology, many questions remain to be 
solved. The cultivation of T. cruzi has been explored in several biomedical researches, 
mainly as a strategy for the understanding of parasite biology and parasite-host inter-
action. Thus, these in vitro methodologies have been used to understand mechanisms 
of parasite invasion, mechanisms of resistance and susceptibility to drugs, identifica-
tion of virulence factors, signaling, cellular metabolism, etc. Our research group has 
been using the T. cruzi cultures to evaluate the potential of new compounds with 
antiparasitic activity for the treatment of Chagas disease [25]. The cultivation meth-
ods also allow to isolate and characterize the circulating T. cruzi genotypes, present in 
triatomines captured in the natural environment of transmission of Chagas disease 
[26]. In addition, other robust molecular and structural biology tools can be applied 
to the study of the biology of T. cruzi using cell culture, namely, functional genomic 
and proteomic studies [27, 28] and structural cryo-microscopy [29].
6. Conclusion
In this chapter, we have shown the importance of cell culture techniques as a 
complementary tool for studies of parasitic biology. Through the cultivation of dif-
ferent evolutionary forms of T. cruzi, we can answer important scientific questions 
in the context of parasitic diseases, more specifically in Chagas disease. In conclu-
sion, this work shows a reflection about the advantages and limitations of T. cruzi 
cultivation techniques in studies of parasitic biology.
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demonstrated that reductive environment using urate, a salt or ester of uric acid, 
could promote epimastigote differentiation with significant increment of trypo-
mastigotes [15]. In addition, Grace medium supplemented with Triatoma infestans 
intestinal homogenate was used for in vitro metacyclogenesis of T. cruzi [16].
Metacyclic trypomastigotes are essential for the understanding of host-pathogen 
interaction and it is remarkable genetic variability between strains. Although, these 
biological stages in axenic medium are difficult to purify, culture remains with epi-
mastigote stages without showing a high efficiency in the purification of metacyclic 
trypomastigotes [8].
Complement-mediated lysis of epimastigotes followed by separation of the 
trypomastigotes by gradient centrifugation through a dense albumin column 
represents a selective method that exploited to purify viable trypomastigotes from 
cells culture medium. Alternate pathway activation seems capable by itself generat-
ing epimastigote lysis and consequent activation of the classical pathway just in the 
presence of serum [17].
Other several techniques such as density separation with Percoll [18, 19] and 
extensive use of chromatography have permitted purifying metacyclic trypo-
mastigotes for the association of specific molecules expressed on this parasite 
stage membrane separation. Chromatography based on the differential plasma 
membrane charge between epimastigotes and trypomastigotes using ion exchange 
chromatography with resins, such as cellulose-DEAE and sephadex, have been 
developed for the purification of metacyclic trypomastigotes [20, 21]. These 
previous chromatography techniques presented a major disadvantage such as the 
decrease in the infective capacity of the obtained trypomastigote [22].
Recently, a new protocol in LIT medium cultures was implemented using sepharose-
DEAE as a resin during purification process, which could recover metacyclic 
trypomastigotes for two different DTUs (I and II). DTU TcI was the one recovered 
a greater amount of these forms, and parasite infectivity in vitro and in vivo was 
maintained [20]. Metacyclogenesis with different DTUs exhibited significantly 
different morphologies and metacyclogenesis pattern [23].
Still it remains crucial to have easy, fast, and reliable tools to obtain purified 
metacyclic trypomastigote forms of T. cruzi. Thus, results acquired with these puri-
fied parasites should be interpreted with caution in order to validated biological, 
chemical, or immunological studies.
4. Advantages and limitation of in vitro Trypanosoma cruzi culture
The entire T. cruzi cycle can be studied in vitro, and it is one of the easiest to 
keep in the laboratory. A crucial point, which is considered to be a basic require-
ment for all the biological assays in vitro system using T. cruzi is the selection of 
methods and adoption of biosafety procedures, including good laboratory facilities 
and laboratory practices and the use of collective and individual protection tools. 
Therefore, the training of personnel involved in the manipulation and cultivation of 
T. cruzi strains is required, especially on the handling of drug-resistant strains.
Probably, the main advantages of the use of in vitro systems for maintenance 
and cultivation of T. cruzi are related to costs and biosafety. The in vitro system of 
T. cruzi cultivation presents some characteristics that deserve to be highlighted:  
(i) reduction of the number of animals used in experimental models of infection, 
(ii) ethical aspects in animal replacement, (iii) less need for laboratory  
infrastructure, (iv) reduced time of experiments compared to in vivo methods, and 
(iv) lower risk of human infection during culture procedures [15].
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As mentioned above, the use of T. cruzi in in vitro assays allows the researcher to 
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The great potential of the in vitro models is the study of the interaction T. cruzi-
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capacity of invasion in all cell types was tested [10, 24]. As yet, in vivo models, 
infected animals, as well as in human, show evidence of a parasite tropism by cells of 
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is observed in vitro as mentioned before. On the other hand, maintained trypomasti-
gote metacyclic in vivo (mice) condition generally increased virulence [14].
However, the in vitro assay does not provide full information on the behavior 
and characteristics about T. cruzi. The complexity of in vivo system is bigger than 
in parasite cultivation system. The mechanisms of parasite-host interaction are 
controlled by cells and innumerable proteins that trigger numerous genetic and 
physiological signals in the parasite. These interactions cannot be accurately evalu-
ated in in vitro systems.
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solved. The cultivation of T. cruzi has been explored in several biomedical researches, 
mainly as a strategy for the understanding of parasite biology and parasite-host inter-
action. Thus, these in vitro methodologies have been used to understand mechanisms 
of parasite invasion, mechanisms of resistance and susceptibility to drugs, identifica-
tion of virulence factors, signaling, cellular metabolism, etc. Our research group has 
been using the T. cruzi cultures to evaluate the potential of new compounds with 
antiparasitic activity for the treatment of Chagas disease [25]. The cultivation meth-
ods also allow to isolate and characterize the circulating T. cruzi genotypes, present in 
triatomines captured in the natural environment of transmission of Chagas disease 
[26]. In addition, other robust molecular and structural biology tools can be applied 
to the study of the biology of T. cruzi using cell culture, namely, functional genomic 
and proteomic studies [27, 28] and structural cryo-microscopy [29].
6. Conclusion
In this chapter, we have shown the importance of cell culture techniques as a 
complementary tool for studies of parasitic biology. Through the cultivation of dif-
ferent evolutionary forms of T. cruzi, we can answer important scientific questions 
in the context of parasitic diseases, more specifically in Chagas disease. In conclu-
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Abstract
The epidemiology of Trypanosoma cruzi in the wild is a particular and highly 
dynamic scenario that needs attention due to the increased alteration of the envi-
ronment caused by different factors including anthropogenic change. This chapter 
is an updated summary about the known reservoir hosts of T. cruzi identified in 
the countries that share the Amazon rainforest. This information will provide 
a better understanding of the ecology of T. cruzi in sylvatic environments. This 
chapter will also contribute to address the potential risks of T. cruzi infection in 
Amazonian communities who are in contact with wild animals through hunting 
and wild meat consumption.
Keywords: Trypanosoma cruzi, Chagas disease, Amazon, parasites, wild animals, 
zoonosis, host
1. Introduction
The Amazon basin comprises multiple South American countries: Brazil 
(63.9%), Peru (15.6%), Bolivia (11.7%), Colombia (5.6%), Ecuador (2.1%), 
Venezuela (0.9%) and Guyana (0.2%). It covers over 1.3 billion hectares with 60% 
of total forest area (Figure 1) [1]. Population density in the Amazon basin is low and 
more than 70% live in urban areas. However, this region is in transition due to both 
climate change as well as anthropogenic activities such as the expansion of agricul-
ture, road paving and logging that lead to accelerated population growth [1, 2].
The environmental conditions of the Amazon basin are favorable for the trans-
mission of multiple vector-borne diseases. Well-known endemic diseases such as 
malaria and Leishmaniasis show the highest incidence in the Americas, and recent 
data shows the circulation of multiple arboviruses [3], with an increasing incidence 
of Dengue fever over time. Trypanosomatids exist in nature since millions of years 
ago, and Chagas disease has been identified in 4000–9000 year-old human mum-
mies from Chile and Peru [4, 5]. Over time, the spread of Chagas disease in the 
Americas expanded from a wild and peridomiciliary cycle to a domestic cycle. This 
occurred through the domiciliation and domestication of triatomines, the primary 
vectors of T. cruzi. Thus, it was suggested that triatomines evolved from non-blood 
sucking insects and became mandatory hematophagous insects after undergoing 
morphological modifications [6, 7]. Likewise, trypanosomes also evolved and 
adapted to this new opportunity [6]. The evolution of T. cruzi was influenced by 
factors related to its dependence on the host and its environment and the reliance 
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The epidemiology of Trypanosoma cruzi in the wild is a particular and highly 
dynamic scenario that needs attention due to the increased alteration of the envi-
ronment caused by different factors including anthropogenic change. This chapter 
is an updated summary about the known reservoir hosts of T. cruzi identified in 
the countries that share the Amazon rainforest. This information will provide 
a better understanding of the ecology of T. cruzi in sylvatic environments. This 
chapter will also contribute to address the potential risks of T. cruzi infection in 
Amazonian communities who are in contact with wild animals through hunting 
and wild meat consumption.
Keywords: Trypanosoma cruzi, Chagas disease, Amazon, parasites, wild animals, 
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1. Introduction
The Amazon basin comprises multiple South American countries: Brazil 
(63.9%), Peru (15.6%), Bolivia (11.7%), Colombia (5.6%), Ecuador (2.1%), 
Venezuela (0.9%) and Guyana (0.2%). It covers over 1.3 billion hectares with 60% 
of total forest area (Figure 1) [1]. Population density in the Amazon basin is low and 
more than 70% live in urban areas. However, this region is in transition due to both 
climate change as well as anthropogenic activities such as the expansion of agricul-
ture, road paving and logging that lead to accelerated population growth [1, 2].
The environmental conditions of the Amazon basin are favorable for the trans-
mission of multiple vector-borne diseases. Well-known endemic diseases such as 
malaria and Leishmaniasis show the highest incidence in the Americas, and recent 
data shows the circulation of multiple arboviruses [3], with an increasing incidence 
of Dengue fever over time. Trypanosomatids exist in nature since millions of years 
ago, and Chagas disease has been identified in 4000–9000 year-old human mum-
mies from Chile and Peru [4, 5]. Over time, the spread of Chagas disease in the 
Americas expanded from a wild and peridomiciliary cycle to a domestic cycle. This 
occurred through the domiciliation and domestication of triatomines, the primary 
vectors of T. cruzi. Thus, it was suggested that triatomines evolved from non-blood 
sucking insects and became mandatory hematophagous insects after undergoing 
morphological modifications [6, 7]. Likewise, trypanosomes also evolved and 
adapted to this new opportunity [6]. The evolution of T. cruzi was influenced by 
factors related to its dependence on the host and its environment and the reliance 
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on vertebrates as a blood source. Trypanosoma cruzi can spread geographically by 
both triatomines flying into different areas and passive carriage in vertebrate hosts 
moving across broad areas [8].
The deforestation of the Amazon basin, 3.6 million hectares of forest lost per 
year between 2000 and 2010, has become an important factor in the domestication 
of triatomines due to the scarcity of blood sources among wildlife. Triatomines and 
other disease vectors have looked for new blood sources and reached areas closer 
to human dwellings. Social inequality and poor public health systems exacerbate 
the impact of these factors, especially in rural areas, and further contribute to the 
transmission of Chagas disease and the emergence of new pathogens.
2. Chagas disease transmission in the Amazon basin
Trypanosomiasis is an ancient enzootic parasitosis in nature, maintained by wild 
animals and infected vectors. In the wild, it is presumably transmitted primarily by 
the oral route through predation of infected vectors or mammals, or by contamination 
of animal nests or shelters with metacyclic forms of the parasite released in the feces 
of infected triatomines or from scent glands of marsupials i.e. Didelphis marsupialis 
(Figure 2) [9, 10]
Besides the wild enzooty, other scenarios for the transmission of T. cruzi in the 
Amazon have been proposed (Figure 2). For instance, antropozoonosis, through 
the accidental transmission of T. cruzi from infected vectors or wild animals to 
humans. This occurs commonly with the invasion of infected vectors and marsupi-
als in human dwellings or when humans invade the forest for different activities 
such as hunting, fishing, logging, tourism, etc. [11]. The invasion of vectors in 
human dwellings may occur during deforestation or when their blood sources such 
as wild mammals are scarce due to deforestation itself, over hunting or during 
Figure 1. 
The Amazon Basin location in South America. Source: FAO, 2015.
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the wet season. Thus, vectors fly from the trees at night attracted by the lights 
and invade the houses in search of blood meals [11, 12]. Nymphs and adults of 
triatomines infected with T. cruzi have been found on palm trees in backyards and 
inside the houses in Amazonian villages. Blood meals from birds, opossum, rodents, 
humans, dogs and horses have been found in the gut of triatomines captured in 
such settings [12].
Trypanosoma cruzi may have different transmission features between areas of 
different degrees of disturbance. One study carried out in the Brazilian Amazon 
found that areas with low and intermediate degree of disturbance had higher 
prevalence of wild mammals with parasitemia detected by hemoculture than in 
areas with greater environmental disturbance caused by human occupation and 
agriculture. Areas with intermediate degrees of disturbance also had the highest 
prevalence of positive domestic mammals detected by IFAT [13]. In contrast, 
seroprevalence did not differ between areas with difference disturbance levels; 
one explanation for this finding may be the difference on the ability of reservoirs 
to infect vectors between geographic areas despite the comparable exposure to 
the parasite.
Occupational transmission scenarios are well documented among palm tree 
gatherers, an economically important activity. Palm trees provide shelter for 
different wild mammals, amphibians and insects. Gatherers of the piassava palm 
(Leopoldinia piassaba) are reportedly bitten by wild triatomines during their camp-
ing months in the forest, possibly due to the lack of other blood sources such as 
wild mammals [14]. Palm gatherers are therefore at higher risk to become infected 
compared to individuals not involved in this activity [15].
Figure 2. 
T. cruzi transmission scenarios in the Amazon Basin. Photo credits: Dr. Pedro Mayor.
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The last scenario is the oral transmission of Chagas disease, often leading to 
outbreaks of acute Chagas disease (ACD). The Amazon basin is the region where 
most of such outbreaks have been reported. Actually, Carlos Chagas himself first 
described ACD in 1909 when a 2-year-old girl from Lassance, Minas Gerais pre-
sented with fever, hepatosplenomegaly and Romaña’s sign [8]. ACD outbreaks have 
occurred in both preserved and human disturbed areas [13], but with exposure of 
humans to the sylvatic cycle as a common factor. Most ACD outbreaks and cases 
are related to the consumption of food contaminated with trypomastigote forms 
as reported with the ingestion of fruits from palm trees such as acaí, bacaba, or the 
ingestion of wild meat [16]. In fact, ACD cases may have increased in the last decade 
[16]. It was reported an increase of notified suspected cases in Pará state in Brazil 
from 2010 to 2016, that may be related to the increase of production to acaí juice dur-
ing those years, but also related to the increase in its consumption since the majority 
of patients indicated a daily consumption of this juice [16]. Consistently with these 
findings, juice contaminated with T. cruzi was able to experimentally infect mice [17, 
18], despite the juice being previously frozen or refrigerated.
In Brazil, T. cruzi infection got more attention only after 1969 when ACD cases 
were reported in Belém, State of Pará [12]. However, sporadic human infections have 
been reported before this date in the Amazon basin. In a serological study by indirect 
inmunoflourescence test in a county of 15 villages in the Brazilian Amazon found 
0.83% (212/25, 451) of prevalence for T. cruzi infection. Children ≤ 10 years had 
positive serological results indicating recent transmission and acute infection [12]. In 
Peru, the first ACD case was reported in 1919 in the southeastern Amazonian depart-
ment of Madre de Dios. Only a few ACD cases have been reported since, although 
multiple cases have been reported in recent years in Amazonian regions such as 
Pasco and Loreto [19]. In Ecuador, Chagas disease was first diagnosed in 1929 in 
Guayas, a coastal province. The first human cases in the Amazon region of Ecuador 
were yet reported in 1991 in Napo and Sucumbíos provinces [20]. Some studies later 
demonstrated the exposure and active transmission of T. cruzi in more Amazonian 
provinces such as Orellana, Pastaza, Morona Santiago [20]. Similar to Brazil, ACD 
cases were also reported in children ranging from 1 to 5 years old in the Ecuadorian 
Amazon region [21]. In Colombia, the T. cruzi haplotype Ia has been isolated among 
ACD cases from the Amazonian departments of Caquetá and Putumayo, including 
children and servicemen who were in contact with the forest [22].
Indigenous communities in the Amazon basin are also affected by T. cruzi 
infection. During 2006 to 2010, six ACD cases were reported among children from 
the Aguaruna, Huambisa and Kandoshi communities in the Peruvian Amazon 
basin. ACD was attributed to either the biting of infected triatomines found inside 
the dwellings or oral transmission by drinking “masato” (a fermented beverage 
made with yuca) or “chapo” (a ripe banana beverage) since no traveling outside 
the community or blood transfusion was recorded [19]. ACD cases in indigenous 
communities in Ecuador Amazon region have been reported since 1987; a seroepi-
demiological study found a 6.0% (61/1011) of positive individuals from 15 of the 
18 studied communities. Likewise, the prevalence increased with age, individuals 
older than 50 showed 18.8% of seroprevalence [21].
3. Trypanosoma cruzi reservoir hosts in the wild
The first T. cruzi infection in Amazonian wildlife was reported in 1924 among 
squirrel monkeys (Saimiri sciureus) [23]. In mammalian hosts, T. cruzi infection 
could develop depending on factors such as the host health status, the transmis-
sion route, the parasite population and co-infection with other parasites. However, 
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reservoir hosts should support the maintenance and dispersion of the parasite 
in nature [9], and therefore be capable of infecting vectors. Vectors can become 
infected depending on the parasitemia in the host’s blood, which varies among host 
species and individuals [9]. This is corroborated by previous studies that showed dif-
ferences in T. cruzi infection rates between species of the same genus. For instance, 
experimental T. cruzi infection in the rodent Thrychomys fosteri was more severe with 
high and long-lasting parasitemia compared to Thrychomys laurentius [24].
Trypanosoma cruzi can infect different mammal species from all forest strata and 
canopy levels. Table 1 lists wild animal species reported positive to T. cruzi infection 
in the Amazon basin. A higher proportion of positive blood culture and serology 
by immunofluorescence antibody test (IFAT) was observed in mammals from the 
Amazon compared to specimens from other biomes (Atlantic forest, Caatinga, 
Cerrado, Pampa and Pantanal) [9]. This study also suggested that 8% of positive 
animals would be sufficient to maintain the T. cruzi cycle in any biome. Different 
mammalian orders seem to participate in the transmission cycle of T. cruzi, but 
Primates, Didelphimorphia, Chiroptera and Carnivora apparently are the primary 
taxa due to their high parasitemias and Discrete Typing Units (DTUs) diversity [9].
TcI, TcIII and TcIV are the reported DTUs circulating in the Amazon basin [25]. 
A very low prevalence of TcIII and TcIV (0.8%) infection was found in 714 T. cruzi 
isolates from five different biomes in Brazil. TcIV was more prevalent than TcIII, and 
no specific association between genotypes and animal species or geographical distri-
bution was suggested [26]. However, these findings may be biased by the methodol-
ogy used in this study or the temporal distribution of these DTUs in nature.
The main taxa for the transmission of T. cruzi in the Amazon basin are reported 
below:
3.1 Didelphimorphia
This order includes the hosts most frequently infected by T. cruzi in all biomes 
of Brazil, presenting high rates of positive hemoculture [9, 26]. Didelphimorphia 
species in the Amazon basin seems to be predominantly infected by TcIII and/or 
TcIV across different biomes. This order includes the most frequent hosts infected 
by TcIII, TcIV or mixed trypanosome/genotypes compared to other mammalian 
taxa [26].
It is suggested that marsupials could act as generalist species due to the diver-
sity of Trypanosoma spp. found simultaneously infecting a single host [9]. For 
instance, a mixed, triple infection with Trypanosoma cascavelli (reported in reptiles), 
Trypanosoma dionisii (reported in bats) and Trypanosoma sp. was reported in 
Monodelphis americana [27]. Other species such as Philander opossum show a high 
prevalence of T. cruzi positive hemoculture implying its ability to infect vectors. 
Philander opossum was also the most abundant species present across different areas 
of the Amazon basin regardless of the season and the degree of land disturbance [13].
Didelphis marsupialis is the specie from this order most commonly reported 
with T. cruzi infection. However, it has been suggested that its presence in a specific 
area may not be directly related to the endemicity of T. cruzi. Low prevalence of 
the parasite was found in an area despite their great abundance of this mammal, 
and it may not be a critical specie for the maintenance of the T. cruzi sylvatic cycle 
in the Amazon basin [13]. Trypanosoma cruzi infection of D. marsupialis could 
take place orally by ingestion of small mammals or triatomines. However, host-to-
host infection could also occur through direct contact with infective metacyclic 
trypomastigotes released by the scent glands of infected marsupials. Scent glands 
have demonstrated being suitable for epimastigotes and their differentiation into 
infective metacyclic forms [10]. Didelphis can also adapt to peridomestic areas, and 
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Order/Genus Specie Methods References
H I P DTU
Artiodactyla




x Zymodeme 1 [46]
Dasypus Dasypus 
novemcinctus
x x TcIV [9, 28, 46, 47]
Tamandua Tamandua 
tetradactyla





Caluromys sp. x x x TcI [9, 46, 47]
Didelphis Didelphis 
marsupialis
x x x TcI, TcII, TcI+ T. 
rangeli, TcI+ TcII, 
TcI+ TcIII




Didelphis sp. x [9]
Gracilinanus Gracilinanus sp. x x x TcI [9, 49]
Marmosa Marmosa 
murina
x x x TcI [9, 13]
Marmosa cinerea x [47]




Marmosops sp. x x x TcI [9]
Metachirus Metachirus 
nudicaudatus
x Zymodeme 1 [46]
Micoureus Micoureus 
demerarae






x Zymodeme 3 [46]
Monodelphis sp. x x x TcI, TcI + TcIV [9]
Philander Philander 
opossum
x x x TcI, TcI+ TcII [9, 13, 46, 47, 49]







x x x TcI+ TcIV [9]
Alouatta caraya x x x TcI+ TcIV [9]
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Order/Genus Specie Methods References







Cebus Cebus albifrons x [33]




Saguinus Saguinus midas 
niger
x Zymodeme 1 [46]




Saimiri sciureus x x [30, 33]
















Cuniculus Cuniculus paca x x [28, 47]
Akodon Akodon 
lindberghi
x x TcI [9]
Cerradomys Cerradomys sp. x [9]
Coendou Coendou 
prehensilis
x x x TcI + T.rangeli [9]




Dasyprocta sp. x x [28, 47]
Echymys Echymys 
chrysurus
x Zymodeme 1 [46]
Rodentia
Holochilus Holochilus sp. x [9]
Hylaeamys Hylaeamys 
megacephalus




Oryzomys Oryzomys capito x [47]
Oryzomys sp. x [9]
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Molossus Molossus major [52]
Molossus ater [52]
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T. cruzi-infected specimens have been found in backyards of houses from different 
villages in the Brazilian Amazon [12].
Histopathological lesions observed in infected marsupials resemble those 
presented by Chagas disease patients. Myocarditis with mononuclear infiltrates, 
cell lysis and inflammatory infiltrates in skeletal muscles, esophagus and small and 
large intestines are other lesions found in natural infection [12].
3.2 Carnivores
Carnivores are likely to be infected by the oral route, and those whose diet 
includes insects or flesh present the highest infection rates [9]. The most reported 
carnivore infected with T. cruzi is the coati (Nasua nasua) [28]. Coatis are terrestrial 
but construct their nests in the high canopy level of large trees, which then serve as 
habitat for triatomines and other insects. Two-thirds of 34 Triatoma and Rhodnius 
triatomines found in 24 coati nests in the Pantanal state in Brazil were positive to T. 
cruzi. The 62.5% (8/8) of 8 nests infested with triatomines were T. cruzi-positive. 
The triatomines blood meal sources identified by precipitation of the stomach 
contents included coati and also rodents, birds and marsupials. Moreover, rodents 
and birds were observed visiting these nests [29].
3.3 Non-human primates
Different species of trypanosomatids have been reported in wild non-human 
primates from the Amazon. The T. cruzi prevalence rates reported in the Brazilian 
Order/Genus Specie Methods References




Noctilio Noctilio labialis [52]
Phyllostomus Phyllostomus 
discolor
x x TcI [9]
Phyllostomus 
hastatus












x x TcI [9]
Trachops Trachops 
cirrhosus
x x TcI [9, 35]
Uroderma Uroderma 
bilobatum
x x TcI [9]
Vampyressa Vampyressa sp. x x TcI [9]
H = hemoculture, I = IFAT, P=PCR.
Table 1. 
Free-ranging wild animal’s species reported positive to Trypanosoma cruzi infection in the Amazon Basin.
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triatomines found in 24 coati nests in the Pantanal state in Brazil were positive to T. 
cruzi. The 62.5% (8/8) of 8 nests infested with triatomines were T. cruzi-positive. 
The triatomines blood meal sources identified by precipitation of the stomach 
contents included coati and also rodents, birds and marsupials. Moreover, rodents 
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Different species of trypanosomatids have been reported in wild non-human 
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Amazon range from 10.3% (17/165) using parasitological methods in captured 
free-ranging non-human primates to 45.5% (45/99) by IFAT in captive and semi-
captive primates [30, 31]. However, the T. cruzi prevalence in wild non-human 
primates of the Amazon basin seems to be lower than the prevalence of T. rangeli, 
with the latter showing lasting parasitemias [32]. Several studies corroborate this 
observation, such as 35.2% versus 10.3% in 165 wild squirrel monkeys captured in 
the Brazilian Amazon [30], and 75.0% versus 10.4% cultures among 96 tamarins 
captured in the Amazonas state in Brazil [32]. In a study conducted in the Peruvian 
Amazon, free-ranging non-human primates had a high prevalence of trypanoso-
matids (64.3% vs. 27.9%) and T. cruzi (8.7% vs. 3.3%) by PCR, compared to captive 
primates, suggesting that parasite transmission occurs more actively in the sylvatic 
cycle. Pitheciidae had the highest trypanosomatid prevalence (20/22, 90.9%) and 
Cebidae had the highest T. cruzi prevalence (15/117, 12.8%) [33]. The difference in 
the prevalence is not well understood but may be related to the route of infection. 
While T. cruzi might be transmitted through either contact with infective forms in 
the triatomine feces or orally, T. rangeli may be primarily transmitted during biting 
by infected triatomines [32].
There is scarce evidence regarding the physiopathology of T. cruzi natural 
infection in free-ranging non-human primates. Electrocardiography abnormali-
ties were found in a few T. cruzi-infected tamarins aged 7 months to 4 years old 
from an Atlantic Forest reserve in Brazil with infection time spanning 6 months 
to almost 5 years. It was estimated that infected individuals were 18 times more 
likely to show detectable electrocardiogram (ECG) abnormalities than those 
uninfected. Likewise, infected non-human primates were prone to have higher 
levels of cardiac injury markers such as MBi, a cardiac lesion marker and total pro-
tein in serum. Although these findings did not suggest a general health problem, 
left ventricular hypertrophy was present in some of the infected tamarins similar 
to the chronic form of Chagas disease in humans [34]. These studies probably 
underestimate the clinical burden since non-human primates with severe cardiac 
lesions probably do not survive in the wild and are therefore not included. Despite 
this limitation, it is important to consider the impact of the physiopathology of 
natural infection, particularly for at risk species. For instance, T. cruzi infec-
tion has been reported in Saguinus bicolor, a critical endangered monkey in the 
Amazon basin [32].
3.4 Quiroptera
It was suggested that bats could be bio-accumulator hosts and dispersers 
of trypanosomatids because of their ability to fly and the great diversity of 
Trypanosoma species found in bats specially compared to other animal taxon [9]. 
Out of 1219 Brazilian bats from 76 genera and 94 species, 14% were positive to 
Trypanosoma sp. by hemoculture and 5% of them were T. cruzi positive in single 
or mixed infections. Although bat is able to be infected with other DTUs most 
bats were infected with TcI, and TcII was not detected. The highest infection 
rate was found in the Amazon basin compared to other biomes, suggesting that 
unaltered areas nurture a high parasite diversity [9]. In the Peruvian Amazon, a 
4.1% T. cruzi infection prevalence in bats was reported, in both hematophagous 
(2.7%; 2/73) and non-hematophagous species (6.2%; 3/48) [35]. Interestingly, 
T. cruzi DNA was detected in the salivary glands of Diaemus youngi, an hema-
tophagous bat [35]. This highlights the importance of studying the transmis-
sion mechanisms of T. cruzi in bats and their public health implications for the 
Amazon basin.
47
Amazonian Reservoir Hosts of Trypanosoma cruzi
DOI: http://dx.doi.org/10.5772/intechopen.86158
4. Wild meat consumption as a potential risk of oral transmission
Trypanosoma cruzi hosts encompass more than 100 wild and domestic mam-
malian species, which in turn belong to eight different taxonomic orders distributed 
in all phytogeography regions of the Neotropics [36]. Since subsistence hunting of 
wild mammals for consumption is one of the main sources of animal protein in the 
Amazon Basin, wild meat constitute a potential source for human infection.
In the Amazon region, wild meat represents an important component of house-
hold food security, income and a key social and cultural driver. Wild meat is still 
a key element in Amazon peoples’ diet and accounts for a high percentage of daily 
protein intake. It is estimated that the wild meat consumption rate in rural settle-
ments of the Amazon Basin is 172 g per person per day [37]. A study found that 39% 
of households in Latin America harvested and consumed wild meat, and depen-
dence was highest among the poorest households [38]. Estimates of the annual wild 
meat harvest in the Northern Peruvian Amazon are 113,000 animals (1680 tons), 
and 89,224 tons of meat per year in the Brazilian Amazon [39, 40]. Furthermore, 
hunting pressure has increased in recent years due to various causes, such as the 
growth of human populations, access to remaining forests, commercialization of 
wild meat, increasing use of efficient modern hunting techniques and erosion of 
traditional hunting institutions due to rapid cultural changes [41].
Notwithstanding its positive nutritional contributions, some serious health 
concerns may be associated with wild meat consumption in the Amazon basin. 
Emerging infectious diseases worldwide are increasing over time and are dominated 
by zoonoses (60%), of which the majority (72%) originates in wildlife [42]. A study 
conducted in the Peruvian Amazon estimated an annually consumption of 45 ani-
mals infected with T. cruzi, translating to 0.75 infected animals typically consumed 
by a large extended family, suggesting recurrent infection opportunities [28].
A few studies from Argentina and Brazil report Chagas disease transmission 
through consumption of raw, poorly cooked meat, blood or contact with carcasses 
of wildlife among children [43]. However, some of these studies did not rule out the 
possibility of vectorial transmission and others have not found proof of exposure to 
infected triatomines. What it is certainly known is that frequently hunted animals 
in the Amazon have been reported as T. cruzi reservoirs [28, 33], and carnivores 
might tend to have higher infection rates than non-carnivores suggesting accumu-
lation through wild meat intake. Thus, the consumption of wild meat may be an 
important risk for human T. cruzi infection in the Amazon Basin, which may hap-
pen particularly during cleaning of wild meat or contamination of cooking utensils 
[13]. Other associated risk factors in rural Amazon societies are poor hygienic 
conditions, unavailability of clean water, inadequate medical care and insufficient 
knowledge about local diseases [44]. Nevertheless, further studies addressing the 
relationship between wild meat consumption and Chagas disease are required to 
better understand the risk of infection in Amazonian communities. Prompt diag-
nosis, notification of cases and epidemiological studies to assess the risk factors that 
trigger ACD outbreaks are greatly needed.
5.  Domestic animals as reservoir hosts of Trypanosoma cruzi in the 
Amazon basin
Domestic animals should be included in epidemiological studies since they 
are good sentinels of disease transmission in a geographic area. In the Amazon, 
several studies report T. cruzi-positive domestic animals such as pigs and dogs 
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the Brazilian Amazon [30], and 75.0% versus 10.4% cultures among 96 tamarins 
captured in the Amazonas state in Brazil [32]. In a study conducted in the Peruvian 
Amazon, free-ranging non-human primates had a high prevalence of trypanoso-
matids (64.3% vs. 27.9%) and T. cruzi (8.7% vs. 3.3%) by PCR, compared to captive 
primates, suggesting that parasite transmission occurs more actively in the sylvatic 
cycle. Pitheciidae had the highest trypanosomatid prevalence (20/22, 90.9%) and 
Cebidae had the highest T. cruzi prevalence (15/117, 12.8%) [33]. The difference in 
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While T. cruzi might be transmitted through either contact with infective forms in 
the triatomine feces or orally, T. rangeli may be primarily transmitted during biting 
by infected triatomines [32].
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ties were found in a few T. cruzi-infected tamarins aged 7 months to 4 years old 
from an Atlantic Forest reserve in Brazil with infection time spanning 6 months 
to almost 5 years. It was estimated that infected individuals were 18 times more 
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uninfected. Likewise, infected non-human primates were prone to have higher 
levels of cardiac injury markers such as MBi, a cardiac lesion marker and total pro-
tein in serum. Although these findings did not suggest a general health problem, 
left ventricular hypertrophy was present in some of the infected tamarins similar 
to the chronic form of Chagas disease in humans [34]. These studies probably 
underestimate the clinical burden since non-human primates with severe cardiac 
lesions probably do not survive in the wild and are therefore not included. Despite 
this limitation, it is important to consider the impact of the physiopathology of 
natural infection, particularly for at risk species. For instance, T. cruzi infec-
tion has been reported in Saguinus bicolor, a critical endangered monkey in the 
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Trypanosoma sp. by hemoculture and 5% of them were T. cruzi positive in single 
or mixed infections. Although bat is able to be infected with other DTUs most 
bats were infected with TcI, and TcII was not detected. The highest infection 
rate was found in the Amazon basin compared to other biomes, suggesting that 
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Domestic animals should be included in epidemiological studies since they 
are good sentinels of disease transmission in a geographic area. In the Amazon, 
several studies report T. cruzi-positive domestic animals such as pigs and dogs 
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[45]. TcI is the primary DTU reported infecting dogs in the Brazilian Amazon [13]. 
Although a higher prevalence of T. cruzi was found in pigs compared to dogs in 
some anthropogenic disturbed areas, dogs present longer parasitemias. Extended 
parasitemia suggests that dogs are better able to infect vectors, thereby acting 
as T. cruzi reservoirs. These domestic animals may become infected by different 
routes, mainly the biting of the infected triatomines since bugs and dogs converge 
near human dwellings [13]. Other routes of transmission would be the ingestion 
of the infected bugs or food contaminated with triatomine feces and predation of 
infected small mammals.
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Role of Proteomics in the Study of 
Trypanosoma cruzi Biology
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Abstract
Proteomics is the science that studies the proteome, which corresponds to the 
global expression of proteins at a given time under determined conditions. In the 
last 20 years, proteomics has emerged as a powerful tool that has allowed the study 
of proteins that are expressed in the cell under normal or altered conditions as well 
as post-translational modifications, such as phosphorylation, glycosidation, acety-
lation, and methylation, among others. In this chapter, we present the main contri-
butions of proteomics to the knowledge of Trypanosoma cruzi biology. Proteomes of 
all T. cruzi life cycle stages, secretomes/exoproteomes, post-translational modifica-
tions such as phosphorylation or acetylation and immunomes, interactomes, and 
glycomes are described. The role of proteomics in the identification of new chemo-
therapeutic targets and potential vaccine candidates will also be discussed.
Keywords: Trypanosoma cruzi, proteomics, subcellular proteomics,  
post-translational modifications, drug resistance, virulence, secretome/exoproteome
1. Introduction
The flagellate protozoan Trypanosoma cruzi is the causative agent of Chagas 
disease, an illness that affects 6–8 million people worldwide [1]. The parasite has a 
complex life cycle, which starts when the triatomines defecate in the vicinity of the 
bite, and in the infective stage, the metacyclic trypomastigote (MT) is carried into 
the wound by scraping and then penetrates across the skin and invades resident 
cells. Once in the cytosol, MTs transform into amastigotes. This proliferative stage 
multiply in the cytosol and, after various rounds of binary fission, transform into 
trypomastigotes, which are released from the cell and disseminated by the blood-
stream invading different organs, spreading the parasitic infection [2].
From a biological and biochemical point of view, T. cruzi is a genetically hetero-
geneous species with a wide variety of strains distributed in different vectors and 
with a great diversity of mammalian hosts. This high genetic variability is related to 
the variability of virulence and clinical manifestations among strains [3]. Currently, 
T. cruzi is classified into seven discrete typing units (DTUs), TcI to TcVI [4], and 
more recently, a new one named Tcbat has been included [5].
2. The proteomics and mass spectrometry
Proteomics is a discipline focused on understanding protein expression in bio-
logical samples and the possible comprehension of the complex physiological and 
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the variability of virulence and clinical manifestations among strains [3]. Currently, 
T. cruzi is classified into seven discrete typing units (DTUs), TcI to TcVI [4], and 
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Proteomics is a discipline focused on understanding protein expression in bio-
logical samples and the possible comprehension of the complex physiological and 
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pathological events using different methods to identify and characterize proteins. 
Thus, proteomics is the study of the proteome, which corresponds to the global pat-
terns of proteins that determine cell expression under a determinate condition [6].
From 1997, when the first paper on the proteome was published [7], proteomics 
studies have become an invaluable tool not only for the study of the global cell 
expression of proteins (the proteome) but also for the dissection of specific 
processes in cell biology and biochemistry, such as the study of proteins that are 
expressed in organelles and post-translational modifications [8, 9]. Moreover, by 
combining proteomics analysis and bioinformatics tools, researchers can report 
much broader projections, including the identification of new chemotherapeutic 
targets, new vaccine candidates, new tumor markers with prognostic or diagnostic 
value [10], and the study of secretomes and immunonomes, among others [11]. 
Thus, a current PubMed search with the keyword “proteomic” delivers 96,688 
published papers.
Initially, Edman sequencing was used, and this method was replaced by 
mass spectrometry (MS). MS allows the separation of different isotopes, which 
is possible due to the use of soft ionization procedures, such as matrix-assisted 
laser desorption/ionization (MALDI) [12] and the electrospray ionization 
method (ESI) [13]. In both cases, the analytes (peptides) are ionized from the solid 
phase (MALDI) or liquid phase (ESI) into the gas phase. Then, liquid chromatog-
raphy (LC) systems can be directly interfaced to mass spectrophotometers. LC 
tandem mass spectrometry (LC-MS/MS) has been applied to proteomics to separate 
peptides, and MS/MS records the intact peptides (full MS) before one precursor 
ion is selected and fragmented. This fragmentation is always induced in a collision 
cell by nitrogen or argon. Then, fragments are recorded in an MS/MS spectrum, 
and this fragmentation pattern reveals a specific mass for each amino acid from the 
peptide [6]. In summary, the amino acids present in the peptide can be determined, 
as well as the peptide sequence, and finally, the protein containing this peptide is 
identified.
In kinetoplastids like T. cruzi, all protein-encoding genes are organized in large 
polycistronic transcription units that produce polycistronic precursor RNAs that are 
then processed to monocistronic mRNAs by the mechanism of trans-splicing [14]. 
Then, translation of specific mRNAs and/or the stability control regulate the gene 
expression [15]. Furthermore, post-translational modifications perform a key func-
tion in order to modulate the T. cruzi protein function. For these reasons, in recent 
years, proteomics has had a crucial role in evaluating protein expression levels in 
different T. cruzi stages or following specific treatments with drugs, inhibitors, or 
natural products, and thus, proteomics studies have been transformed in an invalu-
able tool to reveal adaptive changes in this protozoan [16].
3. The T. cruzi proteome
A proteomic analysis of the human pathogen T. cruzi using two-dimensional 
electrophoresis (2-DE) was initially reported by Paba et al. [17]. A T. cruzi com-
parative proteome analysis of different stages was performed. This study showed 
that few proteins displayed significant differential expression among the three 
developmental T. cruzi stages. Using matrix-assisted laser desorption/ionization 
time-of-flight (MALDI-TOF) mass spectrometry peptide mass fingerprinting, the 
researchers identified 26 proteins. Among these, 19 different proteins were identi-
fied, mainly heat shock proteins (HSP; chaperones, HSP 60, HSP 70, and HSP 90), 
elongation factors, glycolytic pathway enzymes (enolase, pyruvate kinase, and 
2,3 bisphosphoglycerate mutase), and structural proteins (KMP 11, tubulin, and 
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paraflagellar rod components). In addition, the same researchers reported a com-
parative proteome analysis of T. cruzi developmental stages. In this study, isotope-
coded affinity tag technology (ICAT) associated with liquid chromatography-mass 
spectrometry peptide sequencing (LC-MS/MS) was used. High-confidence 
sequence information and expression levels for 41 T. cruzi polypeptides, includ-
ing metabolic enzymes, paraflagellar rod components, tubulins, and heat shock 
proteins, were reported. Twenty-nine proteins displayed similar expression levels 
in trypomastigotes as well as amastigotes, nine proteins displayed higher levels in 
trypomastigotes than amastigotes, and three proteins showed higher expression in 
amastigotes than trypomastigotes [18].
In addition, Parodi-Talice et al. [16] described a standardized and reproducible 
protocol for analyzing T. cruzi proteins by 2-DE, which generated protein reference 
maps of this parasite. In this report, tubulins, HSP, and prostaglandin F2α synthase 
were three of the most abundant proteins reported in T. cruzi.
A proteomic analysis of all T. cruzi stages was performed. Peptidic sequences 
from 2784 proteins in 1168 protein groups from the annotated T. cruzi genome were 
reported in all parasite stages. Protein products were identified from >1000 genes 
annotated as “hypothetical” in the parasite genome, including integrants of the 
mucin-associated surface proteins (MASP). The four parasite stages appear to use 
distinct energy sources, including histidine for stages present in the insect vectors 
and fatty acids by intracellular amastigotes [19]. In contrast, a study that identified 
basic proteins reported different enzymes related to amino acid metabolism in 
epimastigotes, whereas trans-sialidases and protein paraflagellar rods were found 
specifically in trypomastigotes [20]. Another proteomics study of T. cruzi trypo-
mastigotes identified 1448 nonredundant proteins, 14% of which corresponded 
to surface proteins, and the majority were anchored via glycophosphatidylinositol 
(GPI) and related to parasite virulence [21]. According to these authors, the high 
diversity of expressed proteins on the trypomastigote surface could have implica-
tions for both invasion and immune evasion strategies. A comparison of the cell 
surface proteomes from different T. cruzi stages revealed that some enzymes 
are stage-specific, although the majority were present in more than one stage. 
Bioinformatics analysis showed that most of the identified proteins were derived 
from the membrane and were involved in cell invasion, adhesion, cell signaling, 
and host immune response modulation [22]. However, the biological role of these 
proteins was not experimentally demonstrated.
The blood trypomastigote (BT) proteome has also been described [23]. In a 
shotgun analysis, 17,394 peptides were reported, corresponding to 7514 proteins of 
which 5901 corresponded to T. cruzi. Trans-sialidases (TS), bioenergetics-related 
enzymes, chaperones, and cytoskeletal proteins were found among the top scoring 
proteins. Gene ontology (GO) studies showed that all T. cruzi compartments were 
evaluated and the most part of proteins were engaged in metabolic processes and/or 
presented catalytic functions. A comparative study among BT and tissue-culture-
derived trypomastigote (TCDT) or metacyclic trypomastigote (MT) proteomic 
profiles identified 2202 proteins uniquely reported in the BTs. These unique pro-
teins were related to (a) surface proteins, (b) the nonclassical secretion pathway, 
(c) cytoskeletal dynamics, (d) the cell cycle and transcription, (e) proteolysis, 
(f) redox metabolism, (g) biosynthetic pathways, (h) bioenergetics, (i) protein 
folding, (j) cell signaling, (k) vesicular traffic, (l) DNA repair, and (m) cell death 
[23]. The Brunoro paper identified many proteins belonging to different metabolic 
parasite pathways and functions that were exclusive to BTs and provided a valuable 
data set for a better biological understanding of this parasite stage.
The T. cruzi cell surface is covered by a dense layer of GPI-anchored molecules. 
These molecules are involved in a variety of interactions between the parasite and 
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pathological events using different methods to identify and characterize proteins. 
Thus, proteomics is the study of the proteome, which corresponds to the global pat-
terns of proteins that determine cell expression under a determinate condition [6].
From 1997, when the first paper on the proteome was published [7], proteomics 
studies have become an invaluable tool not only for the study of the global cell 
expression of proteins (the proteome) but also for the dissection of specific 
processes in cell biology and biochemistry, such as the study of proteins that are 
expressed in organelles and post-translational modifications [8, 9]. Moreover, by 
combining proteomics analysis and bioinformatics tools, researchers can report 
much broader projections, including the identification of new chemotherapeutic 
targets, new vaccine candidates, new tumor markers with prognostic or diagnostic 
value [10], and the study of secretomes and immunonomes, among others [11]. 
Thus, a current PubMed search with the keyword “proteomic” delivers 96,688 
published papers.
Initially, Edman sequencing was used, and this method was replaced by 
mass spectrometry (MS). MS allows the separation of different isotopes, which 
is possible due to the use of soft ionization procedures, such as matrix-assisted 
laser desorption/ionization (MALDI) [12] and the electrospray ionization 
method (ESI) [13]. In both cases, the analytes (peptides) are ionized from the solid 
phase (MALDI) or liquid phase (ESI) into the gas phase. Then, liquid chromatog-
raphy (LC) systems can be directly interfaced to mass spectrophotometers. LC 
tandem mass spectrometry (LC-MS/MS) has been applied to proteomics to separate 
peptides, and MS/MS records the intact peptides (full MS) before one precursor 
ion is selected and fragmented. This fragmentation is always induced in a collision 
cell by nitrogen or argon. Then, fragments are recorded in an MS/MS spectrum, 
and this fragmentation pattern reveals a specific mass for each amino acid from the 
peptide [6]. In summary, the amino acids present in the peptide can be determined, 
as well as the peptide sequence, and finally, the protein containing this peptide is 
identified.
In kinetoplastids like T. cruzi, all protein-encoding genes are organized in large 
polycistronic transcription units that produce polycistronic precursor RNAs that are 
then processed to monocistronic mRNAs by the mechanism of trans-splicing [14]. 
Then, translation of specific mRNAs and/or the stability control regulate the gene 
expression [15]. Furthermore, post-translational modifications perform a key func-
tion in order to modulate the T. cruzi protein function. For these reasons, in recent 
years, proteomics has had a crucial role in evaluating protein expression levels in 
different T. cruzi stages or following specific treatments with drugs, inhibitors, or 
natural products, and thus, proteomics studies have been transformed in an invalu-
able tool to reveal adaptive changes in this protozoan [16].
3. The T. cruzi proteome
A proteomic analysis of the human pathogen T. cruzi using two-dimensional 
electrophoresis (2-DE) was initially reported by Paba et al. [17]. A T. cruzi com-
parative proteome analysis of different stages was performed. This study showed 
that few proteins displayed significant differential expression among the three 
developmental T. cruzi stages. Using matrix-assisted laser desorption/ionization 
time-of-flight (MALDI-TOF) mass spectrometry peptide mass fingerprinting, the 
researchers identified 26 proteins. Among these, 19 different proteins were identi-
fied, mainly heat shock proteins (HSP; chaperones, HSP 60, HSP 70, and HSP 90), 
elongation factors, glycolytic pathway enzymes (enolase, pyruvate kinase, and 
2,3 bisphosphoglycerate mutase), and structural proteins (KMP 11, tubulin, and 
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paraflagellar rod components). In addition, the same researchers reported a com-
parative proteome analysis of T. cruzi developmental stages. In this study, isotope-
coded affinity tag technology (ICAT) associated with liquid chromatography-mass 
spectrometry peptide sequencing (LC-MS/MS) was used. High-confidence 
sequence information and expression levels for 41 T. cruzi polypeptides, includ-
ing metabolic enzymes, paraflagellar rod components, tubulins, and heat shock 
proteins, were reported. Twenty-nine proteins displayed similar expression levels 
in trypomastigotes as well as amastigotes, nine proteins displayed higher levels in 
trypomastigotes than amastigotes, and three proteins showed higher expression in 
amastigotes than trypomastigotes [18].
In addition, Parodi-Talice et al. [16] described a standardized and reproducible 
protocol for analyzing T. cruzi proteins by 2-DE, which generated protein reference 
maps of this parasite. In this report, tubulins, HSP, and prostaglandin F2α synthase 
were three of the most abundant proteins reported in T. cruzi.
A proteomic analysis of all T. cruzi stages was performed. Peptidic sequences 
from 2784 proteins in 1168 protein groups from the annotated T. cruzi genome were 
reported in all parasite stages. Protein products were identified from >1000 genes 
annotated as “hypothetical” in the parasite genome, including integrants of the 
mucin-associated surface proteins (MASP). The four parasite stages appear to use 
distinct energy sources, including histidine for stages present in the insect vectors 
and fatty acids by intracellular amastigotes [19]. In contrast, a study that identified 
basic proteins reported different enzymes related to amino acid metabolism in 
epimastigotes, whereas trans-sialidases and protein paraflagellar rods were found 
specifically in trypomastigotes [20]. Another proteomics study of T. cruzi trypo-
mastigotes identified 1448 nonredundant proteins, 14% of which corresponded 
to surface proteins, and the majority were anchored via glycophosphatidylinositol 
(GPI) and related to parasite virulence [21]. According to these authors, the high 
diversity of expressed proteins on the trypomastigote surface could have implica-
tions for both invasion and immune evasion strategies. A comparison of the cell 
surface proteomes from different T. cruzi stages revealed that some enzymes 
are stage-specific, although the majority were present in more than one stage. 
Bioinformatics analysis showed that most of the identified proteins were derived 
from the membrane and were involved in cell invasion, adhesion, cell signaling, 
and host immune response modulation [22]. However, the biological role of these 
proteins was not experimentally demonstrated.
The blood trypomastigote (BT) proteome has also been described [23]. In a 
shotgun analysis, 17,394 peptides were reported, corresponding to 7514 proteins of 
which 5901 corresponded to T. cruzi. Trans-sialidases (TS), bioenergetics-related 
enzymes, chaperones, and cytoskeletal proteins were found among the top scoring 
proteins. Gene ontology (GO) studies showed that all T. cruzi compartments were 
evaluated and the most part of proteins were engaged in metabolic processes and/or 
presented catalytic functions. A comparative study among BT and tissue-culture-
derived trypomastigote (TCDT) or metacyclic trypomastigote (MT) proteomic 
profiles identified 2202 proteins uniquely reported in the BTs. These unique pro-
teins were related to (a) surface proteins, (b) the nonclassical secretion pathway, 
(c) cytoskeletal dynamics, (d) the cell cycle and transcription, (e) proteolysis, 
(f) redox metabolism, (g) biosynthetic pathways, (h) bioenergetics, (i) protein 
folding, (j) cell signaling, (k) vesicular traffic, (l) DNA repair, and (m) cell death 
[23]. The Brunoro paper identified many proteins belonging to different metabolic 
parasite pathways and functions that were exclusive to BTs and provided a valuable 
data set for a better biological understanding of this parasite stage.
The T. cruzi cell surface is covered by a dense layer of GPI-anchored molecules. 
These molecules are involved in a variety of interactions between the parasite and 
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its vertebrate and invertebrate hosts. GPI-anchored rich fractions and other T. cruzi 
membrane proteins were obtained from epimastigotes (EPIs) and MTs and then 
submitted to two-dimensional liquid chromatography coupled to tandem mass 
spectrometry (2D-LC-MS/MS). A total of 98 MT proteins and 280 EPI proteins 
were identified. Of those, approximately 65% (n = 245) had predicted lipid post-
translational modification sites (i.e., GPI-anchor, myristoylation, or prenylation), 
signal-anchor sequences, or transmembrane domains that could explain their 
solubility in detergent solution. This report showed that MTs, but not EPIs, express 
a large repertoire of surface glycoproteins, such as GP90 and GP82, which are 
involved in host cell adhesion and invasion. Taken together, these results showed 
that T. cruzi displays stage-specific protein profiles that are related to the biology of 
each T. cruzi stage [24].
A map of soluble proteins from epimastigotes of T. cruzi CL Brener was generated 
using 2-DE combined with MS. The analysis showed that several proteins, such as 
tubulin and heat shock proteins, were found in multiple isoforms. The enzyme argi-
nine kinase was also found. This enzyme is absent in mammalian cells and, accord-
ing to the authors, could represent a potential new chemotherapeutic target [25].
Using conditions optimized for the 6–11 pH range, researchers compared the 
proteomes of TCDTs and extracellular amastigote-like parasites by MALDI-TOF/
TOF. The alkaline 2-DE gels from TCDTs and extracellular amastigotes showed that 
proteins with a pI over 7.0 were very well depicted (= 65% of proteins detected). 
Furthermore, the differences in protein expression among the human-hosted 
T. cruzi stages were in agreement with former proteomics reports and were related 
to the biological properties of each parasite stage [26].
4. The T. cruzi secretome/exoproteome
Adhesion and invasion are the first stages of interaction between an obligate 
intracellular pathogen and its host cell. This process involves cell surface molecules 
and secreted molecules. Then, the molecules that are released from pathogens may 
play a critical role during the establishment of infection, especially in immunomod-
ulation or immune evasion, as well as in migration across host tissues, cell adhesion, 
cell-cell communication, differentiation, proliferation, and morphogenesis [27, 28].
The term secretome was first introduced in a bioinformatics survey of proteins 
secreted by Bacillus subtilis [29]. The authors defined the secretome as the subset of 
the proteome that is secreted, in addition to the components of cellular machinery 
used for protein secretion. However, these released proteins are not only secreted 
proteins but also proteins that arise from other export mechanisms. Thus, the best 
term to describe the protein content found in the extracellular proximity of a given 
biological system is the “exoproteome” [30].
According to [31], T. cruzi releases proteins associated with two types of vesicles. 
The large vesicles (LVs), named ectosomes, arise from the plasma membrane, and 
small vesicles (SVs), similar to exosomes, are released by the flagellar pocket. A 
third fraction was enriched in soluble proteins and was not associated with extracel-
lular vesicles (EVs) [31]. Label-free quantitative proteomics analysis showed the 
presence of proteins associated with metabolism, signaling, packaging of nucleic 
acids, parasite survival, and virulence [31].
The T. cruzi exoproteome of TCDTs (Y strain) was recently character-
ized. NanoLC-MS/MS analysis resulted in the identification of 540 proteins. 
Bioinformatics analysis predicted most identified proteins as secreted, predomi-
nantly by nonclassical pathways, and suggested that these proteins are involved in 
host cell interaction. Some proteins possess predicted GPI-anchor signals; these 
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proteins are mostly TS, MASP, and surface glycoproteins. The existence of various 
related proteins to similar functions in the exoproteome likely reflects this parasite’s 
enhanced mechanisms for adhesion, invasion, and internalization of different host 
cell types and immune evasion [32].
Considering that Chagas disease is a chronic infection in which amastigote forms 
remain for a long time, the T. cruzi laboratory examination using direct observation 
is tricky, and although antibody detection tests are sensitive, they may give false-
positive results. The implementation of novel fast assays aimed for the identifica-
tion of excretory/secretory parasite-derived molecules in serum would be a useful 
contribution in the diagnosis of human T. cruzi infection. Brossas and coworkers 
[33] investigated the proteins secreted by T. cruzi using MS analyses of conditioned 
culture media devoid of serum, collected during the emergence of trypomastigotes 
from infected Vero cells. Indeed, the secretomes of two T. cruzi strains from DTU 
TcVI (VD and CL Brener) were compared. This study led to the identification of 
591 T. cruzi proteins. Three hundred sixty-three proteins were common to both 
strains, and most belong to different multigenic super families (e.g., TcS, GP63, 
MASP, and DGF1). Finally, a report of 94 secreted proteins, present in both DTU 
TcVI strains that do not correspond to the members of multigene families, was also 
established. This paper offers the first comparative study of the secretomes from 
two different T. cruzi strains of DTU TcVI. Then, Brossas and coworkers’ papers 
identified a subset of common secreted proteins that could have a potential role as 
serum biomarkers for T. cruzi infection [33].
A novel family of T. cruzi surface membrane proteins (TcSMPs), which are con-
served among different T. cruzi lineages and have orthologs in other Trypanosoma 
species, was described. Several lines of evidence suggest that TcSMP is a membrane-
spanning protein located at the cellular surface and is also released into the extra-
cellular milieu. TcSMP displayed a signal anchor and a C-terminal hydrophobic 
sequence predicted to be a transmembrane domain. In addition, proteomic TcSMP 
peptides previously found in a membrane-enriched fraction were identified in 
membrane vesicles as well as in soluble forms in the T. cruzi secretome. TcSMP 
proteins were also located intracellularly, likely associated with membrane-bound 
structures. These proteins were shown to inhibit metacyclic trypomastigote entry 
into host cells. TcSMPs could bind to mammalian cells and trigger Ca2+ signaling 
and lysosome exocytosis. This evidence strongly suggests the involvement of these 
proteins in parasite invasion [34].
5. T. cruzi subcellular proteomics
A combination of MS-based proteomics methods and traditional biochemical 
cell fractionation protocols had been used to characterize subcellular organization. 
The protein contents of specific subcellular compartments can thus be identified 
following specific enrichment strategies that concentrate and enrich organelles and 
subcompartments of the cell [8].
T. cruzi reservosomes show concentrated proteins and lipids obtained from 
medium together with the main proteolytic enzymes originating from the secretory 
pathway, being at the same time a storage organelle and the main site of protein 
degradation and endpoint of the parasite endocytic pathway. By cell fractionation 
and LC-MS/MS, the EPI reservosome-resident proteins were identified in a total 
of 709 T. cruzi-specific proteins. Among these, 456 had predicted functions and 
253 were described as hypothetical proteins. The existence of a high number of 
previously reported proteins was confirmed. In addition, new different classes 
of proteins were reported. Among them, transport proteins, proton pumps, and 
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its vertebrate and invertebrate hosts. GPI-anchored rich fractions and other T. cruzi 
membrane proteins were obtained from epimastigotes (EPIs) and MTs and then 
submitted to two-dimensional liquid chromatography coupled to tandem mass 
spectrometry (2D-LC-MS/MS). A total of 98 MT proteins and 280 EPI proteins 
were identified. Of those, approximately 65% (n = 245) had predicted lipid post-
translational modification sites (i.e., GPI-anchor, myristoylation, or prenylation), 
signal-anchor sequences, or transmembrane domains that could explain their 
solubility in detergent solution. This report showed that MTs, but not EPIs, express 
a large repertoire of surface glycoproteins, such as GP90 and GP82, which are 
involved in host cell adhesion and invasion. Taken together, these results showed 
that T. cruzi displays stage-specific protein profiles that are related to the biology of 
each T. cruzi stage [24].
A map of soluble proteins from epimastigotes of T. cruzi CL Brener was generated 
using 2-DE combined with MS. The analysis showed that several proteins, such as 
tubulin and heat shock proteins, were found in multiple isoforms. The enzyme argi-
nine kinase was also found. This enzyme is absent in mammalian cells and, accord-
ing to the authors, could represent a potential new chemotherapeutic target [25].
Using conditions optimized for the 6–11 pH range, researchers compared the 
proteomes of TCDTs and extracellular amastigote-like parasites by MALDI-TOF/
TOF. The alkaline 2-DE gels from TCDTs and extracellular amastigotes showed that 
proteins with a pI over 7.0 were very well depicted (= 65% of proteins detected). 
Furthermore, the differences in protein expression among the human-hosted 
T. cruzi stages were in agreement with former proteomics reports and were related 
to the biological properties of each parasite stage [26].
4. The T. cruzi secretome/exoproteome
Adhesion and invasion are the first stages of interaction between an obligate 
intracellular pathogen and its host cell. This process involves cell surface molecules 
and secreted molecules. Then, the molecules that are released from pathogens may 
play a critical role during the establishment of infection, especially in immunomod-
ulation or immune evasion, as well as in migration across host tissues, cell adhesion, 
cell-cell communication, differentiation, proliferation, and morphogenesis [27, 28].
The term secretome was first introduced in a bioinformatics survey of proteins 
secreted by Bacillus subtilis [29]. The authors defined the secretome as the subset of 
the proteome that is secreted, in addition to the components of cellular machinery 
used for protein secretion. However, these released proteins are not only secreted 
proteins but also proteins that arise from other export mechanisms. Thus, the best 
term to describe the protein content found in the extracellular proximity of a given 
biological system is the “exoproteome” [30].
According to [31], T. cruzi releases proteins associated with two types of vesicles. 
The large vesicles (LVs), named ectosomes, arise from the plasma membrane, and 
small vesicles (SVs), similar to exosomes, are released by the flagellar pocket. A 
third fraction was enriched in soluble proteins and was not associated with extracel-
lular vesicles (EVs) [31]. Label-free quantitative proteomics analysis showed the 
presence of proteins associated with metabolism, signaling, packaging of nucleic 
acids, parasite survival, and virulence [31].
The T. cruzi exoproteome of TCDTs (Y strain) was recently character-
ized. NanoLC-MS/MS analysis resulted in the identification of 540 proteins. 
Bioinformatics analysis predicted most identified proteins as secreted, predomi-
nantly by nonclassical pathways, and suggested that these proteins are involved in 
host cell interaction. Some proteins possess predicted GPI-anchor signals; these 
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proteins are mostly TS, MASP, and surface glycoproteins. The existence of various 
related proteins to similar functions in the exoproteome likely reflects this parasite’s 
enhanced mechanisms for adhesion, invasion, and internalization of different host 
cell types and immune evasion [32].
Considering that Chagas disease is a chronic infection in which amastigote forms 
remain for a long time, the T. cruzi laboratory examination using direct observation 
is tricky, and although antibody detection tests are sensitive, they may give false-
positive results. The implementation of novel fast assays aimed for the identifica-
tion of excretory/secretory parasite-derived molecules in serum would be a useful 
contribution in the diagnosis of human T. cruzi infection. Brossas and coworkers 
[33] investigated the proteins secreted by T. cruzi using MS analyses of conditioned 
culture media devoid of serum, collected during the emergence of trypomastigotes 
from infected Vero cells. Indeed, the secretomes of two T. cruzi strains from DTU 
TcVI (VD and CL Brener) were compared. This study led to the identification of 
591 T. cruzi proteins. Three hundred sixty-three proteins were common to both 
strains, and most belong to different multigenic super families (e.g., TcS, GP63, 
MASP, and DGF1). Finally, a report of 94 secreted proteins, present in both DTU 
TcVI strains that do not correspond to the members of multigene families, was also 
established. This paper offers the first comparative study of the secretomes from 
two different T. cruzi strains of DTU TcVI. Then, Brossas and coworkers’ papers 
identified a subset of common secreted proteins that could have a potential role as 
serum biomarkers for T. cruzi infection [33].
A novel family of T. cruzi surface membrane proteins (TcSMPs), which are con-
served among different T. cruzi lineages and have orthologs in other Trypanosoma 
species, was described. Several lines of evidence suggest that TcSMP is a membrane-
spanning protein located at the cellular surface and is also released into the extra-
cellular milieu. TcSMP displayed a signal anchor and a C-terminal hydrophobic 
sequence predicted to be a transmembrane domain. In addition, proteomic TcSMP 
peptides previously found in a membrane-enriched fraction were identified in 
membrane vesicles as well as in soluble forms in the T. cruzi secretome. TcSMP 
proteins were also located intracellularly, likely associated with membrane-bound 
structures. These proteins were shown to inhibit metacyclic trypomastigote entry 
into host cells. TcSMPs could bind to mammalian cells and trigger Ca2+ signaling 
and lysosome exocytosis. This evidence strongly suggests the involvement of these 
proteins in parasite invasion [34].
5. T. cruzi subcellular proteomics
A combination of MS-based proteomics methods and traditional biochemical 
cell fractionation protocols had been used to characterize subcellular organization. 
The protein contents of specific subcellular compartments can thus be identified 
following specific enrichment strategies that concentrate and enrich organelles and 
subcompartments of the cell [8].
T. cruzi reservosomes show concentrated proteins and lipids obtained from 
medium together with the main proteolytic enzymes originating from the secretory 
pathway, being at the same time a storage organelle and the main site of protein 
degradation and endpoint of the parasite endocytic pathway. By cell fractionation 
and LC-MS/MS, the EPI reservosome-resident proteins were identified in a total 
of 709 T. cruzi-specific proteins. Among these, 456 had predicted functions and 
253 were described as hypothetical proteins. The existence of a high number of 
previously reported proteins was confirmed. In addition, new different classes 
of proteins were reported. Among them, transport proteins, proton pumps, and 
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enzymes were also identified. According to the authors, the definition of the 
reservosome protein profile could be a good tool to assess the molecular signatures, 
identify molecular markers, and understand the relationship with different parasite 
organelles [35].
The EPI transition from the exponential growth phase to the stationary phase is 
a key step that recapitulates the early molecular events of T. cruzi metacyclogenesis, 
opening new possibilities for understanding this process. Thus, a quantitative shot-
gun proteomics study of the T. cruzi EPIs in the exponential and stationary growth 
phases was performed. More than 3000 proteins were identified and quantified, 
stressing the regulation of proteins engaged in various subcellular compartments. 
Ribosomal proteins were positively regulated in the exponential phase, in agree-
ment with the high proliferative rate of this growth phase. Autophagy-related 
proteins were positively regulated in the stationary growth phase, showing the 
beginning of the metacyclogenesis. Otherwise, this paper reported the regulation 
of N-terminally acetylated proteins during growth phase transitioning, adding a 
new layer of regulation to this process. Thus, this paper reported a proteome-wide 
rewiring during T. cruzi differentiation from the EPIs’ proliferative exponential 
phase to the stationary growth phase, which is the step before cell transformation 
into the MT stage [36].
In the eukaryotic cell, chromatin-associated proteins are key regulators of many 
important processes. By high-resolution MS, the T. cruzi chromatin proteome was 
investigated using three different protocols and comparing it between two parasite 
stages, EPIs and TCDTs. More than 2000 proteins were identified and quantified 
both in chromatin and nonchromatin extracts. In addition to histones and other 
known nuclear proteins, trypanosome chromatin also contains metabolic proteins 
(mainly from carbohydrate pathways), cytoskeleton components, and many other 
proteins with unknown functions. In addition, EPIs and TCDTs also differ greatly 
regarding their chromatin-associated factor composition and amount. Although 
the nucleosome content was the same for both stages, the remaining proteins were 
rarely detected in TCDTs, suggesting that they have naked chromatin. Proteins 
associated with DNA proliferation, such as proliferation cell nuclear antigen 
(PCNA), replication protein A (RPA), and DNA topoisomerases, were exclusively 
found in the chromatin of EPIs. However, TCDTs showed an enrichment of a his-
tone H2B variant. Moreover, nearly 20% of the EPIs’ chromatin-associated proteins 
were expressed in TCDTs but were placed in the nonchromatin space. Several types 
of proteins, including phosphatases and a Ran-binding protein, that may be trans-
ported among chromatin and the nonchromatin space during differentiation were 
also identified. These results indicated that the replicative state in trypanosomes 
involves an increase in chromatin-associated protein content. Given that trypano-
somes are early-branching organisms, these data could enhance our understanding 
of chromatin-associated processes in other cell types [37].
T. cruzi proliferation displays unique features, such as the absence of chromo-
some condensation and closed mitosis. Thus, T. cruzi epimastigotes were lysed, and 
the nuclear fraction was isolated to study the proteome by LC-MS/MS. A total of 
864 proteins were identified, of which 272 were annotated as putative uncharacter-
ized proteins and 275 had not been previously reported in the T. cruzi proteome. 
Bioinformatics analysis using the Database for Annotation, Visualization, and 
Integrated Discovery (DAVID) was carried out, and proteins were grouped into 
nuclear proteins in 65 gene clusters, wherein the clusters with the highest enrich-
ment scores harbored members with chromatin organization and DNA-binding 
functions [38].
Contractile vacuole complexes are critical components of cell volume regulation 
and have been shown to have other functional roles in several free-living protists. 
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However, very little was known about the functions on T. cruzi. A proteomics and 
bioinformatics approach to identify proteins localized to the contractile vacuole was 
performed using the T. cruzi epimastigote-enriched fraction of contractile vacuoles, 
which was analyzed by one-dimensional gel electrophoresis and LC-MS/MS. A total 
of 109 newly detected proteins were identified, including at least 39 members of the 
dispersed gene family 1 (DGF-1). This observation suggested that many members 
of this family are simultaneously expressed in EPIs. In addition, several homologs 
with known localizations in contractile vacuoles of other organisms were selected. 
GFP-fusion proteins or specific antibodies were used to determine the localiza-
tion of each protein. Six of these putative proteins (Rab11, Rab32, AP180, ATPase 
subunit B, VAMP1, and phosphate transporter) were mostly located in the vacuole 
bladder. However, TcSNARE2.1, TcSNARE2.2, and calmodulin were located in the 
spongiome. Calmodulin was a cytoplasmic protein. These observations confirmed 
the usefulness of merged subcellular fractionation, proteomics assays, and bioin-
formatics methods in order to know the location of organellar proteins that could be 
hard to identify when global proteomic approaches are used [39].
Several lines of evidence suggest that the translational system in trypanosomatids 
shows important differences compared to those of other eukaryotes. A careful data 
mining quest for ribosomal protein genes in the T. cruzi genome database coupled 
with MS of isolated T. cruzi ribosomes was performed. The findings suggested that 
T. cruzi ribosomal proteins have around 50% sequence identity to yeast proteins. In 
addition, some trypanosomal proteins were longer than yeast proteins because of the 
existence of many N- or C-terminal extensions, which are unique to trypanosoma-
tids. In detail, L19 and S21 have shown C-terminal extensions of 168 and 164 amino 
acids, respectively. Even more, two 60S subunit proteins that had not been formerly 
found in the T. cruzi whole proteome, namely, L22 and L42, were detected [40].
6. Parasite biology and reversible post-translational modifications
In eukaryotes, histones are well-conserved proteins that form the basic structure 
of chromatin and undergo several post-translational modifications, which are 
important for the control of transcription, replication, DNA damage repair, and 
chromosome condensation [41].
The processes by which T. cruzi acquires infectivity and survives in different 
hosts involve rapid adaptations to new environments and tight regulation of gene 
expression, mainly post-transcriptionally. Nevertheless, the chromatin structure/
organization of trypanosomatids is similar to that of other eukaryotes, includ-
ing histone variants and post-translational modifications. Evidence suggests that 
epigenetic mechanisms also play an important role in the parasite, indicating that 
new epigenetic targets can be used for chemotherapeutic intervention. From this 
perspective, MS-based large-scale proteomics has been used to identify T. cruzi 
post-transcriptional modifications in T. cruzi canonical and variant histones. A 
total of 13 distinct modification types were identified, including 9 newly described 
chemical modifications for trypanosomatids, which included novel and unusual 
modifications, such as alternative lysine acylations, serine/threonine acetylation, 
and N-terminal methylation. In the same way, two hundred conserved and unique 
post-transcriptional sites in the tails and globular regions of all canonical and vari-
ant histones were identified. These results provided the first comprehensive map of 
T. cruzi histone marks and provided new evidence that allowed us to gain a deeper 
understanding of the epigenetic mechanisms that operate in T. cruzi. This report 
could provide information to identify potential candidates for the development of 
new epigenetic drugs [42].
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enzymes were also identified. According to the authors, the definition of the 
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involves an increase in chromatin-associated protein content. Given that trypano-
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some condensation and closed mitosis. Thus, T. cruzi epimastigotes were lysed, and 
the nuclear fraction was isolated to study the proteome by LC-MS/MS. A total of 
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Contractile vacuole complexes are critical components of cell volume regulation 
and have been shown to have other functional roles in several free-living protists. 
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However, very little was known about the functions on T. cruzi. A proteomics and 
bioinformatics approach to identify proteins localized to the contractile vacuole was 
performed using the T. cruzi epimastigote-enriched fraction of contractile vacuoles, 
which was analyzed by one-dimensional gel electrophoresis and LC-MS/MS. A total 
of 109 newly detected proteins were identified, including at least 39 members of the 
dispersed gene family 1 (DGF-1). This observation suggested that many members 
of this family are simultaneously expressed in EPIs. In addition, several homologs 
with known localizations in contractile vacuoles of other organisms were selected. 
GFP-fusion proteins or specific antibodies were used to determine the localiza-
tion of each protein. Six of these putative proteins (Rab11, Rab32, AP180, ATPase 
subunit B, VAMP1, and phosphate transporter) were mostly located in the vacuole 
bladder. However, TcSNARE2.1, TcSNARE2.2, and calmodulin were located in the 
spongiome. Calmodulin was a cytoplasmic protein. These observations confirmed 
the usefulness of merged subcellular fractionation, proteomics assays, and bioin-
formatics methods in order to know the location of organellar proteins that could be 
hard to identify when global proteomic approaches are used [39].
Several lines of evidence suggest that the translational system in trypanosomatids 
shows important differences compared to those of other eukaryotes. A careful data 
mining quest for ribosomal protein genes in the T. cruzi genome database coupled 
with MS of isolated T. cruzi ribosomes was performed. The findings suggested that 
T. cruzi ribosomal proteins have around 50% sequence identity to yeast proteins. In 
addition, some trypanosomal proteins were longer than yeast proteins because of the 
existence of many N- or C-terminal extensions, which are unique to trypanosoma-
tids. In detail, L19 and S21 have shown C-terminal extensions of 168 and 164 amino 
acids, respectively. Even more, two 60S subunit proteins that had not been formerly 
found in the T. cruzi whole proteome, namely, L22 and L42, were detected [40].
6. Parasite biology and reversible post-translational modifications
In eukaryotes, histones are well-conserved proteins that form the basic structure 
of chromatin and undergo several post-translational modifications, which are 
important for the control of transcription, replication, DNA damage repair, and 
chromosome condensation [41].
The processes by which T. cruzi acquires infectivity and survives in different 
hosts involve rapid adaptations to new environments and tight regulation of gene 
expression, mainly post-transcriptionally. Nevertheless, the chromatin structure/
organization of trypanosomatids is similar to that of other eukaryotes, includ-
ing histone variants and post-translational modifications. Evidence suggests that 
epigenetic mechanisms also play an important role in the parasite, indicating that 
new epigenetic targets can be used for chemotherapeutic intervention. From this 
perspective, MS-based large-scale proteomics has been used to identify T. cruzi 
post-transcriptional modifications in T. cruzi canonical and variant histones. A 
total of 13 distinct modification types were identified, including 9 newly described 
chemical modifications for trypanosomatids, which included novel and unusual 
modifications, such as alternative lysine acylations, serine/threonine acetylation, 
and N-terminal methylation. In the same way, two hundred conserved and unique 
post-transcriptional sites in the tails and globular regions of all canonical and vari-
ant histones were identified. These results provided the first comprehensive map of 
T. cruzi histone marks and provided new evidence that allowed us to gain a deeper 
understanding of the epigenetic mechanisms that operate in T. cruzi. This report 
could provide information to identify potential candidates for the development of 
new epigenetic drugs [42].
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In trypanosomatids such as T. cruzi, the regulation of gene expression is 
mostly post-transcriptional. The stability of mRNA and the possibility to accede 
to polysomes are believed to be strongly regulated, enabling T. cruzi to accom-
modate to various environmental situations that occur through its life cycle. 
Post-transcriptional regulation needs the association among mRNAs and specific 
proteins to shaping the complexes named ribonucleoproteins (mRNP). The 
dynamic association among proteins and mRNAs was studied through poly(T) 
beads to purify and characterize proteins and protein complexes linked to poly-A+ 
mRNAs. The protein contents of these fractions were studied by LC-MS/MS. A 
number of 542 protein components of the mRNP complexes associated with 
mRNAs were detected. Among them, 24 of the retrieved proteins were common to 
all fractions, whereas others were only found in an individual fraction: EPI poly-
somal (0.37%) and post-polysomal (2.95%) fractions and stress polysomal (13.8%) 
and post-polysomal (40.78%) fractions. This proteomic approach provided the first 
insight into the composition and dynamics of T. cruzi mRNPs [43].
Protein acetylation is also a post-translational modification that regulates several 
cellular pathways. Using proteomics, researchers identified 389 ε-lysine-acetylated 
sites in 235 proteins in T. cruzi epimastigotes. Lysine-acetylated protein sites were 
enriched in enzymes involved in oxidation/reduction balance, which is required for 
parasite survival in the host. These observations provide evidence that in T. cruzi, 
protein acetylation participates in the differential regulation of several cellular 
pathways and helps elucidate the mechanisms involved in parasite infection and 
survival [44].
In early-branched organisms, histones appear to be less conserved and contain 
alternative sites for modifications, which could reveal evolutionary unique func-
tions of histone modifications in gene expression and other chromatin-based pro-
cesses. Using high-resolution MS, researchers studied the T. cruzi trypomastigote 
and epimastigote histone post-translational modifications. A total of 44 new modi-
fications were detected: 18 acetylations, 7 monomethylations, 7 dimethylations, 
7 trimethylations, and 4 phosphorylations. Epimastigotes contained more histone 
modifications than trypomastigotes. Acetylations of lysines at the C-terminus 
of histone H2A and methylations of lysine 23 of histone H3 were reported to be 
enriched in MT or TCDT. Contrasting with that, protein phosphorylation at serine 
23 of H2B and methylation of lysine 76 of histone H3 predominated in epimasti-
gotes. In parasites undergoing mitosis and cytokinesis, the existence of one or two 
methylations in lysine 76 was reported. These observations helped reveal the role of 
histone modifications in gene expression control and cell cycle regulation in T. cruzi 
[45]. However, epigenetic events, such as histone acetylation, affected DNA topol-
ogy, replication, and gene expression. Histone deacetylases are involved in chroma-
tin compaction and post-translational modifications of cytoplasmic proteins, such 
as tubulin. Given these facts, histone deacetylase inhibitors, such as trichostatin A, 
were evaluated by de Oliveira Santos and coworkers to determine their effects on  
T. cruzi epimastigote cell proliferation, viability, cell cycle, and ultrastructure, as 
well as on histone acetylation and tubulin expression. A quantitative proteomics 
study showed an increase in histone acetylation after trichostatin A treatment, 
suggesting that deacetylase inhibitors may represent excellent tools for elucidating 
trypanosomatid cell biology [46].
Protein N-myristoylation is catalyzed by N-myristoyltransferase (NMT), 
an essential and potential drug target in T. cruzi. Roberts and Fairlamb used a 
combination of label-free and stable isotope labeling of cells in culture (SILAC)-
based proteomics approaches when parasites were treated with or without the 
N-myristoyltransferase inhibitor DDD85646. A total of 56 proteins present in 
at least two out of the three experimental studies were identified. Among these, 
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6 were probably to be false positives, with the remainder 50 starting with the 
amino acids MG at the N-terminus in one or more of the T. cruzi genomes. The 
greater part of these were proteins of unknown function (32), with the remaining 
(18) involved in a different spectrum of key cellular and metabolic roles, such 
as intracellular transport, cell signaling, and protein turnover. In conclusion, 
the results showed that 0.43–0.46% of the T. cruzi proteome corresponded to 
N-myristoylated proteins, slightly lower than that reported in other eukaryotic 
organisms (0.5–1.7%) [47].
Glycoproteins are very attractive therapeutic candidate targets because they 
mediate key processes during the T. cruzi life cycle, such as cellular recognition, host 
cell invasion and adhesion, and immune evasion. Using subcellular fractionation, 
lectin affinity, and SILAC, Atwood et al. [48] conducted a T. cruzi trypomastigote 
glycoproteomics analysis, which described the identification of organelles and cell 
surface N-linked glycoproteins of T. cruzi. These researchers identified 36 glycosyl-
ation sites on 35 glycopeptides that mapped to 29 glycoproteins. They also presented 
the first evidence for 11 T. cruzi-specific glycoproteins and provided experimental 
data indicating that the MASP and dispersed gene family (DGF-1) were post-
translationally modified by N-linked glycans. In another study using lectin-based 
and hydrophilic interaction liquid chromatography followed by high-resolution 
LC-MS/MS, a comprehensive glycoproteomics analysis was performed in T. cruzi 
epimastigotes and trypomastigotes. After treatment with glycanases, a number 
of 1306 N-glycosylation sites in NxS/T/C motifs were reported from 690 T. cruzi 
glycosylated proteins. Among them, 170 and 334 glycoproteins were solely detected 
in EPI and trypomastigotes, respectively. In addition, global site-specific charac-
terization of the N- and O-linked glycan heterogeneity in the two T. cruzi life stages 
was reached by intact glycopeptide methods, detecting 144/466 unique N-linked 
and 10/97 unique O-linked intact glycopeptides in epimastigotes/trypomastigotes, 
respectively. Thus, T. cruzi displays a pattern of stage-specific glycoprotein expres-
sion that may be the result of parasite interactions with vertebrate and invertebrate 
hosts during its life cycle [49].
In eukaryotic cells, SUMOylation is an important protein post-translational 
modification. The C-terminus of proteolytically activated small ubiquitin-like 
modifier (SUMO) is covalently bound to a lysine residue of the target protein by 
an isopeptide bond through a pathway that involves an E1-activating enzyme, an 
E2-conjugating enzyme, and a transfer to the target, in occasions with the support 
of a protein ligase [50]. The modification is reversed by a protease, which is also 
responsible for SUMO ripening. Several proteins have been described as SUMO 
targets and were shown to participate in the regulation of cell cycle progression, 
transcription, translation, ubiquitination, and DNA repair [50]. Orthologous 
genes corresponding to the SUMOylation pathway have been reported in T. cruzi. 
Furthermore, the SUMOylation system appears to be functionally active in the 
parasite. An immunofluorescence analysis showed that T. cruzi SUMO (TcSUMO) 
was predominantly found in the nucleus. To identify SUMOylation targets and 
further elucidate their physiological roles, researchers generated transfectant 
T. cruzi epimastigote lines expressing a double-tagged T. cruzi SUMO, and 
SUMOylated proteins were enriched by tandem affinity chromatography. By 
two-dimensional LC-MS/MS, a total of 236 proteins with different biological roles 
were reported as possible T. cruzi SUMO targets. Among these, metacaspase-3 was 
confirmed as a bona fide SUMOylation substrate by a biochemical approaches. 
The application of proteomics methods in many different biological systems has 
allowed to know that orthologs of putative T. cruzi SUMOylated proteins are 
equally modified, suggesting that conserved mechanisms could operate for protein 
SUMOylation [51].
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For the role of phosphorylation, kinase inhibitors have been suggested as novel 
antiparasitic agents. However, a fundamental understanding of the cell signaling 
pathways requires a detailed analysis of the involved phosphorylated proteins. 
A MS-based phosphoproteomic map of T. cruzi epimastigotes was performed by 
LC-MS/MS, dual-stage fragmentation, and multistage activation method. A total of 
237 phosphorylated peptides from 119 different proteins were identified. Moreover, 
220 phosphorylation sites were unequivocally mapped: 148 on serine, 57 on threo-
nine, and 8 on tyrosine. Even more, immunoprecipitation and immunoblot assays 
reported the existence of at least seven tyrosine-phosphorylated proteins in T. cruzi. 
The phosphorylated proteins were submitted to GO, InterPro, and BLAST scan 
and classified according to their roles in cell structure, motility, cellular transport, 
metabolic pathways, pathogenesis, DNA/RNA/protein turnover, and signaling. 
These phosphoproteomic information provided novel perspectives into T. cruzi 
phosphorylation pathways and the potential roles of the identified phosphoproteins 
in T. cruzi biology and reinforced the idea that kinases are parasite drug targets [52].
Furthermore, a phosphoproteomic approach was performed to determine the 
role of transforming growth factor beta (TGF-β) in T. cruzi biology. Then, EPI  
(Y strain) was incubated with TGF-β for 1, 5, 30, and 60 min, which promoted remod-
eling of the parasite phosphorylation network and protein expression pattern. To 
identify parasite proteins involved in the TGF-β response, researchers performed 
2-DE and MS. The modified proteins were engaged in many parasite functions, such 
as proteolysis, metabolism, heat shock response, cytoskeleton arrangement, oxida-
tive stress regulation, translation, and signal transduction. After TGF-β treatment, 
a number of 75 protein spots were found to be positively or negatively regulated 
more than twofold. Among these, 42 were detected by MS, highlighting, among 
these, cruzipain, the main T. cruzi papain-like cysteine protease. In these experi-
ments, TGF-β addition favored epimastigote proliferation, corroborating 2-DE data 
in which proteins previously described to be involved in this process were positively 
stimulated by TGF-β [53].
The MT proteome, which showed differential expression of some proteins 
during metacyclogenesis [54], has also been determined. Metacyclogenesis is the 
process by which T. cruzi epimastigotes differentiate into metacyclic trypomas-
tigotes and acquire the ability to infect cells and resist complement lysis. This 
process obviously requires the expression of a new set of proteins associated 
with parasite virulence. This critical step in parasite biology was first studied 
by Parodi-Talice and coworkers [55] who analyzed the process by 2-DE coupled 
to MALDI-TOF MS. A large proportion of unique proteins expressed during 
metacyclogenesis were observed. Interestingly, 50% of the spots were found to 
differ between epimastigotes and trypomastigotes. The study provided a 2D map 
of MT. Sixty-six protein spots were successfully identified, corresponding to 43 
different proteins. The expression profiles allowed protein identification during 
metacyclogenesis and categorize the proteins into three groups in accordance to 
their maximal level of expression. Various isoforms for a number of proteins, 
some of them displaying differential expression during metacyclogenesis, were 
detected. These information suggested that post-translational modifications may 
be an essential component of the parasite’s biological program to regulate gene 
expression during metacyclogenesis. The Parodi-Talice and coworkers’ paper 
contributed to the identification of relevant proteins implicated in the metacy-
clogenesis process, providing relevant information about the pathways involved 
in T. cruzi epimastigote differentiation into MTs [55]. However, a quantitative 
MS-based proteomics study of T. cruzi metacyclogenesis was performed, and 
almost 3000 proteins expressed during the process were quantified. Relevant 
proteins and pathways involved in the parasite’s differentiation and infectivity 
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acquisition were identified, opening new perspectives for further studies that 
could lead to the identification of new chemotherapeutics targets [54].
Studies of the T. cruzi phosphoproteome and the nuclear subproteome were also 
performed [56], and the results showed that the T. cruzi nuclear subproteome was 
composed of several members of the HSP family and members of the “retrotrans-
poson hot spot” (RHS) protein family as reported by De Castro Moreira Dos Santos 
et al. (2015).
The differentiation from trypomastigotes into amastigotes, called amastigo-
genesis, has also been studied in vitro by incubating TCDTs in acidic DMEM to 
perform a comprehensive quantitative proteomics and phosphoproteomics analysis 
of T. cruzi amastigogenesis. Regulated proteins and pathways involved in coordinat-
ing amastigogenesis were also identified, indicating that a significant proportion of 
the regulated proteins were membrane proteins. The authors further reported that 
modulated phosphorylation events coordinated by protein kinases and phospha-
tases are involved in signaling pathways and were triggers after incubation in acidic 
medium [22].
One of the least studied differentiation processes is the passage of infective 
trypomastigotes to epimastigotes, termed epimastigogenesis [57]. To resolve this 
issue, researchers established an in vitro and in vivo model for epimastigogen-
esis, enabling the characterization of a new infective morphological stage called 
“recently differentiated epimastigotes.” This stage was infective and resistant to 
complement-mediated lysis both in vitro and in vivo. Shotgun proteomics of all 
T. cruzi stages revealed that several proteins were upregulated only in recently 
differentiated epimastigotes (including ERO1, multidrug resistance protein E and 
ABC transporters). This evidence suggests a role for these proteins in complement-
system resistance, as previously observed for other organisms [58, 59]. As indi-
cated by the proteomics analysis, this stage contains a minimal and distinct set of 
molecules required for in vitro and in vivo infectivity, suggesting a putative role of 
epimastigotes in T. cruzi infection of mammalian cells [60].
A validated, constraint-based model of the core metabolism of T. cruzi strain CL 
Brener was carried out. The model includes 4 compartments (extracellular space, 
cytosol, mitochondrion, glycosome), 51 transport reactions, and 93 metabolic 
reactions covering carbohydrates, amino acids, and energy metabolism. In addi-
tion, several replicate high-throughput proteomic data sets were used to specifically 
examine the metabolism of T. cruzi epimastigotes. This paper shows the usefulness 
of constraint-based models for incorporating several sources of information (e.g., 
genomics, primary biochemical literature, proteomics) to build testable hypotheses. 
This model constitutes and focuses on the systematic analysis of T. cruzi metabo-
lism under a broad spectrum of conditions and disturbances and should possibly 
contribute to identify new drug targets [61].
T. cruzi is always subjected to sudden temperature shifts during its life cycle. 
The adaptive capacity to these changes is critical for parasite survival, reproduc-
tion, and transmission. These changes may modify the profile of protein expression 
that participates in homeostasis during the course of stress treatment. Thus, the 
proteome of T. cruzi EPI exposed to heat shock was analyzed by 2-DE followed by 
MS for protein identification. A total number of 24 spots differing in abundance 
were reported. Of the 24 modified spots, 19 showed a higher intensity and 5 
showed a smaller intensity in relation to the control. Various functional categories 
of the reported proteins were determined: metabolism, cell defense, hypothetical 
proteins, protein fate, protein synthesis, cellular transport, and cell cycle. Proteins 
engaged in the interaction with the cellular environment were reported too [62].
A proteomics analysis of an organellar cell fraction from T. cruzi CL Brener 
epimastigotes was reported by Ferella et al. [63]. A total number of 396 proteins were 
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For the role of phosphorylation, kinase inhibitors have been suggested as novel 
antiparasitic agents. However, a fundamental understanding of the cell signaling 
pathways requires a detailed analysis of the involved phosphorylated proteins. 
A MS-based phosphoproteomic map of T. cruzi epimastigotes was performed by 
LC-MS/MS, dual-stage fragmentation, and multistage activation method. A total of 
237 phosphorylated peptides from 119 different proteins were identified. Moreover, 
220 phosphorylation sites were unequivocally mapped: 148 on serine, 57 on threo-
nine, and 8 on tyrosine. Even more, immunoprecipitation and immunoblot assays 
reported the existence of at least seven tyrosine-phosphorylated proteins in T. cruzi. 
The phosphorylated proteins were submitted to GO, InterPro, and BLAST scan 
and classified according to their roles in cell structure, motility, cellular transport, 
metabolic pathways, pathogenesis, DNA/RNA/protein turnover, and signaling. 
These phosphoproteomic information provided novel perspectives into T. cruzi 
phosphorylation pathways and the potential roles of the identified phosphoproteins 
in T. cruzi biology and reinforced the idea that kinases are parasite drug targets [52].
Furthermore, a phosphoproteomic approach was performed to determine the 
role of transforming growth factor beta (TGF-β) in T. cruzi biology. Then, EPI  
(Y strain) was incubated with TGF-β for 1, 5, 30, and 60 min, which promoted remod-
eling of the parasite phosphorylation network and protein expression pattern. To 
identify parasite proteins involved in the TGF-β response, researchers performed 
2-DE and MS. The modified proteins were engaged in many parasite functions, such 
as proteolysis, metabolism, heat shock response, cytoskeleton arrangement, oxida-
tive stress regulation, translation, and signal transduction. After TGF-β treatment, 
a number of 75 protein spots were found to be positively or negatively regulated 
more than twofold. Among these, 42 were detected by MS, highlighting, among 
these, cruzipain, the main T. cruzi papain-like cysteine protease. In these experi-
ments, TGF-β addition favored epimastigote proliferation, corroborating 2-DE data 
in which proteins previously described to be involved in this process were positively 
stimulated by TGF-β [53].
The MT proteome, which showed differential expression of some proteins 
during metacyclogenesis [54], has also been determined. Metacyclogenesis is the 
process by which T. cruzi epimastigotes differentiate into metacyclic trypomas-
tigotes and acquire the ability to infect cells and resist complement lysis. This 
process obviously requires the expression of a new set of proteins associated 
with parasite virulence. This critical step in parasite biology was first studied 
by Parodi-Talice and coworkers [55] who analyzed the process by 2-DE coupled 
to MALDI-TOF MS. A large proportion of unique proteins expressed during 
metacyclogenesis were observed. Interestingly, 50% of the spots were found to 
differ between epimastigotes and trypomastigotes. The study provided a 2D map 
of MT. Sixty-six protein spots were successfully identified, corresponding to 43 
different proteins. The expression profiles allowed protein identification during 
metacyclogenesis and categorize the proteins into three groups in accordance to 
their maximal level of expression. Various isoforms for a number of proteins, 
some of them displaying differential expression during metacyclogenesis, were 
detected. These information suggested that post-translational modifications may 
be an essential component of the parasite’s biological program to regulate gene 
expression during metacyclogenesis. The Parodi-Talice and coworkers’ paper 
contributed to the identification of relevant proteins implicated in the metacy-
clogenesis process, providing relevant information about the pathways involved 
in T. cruzi epimastigote differentiation into MTs [55]. However, a quantitative 
MS-based proteomics study of T. cruzi metacyclogenesis was performed, and 
almost 3000 proteins expressed during the process were quantified. Relevant 
proteins and pathways involved in the parasite’s differentiation and infectivity 
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acquisition were identified, opening new perspectives for further studies that 
could lead to the identification of new chemotherapeutics targets [54].
Studies of the T. cruzi phosphoproteome and the nuclear subproteome were also 
performed [56], and the results showed that the T. cruzi nuclear subproteome was 
composed of several members of the HSP family and members of the “retrotrans-
poson hot spot” (RHS) protein family as reported by De Castro Moreira Dos Santos 
et al. (2015).
The differentiation from trypomastigotes into amastigotes, called amastigo-
genesis, has also been studied in vitro by incubating TCDTs in acidic DMEM to 
perform a comprehensive quantitative proteomics and phosphoproteomics analysis 
of T. cruzi amastigogenesis. Regulated proteins and pathways involved in coordinat-
ing amastigogenesis were also identified, indicating that a significant proportion of 
the regulated proteins were membrane proteins. The authors further reported that 
modulated phosphorylation events coordinated by protein kinases and phospha-
tases are involved in signaling pathways and were triggers after incubation in acidic 
medium [22].
One of the least studied differentiation processes is the passage of infective 
trypomastigotes to epimastigotes, termed epimastigogenesis [57]. To resolve this 
issue, researchers established an in vitro and in vivo model for epimastigogen-
esis, enabling the characterization of a new infective morphological stage called 
“recently differentiated epimastigotes.” This stage was infective and resistant to 
complement-mediated lysis both in vitro and in vivo. Shotgun proteomics of all 
T. cruzi stages revealed that several proteins were upregulated only in recently 
differentiated epimastigotes (including ERO1, multidrug resistance protein E and 
ABC transporters). This evidence suggests a role for these proteins in complement-
system resistance, as previously observed for other organisms [58, 59]. As indi-
cated by the proteomics analysis, this stage contains a minimal and distinct set of 
molecules required for in vitro and in vivo infectivity, suggesting a putative role of 
epimastigotes in T. cruzi infection of mammalian cells [60].
A validated, constraint-based model of the core metabolism of T. cruzi strain CL 
Brener was carried out. The model includes 4 compartments (extracellular space, 
cytosol, mitochondrion, glycosome), 51 transport reactions, and 93 metabolic 
reactions covering carbohydrates, amino acids, and energy metabolism. In addi-
tion, several replicate high-throughput proteomic data sets were used to specifically 
examine the metabolism of T. cruzi epimastigotes. This paper shows the usefulness 
of constraint-based models for incorporating several sources of information (e.g., 
genomics, primary biochemical literature, proteomics) to build testable hypotheses. 
This model constitutes and focuses on the systematic analysis of T. cruzi metabo-
lism under a broad spectrum of conditions and disturbances and should possibly 
contribute to identify new drug targets [61].
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determined by LC-MS/MS. Among these, 138 were reported as hypothetical in the 
genome databases, and the remainder was allocated to many metabolic and biosyn-
thetic pathways, transport, and structural functions. Comparative studies with an 
entire cell proteome are made possible to validate the expression of 173 additional 
proteins. Among these, 38 proteins previously detected in other stages were not 
found in the only large-scale study of the total EPI proteome. A chosen set of identi-
fied proteins was further studied in order to know their gene copy number, sequence 
variation, transmembrane domains, and targeting signals. The genes were cloned, 
and the recombinant proteins were expressed with a c-myc epitope tag in T. cruzi 
EPIs. Immunofluorescence microscopy showed the location of these proteins in dif-
ferent cellular compartments, such as the ER, acidocalcisome, mitochondrion, and 
putative cytoplasmic transport or delivery vesicles. These pieces of evidences rein-
force the idea that the use of enriched subcellular fractions allowed the identification 
of T. cruzi proteins that were unnoticed by whole cell proteomics approaches [63].
7. Proteomics in experimental chemotherapy and drug resistance
Chagas disease chemotherapy is based mainly on benznidazole (Bz) and 
nifurtimox (Nx), developed more than four decades ago, which are very efficient 
nitroderivatives against the acute stage but present limited efficacy during the 
chronic phase. In fact, both are far from ideal due to substantial secondary side 
effects, limited efficacy against different parasite isolates, the need for long-term 
therapy, and their well-known poor activity in the late chronic phase. Thus, iden-
tification of improved drugs to treat T. cruzi-infected people is urgently needed. 
Even though many different kinds of natural and synthetic compounds have been 
described to have in vitro and in vivo activity against T. cruzi, since the introduction 
of Bz and Nf, only scarce chemotherapeutic compounds, such as allopurinol and 
some sterol inhibitors, have moved to clinical assays.
The proteome of two T. cruzi strains after piplartine treatment was reported 
[64]. Considerable changes in the expression of enzymes involved in parasite 
protection against oxidative stress, such as tryparedoxin peroxidase (TXNPx) 
and methionine sulfoxide reductase (MSR), were observed in both strains. These 
findings suggested that inhibition of these enzymes could be potential chemothera-
peutic targets.
The trypanocidal effects of naturally occurring quinones and their derivatives 
and naphthoimidazoles derived from β-lapachone N1, N2, and N3 were the stron-
gest. To assess the molecular mechanisms of action of these compounds, researchers 
studied treated bloodstream trypomastigotes by 2D-DIGE followed by MALDI-
TOF/TOF. A total of 61 differentially abundant protein spots were identified when 
comparing the control with the N1, N2, or N3 treatment for 34 identified spots. 
The differentially abundant proteins included activated protein kinase C recep-
tor, tubulin isoforms, asparagine synthetase, arginine kinase, elongation factor 2, 
enolase, guanine deaminase, heat shock proteins, hypothetical proteins, paraflagel-
lar rod components, RAB GDP dissociation inhibitor, succinyl-CoA ligase, ATP 
synthase subunit B, and methionine sulfoxide reductase. These information allowed 
the identification of different modes of action for N1, N2, and N3, which indicate a 
great variety of metabolic pathways involved and open new avenues for the devel-
opment of new trypanocidal drugs [65].
In addition, proteomics was used to identify proteins involved in N1, N2, and N3 
trypanocidal activity. In epimastigotes, naphthoimidazoles are involved in multiple 
mechanisms: (a) redox metabolism, (b) energy production, (c) ergosterol biosyn-
thesis, (d) cytoskeleton assembly, (e) protein metabolism and biosynthesis, and 
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(f) chaperone modulation. These compounds were able to induce an imbalance in 
crucial pathways of the parasite, leading to the loss of metabolic homeostasis and T. 
cruzi death [66].
A proteomic analysis of T. cruzi resistance to Bz was reported initially by 
Andrade et al. [67]. The differential proteomes of T. cruzi with selected in vivo 
resistance to Bz (BZR and Clone27R), its susceptible pairs (BZS and Clone9S), and 
a pair from a population with benznidazole in vitro-induced resistance (17LER) 
and the susceptible pair 17WTS were studied by 2-DE followed by MS. Among 137 
spots studied through MS, 110 were detected as 56 distinct proteins. Among the 
56 different proteins, 36 were detected in resistant, 9 in susceptible, and 11 in both 
phenotypes. In the group of the proteins identified in resistant samples, five were 
found in Cl 27R and in BZR (calpain-like cysteine peptidase, hypothetical protein 
conserved 26 kDa, putative peptidase, peroxiredoxin, and tyrosine amino transfer-
ase) and four in Cl 27R and 17LER (cyclophilin A, glutamate dehydrogenase, iron 
superoxide dismutase, and nucleoside diphosphate kinase). However, the proteins 
detected in Bz-susceptible samples, PGF-2a, were found in BZS and 17WTS. A 
functional category study has shown that proteins engaged in transcription and 
protein destination were overexpressed in the Bz-resistant phenotype. This report 
provided large-scale, proteomic information to obtain a better knowledge of the 
mechanism involved in T. cruzi resistance to Bz [67].
8. Laboratory diagnostic and protein identification
Immune complexes (ICs) are the direct result of humoral immune responses. 
Therefore, the identification of foreign constituents or autoantigens within ICs 
might provide new insights into the immunopathology of infectious diseases. 
Ohyama and coworkers [68] studied the immune complexome of plasma samples 
obtained from T. cruzi-infected patients. Then, 20 seropositive plasma samples, 
including cardiac and/or megacolon chronic patients (n = 11) and asymptomatic 
patients (n = 9), were analyzed together with 10 seronegative healthy people to 
investigate the antigens linked to circulating ICs. In this study, 39 T. cruzi antigens 
and 114 human autoantigens particular to patients with Chagas disease were 
identified. In this report, two T. cruzi antigens (surface protease GP63 and glucose-
6-isomerase) and six human autoantigens (CD180 antigen, ceruloplasmin, fibrino-
gen beta chain, fibrinogen beta chain isoform 2 preprotein, isoform gamma-A of 
fibrinogen γ-chain, serum paraoxonase) were reported in more than 50% of the 
patients evaluated. Human isoforms short of complement factor H-related protein 2 
and T. cruzi TS were most often found in the asymptomatic forms of Chagas disease 
(5/9 for both) compared with the determinate Chagas (0/11, P = 0·046 for human, 
1/11, P = 0·0498 for T. cruzi). The authors conclude that the Chagas disease immune 
complexome may reflect the difference in immune status among different clinical 
stages of chronic form of T. cruzi infection [68].
In a successful translation of proteomic-based studies into accessible tools for 
bench diagnosis, Ruiz-Lancheros and coworkers [69] reported the value of apo-
lipoprotein A-1 and fibronectin fragments as markers of parasitological cure for 
congenital Chagas disease in Bz-treated children [69].
Using a proteomics approach, researchers identified a T. cruzi protein phos-
phatase 2A in a cytosolic extract previously purified in a microcystin-Sepharose 
affinity column. This strategy enables the cloning and expression of this protein 
phosphatase, which is involved in T. cruzi differentiation from trypomastigotes to 
amastigotes [70]. A proteomics approach was also used to identify a T. cruzi alfa 5 
proteasome subunit, previously recognized by the monoclonal antibody 7E5 [71].
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crucial pathways of the parasite, leading to the loss of metabolic homeostasis and T. 
cruzi death [66].
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9. Host-parasite interaction
To investigate changes in the cells’ phosphoprotein pattern after infection, 
researchers used proteome profiler human phospho-kinase arrays to investigate the 
molecular mechanism of T. cruzi-induced alteration of the colon during the early 
infection phase of primary human colonic epithelial cells (HCoEpiCs) infected 
with T. cruzi trypomastigotes at different time points. Significant changes in the 
phosphorylation pattern that could be related to cellular deregulation in colonic epi-
thelial cells after parasite infection were observed, including a significant increase 
in the levels of phosphorylated heat shock protein (p-HSP) 27 and transcription 
factors such as c-Jun and CREB. A significant upregulation of phospho (p-) Akt 
S473 and p-JNK, which may directly or indirectly modulate CREB and c-Jun 
phosphorylation, respectively, was also observed together with increased levels of 
phosphorylated CREB and c-Jun in the nucleus. In addition, p-c-Jun and p-CREB 
colocalized in the nucleus after 180 min of T. cruzi infection. A greater level of p-c-
Jun and p-CREB has been associated with inflammatory and profibrotic responses. 
T. cruzi infection of HCoEpiCs provokes an enhanced expression of thrombos-
pondin-1 (TSP-1), which is fibrogenic at higher levels. The authors also found that 
T. cruzi infection influenced the expression of some transcription factors, such as 
NF-kB and JAK2-STAT1, which can enhance proinflammatory flux. Bioinformatics 
studies of the phosphoprotein networks derived using the phosphoprotein informa-
tion serve as a blueprint for T. cruzi-mediated cellular differentiation of HCoEpiCs 
in the lapse of the acute phase of parasite infection.
T. cruzi was shown to release vesicles containing a wide range of surface mol-
ecules to affect the host immune responses and cell invasion [72]. A proteomics 
study reported different compositions of extracellular vesicles released by two 
T. cruzi strains associated with their distinct interaction with host cells [73]. The sec-
retomes of two distinct T. cruzi strains (Y and YuYu), which were previously shown 
to differentially modulate host immune responses, were compared. Extracellular 
vesicles (EVs) obtained from tissue culture-derived trypomastigotes of both strains 
were purified and quantitated. Proteomics studies confirmed the higher concentra-
tions of proteins encoded by the trans-sialidase (TS) gene superfamily, MASPs, and 
several well-known exosomal proteins in the YuYu strain, which also have shown a 
significant difference among purified EVs and the vesicle-free fraction compared 
to the Y strain. In order to know if those differences were associated with T. cruzi 
infectivity, J774 phagocytic cells and LLC-MK2 non-phagocytic cells were previ-
ously incubated with isolated EVs from both strains and then infected with TCDTs 
from Y strain. EVs liberated by the YuYu strain provoked smaller levels of infection 
but an increased intracellular proliferation in J774 macrophages than EVs from the Y 
strain. On the other hand, YuYu strain-derived EVs induced greater levels of infec-
tion of LLC-MK2 cells than Y strain-derived EVs. In summary, the quantitative and 
qualitative differences in EVs and released proteins from distinct T. cruzi strains may 
be correlated with the parasite capacity to be infective and virulent [73].
The involvement of host cell-derived microvesicles (MVs) during the early 
interaction between T. cruzi MTs and THP-1 cells was previously demonstrated. 
To determine the contribution of different parasite stages and their extracellular 
vesicles in the interaction with host cells, researchers assessed TCDTs, MTs, and 
EPIs, which were shown to provoke distinct levels of MV liberated from THP-1 
cells. Nevertheless, only MTs and TCDTs could enhance parasite cell invasion. 
Fluorescence resonance energy transfer microscopy showed that THP-1-derived 
MVs can fuse with parasite-derived MVs. Additionally, MVs released from the 
TCT-THP-1 interaction displayed a bigger fusogenic ability than those from the 
META- or EPI-THP-1 interaction. However, by proteomics, a greater concentration 
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of proteins from MTs (25%) than TCDTs (12%) or EPIs (5%) was detected in MVs 
from the parasite-THP-1 interaction. Lastly, sera from patients with chronic Chagas 
disease at the indeterminate or cardiac phase were able to identify antigens in 
THP-1-derived MVs resulting only from interaction with META or TCDTs forms. 
Elucidation of the cellular traffic pathways and the role of MVs in modulation of 
host immune system could supply significant hints with respect to Chagas disease 
pathophysiology [74].
T. cruzi has two tryparedoxins (TcTXNI and TcTXNI) pertaining to the thiore-
doxin superfamily. TXNs are oxidoreductases that have a role in electron transfer 
between trypanothione and peroxiredoxins [75, 76]. This represents a difference 
with the mammalian cells, in which these roles are performed by thioredoxins. These 
differences make TXNs a new and interesting chemotherapeutic target. T. cruzi 
tryparedoxin 1 (TcTXN1) is a cytoplasmic and constitutively expressed protein in 
T. cruzi. To elucidate the T. cruzi redox interactome, an active-site mutant protein 
lacking the resolving cysteine was designed. Then, the in vitro complex formation 
among the mutated TcTXN1 and its natural partner, the cytoplasmic peroxiredoxin, 
was validated. By the expression of this mutant protein in parasites with an additional 
6xHis-tag, heterodisulfide complexes were purified and identified by 2-DE/MS. This 
allowed us to identify 15 TcTXN1 proteins that were involved in 2 main processes: 
oxidative metabolism and protein synthesis and degradation. This type of experiment 
allowed the discovery of several putative TcTXN1-interacting proteins and contrib-
uted to a better understanding of the redox T. cruzi interactome [77]. In another 
work, the study was extended to TcTXNII. TcTXNII is a transmembrane protein 
anchored to the mitochondria surface and endoplasmic reticulum, with a cytoplasmic 
orientation of the redox domain. This protein is expressed during the metacyclogen-
esis process. To further characterize the redox interactome of T. cruzi, an active-site 
mutant TcTXNII lacking the resolving cysteine was designed, and through the 
expression of this mutant protein and incubation with T. cruzi proteins, heterodi-
sulfide complexes were isolated and identified by mass spectrometry. This approach 
allowed the identification of 16 TcTXNII-interacting proteins that are involved in a 
wide range of cellular processes. Thus, this report indicated the relevance of TcTXNII 
and contributed to a better understanding of the T. cruzi redox interactome [77].
TcI isolates of T. cruzi exploit the antioxidant network for enhanced intracellular 
survival in macrophages and virulence in mice. In these reports, the TcI strains 
Colombiana (COL) and SylvioX10/4 (SYL) and a cultured clone (TCC) displayed 
distinct biological features in an experimental murine infection, including high 
parasitemia and symptomatic cardiomyopathy (SYL), low parasitemia and high tis-
sue tropism (COL), and no pathogenicity (TCC). A proteomic study of the EPI and 
TCDT stages by 2-DE and MALDI-TOF MS, followed by functional annotation of 
the differential proteome data sets (≥twofold change, P < 0.05) demonstrated that 
(i) many proteins were engaged in cytoskeletal assembly and remodeling essential 
for flagellar wave frequency and amplitude and forward motility of the parasite 
and (ii) the parasite-specific antioxidant network was improved in COL and SYL 
(versus TCC) trypomastigotes. Immunoblots reveal the increased protein levels of 
cytoplasmic and mitochondrial tryparedoxin peroxidases and their substrate (try-
paredoxin) and iron superoxide dismutase in COL and SYL (versus TCC) trypo-
mastigotes. In addition, COL and SYL (but not TCC) were resistant to experimental 
treatment with oxidants such as H2O2 and peroxynitrite [ONOO(−)]. These parasite 
isolates were able to resist the intracellular superoxide and nitric oxide response in 
macrophages and were not killed by them. These observations indicate that protein 
expression focused on increased motility and control of macrophage-derived free 
radicals may represent a survival and persistence strategy developed by TcI isolates 
of T. cruzi [78].
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9. Host-parasite interaction
To investigate changes in the cells’ phosphoprotein pattern after infection, 
researchers used proteome profiler human phospho-kinase arrays to investigate the 
molecular mechanism of T. cruzi-induced alteration of the colon during the early 
infection phase of primary human colonic epithelial cells (HCoEpiCs) infected 
with T. cruzi trypomastigotes at different time points. Significant changes in the 
phosphorylation pattern that could be related to cellular deregulation in colonic epi-
thelial cells after parasite infection were observed, including a significant increase 
in the levels of phosphorylated heat shock protein (p-HSP) 27 and transcription 
factors such as c-Jun and CREB. A significant upregulation of phospho (p-) Akt 
S473 and p-JNK, which may directly or indirectly modulate CREB and c-Jun 
phosphorylation, respectively, was also observed together with increased levels of 
phosphorylated CREB and c-Jun in the nucleus. In addition, p-c-Jun and p-CREB 
colocalized in the nucleus after 180 min of T. cruzi infection. A greater level of p-c-
Jun and p-CREB has been associated with inflammatory and profibrotic responses. 
T. cruzi infection of HCoEpiCs provokes an enhanced expression of thrombos-
pondin-1 (TSP-1), which is fibrogenic at higher levels. The authors also found that 
T. cruzi infection influenced the expression of some transcription factors, such as 
NF-kB and JAK2-STAT1, which can enhance proinflammatory flux. Bioinformatics 
studies of the phosphoprotein networks derived using the phosphoprotein informa-
tion serve as a blueprint for T. cruzi-mediated cellular differentiation of HCoEpiCs 
in the lapse of the acute phase of parasite infection.
T. cruzi was shown to release vesicles containing a wide range of surface mol-
ecules to affect the host immune responses and cell invasion [72]. A proteomics 
study reported different compositions of extracellular vesicles released by two 
T. cruzi strains associated with their distinct interaction with host cells [73]. The sec-
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Fluorescence resonance energy transfer microscopy showed that THP-1-derived 
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TCT-THP-1 interaction displayed a bigger fusogenic ability than those from the 
META- or EPI-THP-1 interaction. However, by proteomics, a greater concentration 
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of proteins from MTs (25%) than TCDTs (12%) or EPIs (5%) was detected in MVs 
from the parasite-THP-1 interaction. Lastly, sera from patients with chronic Chagas 
disease at the indeterminate or cardiac phase were able to identify antigens in 
THP-1-derived MVs resulting only from interaction with META or TCDTs forms. 
Elucidation of the cellular traffic pathways and the role of MVs in modulation of 
host immune system could supply significant hints with respect to Chagas disease 
pathophysiology [74].
T. cruzi has two tryparedoxins (TcTXNI and TcTXNI) pertaining to the thiore-
doxin superfamily. TXNs are oxidoreductases that have a role in electron transfer 
between trypanothione and peroxiredoxins [75, 76]. This represents a difference 
with the mammalian cells, in which these roles are performed by thioredoxins. These 
differences make TXNs a new and interesting chemotherapeutic target. T. cruzi 
tryparedoxin 1 (TcTXN1) is a cytoplasmic and constitutively expressed protein in 
T. cruzi. To elucidate the T. cruzi redox interactome, an active-site mutant protein 
lacking the resolving cysteine was designed. Then, the in vitro complex formation 
among the mutated TcTXN1 and its natural partner, the cytoplasmic peroxiredoxin, 
was validated. By the expression of this mutant protein in parasites with an additional 
6xHis-tag, heterodisulfide complexes were purified and identified by 2-DE/MS. This 
allowed us to identify 15 TcTXN1 proteins that were involved in 2 main processes: 
oxidative metabolism and protein synthesis and degradation. This type of experiment 
allowed the discovery of several putative TcTXN1-interacting proteins and contrib-
uted to a better understanding of the redox T. cruzi interactome [77]. In another 
work, the study was extended to TcTXNII. TcTXNII is a transmembrane protein 
anchored to the mitochondria surface and endoplasmic reticulum, with a cytoplasmic 
orientation of the redox domain. This protein is expressed during the metacyclogen-
esis process. To further characterize the redox interactome of T. cruzi, an active-site 
mutant TcTXNII lacking the resolving cysteine was designed, and through the 
expression of this mutant protein and incubation with T. cruzi proteins, heterodi-
sulfide complexes were isolated and identified by mass spectrometry. This approach 
allowed the identification of 16 TcTXNII-interacting proteins that are involved in a 
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and contributed to a better understanding of the T. cruzi redox interactome [77].
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Colombiana (COL) and SylvioX10/4 (SYL) and a cultured clone (TCC) displayed 
distinct biological features in an experimental murine infection, including high 
parasitemia and symptomatic cardiomyopathy (SYL), low parasitemia and high tis-
sue tropism (COL), and no pathogenicity (TCC). A proteomic study of the EPI and 
TCDT stages by 2-DE and MALDI-TOF MS, followed by functional annotation of 
the differential proteome data sets (≥twofold change, P < 0.05) demonstrated that 
(i) many proteins were engaged in cytoskeletal assembly and remodeling essential 
for flagellar wave frequency and amplitude and forward motility of the parasite 
and (ii) the parasite-specific antioxidant network was improved in COL and SYL 
(versus TCC) trypomastigotes. Immunoblots reveal the increased protein levels of 
cytoplasmic and mitochondrial tryparedoxin peroxidases and their substrate (try-
paredoxin) and iron superoxide dismutase in COL and SYL (versus TCC) trypo-
mastigotes. In addition, COL and SYL (but not TCC) were resistant to experimental 
treatment with oxidants such as H2O2 and peroxynitrite [ONOO(−)]. These parasite 
isolates were able to resist the intracellular superoxide and nitric oxide response in 
macrophages and were not killed by them. These observations indicate that protein 
expression focused on increased motility and control of macrophage-derived free 
radicals may represent a survival and persistence strategy developed by TcI isolates 
of T. cruzi [78].
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10. T. cruzi typing
T. cruzi strains have been allocated to seven genetic groups (TcI-TcVI and TcBat), 
called discrete typing units (DTUs), which constitute groups of parasite isolates 
that differ in geographical origins, virulence, pathogenicity, and immunological 
properties [79]. In addition, several clinical manifestations (from asymptomatic to 
extremely severe illness) have been intended to be linked to T. cruzi genetic variabil-
ity. For this reason, many DTU typing approaches have been proposed. Recently, a 
T. cruzi strain typing assay using MS2 peptide spectral libraries (Tc-STAMS2) was 
developed [80]. The Tc-STAMS2 methodology used shotgun proteomics associated 
with a spectral library quest to assign and discriminate T. cruzi strains independent 
of genome information. This approach was based on the built of a library of MS/MS 
peptide spectra constructed using genotyped T. cruzi reference strains. For iden-
tification, the MS/MS peptide spectra of unheard T. cruzi isolated were identified 
by the spectral matching algorithm SpectraST. The Tc-STAMS2 approach enabled 
right identification of all DTUs with high reliance. The approach was robust toward 
distinct sample preparations, length of chromatographic gradients, and fragmenta-
tion techniques.
The Tc-STAMS2 procedure allowed T. cruzi strain typing using MS/MS spectra 
as discriminatory functions and allowed the differentiation of TcI-TcVI DTUs. 
Similar to genomic-based procedures, the Tc-STAMS2 method permits identifica-
tion of strains within DTUs. Its robustness toward different experimental and 
biological variables makes it an invaluable complementary methodology to the 
existing T. cruzi genotyping assays. Furthermore, this approach may be applied to 
identify DTU-specific properties correlated with the strain phenotype [73].
A proteomics analysis of two T. cruzi zymodeme 3 strains was also performed. 
In fact, two T. cruzi Z3 strains, designated 3663 and 4167, isolated from Brazilian 
Amazon triatomines were studied. These strains exhibited different infection 
patterns for Vero cells, in which 3663 trypomastigotes were much less infective than 
4167 trypomastigotes. By proteomics, the differences in the global protein expres-
sion profiles of these two Z3 strains were investigated. Two-dimensional (2D) pro-
tein maps were obtained, and some spots were identified by MS. The study showed 
a meaningful difference in the expression profiles of several proteins in both strains. 
One of them was cruzipain, a key virulence factor. These data were corroborated 
by flow cytometric analysis using an anti-cruzipain antibody. This difference could 
contribute to the infectivity profiles observed for each strain by in vitro assays using 
different cell lines [81].
A phylogenetic character mapping of 26 stocks of T. cruzi and 2 stocks of the 
sister taxon T. cruzi marinkellei was performed to test for possible associations 
between T. cruzi-subspecific phylogenetic diversity and levels of protein expression, 
as examined by proteomics analysis and MS. A strong correlation (P < 10(−4)) was 
observed between genetic distance, as established by multilocus enzyme electro-
phoresis, and proteomic dissimilarities estimated by proteomic Euclidian distances. 
Several proteins were found to be specifically associated with T. cruzi DTUs. This 
study explored the previously uncharacterized links between T. cruzi infraspecific 
phylogenetic diversity and gene expression [82].
11. Immune response
One major problem in developing a rational search for T. cruzi vaccine candi-
dates is the restricted information with respect to the proteins that are expressed 
by different strains, clones, and isolates included in the different parasite DTUs. 
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A proteomics study of T. cruzi trypomastigotes identified 1448 nonredundant 
proteins, of which close to 14% of the found peptidic sequences corresponded to 
surface proteins, mostly of which were GPI-anchored and associated with T. cruzi 
virulence. Immunoinformatics approaches reported a high number of peptides 
with predicted high-binding capacity for class I and class II molecules of the major 
histocompatibility complex (MHC). The many different types of proteins exposed 
on the trypomastigote surface membrane could have several consequences for 
parasite cell invasion and evasion of the immune response. Finally, a rational survey 
to identify potential T-cell epitopes that may be evaluated and validated to develop a 
prophylactic vaccine to protect against T. cruzi infection was performed [21].
T. cruzi BT proteins were immunoprecipitated using serum antibodies obtained 
from asymptomatic or cardiac (stages B1 and C) patients with different forms of the 
disease and from healthy people used as controls. Proteins recognized by sera from 
Chagas disease patients were identified and quantified by MS, and changes in the 
recognition patterns were further evaluated. Compared to asymptomatic samples, 
IgG from stage C patients mainly identify the I/6 autoantigen, whereas IgG from 
B1 patients resulted in a greater recognition of dihydrolipoamide acetyltransferase 
precursor, calpain cysteine peptidase, and two variants of CAP5.5. In this paper, 
CAP5.5 identification by human serum immunoglobulin from patients with early 
myocarditis resulted in a 23-fold abundance variation when compared to sera 
obtained from asymptomatic patients. These results strongly suggest the role of 
CAP5.5 in Chagas disease cardiomyopathy.
The lack of appropriate biomarkers to assess treatments and evolution of this 
disease is the main limitation for clinical trials and patient medical evaluation. 
Accordingly, these observations may contribute to a better comprehension of T. cruzi 
pathogenesis and to evaluating potential candidates for developing vaccine and diag-
nostic tests, in addition to the clinical applicability of suitable biomarkers for patient 
follow-up and prognosis [83].
The major protein antigens targeted by the diverse antibodies of T. cruzi-infected 
mice were studied. To detect global IgG antibody specificities, sera from infected 
mice were immunoblotted against whole T. cruzi extracts. The most immunogenic 
T. cruzi proteins were identified by proteomics using MALDI-TOF-TOF. Among 
these proteins, pyruvate phosphate dikinase, Hsp-85, and β-tubulin were recognized 
by mouse IgG as the major protein bands. The T. cruzi β-tubulin gene was cloned 
and expressed in Escherichia coli, and recombinant T. cruzi β-tubulin was used to 
immunize mice. Immunized animals increased their specific IgG reactivity and were 
protected against T. cruzi infection. These results strongly suggest that proteomics, 
used for repertoire analysis, is a valid tool to identify protective antigens that could 
be vaccine candidates to protect against T. cruzi infection [84].
12. Concluding remarks and future directions
T. cruzi infection is a major health issue in America and also in the rest of 
the world, where around 8 million people are infected by T. cruzi and the other 
28  million are exposed to the parasite infection. Even more, ~20,000 people die each 
year, mainly as a result of cardiac problem. Currently, immunoprophylactic strate-
gies have not been developed, and chemotherapy is so far from optimal, based on 
two old drugs, Nf and Bz. However, these drugs are more active in the acute form of 
Chagas disease and display several side effects.
In the last 15 years, a considerable number of proteomics studies have contrib-
uted to a better understanding of the biology and biochemistry of T. cruzi. In fact, 
the proteomes of the different life cycle stages of the parasite have been described, 
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including the proteomes of different zymodemes and different parasite DTUs. 
Using a typical experimental workflow as described in Figure 1, many different 
proteomics strategies have been reported. These allowed to determine the composi-
tion of different organelles, such as ribosomes, contractile vacuoles, reservosomes, 
and nuclear protein contents. These proteomics analyses have contributed to the 
knowledge of the products excreted/secreted by the parasite and have also allowed 
us to identify the contents of the microvesicles released by different parasite stages 
and their interaction with host cells. The study of post-translational modifications 
has also been possible and has contributed to the knowledge of parasite phos-
phorylation, glycosidation, myristoylation, SUMOylation, histone acetylation, 
and methylation. Proteomics has also helped elucidate critical biological processes, 
such as metacyclogenesis, amastigogenesis, and epimastigogenesis. The pathways 
involved in resistance to Bz and in the action mode of napthoimidazoles isolated 
from β-lapachone have been studied by proteomics approaches. Interactomics 
studies that demonstrated typing using M2 peptide spectral libraries and identifica-
tion of cure markers are also among the major achievements of proteomics in the 
research field of T. cruzi and Chagas disease. In all of these cases, special care was 
taken in sample preparation, and it was always cleaned using “Stage tip” (or other 
close related system) in order to remove sample contaminants. In some experiments 
quantitative proteomics was performed using label-free methods, while in others 
labeling was performed using iTRAQ , ICAT, SILAC, or others. In all cases, digested 
proteins were submitted to liquid chromatography systems directly interfaced to 
mass spectrophotometers (Figure 1).
Figure 1. 
Flow diagram of the main events in Trypanosoma cruzi proteomics. Qualitative and quantitative analyses 
using different parasite stages can be performed. Then, the proteins can be precipitated or separated by SDS-
PAGE. Proteins are digested, in the gel or in solution using proteases, such as trypsin and Lys C. The peptides 
are subjected to a cleaning phase, and the peptides can be labeled using techniques such as ICAT, ITRAQ , 
and SILAC or not be labeled, using label-free quantification (LFQ ). Finally, the samples are subjected to a 
ultrahigh-pressure liquid chromatography (UHPLC) associated to mass spectrometry (MS). The information 
obtained is submitted to bioinformatics analysis using software such as MaxQuant (or others), for quantitative 
proteomics analysis, and then by Andromeda to obtain the sequence of the peptides in the different databases 
and Perseus (or others) to obtain classifications, proteomics interactions, post-transductional modifications, 
and metabolic pathways.
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However, we still expect major contributions of proteomics in many aspects of 
parasite biology and in various clinical aspects. The subproteomes of acidocalci-
somes and the kinetoplast-mitochondrion complex could reveal important informa-
tion about parasite biology.
In addition, the identification of new biomarkers with diagnostic and prognostic 
value and for established cure criteria is needed, and proteomics would contribute 
to this field. In the same way, the identification and validation of new chemothera-
peutic targets to develop new and more efficient drugs and the identification of new 
potential vaccine candidates could also be an expected contribution.
Furthermore, in the future, considering the concept of “precision medicine” 
or “personalized medicine,” proteomics will offer the opportunity to characterize 
strains isolated from infected patients, identify its DTU, and define appropriate 
treatments and perhaps appropriate immunoprophylaxis. Moreover, the identifica-
tion of human sera biomarkers that allow us to predict which patients with the 
undetermined forms of Chagas disease show cardiomyopathy or digestive tract 
involvement would be a relevant contribution of clinical proteomics.
Recently, San Francisco et al. [85] reported that the in vitro invasion capacity 
and in vivo Balb/c mouse infectiveness of a highly virulent T. cruzi cell line were 
strongly reduced by parasite pretreatment with antisense oligonucleotides target-
ing trans-sialidase or complement regulatory proteins or with E64d to inhibit 
cruzipain activity. However, the parasite infectivity was not completely blocked, 
suggesting that other players, different from these proteins, could be involved in 
T. cruzi virulence. Thus, for comparison of the proteomic profiles of highly virulent 
and low-virulent cell lines of T. cruzi, the molecular bases of T. cruzi virulence 
will be established. For the T. cruzi secretome, different interactions among T. 
cruzi secreted proteins and host cell signaling pathways have been proposed [86]. 
However, the role of these proteins in virulence and modulation of the host immune 
system has not been shown experimentally. T. cruzi secretome studies and immu-
nomics analyses using acute sera of animals or infected patients in the acute phase 
of the infection would help elucidate the mechanisms that T. cruzi uses to subvert 
the host immune response.
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ultrahigh-pressure liquid chromatography (UHPLC) associated to mass spectrometry (MS). The information 
obtained is submitted to bioinformatics analysis using software such as MaxQuant (or others), for quantitative 
proteomics analysis, and then by Andromeda to obtain the sequence of the peptides in the different databases 
and Perseus (or others) to obtain classifications, proteomics interactions, post-transductional modifications, 
and metabolic pathways.
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However, we still expect major contributions of proteomics in many aspects of 
parasite biology and in various clinical aspects. The subproteomes of acidocalci-
somes and the kinetoplast-mitochondrion complex could reveal important informa-
tion about parasite biology.
In addition, the identification of new biomarkers with diagnostic and prognostic 
value and for established cure criteria is needed, and proteomics would contribute 
to this field. In the same way, the identification and validation of new chemothera-
peutic targets to develop new and more efficient drugs and the identification of new 
potential vaccine candidates could also be an expected contribution.
Furthermore, in the future, considering the concept of “precision medicine” 
or “personalized medicine,” proteomics will offer the opportunity to characterize 
strains isolated from infected patients, identify its DTU, and define appropriate 
treatments and perhaps appropriate immunoprophylaxis. Moreover, the identifica-
tion of human sera biomarkers that allow us to predict which patients with the 
undetermined forms of Chagas disease show cardiomyopathy or digestive tract 
involvement would be a relevant contribution of clinical proteomics.
Recently, San Francisco et al. [85] reported that the in vitro invasion capacity 
and in vivo Balb/c mouse infectiveness of a highly virulent T. cruzi cell line were 
strongly reduced by parasite pretreatment with antisense oligonucleotides target-
ing trans-sialidase or complement regulatory proteins or with E64d to inhibit 
cruzipain activity. However, the parasite infectivity was not completely blocked, 
suggesting that other players, different from these proteins, could be involved in 
T. cruzi virulence. Thus, for comparison of the proteomic profiles of highly virulent 
and low-virulent cell lines of T. cruzi, the molecular bases of T. cruzi virulence 
will be established. For the T. cruzi secretome, different interactions among T. 
cruzi secreted proteins and host cell signaling pathways have been proposed [86]. 
However, the role of these proteins in virulence and modulation of the host immune 
system has not been shown experimentally. T. cruzi secretome studies and immu-
nomics analyses using acute sera of animals or infected patients in the acute phase 
of the infection would help elucidate the mechanisms that T. cruzi uses to subvert 
the host immune response.
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The genome of Trypanosoma cruzi was first made available in 2005, and the 
intrinsic genome complexity of this parasite has hindered high-quality genome 
assembly and annotation. Recent technological developments in long read sequenc-
ing allowed to circumvent this problem, showing very interesting features in the 
genome architecture of T. cruzi, allowing to accurately estimate gene copy numbers, 
abundance and distribution of repetitive sequences (including satellites and retroele-
ments), and the complexity of multigene families implied in host-parasite interac-
tions. The genome of T. cruzi is composed of a “core compartment” and a “disruptive 
compartment” which exhibit opposite GC content and gene composition, with high 
differences on their regulatory regions. The novel tandem and dispersed repetitive 
sequences identified, in addition to recombination events, allows to conclude that 
genome plasticity is a key survival strategy during its complex life cycle.
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1. Introduction
The complex genome of Trypanosoma cruzi reflects its complex life. These 
parasites are able to invade almost any kind of cell to freely circulate in blood or 
extracellular matrix, to pass through the digestive tract of its insect vector and 
survive after being eliminated in feces. This stressful lifestyle strongly requires 
a fine regulation of gene expression, which in turn is reflected on its genome orga-
nization. Although the focus of this chapter is the nuclear genome (hereinafter 
called generically “genome”), it is worth mentioning that Trypanosomatids have 
another genome that contained in their single mitochondria called kinetoplast 
DNA. This exhibits unique architectural and functional features: it consists of 
a dense network of two types of circular DNA molecules called maxicircles and 
minicircles. Maxicircles, of several kb in length, are equivalent to regular mtDNA 
of other eukaryotes, whereas minicircles are much shorter (seldom longer than 
2 kb) and encode gRNAs. These are short RNA molecules responsible for guiding 
RNA editing, a process of posttranscriptional modifications that consists in the 
addition and deletion of uridines. Although editing is not exclusive of trypanoso-
matids, only in this group it involves massive changes in several (mitochondrialy 
encoded) genes.
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another genome that contained in their single mitochondria called kinetoplast 
DNA. This exhibits unique architectural and functional features: it consists of 
a dense network of two types of circular DNA molecules called maxicircles and 
minicircles. Maxicircles, of several kb in length, are equivalent to regular mtDNA 
of other eukaryotes, whereas minicircles are much shorter (seldom longer than 
2 kb) and encode gRNAs. These are short RNA molecules responsible for guiding 
RNA editing, a process of posttranscriptional modifications that consists in the 
addition and deletion of uridines. Although editing is not exclusive of trypanoso-
matids, only in this group it involves massive changes in several (mitochondrialy 
encoded) genes.
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Trypanosomes have peculiarities in transcription and genome organization 
that differentiate them from the majority of eukaryotes. Protein-coding genes are 
organized in clusters separated by relatively short intergenic regions, located on the 
same DNA strand [1] and—with a few exceptions—do not contain introns. Clusters 
are transcribed as long nuclear polycistronic units, and maturation implies 3′ polyad-
enylation—characteristic of eukaryotes—and trans-splicing, a peculiar mechanism 
of mRNA maturation. Trans-splicing is the process by which two RNAs encoded in 
different genome locations (trans) react to form a unique transcript, where the 5′ 
moiety contains the spliced leader sequence (~40 nt), and the rest contains the tran-
scribed gene [2, 3]. The spliced leader (SL) is transcribed from a tandem array as a 
precursor of ~140 nt whose 3′ end is removed and SL inserted to an AG splice-accep-
tor site on a pre-mRNA molecule, through a molecular mechanism that resembles 
cis-splicing [4–6]. Usually polypyrimidine-rich motifs precede AG splice acceptor. 
Since SL-RNA is the target of capping, trans-splicing is responsible for the addition 
of the 7-methylguanosine cap-like (cap4) on RNAs [7]. It has been described decades 
ago that this process is coupled to the polyadenylation of the 3′ end of the upstream 
gene, co-transcriptionally. As a consequence, a molecule of mature mRNA (capped, 
trans-spliced and polyadenylated) is released from the polycistron and exported 
to the cytoplasm, where it can be translated. Unlike other organisms, where trans-
splicing also occurs, in trypanosomatids it affects almost all genes. Therefore, in 
trypanosomes the 5′ UTR is the sequence segment located between the SL and the 
start codon, whereas the 3′ UTR is defined in the same way as in other eukaryotes. 
With the exception of genes tandemly repeated, polycistronic units do not contain 
functionally related genes, and usually individual genes from the same transcription 
unit can show markedly different expression patterns along life cycle [1, 3]. Gene 
expression in trypanosomes is regulated mainly at the posttranscriptional level, and 
numerous studies have shown the relevance of 3′ UTR regions in regulation, affect-
ing mRNA stability or translation, and hence differential expression [3, 8]. Different 
elements in the 3′ UTRs together with the presence of a high number of RNA binding 
proteins could explain, at least in part, differential expression [9–11], although the 
exact mechanisms allowing gene specificity are still unknown.
An important issue that still is not clear is whether T. cruzi constitutes a single 
species or a complex of species. Initially two groups of T. cruzi were described 
(I and II) based on biological and biochemical criteria as well as molecular techniques 
[12]. The first study using molecular phylogeny (sequences of coding genes) clearly 
showed that at least three major lineages (A, B and C) were present in this parasite 
[13], and that the distances between these groups are equivalent to the distance 
between different species of Leishmania. Currently six groups or discrete typing 
units (DTUs) named TcI-TcVI were proposed [14], and T. cruzi isolates from bats 
were included as a seventh DTU [15, 16]; where TcV and TcVI are hybrid lineages 
derived from haplotypes TcII and TcIII [16]. However, the high biological and 
genetic diversity of the T. cruzi strains, even at the intra-DTU level, indicates that 
DTUs constitute a useful working definition, but not a definitive classification. The 
new era of genomic studies through next generation sequencing (NGS) is providing 
new insights on the above-mentioned unsolved questions.
2. Genome organization
2.1 Chromosomes
In T. cruzi mitosis occurs without a complete disruption of nuclear envelope. In 
addition, although nucleosomes are present, chromatin does not condense up to 
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chromosomes, so they cannot be visualized by microscopy. This feature has made 
classic cytogenetic studies unsuitable for these parasites. Instead, T. cruzi karyotype 
has been determined by molecular biology techniques, mainly pulsed field gel 
electrophoresis (PFGE) in combination with Southern blot [17–19]. Early studies 
revealed complex chromosomal patterns, evidenced by different PFGE profiles 
among strains, and allowed to infer that T. cruzi was at minimum diploid [20]. Size of 
chromosomal bands ranges from 0.45 to 4 Mb, without minichromosomes, and the 
number of chromosomes was estimated mainly through probes used as genetic mark-
ers. Depending on the probes and PFGE conditions, chromosomes ranged between 19 
to 40 per haploid genome, showing that T. cruzi is mainly diploid, although the sizes 
of homologous chromosomes can differ significantly [17–19, 21–23].
A milestone was achieved in 2005 when the draft genomes of L. major, T. brucei, 
and T. cruzi were simultaneously published and referred as to the “TriTryps” 
[24–26]. This opened a new era in biology research on these parasites. A distinctive 
feature in T. cruzi was the already known highly repetitive nature of its genome 
(50%): in fact 5–10% of the genome is composed by the 195 bp satellite, and the rest 
of the repetitive DNA is composed of multigene families, tandem repeats and ret-
rotransposable elements [27]. This feature gave rise to a highly fragmented assem-
bly, resulting in that chromosome number and structure or, at least large contigs, 
could not be obtained. Attempts to recover full length chromosome sequencing, 
used a combined strategy based on synteny maps with T. brucei chromosomes and 
BAC ends sequencing. By this means 41 virtual chromosomes were obtained for the 
hybrid CL-Brener strain. Although this strategy represented a substantial improve-
ment in comparison to previous versions of the genome, the issue of assembly 
fragmentation remained as a limitation for diverse types of analyses that require 
high precision. A recent milestone in the area was the first publication of long read 
sequencing of two T. cruzi genomes (Dm28c and TCC strains), which allowed to 
circumvent the limitation of high fragmentation imposed by the Sanger method 
[28], as well as by short reads NGS methods. Using this approach, also described for 
Bug strain [29], contigs of more than 1 Mb were obtained, probably covering whole 
chromosomes, but fragmentation still persists in some regions of the genomes. 
The exact number of chromosomes and their organization will be finally achieved 
through the combination of long read sequencing methods, optical maps techniques 
and polymer-based modeling, a field that has undergone a dramatic acceleration in 
the last decade [30].
2.2 Ploidy
Although PFGE and fluorescence cytophotometry were useful methods to 
depict the complex variability of T. cruzi karyotypes, it was not until the advent 
of next generation sequencing techonologies (NGS) that ploidy—or chromo-
somal copy number variation (CCNV)—analyses could be studied more in detail. 
Aneuploidy, the gain or loss of chromosomal copies, is of particular importance 
since it gives clues about the relevance of genome plasticity in the context of 
parasite fitness. This phenomenon has been detailed studied in Leishmania spp., 
whose “mosaic” aneuploidies—ploidy variations within isolates from a strain and 
even between individual cells from a population – were related to drug resistance, 
regulation on gene expression, or host adaptation [31–33]. On the contrary, PFGE, 
fluorescence cytophotometry and high-throughput sequencing data analyses agreed 
on the ploidy stability of T. brucei and its subspecies: T. b. brucei, T. b. gambiense 
and T. b. rhodesiense [34–36]. Remarkably, a field isolated T. congolense triploid was 
reported, suggesting that Salivarian evolutionary lineage species, such as T. brucei 
and T. congolense, can sustain euploidies but not massive aneuploidies [37].
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In T. cruzi, since CCNV analysis deeply depends on high quality, chromosome-
level assembled reference genomes, it was extremely difficult to implement. 
However, in spite of this limitation, some approaches were done using CLBrener 
genome as reference [38]. Taking into account the poorly assemble reference 
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55,2 929 200.364 64 51,3 - - PacBio [29]
CL Brener TcVI 
(hybrid)
89,9 29.495 88.624 212 51,7 23696 19607 Sanger [25]
Esmeraldo-
like*




32,5 41 -- -- -- 11398 10831 -- [49]
Dm28c TcI 27,3 1.210 78.389 86 50,6 11398 11348 454 [81]
G TcI 25,2 1.450 74.655 91 47,4 13488 12708 454 [82]
CL TcVI 
(hybrid)
65,0 7.764 73.547 95 39,8 34248 32278 454 [82]
S23b TcII 28,1 7.145 20.992 332 45,2 - - Illumina [38]
S92a TcII 27,1 7.134 20.493 310 46,4 - - Illumina [38]
S11 TcII 28,5 7.855 18.630 346 45,1 - - Illumina [38]
S44a TcII 17,2 4.971 17.818 232 45,0 - - Illumina [38]
S15 TcII 27,5 9.197 17.779 370 46,2 - - Illumina [38]
231 TcIII 35,4 8.469 14.202 586 48,6 - - Illumina [83]
S162a TcII 27,3 8.588 12.390 448 45,3 - - Illumina [38]
Y TcII 39,0 9.821 11.962 561 49,8 - - Illumina [29]
Ycl4 TcII 26,1 6.664 10.716 560 46,6 - - Illumina [38]
Ycl2 TcII 25,9 6.884 10.600 563 46,6 - - Illumina [38]
Ycl6 TcII 25,8 6.967 10.394 549 46,6 - - Illumina [38]
S154a TcII 19,3 6.946 5.877 859 49,6 - - Illumina [38]
Y TcII 30,0 8.952 5.474 1305 50,6 - - 454 [39]
Colombiana TcI 30,9 9.338 5.189 1394 50,8 - - 454 [39]
Sylvio X10/1 TcI 38,6 27.019 2.307 2599 51,2 10861 10847 454 [53, 84]
Arequipa TcI 19,1 10.224 1.932 3156 50,9 - - 454 [39]
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genome at that moment, and the repetitive nature of T. cruzi genome, only reads 
with high mapping quality were used in CCNV estimations. The single-copy 
genes ploidy estimation (SCoPE) was the methodology utilized by the authors. In 
this methodology, estimation of chromosomal somy is based on the ratio between 
the mean coverage of all single-copy genes (unique genomic sequences) in a given 
chromosome and the genome coverage. After including several T. cruzi strains 
from different DTUs, authors proposed that—as was observed in Leishmania—
the aneuploidy pattern varies among and within T. cruzi lineages. In addition, as 
observed with PFGE, CCNV is considerably frequent between T. cruzi strains, 
including those within a same DTU. Authors propose that TcI appears to be 
more stable, and TcII had large differences between strains, suggesting that 
this mechanism is widely used by the parasite to expand groups of genes [39]. 
Nevertheless, unlike L. donovani, CCNV on T. cruzi seems to be stable on parasite 
population, at least for TcII analysis on Y strain and derived clones [38].
2.3 Genome size
The genome size of T. cruzi has been estimated by different methodologies 
such as flow cytometry, renaturation kinetic analysis, microfluorometry, chemical 
analysis, molecular karyotyping and genome sequencing. Every approach agreed 
on that T. cruzi genome size is variable. Polymorphism has been shown between 
DTUs, between strains within the same DTU, and even between isolates from the 
same strain [40–47]. From a wide genome size quantification and analysis including 
more than fifty strains from DTUs TcI to TcVI [46] it was found that: (i) maximum 
difference observed between strains was 47.5%; (ii) TcI was the smallest genome, 
(iii) TcV and TcVI were the least variable, (iv) parental genomes mean gene content 
(TcI: 88.4 Mb, TcII: 106.5 Mb, TcIII: 119.2 Mb), and similar results on the reduced 
size of TcI, with few exceptions was further observed [47].
Genome size estimation by bioinformatic analysis of NGS data, as was men-
tioned before, is hampered due to the massive presence of repetitive sequence 
regions, which reach up to 50% of the genome [25, 48]. This generates assembly 
fragmentation and collapse—gene and repetitive sequences, leading to copy 
number underestimation—which represents a challenge to the correct genome size 
estimation. In fact, as reflected on Table 1, the assembly size is far below the esti-
mations made by DNA measurements methods. Only third generation sequenced 
genomes appear to represent more accurate figures [28, 29].
3. Genome architecture and composition
The publication the of first T. cruzi genome in 2005 [25] was a cornerstone of 
the study of its genome complexity. Although the CL-Brener sequenced strain 
turned out to be a hybrid that made the analyzes more arduous, at that time it 
was corroborated that more than 50% of the genome of T. cruzi corresponds to 
repetitive sequences—mainly retrotrasposons, multigenic families and tandem 
repeats—including the discovery of the new gene family of a new family of 
mucin associated surface proteins (MASP). Around 12,500 genes could be 
 identified, but the assembly was fragmented into more than 5400 scaffolds 
(ordered contigs usually joined with unknown sequences filled as “N”), and the 
complete sequence of the genome was not obtained, being the total genome size 
about 67 Mb (half of it corresponding to each haplotype). Later on, based on 
the scaffolds already defined [25], BAC ends sequencing and synteny maps with 
T.  brucei, it was possible to recover full length pseudo-chromosomes [49], although 
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genome at that moment, and the repetitive nature of T. cruzi genome, only reads 
with high mapping quality were used in CCNV estimations. The single-copy 
genes ploidy estimation (SCoPE) was the methodology utilized by the authors. In 
this methodology, estimation of chromosomal somy is based on the ratio between 
the mean coverage of all single-copy genes (unique genomic sequences) in a given 
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more than fifty strains from DTUs TcI to TcVI [46] it was found that: (i) maximum 
difference observed between strains was 47.5%; (ii) TcI was the smallest genome, 
(iii) TcV and TcVI were the least variable, (iv) parental genomes mean gene content 
(TcI: 88.4 Mb, TcII: 106.5 Mb, TcIII: 119.2 Mb), and similar results on the reduced 
size of TcI, with few exceptions was further observed [47].
Genome size estimation by bioinformatic analysis of NGS data, as was men-
tioned before, is hampered due to the massive presence of repetitive sequence 
regions, which reach up to 50% of the genome [25, 48]. This generates assembly 
fragmentation and collapse—gene and repetitive sequences, leading to copy 
number underestimation—which represents a challenge to the correct genome size 
estimation. In fact, as reflected on Table 1, the assembly size is far below the esti-
mations made by DNA measurements methods. Only third generation sequenced 
genomes appear to represent more accurate figures [28, 29].
3. Genome architecture and composition
The publication the of first T. cruzi genome in 2005 [25] was a cornerstone of 
the study of its genome complexity. Although the CL-Brener sequenced strain 
turned out to be a hybrid that made the analyzes more arduous, at that time it 
was corroborated that more than 50% of the genome of T. cruzi corresponds to 
repetitive sequences—mainly retrotrasposons, multigenic families and tandem 
repeats—including the discovery of the new gene family of a new family of 
mucin associated surface proteins (MASP). Around 12,500 genes could be 
 identified, but the assembly was fragmented into more than 5400 scaffolds 
(ordered contigs usually joined with unknown sequences filled as “N”), and the 
complete sequence of the genome was not obtained, being the total genome size 
about 67 Mb (half of it corresponding to each haplotype). Later on, based on 
the scaffolds already defined [25], BAC ends sequencing and synteny maps with 
T.  brucei, it was possible to recover full length pseudo-chromosomes [49], although 
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still maintaining thousands of sequences as “unassigned contigs.” Since these 
initial publications, several T. cruzi genomes have been reported to be sequenced 
by NGS, although massive sequencing could not improve the low resolution in 
complex and highly fragmented regions (Table 1 and cites therein).
The advent of long read sequencing technologies helped to tackle part of the 
assembly fragmentation issue, and to better understand T. cruzi genome complex-
ity. In 2018 the genomes of two T. cruzi strains (Dm28c and TCC, belonging to 
TcI and TcVI respectively) were sequenced by using Pacbio technology, showing 
substantial improvements: assemblies of Dm28c and TCC were of 53.2 and 86.7 Mb 
distributed in 599 and 1142 contigs, respectively, which implied a high reduction of 
fragmentation [28] (see N50 stats, Table 1). Completeness of these genomes was 
achieved, obtaining for the case of Dm28c all its haploid genome, totaling 53.3 Mb. 
This size is consistent with the most precise estimations made by fluorescent nucleic 
acid dye [47]. For the hybrid strain TCC, composed of two relatively divergent 
parental lineages, it is assumed that the diploid size that includes both parental 
haplotypes should be recovered, i.e., 106–122 Mb for TCC [46, 47], which compared 
with the 86.7 Mb indicates that segregation cannot be achieved in those regions 
with high identity. The ability to separate haplotypes opens new possibilities for the 
study of the evolutionary processes that occurred in T. cruzi and can be useful to 
provide insights on how hybrids were generated and evolved. Moreover, recombina-
tion events can be identified and studied [28]. The hybrid strain Bug 2148 (TcV) 
was recently long-read sequenced and assembled in 934 contigs, also resolving the 
fragmentation in a large degree; although the expected genome size is 106–135 Mb 
[46, 47], the total assembly size is 55.2 Mb and it is striking that there is no evidence 
of haplotype separation [29] as would be expected for a hybrid strain.
Even using this new technology, these assemblies still have some fragmentation 
mainly due to the size of the tandem repeats. In particular, the well-characterized 
195 bp satellite that can reach clusters of 50 kb, contributes as a major factor to 
assembly fragmentation avoiding its complete resolution [50–52]. In fact, these 
genomes contain several contigs entirely composed of this repeat, which together 
encompasses more than 5% of the genome (see below).
3.1 Genome compartments and gene composition
Since genomic annotation, especially in T. cruzi, is arduous and often the goal 
of genomic sequencing escapes the annotation, it has not been performed in all 
genomes. For those genomic projects of T. cruzi that have the annotation (see Table 1) 
quite similar number of coding genes per haplotype was determined, a minimum of 
~10,800 for Sylvio [53] and a maximum of 15,300 for Dm28c [28]. These genes can be 
divided into two large groups, those of well conserved core genes, and those coding for 
the multigenic surface families, several of which are unique for T. cruzi (see below). 
In fact, the improvements in the assemblies allowed us to determine that the genome 
of T. cruzi is composed of two compartments. These compartments, called “core” and 
“disruptive” [28] vary in gene content and nucleotide composition. The “core com-
partment” is composed of conserved and hypothetical conserved genes, it has a lower 
GC content (48%) and exhibits synteny conservation with T. brucei and L. major, 
whereas the “disruptive compartment” is mainly composed by the surface multigene 
families trans-sialidase, MASP, and mucins, and exhibits a higher GC content (53%).
3.2 Gene organization
As mentioned, genes in trypanosomatids are organized into non-overlapping 
clusters on the same DNA strand with unrelated predicted functions. Genes are 
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transcribed as polycistrons and subsequently trans-spliced and polyadenylated. 
In T. cruzi gene clusters can range from ~30 to 500 kb separated by divergent or 
convergent strand-switch regions (SSR) [54]. Although no evidence of shared 
consensus motive or patterns has been found among them, the SSR are function-
ally active. For instance, transcription initiation and termination take place [2, 55, 
56], but it is also observed that they are involved in the origin of DNA replication 
[57], and centromeric function [58, 59]. The SSRs exhibit some properties such as a 
different composition in comparison to the rest of the genome and higher intrinsic 
curvature [60, 61], associated in turn with transcriptional regulation. Indeed SSRs 
from the disruptive compartment are longer than those from the core compartment 
(mean length ~4.5kb and ~1.5kb respectively).
4. Trypanosoma cruzi repetitive genome
One of the outstanding features of the T. cruzi genome is its repetitive nature. 
Three types of sequences contribute to this characteristic: multigenic families, 
retrotransposons and satellite DNA (tandem repeat sequences).
4.1 Multigene Families
A main characteristic of T. cruzi genome is the large number of multigene 
families, many of them having hundreds of members. The largest families in T. cruzi 
genome are shown in Table 2. TS, Mucins and MASP are located in the disruptive 
compartment of the genome, whereas GP63, DGF-1 and RHS are distributed in 
both compartments [28]. We will focus on families from the disruptive compart-
ment (MASP, Mucins and TS), and GP63 as an example of a very expanded family 
in T. cruzi. It is noteworthy that these families code for proteins directly involved in 
interaction with the host, both at the cellular level (adhesion, invasion, infection) 
and in immune modulation responses, mainly because most of TS, Mucins, MASP 
and GP63 proteins are GPI anchored, i.e., they are constitutive part of the function-
ally relevant cell surface of T. cruzi.
Table 2. 
Gene families groups in T. cruzi.
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4.1.1 Trans-sialidases
Trans-sialidases and trans-sialidase-like proteins (TS) constitute a large and 
polymorphic superfamily [25, 28, 29] whose name comes from the ability to trans-
fer sialic acid from host glycoconjugates to parasite’s mucins [70, 62]. This activity 
is highly relevant since T. cruzi is unable to synthesizes sialic acid de novo, and 
sialic acid containing glycoproteins are demonstrated to be relevant for infection 
[70, 62, 63]. However, only a very few members of TS family are predicted to be 
enzymatically active [29], whereas the rest of them have other relevant roles such 
as binding to host molecules, immunomodulation, apoptosis or invasion [64]. It 
should be very important to rename this family since its current denomination 
leads to confusion. The hallmark of the family is the presence of the canonical 
amino acid motif VTVXNVXLYNR, although some members have a degener-
ated version of it [64]. TS proteins can be secreted or membrane anchored, in 
which case they exhibit an N-terminal signal peptide and GPI signal sequence 
at the C-terminal region of the protein. Genomic analysis of TS gene family in 
CL-Brener revealed that TS family was clustered in eight groups, which were clas-
sified by the presence or absence of additional motifs like FRIP, Asp box and the 
SAPA [65, 66]. In this classification the Group I is defined as those sequences with 
a predicted enzymatic activity, which corresponds to 4% of the total TS genes 
[67]. By long read sequencing, a more precise gene copy number could be deter-
mined on TCC and Dm28c strains: 1734 and 1491 TS genes respectively; with these 
new protein sequences the classification should be updated. Draws the attention 
that both strains exhibit a substantially high percentage of pseudogenes: 41.6% 
in TCC and 38% in Dm28c [28], which suggest that they could not constitute 
“inert material.” This point deserves further studies to determine if pseudogenes 
are expressed, and/or can constitute a source of variability, among their possible 
functions. Most of TS genes are overexpressed in trypomastigotes, but a small 
percentage are upregulated in amastigotes or epimastigotes at the transcriptional 
level [68].
4.1.2 Mucins
Mucins and mucin like glycoproteins are the main acceptors of sialic acid 
through the trans-sialidase TS activity [69], and participate in adhesion, protection 
against lysis, invasion and immune evasion [70]. The first mucin-like gene cloned 
and the predicted protein exhibited an internal tandem repeat with the canoni-
cal sequence T8LP2, flanked by an N-terminal signal peptide and a C-terminal 
GPI anchor signal sequence. Further studies revealed the presence of a complex 
family with genes coding for proteins with similar N and C termini but with non-
repetitive, variable and serine and threonine rich domains, also classified as mucins. 
Those groups with repetitive domains and without repetitive domains were desig-
nated TcMUCI and TcMUCII [10], and the presence of a mosaic sequences between 
both groups led to the proposal of a common ancestor and further diversification 
[70]. Another group of smaller mucin genes, TcSMUG [71], are expressed in the 
insect stages, and were subclassified in large and small TcSMUG (L and S) [70]. 
Due to the complexity of this family manual curation is needed for annotation of 
these genes. Our group used the following criteria: genes exhibiting an N-terminal 
signal peptide, a C-terminal GPI anchor signaling, and T rich sequences such as 
T8KP2, T6-8KAP or T6-8QAP, finding 1018 and 574 mucin genes in TCC and Dm28c 
respectively [28], and around 20% were classified as pseudogenes in both strains. 
Regarding the expression of TcMUC and TcSMUG in life stages of Trypanosoma 
cruzi, trypomastigotes presented higher expression levels of both TcMUC groups, 
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and in contrast with biochemical reports [70], in amastigotes the highest expressed 
mucins belong to TcMUCII instead of TcMUCI [68].
4.1.3 MASPs
One of the most surprising result after assembly and annotation of the first T. 
cruzi genome [25], was the discovery of a new gene family composed of approxi-
mately 1300 genes, and named as mucin associated surface protein (MASP), 
because of their location in proximity or clustered with mucin genes. MASP 
family is characterized by conserved N-terminal signal peptide, a conserved 
C-terminal domain containing a GPI anchor addition site, and a variable central 
region [25]. One of the proposed roles of this gene family is the immune system 
evasion during the acute phase of Chagas disease [72]. CL-Brener clone contains 
1377 masp genes, among which 771 appear to be intact genes and 433 (31%) are 
pseudogenes [25], and analysis in Dm28c and TCC yield similar results: 1045 and 
1332 genes where 36 and 33% respectively are pseudogenes [28]. Regarding the 
expression of this gene family, 97% of masp genes are upregulated in trypomasti-
gotes, and a discrete number of genes are expressed specifically in amastigotes or 
epimastigotes [68].
4.1.4 GP63
GP63 are GPI anchored metalloproteases present in the Tritryps. However, 
whereas L. major contains six gp63 genes and T. brucei has thirteen copies, in T. 
cruzi this family is widely expanded: 400 genes or pseudogenes were identified 
in CL-Brener [25] and Dm28c [28], and more than 700 in TCC [28]. Strikingly, 
more than 60% of these genes on the three strains are annotated as pseudogenes. 
Although the role of this family in innate immune evasion and invasion, has been 
extensively studied in Leishmania [73, 74], little is known about its role in T. cruzi. 
The reason of the expansion of this gene family in the T. cruzi genome remains to be 
elucidated as well as its role on this parasite. Transcriptomic analysis revealed that 
most of the members are highly expressed in trypomastigotes, whereas a few genes 
are expressed almost exclusively in amastigotes. Interestingly, phylogenetic analysis 
using 3′ UTR sequences of gp63 genes showed three groups of sequences clearly dis-
tinguished; one group associated with genes highly expressed in trypomastigotes, 
another one with genes highly expressed in amastigotes, and a third group of genes 
with almost no expression in any stage of the parasite [68]. This result strongly 
supports a major role of the 3′ UTR in posttranscriptional regulation of this family 
that deserves further studies.
4.2 Transposable elements
Transposable elements (TEs) are repeated DNA sequences, which have the ability 
to move from one to another locus in the genome. This was why they have been 
referred to as “junk” DNA, selfish sequences or genomic parasites. However, growing 
evidence is indicating the great importance that TEs play in the evolution of genes and 
genomes in a wide range of organisms, including trypanosomatids [75, 76]. T. cruzi 
genome lacks class II elements (DNA transposons), bearing only class I retroele-
ments. Within them—according to Wicker [77] TEs classification—T. cruzi presents 
three autonomous families: VIPER, a tyrosine recombinase (YR) element which 
belongs to the DIRS order; L1Tc, a non-LTR element of the ingi clade; and CZAR, also 
a non-LTR element from the CRE clade which is site-specific, inserting only on the 
SL gene [25, 76, 78]. On the other hand, non-autonomous elements have been also 
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identified. SIRE, have similarity with the VIPER 5′ and 3′ ends, resembling what now-
adays are called solo-LTR. NARTc is the non-autonomous couple of L1Tc elements, 
as has been classically described for LINE/SINE-like couples. Finally, TcTREZO has 
been described as another site-specific retroelement, inserted within masp genes [79]. 
Although it has been characterized as a non-LTR retroelement due to the presence of a 
poly-A tail and a secondary structure which will be promoting its retrotranscription, 
no conserved domains have been detected on this element. Hence, TcTREZO could 
be an ancient non-autonomous retroelement. All of the VIPER, CZAR and TcTREZO 
copies are defective (no complete domains where found), whereas L1Tc was the only 
one which showed putative active copies [28].
4.3 Tandem repeats
Although NGS platforms implied an enormous progress for our knowledge 
about genomes composition and evolution, tandem repeats were not that benefited. 
Tandem repeats are commonly classified in micro, mini and macro-satellite, depend-
ing on their monomer or cluster length. Microsatellites are those whose monomers 
are from 2 to 5 bp, minisatellites from 15 to 100 bp, and finally macrosatellites or 
just called satellites involves repeats greater than 100 bp [80]. Even with very deep 
genome coverage, short read lengths cause problems for de novo assemblies, espe-
cially in tandem repeat rich regions. Due to this trouble, tandem repeats can be con-
sidered as neglected sequences in the majority of genome analyses. Although great 
efforts were done, fragmentation of the genome assembly occurs frequently where 
repeated sequences are located. In fact, the massive major 195 bp satellite (TcSAT1 
named in repbase) described for the first time by Sloof et al. [50], represents a huge 
challenge for contig assembly. Although PacBio reads enable to develop an improved 
assembly and characterization of tandem repeats characterization and assembly, 
the size of some clusters exceeds that of the reads. In fact, some small-size contigs 
(50 kb) are composed entirely by the 195 bp satellite sequence.
In summary, genomic studies are essential for understanding Trypanosoma cruzi 
biology, and the new technologies will give responses to still unanswered questions: 
Which molecular mechanisms allow to regulate specific genes, without consensus 
sequences? Is Trypanosoma cruzi a unique species? How many chromosomes do 
they have? How are chromosomes organized? Which role plays the highly repeti-
tive genome on its plasticity? And we can continue, to reinforce the idea that much 
remains to be done.
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Abstract
Trypanosoma cruzi is the causal agent of Chagas disease that affects 6–7 million 
people around the world, principally in Latin America. This disease is character-
ized for the presence of an acute phase in which the host immune response plays 
a central role in the elimination of the parasite. If the parasite is not efficiently 
eliminated, patients can remain asymptomatic or develop a chronic infection. One 
of the cells that are primarily infected with this intracellular parasite is macrophages 
(Mϕ). Mϕ present a wide array of activation states with classically activated mac-
rophages in one pole (CAMϕ) and alternatively activated macrophages (AAMϕ) 
in the other. One of the most important differences between these two activation 
states is the presence of the inducible nitric oxide synthase (iNOS or NOS2) in 
CAMϕ and arginase 1 (Arg-1) in AAMϕ; both enzymes share the same substrate, 
l-arginine, and are reciprocally regulated by the action of Th1 cytokines in the case 
of NOS2 and Th2 cytokines in the case of Arg-1. The activation of CAMϕ permits 
the production of nitric oxide (NO), highly trypanotoxic, while the activation 
of AAMϕ allows the synthesis of polyamines, necessary for parasite duplication. 
l-arginine is a very important metabolite situated in the center between the elimi-
nation and perpetuation of T. cruzi.
Keywords: arginase-1, l-arginine, inducible nitric oxide synthase,  
macrophages, trypanosoma cruzi
1. Introduction
Trypanosoma cruzi is the causal agent of Chagas disease that affects 6–7 million 
people around the world, mainly in Latin America [1], although in the last years it 
has also become a potential public health problem in developed countries due to the 
constant migrations with cases reported in the USA, Canada, Europe, Japan, and 
Australia [2].
This intracellular obligate parasite enters the human host in the form of meta-
cyclic promastigotes that are released from the triatomine feces during the blood 
meal, through damaged skin or mucosae. Alternatively, infection can occur through 
other routes such as oral, congenital, blood transfusions, or organ transplants. 
After entering the host, trypomastigotes are phagocytized mainly by macrophages, 
where they transform to amastigotes, the intracellular form that has the ability to 
replicate. In order to evade the host immune response and ensure its persistence 
inside macrophages, Trypanosoma has developed multiple strategies. One of these 
has as a target l-arginine metabolism. Macrophages can eliminate amastigotes or 
permit their survival depending on the balance of two inducible enzymes nitric 
96
Biology of Trypanosoma cruzi
[70] Buscaglia CA et al. Trypanosoma 
cruzi surface mucins: Host-dependent 
coat diversity. Nature Reviews 
Microbiology. 2006;4(3):229-236
[71] Urban I et al. Molecular diversity 
of the Trypanosoma cruzi TcSMUG 
family of mucin genes and proteins. The 
Biochemical Journal. 2011;438(2):303-313
[72] dos Santos SL et al. The MASP 
Family of Trypanosoma cruzi: Changes 
in gene expression and antigenic profile 
during the acute phase of experimental 
infection. PLoS Neglected Tropical 
Diseases. 2012;6(8)
[73] Yao C, Donelson JE, Wilson ME.  
The major surface protease (MSP or 
GP63) of Leishmania sp. biosynthesis, 
regulation of expression, and function. 
Molecular and Biochemical Parasitology. 
2003;132(1):1-16
[74] Brittingham A et al. Role of the 
Leishmania surface protease gp63 in 
complement fixation, cell adhesion, 
and resistance to complement-mediated 
lysis. The Journal of Immunology. 
1995;155(6):3102-3111
[75] Bringaud F et al. Members of a large 
retroposon family are determinants of 
post-transcriptional gene expression 
in Leishmania. PLoS Pathogens. 
2007;3(9):e136
[76] Thomas MC et al. The biology and 
evolution of transposable elements 
in parasites. Trends in Parasitology. 
2010;26(7):350-362
[77] Wicker T et al. A unified 
classification system for eukaryotic 
transposable elements. Nature Reviews 
Genetics. 2007;8(12):973
[78] Bringaud F et al. Role of transposable 
elements in trypanosomatids. Microbes 
and Infection. 2008;10(6):575-581
[79] Souza RT et al. New Trypanosoma 
cruzi repeated element that shows site 
specificity for insertion. Eukaryotic 
Cell. 2007;6(7):1228-1238
[80] Charlesworth B, Sniegowski P, 
Stephan W. The evolutionary dynamics 
of repetitive DNA in eukaryotes. Nature. 
1994;371(6494):215
[81] Grisard EC et al. Trypanosoma 
cruzi clone Dm28c draft genome 
sequence. Genome Announcements. 
2014;2(1):pii:e01114-13
[82] Bradwell KR et al. Genomic 
comparison of Trypanosoma conorhini 
and Trypanosoma rangeli to Trypanosoma 
cruzi strains of high and low virulence. 
BMC Genomics. 2018;19(1):770
[83] Baptista RP et al. Assembly of highly 
repetitive genomes using short reads: 
The genome of discrete typing unit III 
Trypanosoma cruzi strain 231. Microbial 
Genomics. 2018;4(4)
[84] Franzén O et al. Comparative 
genomic analysis of human infective 
Trypanosoma cruzi lineages with 
the bat-restricted subspecies T. 




l-arginine Metabolism in the 
Infection with Trypanosoma cruzi
Laila Gutiérrez-Kobeh and Arturo A. Wilkins-Rodríguez
Abstract
Trypanosoma cruzi is the causal agent of Chagas disease that affects 6–7 million 
people around the world, principally in Latin America. This disease is character-
ized for the presence of an acute phase in which the host immune response plays 
a central role in the elimination of the parasite. If the parasite is not efficiently 
eliminated, patients can remain asymptomatic or develop a chronic infection. One 
of the cells that are primarily infected with this intracellular parasite is macrophages 
(Mϕ). Mϕ present a wide array of activation states with classically activated mac-
rophages in one pole (CAMϕ) and alternatively activated macrophages (AAMϕ) 
in the other. One of the most important differences between these two activation 
states is the presence of the inducible nitric oxide synthase (iNOS or NOS2) in 
CAMϕ and arginase 1 (Arg-1) in AAMϕ; both enzymes share the same substrate, 
l-arginine, and are reciprocally regulated by the action of Th1 cytokines in the case 
of NOS2 and Th2 cytokines in the case of Arg-1. The activation of CAMϕ permits 
the production of nitric oxide (NO), highly trypanotoxic, while the activation 
of AAMϕ allows the synthesis of polyamines, necessary for parasite duplication. 
l-arginine is a very important metabolite situated in the center between the elimi-
nation and perpetuation of T. cruzi.
Keywords: arginase-1, l-arginine, inducible nitric oxide synthase,  
macrophages, trypanosoma cruzi
1. Introduction
Trypanosoma cruzi is the causal agent of Chagas disease that affects 6–7 million 
people around the world, mainly in Latin America [1], although in the last years it 
has also become a potential public health problem in developed countries due to the 
constant migrations with cases reported in the USA, Canada, Europe, Japan, and 
Australia [2].
This intracellular obligate parasite enters the human host in the form of meta-
cyclic promastigotes that are released from the triatomine feces during the blood 
meal, through damaged skin or mucosae. Alternatively, infection can occur through 
other routes such as oral, congenital, blood transfusions, or organ transplants. 
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oxide synthase (iNOS or NOS2) and arginase-1 (Arg-1) that share the same sub-
strate: l-arginine. During the activation of macrophages in the context known as 
classical activation, l-arginine is metabolized by iNOS giving rise to the production 
of nitric oxide (NO), one important trypanotoxic agent that permits these cells to 
destroy the parasite. On the other hand, during the activation of macrophages in the 
context known as alternative activation, l-arginine is metabolized by Arg-1 giving 
rise to the production of polyamines that favor multiplication and persistence of 
Trypanosoma in these cells. Thus, l-arginine is situated as a frontier between the 
elimination and survival of Trypanosoma in macrophages, and its metabolism is a 
determinant factor for the evolution of the disease.
2. Phases of the infection with Trypanosoma cruzi
The infection with T. cruzi presents an acute phase that is auto-limiting and can 
go unnoticed in many infected individuals. During this phase, parasites actively 
duplicate in different cells and tissues such as macrophages; muscular cells of 
smooth, striated, and cardiac muscles; adipocytes; and cells of the central nervous 
system [3]. While some patients succumb during the acute phase of the disease, the 
development of an adaptive immune generally permits the control of infection with 
T. cruzi. If the parasite is not completely eradicated, individuals remain infected 
for life, and a dynamic equilibrium is established with the parasite that results in 
different clinical outcomes. In this way, while many individuals chronically infected 
remain in an asymptomatic intermediate phase, a significant proportion (30–35%) 
of patients develop cardiac or digestive manifestations that can drive them to 
congestive cardiac failure, arrhythmias, and eventually death or develop colon or 
esophageal megasyndromes. All of these are irreversible pathologic changes that 
occur even though the presence of the parasite is scarce. One experimental model 
that recapitulates chagasic myocarditis is present in infected mice for long periods 
with different T. cruzi strains that develop chronic lesion in the myocardium [4, 5].
3. Generalities of l-arginine
ʟ-arginine is one of the most versatile amino acids at the metabolic level. Besides 
serving as a precursor for protein synthesis, it is also a precursor of multiple 
compounds of great biologic importance such as urea, nitric oxide, polyamines, 
l-proline, glutamate, creatinine, and agmatine (Figure 1) [6, 7].
In adult mammals, ʟ-arginine is a nonessential amino acid; nevertheless, during 
childhood and certain physiologic or pathologic conditions (e.g., pregnancy, sepsis, 
trauma, catabolic stress, intestinal or renal damage), it is considered as a semi-
essential amino acid or conditioned nonessential, due to the fact that its consumption 
exceeds the capacity of being synthesized by the organism and has to be supplied 
exogenously [8–10]. In mammals, the provision of l-arginine depends on its procure-
ment through the protein diet, endogenous synthesis (de novo synthesis), and its 
release during the process of protein replacement (Figure 1) [6]. Approximately 40% 
of the l-arginine that is obtained from the protein diet is catabolized in the intestine 
before entering the circulation [11]. In the absence of the contribution by the protein 
diet, approximately 80% of the ʟ-arginine that enters the circulation derives from 
the protein replacement, and the remaining percentage is obtained through the 
novo synthesis [11]. l-arginine metabolism occurs basically in the liver and kidney; 
nevertheless, other tissues and cells also possess the required enzymes to metabolize 
it, including some cells of the immune response [12]. Regarding last point, it is 
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interesting to note that a complete urea cycle has been described in macrophages 
[13]. Although only two enzymes directly involved in l-arginine synthesis have been 
identified (arginine succinate synthetase and arginine succinate lyase that are the 
third and fourth enzymes of the urea cycle), four enzymes utilize this amino acid 
as substrate: arginine decarboxylase, arginine/glycine aminotransferase, different 
isoforms of arginase (Arg), and the different isoforms of the nitric oxide synthases 
(NOS), the last two being the most studied and characterized [12]. In mammals two 
arginase isoforms exist, Arg-1 and Arg-2, that catalyze the same reaction but differ 
in cellular expression and subcellular localization. Arg-1 is cytosolic and is highly 
expressed in the liver and some cells of the immune response. Compared to Arg-1, 
Arg-2 is mitochondrial and is expressed in a great variety of peripheral tissues, 
mainly in the kidney, prostate, small intestine, and mammary glands during lacta-
tion [14]. Regarding NOS, this enzyme is present in three isoforms: neuronal NOS 
(nNOS or NOS1), inducible nitric oxide synthase (iNOS or NOS2), and endothelial 
NOS (eNOS or NOS3). NOS 1 is expressed in specific neurons of the central nervous 
system (CNS), and NOS3 is mostly expressed in endothelial cells [15]. NOS 2 is not 
usually expressed in cells, but its expression can be induced by bacterial lipopolysac-
charide, cytokines, and other agents. Although primarily identified in macrophages, 
the expression of this enzyme can be stimulated in almost any cell or tissue, provided 
that the appropriate inducing agents are present [16].
4.  l-arginine metabolism in the immune response: special emphasis in 
macrophages
In the immune response, ʟ-arginine metabolism through NOS2 and Arg-1 has a 
pivotal role in the regulation of the effector capabilities of macrophages, dendritic 
cells, and neutrophils [17–20] during infectious processes caused by a great variety 
of microorganisms: different species of Mycobacterium, Leishmania, Trypanosoma, 
Schistosoma, and Salmonella, among others [21, 22].
l-arginine metabolism in the immune response acquired great relevance with 
the discovery that murine macrophages express both NOS2 and Arg-1 and that their 
expression is reciprocally regulated by the action of Th1/proinflammatory cyto-
kines (e.g., IFN-γ and TNF-α) and Th2/anti-inflammatory (e.g., IL-4, IL-10, and 
IL-13) that determine the activation state of macrophages [19, 23–27].  
Figure 1. 
Sources of L-arginine in mammals and its metabolic products.
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interesting to note that a complete urea cycle has been described in macrophages 
[13]. Although only two enzymes directly involved in l-arginine synthesis have been 
identified (arginine succinate synthetase and arginine succinate lyase that are the 
third and fourth enzymes of the urea cycle), four enzymes utilize this amino acid 
as substrate: arginine decarboxylase, arginine/glycine aminotransferase, different 
isoforms of arginase (Arg), and the different isoforms of the nitric oxide synthases 
(NOS), the last two being the most studied and characterized [12]. In mammals two 
arginase isoforms exist, Arg-1 and Arg-2, that catalyze the same reaction but differ 
in cellular expression and subcellular localization. Arg-1 is cytosolic and is highly 
expressed in the liver and some cells of the immune response. Compared to Arg-1, 
Arg-2 is mitochondrial and is expressed in a great variety of peripheral tissues, 
mainly in the kidney, prostate, small intestine, and mammary glands during lacta-
tion [14]. Regarding NOS, this enzyme is present in three isoforms: neuronal NOS 
(nNOS or NOS1), inducible nitric oxide synthase (iNOS or NOS2), and endothelial 
NOS (eNOS or NOS3). NOS 1 is expressed in specific neurons of the central nervous 
system (CNS), and NOS3 is mostly expressed in endothelial cells [15]. NOS 2 is not 
usually expressed in cells, but its expression can be induced by bacterial lipopolysac-
charide, cytokines, and other agents. Although primarily identified in macrophages, 
the expression of this enzyme can be stimulated in almost any cell or tissue, provided 
that the appropriate inducing agents are present [16].
4.  l-arginine metabolism in the immune response: special emphasis in 
macrophages
In the immune response, ʟ-arginine metabolism through NOS2 and Arg-1 has a 
pivotal role in the regulation of the effector capabilities of macrophages, dendritic 
cells, and neutrophils [17–20] during infectious processes caused by a great variety 
of microorganisms: different species of Mycobacterium, Leishmania, Trypanosoma, 
Schistosoma, and Salmonella, among others [21, 22].
l-arginine metabolism in the immune response acquired great relevance with 
the discovery that murine macrophages express both NOS2 and Arg-1 and that their 
expression is reciprocally regulated by the action of Th1/proinflammatory cyto-
kines (e.g., IFN-γ and TNF-α) and Th2/anti-inflammatory (e.g., IL-4, IL-10, and 
IL-13) that determine the activation state of macrophages [19, 23–27].  
Figure 1. 
Sources of L-arginine in mammals and its metabolic products.
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Th1 cytokines activate macrophages in a classical way (CAMФ) and induce the 
expression and function of NOS2, while Th2 cytokines activate macrophages in an 
alternative way (AAMФ) and induce the expression and function of Arg-1.
NOS2 or iNOS is an oxide-reductase responsible for the synthesis of l-citrulline 
and nitric oxide (NO•) from ʟ-arginine in the presence of NADPH and oxygen. 
This reaction occurs through two successive reactions: the monooxygenation of 
ʟ-arginine that drives to the production of the intermediary Nω-OH- l-arginine 
(NOHA) and the subsequent hydrolysis of this last compound, thus producing 
ʟ-citrulline and NO• (Figure 2). NOS2 generates both NO• and superoxide (O2−) 
that together react to form the radical peroxynitrite (ONOO−) [28]. This last 
compound has been identified as a reactive species derived both from oxygen and 
nitrogen (RONS) that constitutes the principal cytostatic or cytotoxic mechanism 
of CAMФ to fight the infections generated by virus, bacteria, fungi, and protozoan 
parasites [20, 23, 26, 29].
5. Immune response to Trypanosoma cruzi
Inside the mammalian host, macrophages represent an important site for the 
duplication of T. cruzi. One of the most important mechanisms in the protective 
immunity against T. cruzi is the activation of macrophages in order to achieve the 
elimination of parasites (Figure 3). CAMϕ are able eliminate T. cruzi thanks to 
Figure 2. 
l-arginine metabolism through iNOS and Arg-1. iNOS, inducible nitric oxide synthase; Arg-1, arginase 1; 
NOHA, Nω–OH-l-arginine; OAT, ornithine-aminotransferase; ODC, ornithine-decarboxylase; NO•, nitric 
oxide; O2−, superoxide, RNOS, oxygen and nitrogen reactive species; ONOO-, peroxynitrite.
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NOS2 and RONS that kill intracellular parasites by the modification of structural 
properties of T. cruzi molecules. On the other hand, the different forms of AAMϕ 
present high levels of mannose receptor (MR) and an overregulation of Arginase 
1 [30]. Arg-1 hydrolyzes ʟ-arginine in urea and ʟ-ornithine; the latter is the 
principal intracellular source for the synthesis of polyamines and trypanothione. 
Polyamines are small cationic molecules required for cellular proliferation and 
macrophage homeostatic processes, besides being vital for the intracellular growth 
of Trypanosoma [19, 31]. Both inducible enzymes share ʟ-arginine as substrate, 
and the expression and function of both enzymes are reciprocally regulated by the 
action of Th1 and Th2 cytokines. Thus, ʟ-arginine is situated as a frontier between 
the elimination and survival of Trypanosoma in host cells, and its metabolism is a 
determinant factor in the evolution of the disease.
In response to the defense mechanisms of the host, parasites have developed 
several strategies in order to escape host immune response and take advantage of 
some host’s molecules. In this way, parasites must reduce the production of toxic 
molecules, including nitric oxide and its derivatives, that are synthesized by the 
immune system, in particular by macrophages [32–34]. In addition, internalized 
parasites of different T. cruzi strains are able to escape from the parasitophorous 
vacuole of resident macrophages [35], a strategy that utilizes a variety of molecules 
with antioxidant properties [36, 37]. Nevertheless, as the infection progresses, the 
evasion strategies displayed by T. cruzi are widely surpassed by the development of 
a humoral specific immune response and the activation of macrophages by IFN-𝛾𝛾 
and other cytokines. As has been previously mentioned, the infection with T. cruzi 
can have an acute or a chronic phase. One of the possible causes of the passage 
from one phase to another is the fact that the effector immune response against the 
parasite is insufficient or inappropriate due to a deficient activation of the specific 
immune response or an excessive regulation of this response.
6. Role of Arg-1 in the infection with Trypanosoma
The induction of Arg-1 in macrophages promotes the infection of parasites of 
the genus Trypanosoma by providing nutrients derived from polyamines, since 
Trypanosoma parasites cannot generate their own source of ornithine through the 
activity of a functional arginase [38, 39]. The increase in arginase activity coun-
teracts the host’s immune response and favors parasite growth. It has been shown 
that in African trypanosomiasis caused by Trypanosoma gambiense, there is an 
increase in the serum level of Arg-1 that returns to basal values after the treatment 
Figure 3. 
l-arginine metabolism in macrophages during T. cruzi infection. In classically activated macrophages 
(CAMФ), inducible nitric oxide synthase (iNOS) expression and function are induced. l-arginine 
metabolism through this enzyme entails the production of nitric oxide that possesses great trypanocidal 
capacity. In alternatively activated macrophages (AAMФ), arginase 1 (Arg-1) expression and function are 
induced. l-arginine metabolism through this enzyme entails the production of polyamines that favor T. cruzi 
multiplication inside macrophages.
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of Trypanosoma [19, 31]. Both inducible enzymes share ʟ-arginine as substrate, 
and the expression and function of both enzymes are reciprocally regulated by the 
action of Th1 and Th2 cytokines. Thus, ʟ-arginine is situated as a frontier between 
the elimination and survival of Trypanosoma in host cells, and its metabolism is a 
determinant factor in the evolution of the disease.
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molecules, including nitric oxide and its derivatives, that are synthesized by the 
immune system, in particular by macrophages [32–34]. In addition, internalized 
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The induction of Arg-1 in macrophages promotes the infection of parasites of 
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Trypanosoma parasites cannot generate their own source of ornithine through the 
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[40]. Similarly, in experimental murine trypanosomiasis caused by Trypanosoma 
brucei, macrophage Arg-1 activity represents a disease susceptibility marker [41]. 
In T. brucei Arg-1 activity is induced by excretion/secretion factors, particularly 
TbKHC1, kinesin H chain, and has been identified as an inductor factor of Arg-1 
[38]. Other studies have demonstrated that the addition of an Arg-1 inhibitor 
reduces parasite growth, which is restored with l-ornithine supplementation. The 
essential requirement of l-ornithine is related with the absence of a functional 
arginase in Trypanosoma [39], which results in a dependence toward host’s arginase 
for the synthesis of polyamines and trypanothione, which are essential for parasite 
survival, growth, and differentiation [42]. The difluoromethylornithine, structural 
analog of l-ornithine, has been used alone or in combination with nifurtimox as an 
effective drug against African trypanosomiasis [43]. Nevertheless, its administration 
is difficult and requires large amounts of i.v. injected fluids, which limits its use in 
remote areas. Thus, it is of utmost importance to find easier ways to select polyamine 
synthesis as a target against Trypanosoma. Alternatively, inhibitors of the route that 
conducts to arginase activity might reduce parasite loads in infected animals.
7. Conclusion
Trypanosoma cruzi is the causal agent of Chagas disease that affects 6–8 million 
people primarily in Latin America. It is an intracellular parasite that infects a variety 
of cells, among which macrophages are a very important target and thus transcen-
dental for the immune response against the parasite. Macrophages can traverse 
through a gradient of stages of activation with classically activated macrophages in 
one end and alternatively activated macrophages in the other. These two phases of 
activation are characterized by the expression of two enzymes that are reciprocally 
regulated and share the same substrate: l-arginine. Classically activated macrophages 
express iNOS of NOS2 that is induced by Th1 cytokines and catalyze the conversion 
of l-arginine to l-citrulline and NO. Contrarily, alternatively activated macrophages 
express Arg-1 that is induced by Th2 cytokines. Thus, l-arginine metabolism is in the 
center of Trypanosoma elimination of survival. The better knowledge of this route 
during the different stages of Trypanosoma infection is of great importance for the 
better comprehension of disease progression and design of drugs.
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Abstract
Trypanosoma cruzi is a protozoan responsible for Chagas disease and has a 
complex life cycle including vertebrate (mammals) and invertebrate (insects) hosts. 
The parasite presents proliferative and infective forms that are challenged through-
out their cycle as different sources of nutrients, pH, immune system, and levels 
of reactive oxygen species (ROS). Although ROS cause damage to cells and tissues 
when their levels are controlled, they are involved in signal transduction pathways 
involved in cell growth and differentiation. Curiously, the proliferation of epimas-
tigote inside the bug insect is favored by high levels of ROS from the digestion of 
blood meal, and it is regulated by a cellular signaling mechanism involving heme 
and CaMKII. On the other hand, the differentiation of epimastigote into metacyclic 
trypomastigote in the rectum occurs in the reduced state. Interestingly, when the 
parasite infects the vertebrate, the immune system recognizes this pathogen and 
macrophages become activated. Thus, NADPH oxidase produces ROS that helps the 
parasite enter the mammalian cells, improving the infection. The parasite thrives 
inside the mammalian cells also involving ROS. Thus, the life cycle of Trypanosoma 
cruzi obeys a fine tuning of the redox state, not affecting the host cells and being 
helpful to the parasite.




Chagas disease was described in 1909 by a Brazilian researcher, Carlos Chagas, 
who discovered a new trypanosomiasis in Minas Gerais, Brazil, during his work on  
an anti-malaria campaign [1, 2]. The disease presents three phases: acute, indeter-
minate, and chronic. The acute phase is asymptomatic and presents nonspecific 
symptoms and signs, such as inflammatory lesions at the site of entry of the parasite 
(chagoma) and fever. At this stage, the parasitic load in the blood is high. The inde-
terminate phase is characterized by the presence of antibodies against T. cruzi and 
absence of clinical manifestations of the disease. The chronic phase of the disease 
involves the cardiac system, digestive system, or both. The patients at this stage may 
develop (1) a Chagas’ heart disease that compromises the cardiac function by increas-
ing the size of the heart and tissue damage (fibrosis) and (2) chronic inflammation 
and destruction of parasympathetic neurons leading to progressive enlargement of 
the esophagus (megaesophagus), sigmoid colon, or rectum (megacolon) [3, 4].
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1.2 The biological cycle of Trypanosoma cruzi
The causative agent of the disease is a flagellate protozoan that belongs to 
the order Kinetoplastida and family Trypanosomatidae, the Trypanosoma cruzi. 
Classically, transmission of Chagas disease occurs through insect vectors of the 
subfamily Triatominae, popularly known as barbers. However, there are other 
transmission routes such as oral, congenital, blood transfusion, organ transplanta-
tion, and laboratory accidents [5].
T. cruzi presents different evolutionary forms that alternate with each other 
throughout its cycle. Trypomastigote forms present in the blood of infected 
vertebrate hosts are ingested by the insect vector, where they differentiate into 
epimastigote replicative forms. These forms undergo another process of differentia-
tion througout the intestine, however this time to infectious and non-replicative 
forms, the metacyclic trypomastigotes. In turn, these are released with the feces and 
penetrate into the vertebrate host through the sting of the triatomines or through 
another portal of entry, such as mucosae. Trypomastigotes are able to invade host 
cells and differentiate into amastigotes in the intracellular environment. Such forms 
multiply through binary divisions and are transformed into the infective trypomas-
tigote forms still within the host cell. With the disruption of the plasma membrane 
of the vertebrate host cell, the trypomastigote forms gain the bloodstream and 
invade other cells and tissues of the mammal or can be sucked in by new triatomine 
restarting the cycle [6].
It is known that during its life cycle T. cruzi is exposed to different redox environ-
ments inside the invertebrate and vertebrate hosts [7, 8] and the ability of T. cruzi to 
adapt to the redox state contributes to the success of the infection [9]. Additionally, 
in terms of a physiological approach, ROS play a vital role in T. cruzi-vector interac-
tions, because heme, a molecule from the insect blood digestion, triggers epimasti-
gote proliferation through a redox-sensitive signaling mechanism [10].
1.3 Redox signaling
Cells generate ROS endogenously and constitutively when oxygen is partially 
reduced in mitochondria-producing oxidants, the so-called reactive oxygen species 
(ROS), such as superoxide radicals (O2•−) and hydrogen peroxide (H2O2) [11]. To 
maintain their hemostasis, cells adopt strategies called antioxidant defense. ROS 
participate in signal transduction pathways involved in cell growth and differentia-
tion [12]. However, when oxidant levels are high, the oxidative/antioxidant balance 
within the cells disrupts the redox signaling and the redox control, which can lead 
to cellular damage [13–16]. This exacerbation of the endogenous production of ROS 
is known as oxidative stress. These oxidant species can lead to lipid peroxidation, 
affecting membrane integrity, DNA damage, and oxidation of sugars and protein 
thiols [14, 15]. On the other hand, controlled ROS increase leads to a temporary 
imbalance that represents the physiological basis for redox regulation [16, 17]. 
Indeed, redox processes have fundamental implications in biology.
In addition to ROS, other reactive species have notable impacts on redox biology, 
including the reactive nitrogen species (RNS), such as nitric oxide, nitrogen dioxide 
(both free radicals), peroxynitrite, and nitrite/nitrate. Besides these, forms of cyste-
ine, methionine, and some low-molecular-mass compounds such as glutathione and 
trypanothione are called reactive sulfur species (RSS). Another group of reactive 
species is the reactive carbonyl species (RCS) including various forms of metaboli-
cally generated aldehydes and electronically excited (triplet) carbonyls. Finally, 
reactive selenium species (RSeS) include low molecular mass such as selenocysteine 
and selenomethionine residues in proteins [17].
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2. ROS and Trypanosoma cruzi
2.1 The journey inside the bug insect
2.1.1 The epimastigotes and redox environment
Evidence in the literature indicates that the interaction between T. cruzi and 
triatomines is essential for the successful spread of Chagas disease [18] and several 
factors and molecules have been shown to be important in establishing the infection. 
After feeding, the insect vector digests the blood in the midgut, where hemoglo-
bin protein degradation occurs and a large amount of heme is released. Heme is a 
molecule known to increase the formation of reactive oxygen species (ROS) and is 
able to alter membrane selectivity and permeability [19, 20]. These reactive species 
can also be generated as a by-product of aerobic metabolism of the parasite [7, 21]. 
Therefore, the former region of the midgut represents an environment rich in nutri-
ents, but it is potentially an oxidative environment as well. Then, Trypanosoma cruzi 
needs to deal with high concentrations of heme and ROS while inhabiting the midgut 
of the vector. The epimastigote form, present in this environment, is the replicative 
and non-infective form that is able to increase its rate of proliferation in the presence 
of heme in a dose-dependent manner [22], and this heme-induced T. cruzi growth is 
associated with calcium-calmodulin-dependent kinase II (CaMKII) activity [23].
Besides heme, ROS have been shown to trigger proliferation of the epimastigote 
forms of Trypanosoma cruzi [10]. According to these authors, the growth of the 
parasites in the presence of these molecules is regulated by a cellular signaling 
mechanism involving CaMKII and the redox status, since the antioxidants, such as 
urate and GSH, inhibited heme-induced ROS and parasite proliferation. In addition, 
Myr-AIP, a specific CaMKII inhibitor, extinguishes heme-induced ROS in epimas-
tigotes, decreasing parasite growth. To exclude the possibility of other molecules 
similar to heme being able to induce a potent proliferative effect on T. cruzi, tests 
were carried out with protoporphyrin IX (PPIX), mesoporphyrin IX (MPIX), Fe 
mesoporphyrin IX (Fe-MPIX), Sn protoporphyrin IX (SnPPIX), and Zn protopor-
phyrin IX (ZnPPIX), and only heme showed a potent proliferative effect [10]. These 
data show that the parasite had to adapt to high concentrations of ROS in order to 
establish itself in such an oxidizing environment.
Heme and two classical oxidants, H2O2 and the well-known superoxide genera-
tor, paraquat, are able to promote the growth of epimastigotes in vitro [24]. This 
effect was reversed in the presence of other reductive molecules (GSH, a thiol-based 
antioxidant found in the hemolymph of triatomines; urate, an important antioxi-
dant rich in the urine of these insects [25], and n-acetylcysteine (NAC), a classic 
antioxidant) suggesting a competition between these molecules of antagonistic 
redox status. An important physiological molecule present in the midgut is hemo-
zoin, a crystal composed of heme dimers [26, 27] that Rhodnius prolixus, a Chagas 
disease vector, uses as an efficient detoxification pathway of heme. The addition of 
this crystal to an epimastigote culture does not produce an increase in the prolifera-
tion of these cells [24].
Thus, the redox environment is considered to be very important for 
Trypanosoma cruzi. Furthermore, the parasite needs ROS for growth inside the 
vector. If this hypothesis is correct, the disturbance of ROS levels in vivo would 
lead to differences in the levels of epimastigote proliferation within the intestine. In 
fact, the heme molecule and ROS are examples of important relationships between 
parasite and vector because they are capable of promoting the proliferation of the 
epimastigote forms, but when the insect is fed with blood and antioxidants, such as 
NAC and urate, the proliferation in vivo decreases as demonstrated in vitro [10, 24]. 
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2. ROS and Trypanosoma cruzi
2.1 The journey inside the bug insect
2.1.1 The epimastigotes and redox environment
Evidence in the literature indicates that the interaction between T. cruzi and 
triatomines is essential for the successful spread of Chagas disease [18] and several 
factors and molecules have been shown to be important in establishing the infection. 
After feeding, the insect vector digests the blood in the midgut, where hemoglo-
bin protein degradation occurs and a large amount of heme is released. Heme is a 
molecule known to increase the formation of reactive oxygen species (ROS) and is 
able to alter membrane selectivity and permeability [19, 20]. These reactive species 
can also be generated as a by-product of aerobic metabolism of the parasite [7, 21]. 
Therefore, the former region of the midgut represents an environment rich in nutri-
ents, but it is potentially an oxidative environment as well. Then, Trypanosoma cruzi 
needs to deal with high concentrations of heme and ROS while inhabiting the midgut 
of the vector. The epimastigote form, present in this environment, is the replicative 
and non-infective form that is able to increase its rate of proliferation in the presence 
of heme in a dose-dependent manner [22], and this heme-induced T. cruzi growth is 
associated with calcium-calmodulin-dependent kinase II (CaMKII) activity [23].
Besides heme, ROS have been shown to trigger proliferation of the epimastigote 
forms of Trypanosoma cruzi [10]. According to these authors, the growth of the 
parasites in the presence of these molecules is regulated by a cellular signaling 
mechanism involving CaMKII and the redox status, since the antioxidants, such as 
urate and GSH, inhibited heme-induced ROS and parasite proliferation. In addition, 
Myr-AIP, a specific CaMKII inhibitor, extinguishes heme-induced ROS in epimas-
tigotes, decreasing parasite growth. To exclude the possibility of other molecules 
similar to heme being able to induce a potent proliferative effect on T. cruzi, tests 
were carried out with protoporphyrin IX (PPIX), mesoporphyrin IX (MPIX), Fe 
mesoporphyrin IX (Fe-MPIX), Sn protoporphyrin IX (SnPPIX), and Zn protopor-
phyrin IX (ZnPPIX), and only heme showed a potent proliferative effect [10]. These 
data show that the parasite had to adapt to high concentrations of ROS in order to 
establish itself in such an oxidizing environment.
Heme and two classical oxidants, H2O2 and the well-known superoxide genera-
tor, paraquat, are able to promote the growth of epimastigotes in vitro [24]. This 
effect was reversed in the presence of other reductive molecules (GSH, a thiol-based 
antioxidant found in the hemolymph of triatomines; urate, an important antioxi-
dant rich in the urine of these insects [25], and n-acetylcysteine (NAC), a classic 
antioxidant) suggesting a competition between these molecules of antagonistic 
redox status. An important physiological molecule present in the midgut is hemo-
zoin, a crystal composed of heme dimers [26, 27] that Rhodnius prolixus, a Chagas 
disease vector, uses as an efficient detoxification pathway of heme. The addition of 
this crystal to an epimastigote culture does not produce an increase in the prolifera-
tion of these cells [24].
Thus, the redox environment is considered to be very important for 
Trypanosoma cruzi. Furthermore, the parasite needs ROS for growth inside the 
vector. If this hypothesis is correct, the disturbance of ROS levels in vivo would 
lead to differences in the levels of epimastigote proliferation within the intestine. In 
fact, the heme molecule and ROS are examples of important relationships between 
parasite and vector because they are capable of promoting the proliferation of the 
epimastigote forms, but when the insect is fed with blood and antioxidants, such as 
NAC and urate, the proliferation in vivo decreases as demonstrated in vitro [10, 24]. 
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Observing the effect of the physiological molecules (heme, hemozoin, and urate), it 
is possible to confirm that there is a modulation between molecules of antagonistic 
redox status, indicating an inhibitory role of reductive molecules on epimastigote 
proliferation and confirming the requirement of an oxidant signal to promote 
the growth of these parasites. Furthermore, in 2017, Nogueira and collaborators 
showed that heme affects the mitochondrial function of T. cruzi epimastigotes and, 
as a consequence, mitochondrial ROS production is increased, triggering parasite 
proliferation [28].
2.1.2 Differentiation of epimastigotes into metacyclic trypomastigotes
Still on its journey inside the vector, Trypanosoma cruzi reaches the rectum of the 
bug. This region greatly favors metacyclogenesis, and one important factor is the 
reductive environment promoted by the high concentration of urate. The levels of 
metacyclic trypomastigotes are increased in the presence of urate and other anti-
oxidants both in vitro and in vivo. On the other hand, the proliferation of epimasti-
gotes decreases in reductive environments [10, 24].
When the blood meal is supplemented with antioxidants, there is a shift in the 
redox status of the gut compartments (anterior midgut, posterior midgut, and 
rectum), increasing differentiation of the parasites in an unusual midgut region and 
greatly favoring metacyclogenesis in the bug rectum. Notably, contrary to prolifera-
tion, the differentiation process appears to be favored by reductive environments [24].
A Trypanosoma cruzi eIF2α kinase (TcK2) was characterized by Augusto and 
collaborators [29] as a transmembrane protein located in organelles that accumulate 
nutrients in the proliferative forms. The heme molecule has been shown to bind 
specifically to the catalytic domain of the kinase, inhibiting its activity. On the 
other hand, in the absence of heme, TcK2 is activated, preventing cell growth and 
inducing the differentiation of epimastigote forms into infectious and nonprolif-
erative forms. Parasites without TcK2 lose this differentiation ability, and heme is 
not stored in reserve organelles, as demonstrated by Lara and collaborators [21], 
remaining in the cytosol. Furthermore, if ROS levels are not controlled in TcK2 null, 
they cause damage to the parasite, including death. Thus, in wild cells, heme has 
been shown to be a key factor for growth control and differentiation by regulating 
an unusual type of eIF2α kinase in T. cruzi [29].
As demonstrated by science, the coevolution between parasites and their insect 
vectors has promoted an elegant strategy for the development and maintenance of 
the protozoa in the invertebrate vector.
2.2  The transmission of the disease: metacyclic trypomastigotes infect the 
vertebrate hosts—a new journey
2.2.1 The participation of NADPH oxidase in the infection
The immune system of the higher vertebrates is able to recognize pathogens and 
respond through their innate immune responses. ROS is an important component 
of this response produced by phagocytes and can be highly toxic. Macrophages are 
one of the first lines of defense in mammals, especially against pathogens [30], and 
become activated facing such challenges.
The O2•− production after NADPH oxidase activation in macrophages is con-
verted inside the phagosome to H2O2 (spontaneously or via superoxide dismutase), 
and this ROS production, termed the “oxidative burst” of activated phagocytic cells, 
usually kills the pathogens. In order to infect the vertebrate host, T. cruzi metacyclic 
trypomastigotes invade macrophages and overcome the highly oxidative conditions 
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generated inside the phagosome. Then, biochemical changes occur [9, 31, 32] 
including antioxidant enzyme activities [33], and, curiously, Trypanosoma cruzi 
depends on ROS involved in this activation process to establish the infection in the 
vertebrate host [8]. The NADPH oxidase (Phox) activation and this O2•− production 
are directly involved in increased infection of macrophages by T. cruzi since mice 
deficient in the gp91phox (Phox KO), subunit of NADPH oxidase, macrophages pres-
ent reduced parasitism [8, 34].
Peroxynitrite is also highly lethal and used by phagocytes against pathogens. It is 
formed when nitric oxide (NO) and O2•− react with each other. Thus, the production 
of peroxynitrite is decreased by the inhibition of ROS or NO production [35]. Paiva 
and collaborators, in 2012, showed that macrophages infected with T. cruzi and acti-
vated with the burst inducer phorbol 12-myristate 13-acetate (PMA) have stimu-
lated the parasite load [36]. In conclusion, the generation and the regulation of the 
ROS level can help these parasites thrive in an oxidative environment [8, 35–37].
2.2.2 Murine models of Chagas disease and ROS
After the infective metacyclic forms invade host cells, macrophages, or cardiac 
cells, for example, they are transformed into the replicative intracellular amastigote 
form [6]. In response to infection, Chagas hearts present increased mitochondrial 
ROS [38, 39] because during T. cruzi infection an inefficient electron transport 
for ATP synthesis occurs in mitochondria [39]. Also, when deficient superoxide 
dismutase (SOD2 or MnSOD) mice are infected with Trypanosoma cruzi, the loss of 
the mitochondrial function increases the oxidative damage of the myocardium in 
Chagas cardiomyopathy and shows the importance of ROS-level regulations [40]. 
Moreover, ROS mobilizes intracellular iron which is essential as a cellular factor 
for amastigote division [30, 36]. ROS, including mitochondrial ROS, contribute to 
oxidative damage that persists during the chronic stage of infection and is involved 
in the functional impairment of the heart [40–42]. Some studies show that cardiac 
parasite load may vary after treatment with antioxidants but depend on the animal 
model and the strain used [42–44]. In fact, Gupta and collaborators [45] demon-
strated that T. cruzi infection increases ROS production in cardiomyocytes and this 
effect is augmented by the pro-inflammatory cytokines. The authors argue that 
the ROS production by cardiomyocytes is not a defense response against T. cruzi. 
Instead, the infection promotes a mitochondrial dysfunction, including ROS pro-
duction. Thus, ROS also participates in the successful infection in mammals.
3. Conclusion
Several groups have carried out research on the influence of the oxidative envi-
ronment on the growth and differentiation of Trypanosoma cruzi in both vertebrate 
and invertebrate hosts. As we have learned in this chapter, the epimastigote, the 
non-infective and proliferative form, has its growth stimulated in the presence of 
oxidative compounds. Conversely, in the presence of antioxidants, or in a reduc-
tive environment, its proliferation becomes compromised. The regulated ROS 
levels also influence, in an orchestrated way, the differentiation of epimastigotes 
into metacyclic trypomastigotes (the infective form). The reductive environment 
increases differentiation, while ROS dramatically decreases its transformation into 
the infective forms. These same metacyclic forms that are formed in the rectum of 
the vector insect invade the vertebrate host by subverting the logic of the phago-
cytes that, by activation of NADPH oxidase, exacerbate the concentration of ROS 
in the intention to kill the pathogens. In fact, the trypomastigote forms of T. cruzi 
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resist ROS and establish themselves in the cells of the vertebrate host differing 
into amastigotes that in cardiomyocytes coexist with increased levels of ROS when 
compared to uninfected hearts. However, these levels of ROS cannot decrease or 
increase indiscriminately.
Thus, we have followed the journey of the parasite Trypanosoma cruzi, both 
in the invertebrate and in the vertebrate hosts, that occurs under adverse redox 
conditions, as if in an orchestra of ROS and antioxidants, and furthermore we can 
observe that its journey through the intestine of the insect, along the mammalian 
bloodstream, and its entry and lodging in mammalian cells are finely and elegantly 
ruled by a redox baton.
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How Does the Main Infective 
Stage of T. cruzi Enter and Avoid 
Degradation in Host Cells? A 
Description of the Pathways and 
Organelles Involved on These 
Processes
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Abstract
Trypanosoma cruzi, the etiological agent of Chagas disease, is an intracellular 
parasite that targets specific proteins of the host cell resulting in the generation 
of a unique parasitophorous vacuole (PV). As an intracellular parasite, T. cruzi 
interacts with cells from the mammalian host. Here we review aspects related with 
the binding of the main infective developmental stage (trypomastigote) to the 
host cell and its recognition by surface-exposed ligands/receptors. This process 
involves numerous signaling pathways and culminates in the entry of the parasite 
and modifications in both cells. The invasion of trypomastigotes occurs through 
multiple endocytic process, assembly of the PV, interaction of this vacuole with the 
endolysosomal system, lysis of the PV membrane, and multiplication of amasti-
gotes within the cell in direct contact with host cell organelles.
Keywords: Trypanosoma cruzi, mammalian cells, host cell interaction,  
endocytic pathways, signaling, parasitophorous vacuole
1. Introduction
Trypanosoma cruzi, the etiological agent of Chagas disease, causes an anthropo-
zoonosis discovered and characterized by Dr. Carlos Chagas in 1909 [1] and recog-
nized by the World Health Organization (WHO) as one of the three most neglected 
tropical diseases of the world [2–4]. Nowadays, up to 8 million people are estimated 
to be infected with Chagas disease only in the Americas. Patients who do not receive 
treatment can develop severe cardiac debility and gastrointestinal organ dysfunc-
tion and may die, and 25 million are at risk of contracting the disease [3, 4]. Due to 
population migration and specific modes of transmission, Chagas disease is spread-
ing beyond its natural geographical boundaries and becoming a global problem [5]. 
Although the protozoan has three major developmental stages, only two are capable 
of infecting mammals (trypomastigotes and amastigotes), and the trypomastigote 
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Figure 1. 
Intracellular cycle of T. cruzi. (A) Attachment of the trypomastigote. (B) Internalization and recruitment and 
fusion of host cell lysosomes. (C) Parasitophorous vacuole is formed and lysosomal content is released.  
(D) Differentiation of trypomastigote to amastigotes. (E) Parasitophorous vacuole membrane disintegration. 
(F) Amastigote division into cytoplasm. (G) Differentiation of amastigotes into trypomastigotes. (H) 
Liberation of parasites into extracellular [12].
stage is the main T. cruzi vector [6]. Recent data indicate the existence of an infec-
tive epimastigote-like stage observed in axenic cultures as well as in the invertebrate 
host [7]. It is important to point out that before publication of this article, it was 
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assumed that replicating epimastigotes present in the insect gut are not infective to 
mammalian host. During the vector infection (caused by a hematophagous insect 
of the family Reduviidae), metacyclic trypomastigotes [8], which penetrate the 
vertebrate host (several mammals, including man), are released along with their 
excreta coming in contact with conjunctiva areas or through small lesions in the 
own site of the bite (favored by the itch caused after the insect’s bite). In turn, meta-
cyclic trypomastigotes are able to invade virtually all cell types in the vertebrate 
host, especially muscle cells, fibroblasts, and macrophages [6]. At this moment, the 
intracellular cycle of T. cruzi begins, where the firing of several signaling cascades 
culminates with the closure of the parasitophorous vacuole (PV) where the parasite 
is found [9, 10]. After the PV closure, the process of differentiation of the parasite 
from the trypomastigote stage to the amastigote stage begins. At the same time, 
fragmentation of the PV membrane takes place most probably due to the increased 
concentration of the Tc-Tox perforin-like protein produced by the parasite [11]. 
After the destruction of the vacuole, the parasite, in the process of differentiation, 
will be found in the cytoplasm of the host cell where it will initiate its multiplication 
and subsequent differentiation for trypomastigotes culminating in the rupture of 
the host cell (Figure 1) [13]. The whole process of formation of the parasitophorous 
vacuole until its rupture counts on the participation of several organelles of the host 
cell. Among these, the best characterized is the participation of host cell endosomes 
and lysosomes. It is the fusion of these organelles with the PV membrane that 
probably allows the increase or expansion of the PV. In addition, this process is 
also responsible for the generation of an acidic environment within the PV, which 
probably will potentiate the action of Tc-Tox and PV membrane fragmentation [13]. 
Wilkowsky and colleagues [14] have shown that early and late endosomes were 
critical for vacuole formation. In addition, other organelles responsible for the pro-
duction of proteins and energy (endoplasmic reticulum (ER), Golgi complex (GC), 
and mitochondria) have also been observed during the initial infection process [11]. 
In this chapter we will discuss the available data on the process of parasite-host cell 
recognition, triggering of the internalization process, and biogenesis of the PV. A 
better understanding of all the processes may identify new potential targets to block 
parasite invasion and may constitute alternative ways to treat Chagas disease.
2. T. cruzi trypomastigote-host cell recognition
The trypomastigote stage of T. cruzi has the ability to invade both professional 
phagocytic cells and nonprofessional phagocytic mammalian cells either in vitro or 
in vivo [15–17]. The kinetics of the T. cruzi’s intracellular cycle varies according to 
the strain, including time duration (Y strain, e.g., has an intracellular cycle that is 
completed between 5 and 7 days), since the initial interaction with trypomastigotes, 
triggering a signaling cascade that culminates with the formation and closure of the 
PV where the parasite will be located for some time [18].
In order for the interaction process and consequent internalization of the parasite 
to occur, there must be a recognition between molecules present on the surface of 
both cells. These processes are complex and involve several adhesion molecules 
(Figure 2), signaling events, and proteolytic activities [10, 19]. Some of these mol-
ecules have been identified as participants in the adhesion and invasion processes, 
such as gp35/50 [20], gp82 (whose expression varies according to the T. cruzi strain 
analyzed) [21], and gp90 [22]. Both gp82 and gp90 are the main metacyclic stage-
specific surface molecules and are extremely important to oral infection [21, 23]. 
However, while glycoprotein 90 is known as a negative modulator of metacyclic 
trypomastigote invasion [24, 25], gp82 binds to an unidentified receptor in host cell 
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in vivo [15–17]. The kinetics of the T. cruzi’s intracellular cycle varies according to 
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However, while glycoprotein 90 is known as a negative modulator of metacyclic 
trypomastigote invasion [24, 25], gp82 binds to an unidentified receptor in host cell 
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surface mediating a calcium-dependent signaling pathway that will be discussed 
below [20, 26]. Although the receptors presented in host cell surface that recognize 
gp82 and gp90 are not known, some data reinforce they are different since the target 
cell’s interaction motif of both glycoproteins is distinct [26]. It is important to point 
out that these molecules are not present in tissue culture-derived trypomastigotes. At 
this stage, the molecules described as present in the membrane are gp85 (recognizes 
extracellular matrix), Ssp3, shed acute-phase antigen (SAPA) (trans-sialidase (TS)), 
oligopeptidases (serine proteases), and penetrin, which bind to heparin, heparan 
sulfate, and collagen [10].
Expression of a family of GPI-anchored glycoproteins, termed trans-sialidases/
neuraminidases, present mainly on the surface of trypomastigotes is capable of 
modifying the exposure of surface glycoconjugates both in host cells and in the 
parasite itself. T. cruzi trans-sialidases (TS) are “shed” from the parasite membrane 
to the external medium through microvesicles. Microvesicles have a complex 
lipid bilayer and are responsible for carrying several molecules derived from the 
parasite, such as lipids, proteins, and nucleic acids [27–29]. Trypomastigote TS 
protein structure is formed by two major regions: an N-terminal catalytic region 
and a C-terminal region. C-terminal presents 12 amino acids repeated in tandem, 
named SAPA. TS can be active or inactive. Inactive TS are lectin-like proteins and 
are capable to bind SAcs and β-galactose [30]. Active TS are modified sialidases 
which, in addition to cleaving sialic acid, may transfer from sialoglycoconjugates 
of the host cell to β-galactose of T. cruzi glycoconjugates [31]. The TS gene family is 
complex, consisting of fourteen members divided into two groups: one translates 
TS present in stages present in mammalian hosts (trypomastigotes), and another 
translocates TS present in specific vector stages (epimastigotes). Although bio-
chemical studies do not demonstrate the presence of TS at the amastigote stage, 
immunocytochemical assays have shown that TS can indeed be expressed in 
amastigotes [32–34]. Pereira et al. [35] observed that about 20–30% of cultured 
Figure 2. 
Schematic model of molecules involved in T. cruzi-host cell interaction [10].
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trypomastigotes had trans-sialidases/neuraminidases on their surface and these 
parasites were more invasive than the population that did not express the enzyme. 
Expression of trans-sialidases in T. cruzi is directly related to infectivity/virulence 
of the parasite since proteome studies indicate that different strains exhibit sig-
nificantly different amounts of TS and TS-containing microvesicles and that host 
cells incubated with larger quantities containing microvesicles of TS before infec-
tion with trypomastigotes will generate a greater infection [36]. Results regarding 
virulence had already been related to TS expression through the analysis of virulent 
and non-virulent strains by transcriptome. In this work it can be observed that the 
expression of TS-coding genes during the differentiation process from intracel-
lular amastigote to trypomastigote (end of intracellular cycle) is much higher in 
the virulent than in the non-virulent strain. Associated with this the transfection 
of avirulent strain with gene allowing the constitutive expression of TS also makes 
the release of trypomastigotes faster [37]. The TS family also includes members 
that have no enzymatic activity but which may also be involved in recognition 
between the parasite and the host cell, such as gp85 [38]. Todeschini and colleagues 
[39] demonstrated that inactive enzymes of the TS family are sialic acid-binding 
proteins and terminal β-galactopyranose (βGalp) residues. In relation to gp85/trans-
sialidase, San Francisco and colleagues [40] demonstrate that this protein plays a 
fundamental importance in invasion since its depletion causes a decrease in T. cruzi 
virulence. The same type of result was reported by Pascuale et al. [41] since inactive 
TS expression in trypomastigotes of a strain that does not express these TS (iTS 
null) allowed a better invasion and increase of the parasitic load in mice demon-
strating that the inactive form may act alternatively or complementing the active TS 
in pathogenesis.
Sialic acid from the host cells has a crucial importance in intracellular cycle of 
T. cruzi, a parasite that does not have the ability to synthesize sialic acids. This mol-
ecule plays an important role in protecting T. cruzi from lysis by serum factors and 
also acting in interaction with host cell. Mucins and TS function as substrate and 
enzyme, respectively, and sialylated mucins are localized in microdomain regions 
of trypomastigotes [42]. During the interaction process involving macrophages, the 
presence of sialic acid on the surface of trypomastigotes hinders the invasion pro-
cess, since the removal of these residues through the use of neuraminidase or their 
blockage through the use of periodic acid or lectins from Limax flavus or Limulus 
polyphemus increases adhesion and internalization rates. It is possible that the pres-
ence of desialylated parasites in macrophages may increase due to the recognition of 
galactose/N-acetyl galactosamine receptors present on the surface of macrophages 
[15, 16]. In relation to sialic acid present on the surface of macrophages, there 
has been an increase in the entry of trypomastigote forms in cells that expose this 
residue when compared to cells that do not expose galactose [15, 43]. The presence 
of sialic acid on the surface of trypomastigotes does not yet have a fully known 
function though it is believed that sialic acid helps adhesion and penetration into 
non-phagocytic cells [34, 44].
It is currently discussed that any class of molecules exposed on the surface of 
mammalian cells has a great receptor potential for molecules exposed on the surface 
of T. cruzi [19]. Most of the receptor classes have carbohydrates in their composi-
tion, such as galactose, mannose, sialic acid residues [19, 44, 45], and lectin-type 
proteins such as galectins (binding to carbohydrate residues present on the surface 
of the parasite). Pineda et al. [46] described binding data from different human 
galectins (gal-1, gal-3, gal-4, gal-7, and gal-8) to different strains of T. cruzi belong-
ing to the six different strains (DTUs). It has been observed that all galectins bind 
preferentially to the infective stages (amastigotes and trypomastigotes) and that 
many can promote higher rates of adhesion and infection to host cells and higher 
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surface mediating a calcium-dependent signaling pathway that will be discussed 
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neuraminidases, present mainly on the surface of trypomastigotes is capable of 
modifying the exposure of surface glycoconjugates both in host cells and in the 
parasite itself. T. cruzi trans-sialidases (TS) are “shed” from the parasite membrane 
to the external medium through microvesicles. Microvesicles have a complex 
lipid bilayer and are responsible for carrying several molecules derived from the 
parasite, such as lipids, proteins, and nucleic acids [27–29]. Trypomastigote TS 
protein structure is formed by two major regions: an N-terminal catalytic region 
and a C-terminal region. C-terminal presents 12 amino acids repeated in tandem, 
named SAPA. TS can be active or inactive. Inactive TS are lectin-like proteins and 
are capable to bind SAcs and β-galactose [30]. Active TS are modified sialidases 
which, in addition to cleaving sialic acid, may transfer from sialoglycoconjugates 
of the host cell to β-galactose of T. cruzi glycoconjugates [31]. The TS gene family is 
complex, consisting of fourteen members divided into two groups: one translates 
TS present in stages present in mammalian hosts (trypomastigotes), and another 
translocates TS present in specific vector stages (epimastigotes). Although bio-
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trypomastigotes had trans-sialidases/neuraminidases on their surface and these 
parasites were more invasive than the population that did not express the enzyme. 
Expression of trans-sialidases in T. cruzi is directly related to infectivity/virulence 
of the parasite since proteome studies indicate that different strains exhibit sig-
nificantly different amounts of TS and TS-containing microvesicles and that host 
cells incubated with larger quantities containing microvesicles of TS before infec-
tion with trypomastigotes will generate a greater infection [36]. Results regarding 
virulence had already been related to TS expression through the analysis of virulent 
and non-virulent strains by transcriptome. In this work it can be observed that the 
expression of TS-coding genes during the differentiation process from intracel-
lular amastigote to trypomastigote (end of intracellular cycle) is much higher in 
the virulent than in the non-virulent strain. Associated with this the transfection 
of avirulent strain with gene allowing the constitutive expression of TS also makes 
the release of trypomastigotes faster [37]. The TS family also includes members 
that have no enzymatic activity but which may also be involved in recognition 
between the parasite and the host cell, such as gp85 [38]. Todeschini and colleagues 
[39] demonstrated that inactive enzymes of the TS family are sialic acid-binding 
proteins and terminal β-galactopyranose (βGalp) residues. In relation to gp85/trans-
sialidase, San Francisco and colleagues [40] demonstrate that this protein plays a 
fundamental importance in invasion since its depletion causes a decrease in T. cruzi 
virulence. The same type of result was reported by Pascuale et al. [41] since inactive 
TS expression in trypomastigotes of a strain that does not express these TS (iTS 
null) allowed a better invasion and increase of the parasitic load in mice demon-
strating that the inactive form may act alternatively or complementing the active TS 
in pathogenesis.
Sialic acid from the host cells has a crucial importance in intracellular cycle of 
T. cruzi, a parasite that does not have the ability to synthesize sialic acids. This mol-
ecule plays an important role in protecting T. cruzi from lysis by serum factors and 
also acting in interaction with host cell. Mucins and TS function as substrate and 
enzyme, respectively, and sialylated mucins are localized in microdomain regions 
of trypomastigotes [42]. During the interaction process involving macrophages, the 
presence of sialic acid on the surface of trypomastigotes hinders the invasion pro-
cess, since the removal of these residues through the use of neuraminidase or their 
blockage through the use of periodic acid or lectins from Limax flavus or Limulus 
polyphemus increases adhesion and internalization rates. It is possible that the pres-
ence of desialylated parasites in macrophages may increase due to the recognition of 
galactose/N-acetyl galactosamine receptors present on the surface of macrophages 
[15, 16]. In relation to sialic acid present on the surface of macrophages, there 
has been an increase in the entry of trypomastigote forms in cells that expose this 
residue when compared to cells that do not expose galactose [15, 43]. The presence 
of sialic acid on the surface of trypomastigotes does not yet have a fully known 
function though it is believed that sialic acid helps adhesion and penetration into 
non-phagocytic cells [34, 44].
It is currently discussed that any class of molecules exposed on the surface of 
mammalian cells has a great receptor potential for molecules exposed on the surface 
of T. cruzi [19]. Most of the receptor classes have carbohydrates in their composi-
tion, such as galactose, mannose, sialic acid residues [19, 44, 45], and lectin-type 
proteins such as galectins (binding to carbohydrate residues present on the surface 
of the parasite). Pineda et al. [46] described binding data from different human 
galectins (gal-1, gal-3, gal-4, gal-7, and gal-8) to different strains of T. cruzi belong-
ing to the six different strains (DTUs). It has been observed that all galectins bind 
preferentially to the infective stages (amastigotes and trypomastigotes) and that 
many can promote higher rates of adhesion and infection to host cells and higher 
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rates of infection to mice. In relation to galectin-1, it was observed that the presence 
of this glycoprotein in human and murine cardiomyocytes is able to prevent infec-
tion with trypomastigotes, one more data that goes against the modulating role of 
galectin in the process of internalization of trypomastigotes [47].
Galectin-3, a protein abundant in the cytoplasm of epithelial cells and macro-
phages, has also been described as a participant in the immune response and infec-
tion processes (in addition to the recognition process between the host and T. cruzi) 
[48, 49]. In addition, it has also been demonstrated that galectin-3 accumulates 
in both the parasite and phagosome entry regions and in tubules and vesicles that 
would derive from the endosomal system, thus suggesting that this protein is also 
an excellent marker of the lysis process of the PV containing this parasite [50]. The 
absence of galectin-3, in addition to increasing intracellular replication in vitro, is 
able to increase parasitemia in vivo by decreasing the secretion of pro-inflammatory 
cytokines and increasing cardiac fibrosis [51], which confirms the important role of 
this glycoprotein in the pathogenesis of Chagas disease.
In addition to all the molecules already mentioned, they also act as endothelin-1 
receptors and bradykinin receptors. Both are used by trypomastigotes in the invasion 
of cardiovascular cells, being very important in the pathogenesis of Chagas disease 
[52]. Cytokeratin 18, fibronectin, laminin, and integrin are also recognized by Tc-85, 
forming a bridge between the parasite and the host cell [19, 53, 54]. Besides, a novel 
family of T. cruzi surface membrane proteins (designated as TcSMP) was detected in 
parasite surface and plays some role on host cell invasion by T. cruzi [54].
3.  Mechanisms of internalization of Trypanosoma cruzi trypomastigotes 
in host cells
The mechanisms that lead to the internalization of trypomastigotes appear to 
be different when one considers the cell type where the internalization will occur. 
Morphological evidence shows that the parasite invades the host cell by an endo-
cytic process that culminates in the formation of a PV. In cells of the immune system 
such as macrophages, which are specialized in phagocytosis events, we observe that 
the process of internalization occurs in two distinct ways. Dvorak and Schumunis 
[55] initially suggested that trypomastigotes forced the membrane of the host cell 
in an event where there is energy expenditure by the two cells involved. Nogueira 
and Cohn [56] observed the formation of projections on the surface of the host cell, 
which leads to a classical phagocytic process.
In cells considered as nonprofessional phagocytic, such as epithelial cells and 
fibroblasts, there appears to be a process of internalization where the parasite is the 
agent of penetration [33]. This process was confirmed by Martins et al. [57], where it 
was shown that metacyclic trypomastigotes (G and CL strains) require ATP to invade 
nonprofessional phagocytic cells. In these cell types, two different strategies are 
known to be involved in the invasion process and formation of the PV: one dependent 
on lysosomes and another one independent of lysosomes. The lysosomal-dependent 
pathway, first described by Tardieux et al. [58], was well characterized in nonprofes-
sional phagocytic cell lines. Signals triggered by the recognition between T. cruzi 
and the host cell lead to the recruitment of lysosomes to the parasite’s entry site, 
which would actively participate in the invasion process [33]. In addition, lysosome 
exocytosis would depend (1) on the performance of microtubules [8] and (2) on 
the regulation of host cell cytoplasmic Ca2+ levels [15]. This process of lysosomal-
dependent invasion would occur in about 20% of the parasites [59]. The fusion of the 
lysosomes with the plasma membrane would thus end up donating the membrane 
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for the formation of the PV in a calcium-dependent process. In addition, a similar 
Ca2+-dependent lysosomal exocytosis mechanism was observed during injury and 
repair of the plasma membrane [60]. Tam et al. [61] demonstrated that the mecha-
nism of injury-dependent endocytosis is directly related to the secretion of a specific 
lysosomal enzyme and acid sphingomyelinase (ASM). ASM would cleave sphingo-
myelin, an abundant sphingolipid in the outer leaflet of the plasma membrane [62], 
forming ceramide, which is internalized by the cell [63–65]. Trypomastigotes are 
able to take advantage of this mechanism by inducing the formation of these vesicles 
rich in ceramides, thus facilitating the invasion process [66]. Over the years, this 
entry mechanism involving plasma membrane repair pathways has been extensively 
studied by several groups. The participation of lysosomal proteins known as Lamp1 
and Lamp2 has been shown to be essential, since the knockout of both proteins 
decreases the entry of trypomastigotes. This decrease in entry is not accompanied by 
inhibition of lysosome exocytosis to the repair region as well as phenotypic modifica-
tion of the host cell or generated PV. It is believed that the decrease in parasite entry 
is due to problems in caveolin-mediated endocytosis and in calcium efflux [67]. 
Considering that there are two distinct pools of lysosomes (cortical and internal) in 
mammalian cells, Hissa and Andrade used cardiomyocytes and observed, through 
the use of specific inhibitors, that trypomastigotes enter into this cell type mainly 
recruiting lysosomes from the more internal cell layer (perinuclear) [52]. Some 
molecules known as SAPs are secreted by microvesicles which are recognized by host 
cells and promote an efflux of perinuclear lysosomes. These molecules probably act 
together with gp82, activating Ca2+ pathway and promoting T. cruzi internalization 
[68]. Another molecule capable to recruit lysosomes to entry site is oligopeptidase also 
involved in Ca2+ efflux [69]. Using non-phagocytic cells it is described that the entry 
of metacyclic trypomastigotes is predominantly due to recruitment of lysosomes, 
whereas entry of cultured trypomastigotes (from the same CL strain) does not 
involve the participation of lysosomes [70]. Recently, Rodrigues et al. [26] observed 
that infection of host cells by metacyclic trypomastigotes is associated with lysosome 
spreading and presence of gp90 (metacyclic trypomastigote surface glycoprotein). 
Strains expressing low amount of surface gp90 are able to recruit more lysosomes to 
the site of infection giving rise to a more successful infection.
In all other mechanisms used by the parasites, there would be no recruit-
ment and exocytosis of lysosomes to the entry site, which are classified as 
lysosomal-independent mechanisms. In these pathways, there is an invagination 
of the plasma membrane of the host cell with the consequent formation of a PV 
without the initial presence of lysosomal markers. In 2002, Wilkowsky et al. 
[14] demonstrated the existence of this lysosomal-independent pathway for the 
invasion of T. cruzi into two nonprofessional phagocytic cell lines. Using Hela 
and CHO cells transfected with Rab5, Rab7, or dinamine-GFP, the presence of 
these endosomal markers in the newly formed vacuole was observed, indicat-
ing that some vacuoles fuse first with early and late endosomes and not with 
lysosomes. Later these events were quantified, and 50% of the parasitophorous 
vacuoles formed used the plasma membrane of the host cell but were enriched 
with PI3-kinase action products and negative for endosomal markers; 20% of 
the other trypomastigote-containing vacuoles were positive for EEA-1 (Rab5 
effector and marker of initial endosomes) and Rab5, and approximately 20% of 
the vacuoles were positive for LAMP-1 (lysosomal marker). Vacuoles from these 
pathways are matured by the gradual fusion of early endosomes as well as of 
lysosomes, which allows the complete formation of the PV [16, 19, 71].  
Both models of interaction are illustrated in Figure 3. In addition to the endoly-
sosomal system, the cytoskeleton and autophagic processes were also related to 
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of this glycoprotein in human and murine cardiomyocytes is able to prevent infec-
tion with trypomastigotes, one more data that goes against the modulating role of 
galectin in the process of internalization of trypomastigotes [47].
Galectin-3, a protein abundant in the cytoplasm of epithelial cells and macro-
phages, has also been described as a participant in the immune response and infec-
tion processes (in addition to the recognition process between the host and T. cruzi) 
[48, 49]. In addition, it has also been demonstrated that galectin-3 accumulates 
in both the parasite and phagosome entry regions and in tubules and vesicles that 
would derive from the endosomal system, thus suggesting that this protein is also 
an excellent marker of the lysis process of the PV containing this parasite [50]. The 
absence of galectin-3, in addition to increasing intracellular replication in vitro, is 
able to increase parasitemia in vivo by decreasing the secretion of pro-inflammatory 
cytokines and increasing cardiac fibrosis [51], which confirms the important role of 
this glycoprotein in the pathogenesis of Chagas disease.
In addition to all the molecules already mentioned, they also act as endothelin-1 
receptors and bradykinin receptors. Both are used by trypomastigotes in the invasion 
of cardiovascular cells, being very important in the pathogenesis of Chagas disease 
[52]. Cytokeratin 18, fibronectin, laminin, and integrin are also recognized by Tc-85, 
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[55] initially suggested that trypomastigotes forced the membrane of the host cell 
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the complex formation process of T. cruzi parasitophorous vacuoles, but there is still 
much controversy about these involvements. The first time that a compound known 
to interfere with actin polymerization inhibitor was used with the aim of study-
ing the entry of T cruzi was reported by Nogueira and Cohn [56]. Subsequently, 
Meirelles et al. [72] using the same compound demonstrated that the  
treatment of chicken macrophages with cytochalasin prevented the entry of  
the parasite without, however, preventing adhesion. This work was the  
first to split the entry’s phase of T. cruzi (adhesion and internalization). On 
the other hand, using another cytochalasin (cytochalasin D—an actin filament 
polymerization inhibitor) as a tool, it was observed that the infection rate of the 
parasite was not significantly altered [33]. Subsequently the Tardieux group [58] 
demonstrated that invasion of T. cruzi into nonprofessional phagocytic cells is sig-
nificantly enhanced by the depolymerization of the host cell actin cytoskeleton. 
The rapid reorganization of actin occurs as a response to the trypomastigote stage, 
suggesting that the direct reorganization of the actin cytoskeleton is a critical step 
for the entry process [18]. The reduction in the entry process was again observed 
in other studies, indicating that this divergence may be related to the observed 
interaction time [73].
In relation to the microtubules, their dynamics are important to facilitate T. cruzi 
invasion targeting lysosomes to entry site [57, 74]. It is also believed that the PV acts 
as a secondary center for the organization of microtubules, as regards the lysosomal 
fusion process at the parasite’s entry site [74]. Besides a protein known as a CLASP1 
(a microtubule plus-end tracking protein) is described as involved in the internal-
ization of T. cruzi integrating actin pathway with microtubules and helping with the 
perinuclear localization of PV [75]. Microtubules are also responsible for carrying 
vesicles such as those positive for Vamp7 (essential for lysosomal fusion and reten-
tion of infection) to the entry site. This transport is dependent on the KIF 5 protein 
(a kinesin) [76]. More recently, Romano et al. [77] have shown that an autophagic 
protein, LC3, would also be present in the PV membrane, also demonstrating that 
the induction of autophagy in the host cell (pharmacological or physiological) 
interferes with the mechanism of trypomastigote invasion. Autophagy mechanism 
also plays a protective role against T. cruzi infection in mice by activation of a host 
immune response [78].
Figure 3. 
Schematic model of T. cruzi internalization and parasitophorous vacuole formation using different entry 
pathways [10].
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4. Endocytic mechanisms involved in trypomastigote infection
Many processes are already described as involved in the entry of T. cruzi trypomas-
tigotes. As already discussed in this topic since 1972, Dvorak and Schumunis [55] had 
already described that the internalization of trypomastigotes in host cells could be by 
endocytic mechanisms. Endocytic processes are currently divided into different classes: 
clathrin-mediated endocytosis, endocytosis mediated by membrane microdomains (pla-
nar and caveolae), macropinocytosis, and phagocytosis. The first endocytic mechanism 
described as a participant in T. cruzi entry into host cells was phagocytosis. The participa-
tion of this mechanism was described by Nogueira and Cohn [56] through the treatment 
of several cell types, peritoneal macrophages, L929, HeLa, and embryo fibroblasts of 
calves with cytochalasin B (a drug that interferes with the extension of actin filaments). 
Afterward, Barbosa et al. [79] demonstrated by transmission electron microscopy that 
trypomastigotes are able to bind to cardiac muscle cells and induce the formation of 
extensive pseudopodia, a typical feature of phagocytic processes. Subsequently several 
reports showed that actin filaments are essential in other endocytic mechanisms, such as 
the macropinocytosis. Cytochalasins B and D are quite specific inhibitors of phagocytic 
activity. When the parasite is internalized via phagocytosis, there is internalization of 
CR3 receptors, β1 integrin, lysosomal membrane glycoproteins (Lpg), and Fc receptors 
(the latter appears only when trypomastigotes are opsonized). The participation of 
toll-2 receptors (“toll-like receptors 2”), as well as membrane components containing 
galactosyl, sialoconjugate, and glycoconjugate residues [80–82], is also demonstrated. 
In general phagocytosis is also a process that can be divided into different subtypes that 
are morphologically distinct. Using scanning electron microscopy, it was demonstrated 
that during internalization of trypomastigotes, the plasma membrane of peritoneal 
macrophages can cover the parasite in a juxtaposed way, with bilateral projections of 
plasma membrane forming a funnel-like structure that can follow the entire extent of 
the parasite’s body, culminating in its total internalization (similar to what is described 
as classical phagocytosis). It has also been observed in the development of structures 
similar to the initial stages of trigger phagocytosis or macropinocytosis, in addition to the 
formation of structures described as coiled-type phagocytosis [19, 82, 83].
The participation of membrane rafts in the invasion of T. cruzi has also been dem-
onstrated [84, 85]. Regions of membrane microdomains (rafts) are small, dynamic, 
cholesterol-rich membrane invagination regions, where sphingolipids, GM1 gan-
gliosides, and caveolae (caveolae are a special type of membrane rafts) concentrate. 
These regions are known as signaling hotspots because they contain several proteins 
that can be deposited by triggering signaling cascades. This topic (signaling activation 
in T. cruzi entry process) will be discussed later in this chapter. More recently it has 
been demonstrated that T. cruzi could also use another endocytic mechanism in the 
invasion of its host cell: macropinocytosis. [86]. This endocytic pathway involves the 
internalization of large areas of plasma membrane along with significant amounts of 
extracellular fluid. It is important to point out the participation of dynamin as a key 
protein for the formation and consequent release of the early PV from the plasma 
membrane. Its inhibition using dynasore or its blockage through an overexpression of 
a dominant-negative mutant of dynamin inhibits the internalization of trypomasti-
gotes, demonstrating that GTPase activity is also important [71, 86].
5. Signaling pathways involved in trypomastigote penetration
There are several external factors that can regulate different types of cellular 
responses. For these responses to occur, it is necessary that a conformational 
change of several proteins takes place, which means that they can now interact 
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the complex formation process of T. cruzi parasitophorous vacuoles, but there is still 
much controversy about these involvements. The first time that a compound known 
to interfere with actin polymerization inhibitor was used with the aim of study-
ing the entry of T cruzi was reported by Nogueira and Cohn [56]. Subsequently, 
Meirelles et al. [72] using the same compound demonstrated that the  
treatment of chicken macrophages with cytochalasin prevented the entry of  
the parasite without, however, preventing adhesion. This work was the  
first to split the entry’s phase of T. cruzi (adhesion and internalization). On 
the other hand, using another cytochalasin (cytochalasin D—an actin filament 
polymerization inhibitor) as a tool, it was observed that the infection rate of the 
parasite was not significantly altered [33]. Subsequently the Tardieux group [58] 
demonstrated that invasion of T. cruzi into nonprofessional phagocytic cells is sig-
nificantly enhanced by the depolymerization of the host cell actin cytoskeleton. 
The rapid reorganization of actin occurs as a response to the trypomastigote stage, 
suggesting that the direct reorganization of the actin cytoskeleton is a critical step 
for the entry process [18]. The reduction in the entry process was again observed 
in other studies, indicating that this divergence may be related to the observed 
interaction time [73].
In relation to the microtubules, their dynamics are important to facilitate T. cruzi 
invasion targeting lysosomes to entry site [57, 74]. It is also believed that the PV acts 
as a secondary center for the organization of microtubules, as regards the lysosomal 
fusion process at the parasite’s entry site [74]. Besides a protein known as a CLASP1 
(a microtubule plus-end tracking protein) is described as involved in the internal-
ization of T. cruzi integrating actin pathway with microtubules and helping with the 
perinuclear localization of PV [75]. Microtubules are also responsible for carrying 
vesicles such as those positive for Vamp7 (essential for lysosomal fusion and reten-
tion of infection) to the entry site. This transport is dependent on the KIF 5 protein 
(a kinesin) [76]. More recently, Romano et al. [77] have shown that an autophagic 
protein, LC3, would also be present in the PV membrane, also demonstrating that 
the induction of autophagy in the host cell (pharmacological or physiological) 
interferes with the mechanism of trypomastigote invasion. Autophagy mechanism 
also plays a protective role against T. cruzi infection in mice by activation of a host 
immune response [78].
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extensive pseudopodia, a typical feature of phagocytic processes. Subsequently several 
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activity. When the parasite is internalized via phagocytosis, there is internalization of 
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toll-2 receptors (“toll-like receptors 2”), as well as membrane components containing 
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In general phagocytosis is also a process that can be divided into different subtypes that 
are morphologically distinct. Using scanning electron microscopy, it was demonstrated 
that during internalization of trypomastigotes, the plasma membrane of peritoneal 
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gliosides, and caveolae (caveolae are a special type of membrane rafts) concentrate. 
These regions are known as signaling hotspots because they contain several proteins 
that can be deposited by triggering signaling cascades. This topic (signaling activation 
in T. cruzi entry process) will be discussed later in this chapter. More recently it has 
been demonstrated that T. cruzi could also use another endocytic mechanism in the 
invasion of its host cell: macropinocytosis. [86]. This endocytic pathway involves the 
internalization of large areas of plasma membrane along with significant amounts of 
extracellular fluid. It is important to point out the participation of dynamin as a key 
protein for the formation and consequent release of the early PV from the plasma 
membrane. Its inhibition using dynasore or its blockage through an overexpression of 
a dominant-negative mutant of dynamin inhibits the internalization of trypomasti-
gotes, demonstrating that GTPase activity is also important [71, 86].
5. Signaling pathways involved in trypomastigote penetration
There are several external factors that can regulate different types of cellular 
responses. For these responses to occur, it is necessary that a conformational 
change of several proteins takes place, which means that they can now interact 
Biology of Trypanosoma cruzi
128
with other molecules leading to their activation, transducing the signal and ampli-
fying it. The conformational change is usually dependent on the action of protein 
kinases or protein phosphatases. The case of the process of interaction between 
Trypanosoma cruzi and host cells is not different since it is also an external process 
that will require an internal response. From this perspective, several studies have 
focused on the investigation of different pathways that coordinate the invasion of 
T. cruzi and that modulate the gene expression of the host cell in response to this 
process [85, 86].
T. cruzi seems to exploit an infinity of cell surface receptors, secondary mes-
sengers, and transcription factors of different pathways to ensure its invasion and 
survival [86–89]. Among the signaling events, the best studied is that which leads 
to a calcium release in the host cells. This calcium release is one of the main respon-
sible for regulating the process of invasion of T. cruzi [9, 18]. Three different models 
have already been proposed by different groups as being responsible for the activa-
tion of this signaling pathway. Among the described models, two involve peptidases 
such as oligopeptidase B and cruzipain, and the third one involves a membrane 
glycoprotein called gp82. Although all three mechanisms activate calcium firing, 
none of them are correlated. The first proposed model is based on the activation of 
the serine peptidase called oligopeptidase B where this enzyme present in the trypo-
mastigote cytosol cleaves an inactive precursor to generate an active calcium agonist 
that is released by the parasite and binds to the receptor present on the surface of 
the host cell. This receptor is coupled to G protein which stimulates phospholipase C 
activity generating inositol 3,4,5-trisphosphate which binds to its receptor releasing 
calcium [90]. The second mechanism, proposed by Scharfstein et al. [91], is based 
on the secretion of cruzipain through the flagellar pocket region. This protein binds 
to a kininogen molecule that is cleaved into short kinin molecules, which in turn 
bind to the bradykinin receptor by stimulating the release of calcium from IP3. 
Cruzipain is also capable to regulate arginase activity increasing T. cruzi survival 
inside the cell through an increase in the production of IL-10 and TGF-β [92]. The 
model based on the activation of the glycoprotein gp82 is known to be bidirectional 
since it has been shown that a peak of calcium is generated not only in the host cell 
but also in the parasite itself. In the case of activation from this glycoprotein, the 
receptor is not yet known [90].
As previously described one of the activated pathways is TGF-β, where mol-
ecules secreted by trypomastigotes stimulate TGF-β receptors and activate the 
transcription of genes regulated by this molecule [93]. Activation of this pathway is 
involved in Chagas disease fibrosis development [94–96]. TGF-β was first described 
as being activated through cruzipain, but it is now known that trypomastigotes are 
capable of exposing phosphatidylserine to the outer layer of the plasma membrane. 
This exposure would be responsible for triggering the TGF signaling pathway in 
macrophages, based on the phosphorylated Smad2 nuclear translocation, leading 
to inhibition of iNOS in infected macrophages. This event would favor intracel-
lular survival of the parasite [97]. More recently, the mechanism used to favor this 
intracellular survival was proposal by Calvet and colleagues [98] using cardio-
myocytes as host cell model. In these cells the TGF-β receptor (TβRII) is localized 
in cardiomyocyte’s costameres, which are also rich in vinculin and associated with 
cytoskeleton (known as a signaling domain). Its activation potentiates Smad2 
phosphorylation. When T. cruzi infection is established, the cytoskeleton is disorga-
nized, disrupting TβRII striations and decreasing Smad2 phosphorylation making 
cardiomyocytes less responsive to exogenous TGF-β stimulation.
Phosphorylation of protein tyrosine kinases is an important step in the regu-
lation of a variety of eukaryotic cell signaling pathways [99]. In professional 
phagocytes, the entry of T. cruzi into macrophages is inhibited by treatment with 
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genistein, a tyrosine kinase inhibitor [79]. It has also been shown that trypomas-
tigotes of the Y strain stimulate tyrosine phosphorylation of a large number of 
proteins [100]. Pretreatment of fibroblasts with genistein does not inhibit entry of 
the parasite [18], suggesting different roles for protein tyrosine kinases in T. cruzi 
invasion of the Y strain in professional phagocytic cells or nonprofessional phago-
cytic cells. In cardiomyocytes and cardiac fibroblasts, tyrosine kinases appear to be 
essential to infection. Tyrosine kinase C (TrkC) is recognized by T. cruzi parasite-
derived neurotrophic factor (PDNF) through neurotrophin receptor culminating in 
the entry of trypomastigotes into cardiac cells, while TrkA activation by the same 
ligand in the same cell types leads to a decrease in oxidative stress [101]. In this same 
sense of protection from the T. cruzi infection, other signaling pathways are also 
activated as, for example, the pathways of Erk11/Erk2 and Jak/STATs [102]. Other 
protein kinases also participate in T. cruzi invasion in host cells, such as protein 
kinase C (PKC), MAP kinases, and phosphatidylinositol 3-kinases (PI3-K) [86, 88, 
97]. Recently the regions known as membrane microdomains have been described 
as signaling platforms. These regions are capable of recruiting a wide range of 
proteins involved in signal transduction processes. These proteins may include tyro-
sine kinase receptors and protein kinases such as PI3 kinase, protein kinase C, Src 
kinase (Lyn and Fyn) family proteins, FAK, bradykinin receptors, GTP (Rac, Rho, 
and Ras), and adapter proteins (Vav, Sos, and Shc). Some of these molecules have 
already had their share in the process of invasion of T. cruzi elucidated, while others 
have not. Proteins such as those from the Src kinases family (responsible for ITAM 
phosphorylation, which is essential for initiating the signal transduction cascade 
that triggers pathogen growth) and adapter proteins such as Vav, although not dem-
onstrated as participants in this process, have been described by Vieira et al. [88] 
as possible phosphorylated proteins during the T. cruzi invasion in macrophages. 
Signaling pathways described as involved in macropinocytosis pathway (Pak1 and 
PKC pathways) are important to the intracellular development of infection [19]. 
More recently, Wnt signaling also has been shown to be an important pathway to 
immunomodulatory functions during T. cruzi infection, regulating the control of 
parasite replication. Activation of Wnt pathway is important to avoid a produc-
tion of pro-inflammatory cytokines and indoleamine 2,3-dioxygenase activity by 
T. cruzi, helping to control the infection [103].
6. Organelles involved in parasitophorous vacuole formation
After the internalization process, T. cruzi resides obligatorily, and temporarily, 
inside a parasitophorous vacuole [10]. Over the years, several groups have described 
that the formation of the vacuole membrane is a complex process related to the par-
ticipation of numerous molecules, depending also on the type of host cell involved 
in the process, i.e., phagocytic lines or nonprofessional phagocytic lines. As regards 
the formation of the PV membrane, it has been previously discussed in this text 
that several components of the host cell have already been described as compo-
nents of the cytoskeleton [19, 73, 104, 105]. The organelle known as endoplasmic 
reticulum (ER) has been described in the literature as a donor membrane for 
phagosome formation, binding directly to the base of this phagosome in formation 
[106]. Recently, our group demonstrated by electron tomography (followed by 3-D 
reconstruction) and fluorescence videomicroscopy that the endoplasmic reticulum 
(ER) participates in the process of formation of the vacuole from initial moments 
until its complete maturation. The participation or not of ER in this process may 
be directly related to the input mechanism used by the parasite at the time of the 
invasion [104].
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reticulum (ER) has been described in the literature as a donor membrane for 
phagosome formation, binding directly to the base of this phagosome in formation 
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be directly related to the input mechanism used by the parasite at the time of the 
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The Golgi complex (CG) plays a central role in eukaryotic cells, serving as an 
intermediary and bidirectional axis of protein and lipid trafficking in the endo-
membrane system [107]. In the case of T. cruzi, Carvalho et al. [82] described that 
after long infection times, there would be no change in GC distribution, remaining 
in the perinuclear region. Recently, transmission electron microscopy showed an 
intimate proximity between the CG and the parasite-containing vacuole. These data 
are of extreme relevance due to the function of GC in eukaryotic cells, i.e., because 
the membrane of the PV containing the parasite is still in the process of formation, 
requiring lipids and proteins from the host cell that would aid its closure as well as 
its expansion. As regards mitochondria, apparently there is no direct link between 
this organelle and the vacuole [104].
7.  Disorganization of the parasitophorous vacuole and the 
endolysosomal system
As discussed above trypomastigotes of T. cruzi use different molecules and 
mechanisms to invade a host cell. Regardless of the chosen mechanism (participa-
tion of plasma membrane components or lysosomes at the site of invasion), the 
parasite will be located inside a vacuole.
Inside the PV the trypomastigotes release the enzyme trans-sialidase/neur-
aminidase, which is responsible for the removal of the sialic acid residues from 
the vacuole membrane. This removal makes it sensitive to the action of another 
enzyme, homologous to factor 9 of human complement, Tc-Tox. The lysis of the 
vacuole membrane by the action of Tc-Tox may be associated with the formation of 
pores in this membrane, which, together with the secretion by the trans-sialidase/
neuraminidase parasite, will lead to the complete fragmentation of the PV mem-
brane [35, 108].
Despite the attempt to determine the exact moment of the T. cruzi exit process 
from the parasitophorous vacuole, this step has not yet been well elucidated. Since 
1989, however, our group has been trying to chart the paths necessary for this 
discovery. Initially Carvalho and De Souza [109] demonstrated by transmission 
electron microscopy that the lysing process of the PV membrane begins to occur 
in the first 2 hours of interaction of the trypomastigote stage in peritoneal mac-
rophages, already suggesting the occurrence of fusion of lysosomes, after entry 
of the parasites. More recently, Reignault and colleagues [50] demonstrate that 
galectin-3 decorates T. cruzi vacuole acting as an important marker to be used also 
for the study of parasitic vacuole lysis of T. cruzi, as it also undergoes a process of 
disorganization with consequent exit of the parasite into the cytoplasm of the host 
cell. Transcriptome studies have shown an extensive remodeling of the intracellular 
T. cruzi in the first 4 hours of trypomastigote invasion (until the parasitophorous 
vacuole disintegration), and these modifications can be associated with a regulation 
of the initial step of host cell invasion [110]. Some modifications occurring in intra-
cellular differentiation processes (trypomastigotes to amastigotes and subsequently 
to trypomastigotes again) may be involved in the process of destruction of PV. One 
of the modifications that seems to be involved with this process is the increase in 
the enzymatic activity of glutamine synthase during the amastigogenesis process. 
This enzyme is normally involved in the process of handling excess ammonia, and 
given the fact that the main energy source of the intracellular forms of T. cruzi is 
from amino acids, the ammonium generation is high. Marim et al. [111] observed 
that the activity blockage of this enzyme impair the progression of the intracel-
lular cycle (amastigotes did not differentiate for trypomastigotes). In this case the 
role of the enzyme is to regulate the intracellular pH by controlling the content of 
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intravacuolar ammonium (generated by the consumption of amino acids in this 
reduced space). It is this acidification process followed by the pH control that allows 
the enzymatic activity that culminates in the release of parasite in the cytoplasmic 
environment allowing the infection to continue [112].
8. Concluding remarks
Host cell invasion and parasite internalization are important steps in the 
evolution of parasitism by several pathogens. These processes present at least two 
important advantages: protection against the host immune response and access to a 
microenvironment rich in metabolic products. Substantial progress has been made 
in understanding the roles of proteins in infection and invasion by T. cruzi. Host cell 
intracellular signaling can combat the infection; but it can also favor parasite entry. 
Parasites hijack the host immune response, phagocytosis, ECM, and antiparasitic 
proteins for their own survival, replication, and immune evasion purposes. The 
complex networks are interconnected and require extensive study to identify intra-
cellular rearrangements that facilitate parasite internalization. A multidisciplinary 
approach is necessary to a better understanding of parasite-host interaction and 
will be critical to better understand Chagas disease physiopathology, diagnosis, and 
treatment.
Acknowledgements
We thank all authors who work with this theme and for the contribution during 
the last years.
Conflict of interest
The authors declare “no conflict of interest.”
Author details
Emile Barrias1*, Lissa C. Reignault2 and Wanderley de Souza2
1 National Institute of Metrology, Quality and Technology (INMETRO), 
Duque de Caxias, Rio de Janeiro, Brazil
2 Federal University of Rio de Janeiro (UFRJ), Rio de Janaeiro, Brazil
*Address all correspondence to: esbarrias@inmetro.gov.br
Biology of Trypanosoma cruzi
130
The Golgi complex (CG) plays a central role in eukaryotic cells, serving as an 
intermediary and bidirectional axis of protein and lipid trafficking in the endo-
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aminidase, which is responsible for the removal of the sialic acid residues from 
the vacuole membrane. This removal makes it sensitive to the action of another 
enzyme, homologous to factor 9 of human complement, Tc-Tox. The lysis of the 
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the enzymatic activity of glutamine synthase during the amastigogenesis process. 
This enzyme is normally involved in the process of handling excess ammonia, and 
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cellular rearrangements that facilitate parasite internalization. A multidisciplinary 
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Abstract
Chagas disease affects low-income nations with health consequences that impact 
the economy of those countries. Interestingly, inhibitors of channels formed by 
proteins of the gap junction family, such as suramin and boldine, exhibit trypanocidal 
activity. Gap junction proteins are integral membrane proteins present in both ver-
tebrates and invertebrates that participate in cellular communication. These proteins 
form gap junction channels, which connect the cytoplasm of neighboring cells or 
non-junctional channels that connect the intra- and extracellular milieu. Interestingly, 
Trypanosoma cruzi modulates the expression of proteins of the gap junction family or 
modify the activity of the channels formed by these proteins in host cells. Moreover, 
Lucifer yellow microinjected into fibroblast was incorporated into associated trypano-
somes of Trypanosoma musculi, suggesting the possibility of direct communication 
via gap junction channels between them. In this chapter, we summarized the current 
knowledge about the possible roles of gap junction family proteins in Chagas disease.
Keywords: connexin, pannexin, innexin, hemichannels, infection
1. Introduction
Chagas disease affects low-income nations with health consequences that 
impact the economy of these countries [1]. Research aimed at understanding their 
biology and identification of potential targets for drug development is the high-
est priority [1]. Interestingly, inhibitors of channels formed by proteins of the 
gap junction family such as suramin and boldine have trypanocidal activity and 
some of them are currently used for treatment of parasitic diseases such Human 
African Trypanosomiasis [2–5]. Also, studies have shown that infections caused by 
Trypanosoma cruzi (T. cruzi) modulate the expression of proteins of the gap junc-
tion family or modify the activity of the channels formed by these proteins in host 
cells [6–11]. Moreover, previous studies have shown gap junction type structures in 
Trypanosoma musculi [12]. In this chapter, we summarized the current knowledge 
about the role of gap junction family proteins in Chagas disease.
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2. Gap junction proteins
Gap junction proteins are present in both vertebrates and invertebrates from 
mesozoa to mammals [13]. The protein families include connexins (Cxs), innexins 
(Inxs) and pannexins (Panxs) [14, 15]. They are integral membrane proteins that 
participate in cellular communication playing a relevant role in several physiological 
processes [15]. In vertebrates, Cxs and Panxs are present, while in invertebrates, 
only Inxs are present [15]. In humans, 21 and 3 genes encode Cx and Panx proteins, 
respectively [14]. Most Cx genes contain two exons and an intron of variable length 
[14]. The Panx1 and Panx2 genes contain 5 exons, while the Panx3 gene contains 4 
exons [16]. Moreover, Inx genes have been found in the phylum Arthropoda [17–20], 
Nematoda [21], Chordata [22], Annelida [23], Platyhelminthes [24], Cnidaria [25], 
and Mollusca [26]. In Drosophila melanogaster, the Inx genes have the potential to 
be differentially spliced [18], while in C. elegans, 15% of genes are found in operons 
and three pairs of the innexins are polycistronic such as inx-12 and inx-13, inx-16 
and inx-17, and inx-21 and inx-22 [27]. Regarding the structure of the protein 
topology, hydropathy plots of several Inx, Cx and Panx proteins have predicted the 
presence of four hydrophobic domains with transmembrane spanning regions and 
the extracellular loops with several highly conserved residues [28]. In contrast, the 
cytoplasmic loop and the carboxy terminus vary extensively in length and amino 
acid composition [28].
2.1 Gap junction channels
Cx and Inx proteins form gap junction channels, which connect the cytoplasm 
of neighboring cells [14, 15]. Moreover, Cx, Panx and Inx proteins form non-junc-
tional channels that connect the intra- and extracellular milieu [14]. Gap junction 
plaques are formed by a variable number of homo- and/or heterotypic gap junction 
channels with distinct biophysical characteristics [29]. Structurally, they are formed 
by oligomers of Cx, Inx, or Panx proteins, which co-oligomerize into the same 
(homomeric) or mixed (heteromeric) channels [30]. Gap junction channels are 
essential in several physiologic functions such as electrical conduction between car-
diomyocytes [31], development and regeneration of skeletal muscle [32], endocrine 
gland secretion [33], and ovarian folliculogenesis [34]. Also, they are implicated in 
pathophysiological conditions such as hereditary deafness [35], cataract [36], and 
tumorigenesis [37].
Gap junction proteins can also form non-junctional channels, which play impor-
tant roles as autocrine/paracrine cellular communication pathways [14]. They are 
permeable to ions and several metabolic and signaling molecules such as glucose, glu-
tamate, glutathione, adenosine, NAD+ (superindice) and ATP among others [14]. It 
has been proposed that Panxs do not form gap junctions, however, they form plasma 
membrane channels (named pannexons) with some properties similar to those of the 
non-junctional channels formed by Inxs or Cxs also called hemichannels [15].
The pannexons are permeable to ATP when are activated with certain stimuli 
such a low oxygen, mechanical stress, and elevated extracellular potassium ion 
concentration [38]. Otherwise, the Panx1 channel is selective for chloride ions and 
exhibits no ATP permeability when stimulated simply by depolarization to positive 
potentials or the C-terminal is cleaved by proteolysis [38]. Since we found increased 
Panx1 channel activity and increase in ATP release in cells infected with T. cruzi 
[11], it suggested that under this condition the Panx1 channel does not undergo 
proteolysis and adopt the large channel configuration [11, 38]. In addition, it has 
been described that Panx1-based channels are regulated by mechanical stress [39]. 
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Inx-based hemichannels are activated by increased extracellular potassium ion 
concentration and by membrane depolarization [40]. Furthermore, Panx1- and 
Inx-based channels are inhibited by low concentration of carbenoxolone (<5 μM) or 
high probenecid concentrations (>500 μM) [41, 42].
Moreover, Cx-based hemichannels are regulated by intracellular acidification 
[43], intracellular Ca2+ [44], intracellular Na+ [45], pro-inflammatory cytokines [46], 
positive membrane potentials [47], phosphorylation [48], and S-nitrosylation [49]. 
They are inhibited by lanthanum chloride, carbenoxolone (>50 μM), and Cx mimetic 
peptides GAP16, GAP27, and GAP19 [15].
3. Gap junction and Chagas
3.1 Connexins
In 1992, Spray’s group showed for the first time that gap junctions were 
altered between rat neonatal cardiomyocytes infected with the Tulahuen 
strain of T. cruzi (Table 1) [6]. They showed that junctional conductance and 
intercellular transfer of Lucifer yellow was reduced between cardiomyocytes 
infected with T. cruzi (Figure 1) [6]. In 1998, the same group described that 
Tulahuen strain of T. cruzi reduced gap junction communication between rat 
astrocytes and between rat leptomeningeal cells as well [7]. Also, these authors 
demonstrated through immunocytochemistry studies that Cx43 reactivity was 
significantly reduced in whole brains from rats acutely infected with T. cruzi [7]. 
In 2008, in vitro studies showed that Y strain of T. cruzi increased the amount of 
Cx43 at 1 hour postinfection and reduced it at 72 hour postinfection in mouse 
cardiomyocytes (Figure 1) [8]. Moreover, they demonstrated through immunob-
lotting analysis that the amount of Cx43 was significantly reduced in heart atria 
and ventricles from mice infected with Y strain of T. cruzi at 11 days postinfec-
tion [8]. In 2009, Waghabi and collaborators demonstrated that the number and 
length of Cx43 plaques were reduced in heart biopsies of human chronic chagasic 
patients [9]. In 2013, we described that CL Brener strain of T. cruzi increased the 
Cx43 hemichannel activity in HeLa cells stably transfected with Cx43 (Figure 1)  
[15]. Also, we observed that the number of amastigotes was 3 times higher in 
Table 1. 
Summary of the studies that describe the effect of T. cruzi on gap junction protein family.
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Summary of the studies that describe the effect of T. cruzi on gap junction protein family.
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HeLa-Cx43 as compared to HeLa parental cells at 48 hours postinfection [15]. In 
2014, Burke and collaborators demonstrated that Brazil strain of T. cruzi reduced 
the amount of Cx43 in brown adipose tissue at 30 and 90 days postinfection 
(Figure 1) [10]. Moreover, T. cruzi infection caused an increased the amount of 
Cx43 protein in white adipose tissue at 30 and 90 days postinfection [10].
3.2 Pannexins
In 2018, we found that H510 strain of T. cruzi increased the Panx1 chan-
nel activity in rat neonatal cardiomyocytes at 1 hour postinfection [11]. 
Interestingly, the increased pannexon activity induced by the parasite was 
directly related to an elevated ATP release [11]. This is relevant because ATP 
has been proposed as a key molecule in T. cruzi host cell invasion [11, 50]. For 
example, blockade of P2Y1 receptors with a MRS2179, a selective P2Y1 antagonist, 
reduced T. cruzi-evoked Ca2+ transients in rat cardiomyocytes [11]. Moreover, 
inhibition of mitochondrial ATP production by treating parasites with rotenone 
plus antimycin A reduced the infectivity of the parasites [50]. Also, pre-treat-
ment with pannexon activity-blocking drugs significantly reduced the number 
of intracellular parasites in cardiomyocytes infected with H510 strain of T. 
cruzi [11]. For instance, cells exposed to 100 μM 10Panx1 or 400 μM probenecid 
showed a 114 ± 2 and 71 ± 2 parasites/500 cells, respectively, versus 5001 ± 2 
parasites/500 cells in control condition [11]. Interestingly, scanning and trans-
mission electron microscopy studies have demonstrated the presence of reminis-
cent gap junction at physical interactions between Trypanosoma musculi and mice 
spleen-derived adherent fibroblasts [12]. Also, Lucifer yellow microinjected into 
fibroblast was incorporated into associated trypanosomes, suggesting that those 
gap junctions were functional [12].
Figure 1. 
Model that summarizes the main effects of the Trypanosoma cruzi on cellular communications mediated by gap 
junction channels. Parasites release a virulence factor that opens Panx1 channels allowing the release of ATP to 
the extracellular milieu [11]. Also, the parasite causes a reduction of intercellular communications mediated 
by gap junctions [6]. Contrarily, the parasite increases the activity of the hemichannels present in the plasma 
membrane of the infected cells [15].
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4. Gap junction channel blocking compounds as antiparasitic drugs
Interestingly, several drugs that block the activity of gap junction channels 
have been described as potent anti-parasitic agents. Among them are: probenecid, 
boldine and suramin, among others (Table 2) [2–4].
4.1 Probenecid
Human clinical trials have shown that probenecid, an inhibitor of a non-junc-
tional channel formed by Panx1 has an antimalarial effect [2]. The authors described 
that 50 μM probenecid caused an increase in the sensitivity of highly resistant V1S 
strain of Plasmodium falciparum to pyrimethamine, sulfadoxine, chlorcycloguanil, 
and dapsone by seven-, five-, three-, and three-folds, respectively [2].
4.2 Suramin
Suramin, a general antagonist of purinergic receptors (P2Y and P2X) [51] and 
blocker of Panx1 channels [52], exhibits anti-parasitic properties [3]. Culture of 
LLC-MK2 cells treated with suramin (500 μM) during the intracellular develop-
ment of T. cruzi, caused morphological changes in the parasites; increase in parasite 
width, and partial or complete detachment between flagella and cell body [3]. 
Interestingly, suramin is one of the 5 approved drugs for treatment of sleeping 
sickness [5].
4.3 Boldine
Boldine, an alkaloid obtained from Boldo tree, which blocks the activity of 
Cx43-formed hemichannels, and Panx1 hemichannels exhibit, an anti-parasitic 
activity [53, 54]. Boldine at concentrations above 500 μM reduces the epimastigotes 
growth of Tulahuen, LQ and DM28c strains of T. cruzi [4]. Since the active com-
pound also inhibited cell respiration, it was suggested that these drugs may block 
the mitochondrial electron transport [4].
Table 2. 
Antiparasitic drugs and channel blocker drugs.
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mission electron microscopy studies have demonstrated the presence of reminis-
cent gap junction at physical interactions between Trypanosoma musculi and mice 
spleen-derived adherent fibroblasts [12]. Also, Lucifer yellow microinjected into 
fibroblast was incorporated into associated trypanosomes, suggesting that those 
gap junctions were functional [12].
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5. Conclusions
Chagas diseases affect predominantly underprivileged areas of Latin 
America, but attention has been increasing lately due to the rise in people 
migration habits, intercontinental travels, and immune suppressed patients [1]. 
Unfortunately, current therapeutic options include only two compounds (nifur-
timox and benznidazole) with considerable toxicity and side effects, so the new 
drug development is of the highest priority [1]. Hemichannels are involved in the 
regulation of plasma membrane permeability in ischemic insults or metabolic 
inhibition [55, 56]. Moreover, alterations of plasma membrane is a common 
phenomenon in parasite-induced infections such malaria and T. cruzi, among 
others [57, 58]. Thus, hemichannels could be key players in parasite-induced 
plasma membrane permeabilization. All the above data support the importance 
of studying the possible role of hemichannels in parasitic infections. They could 
be potential targets for the development of new compounds to limit parasite 
infections or tissue/organ damage induced by their presence.
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Trypanosoma cruzi Infection: 
Mechanisms of Evasion of 
Immune Response
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Abstract
Trypanosoma cruzi has a complex life cycle that involves a vertebrate as well as an 
invertebrate host. In this, last two stages are present: trypomastigotes, the flagel-
lated and infective stage and the amastigote, which is the replicative stage. T. cruzi 
is considered one of the most successful intracellular parasites, because it cannot be 
eliminated by the immune system and has the capacity of invading, surviving, and 
replicating inside the host cells. The effects that the infection has over the immune 
system have been widely studied at the molecular and cellular level. However, 
understanding the mechanisms that the parasite uses to evade the immune system 
to persist in the infected individual is necessary for the effective development 
of drugs and/or vaccines. In this chapter, a compilation of the already described 
mechanisms will be carried out.
Keywords: Trypanosoma cruzi, immune system, T. cruzi immune evasion, immune 
modulation
1. Introduction
Chagas disease or American trypanosomiasis is a potentially life-threatening 
illness caused by the protozoan parasite, Trypanosoma cruzi. It is found mainly in 21 
Latin American countries, where it is a mostly vector borne. An estimated 8 million 
people are infected worldwide, mostly in Latin America. Chagas disease has spread 
to the other continents over the last century mainly because of enhanced means of 
travel and global population movement to and from Latin America. It is estimated 
that over 10,000 people die every year from clinical manifestations of Chagas 
disease and more than 25 million people risk acquiring the disease [1].
Chagas disease is characterized by two stages, the initial phase is known as acute 
phase and lasts a few weeks and is characterized by an elevated parasitemia associated 
with fever, headache, nausea, that is rarely lethal and a severe hepatomegaly. The acute 
phase is followed by a chronic phase, which remains asymptomatic for many years. The 
parasites are then difficult to observe in the blood, and the other symptoms are also less 
severe. Most patients remain in this indeterminate stage for life (absence of any symp-
tom), 5–10% of the people will develop anatomical and functional abnormalities at 
their esophagus and their colon, while 20–40% starts presenting a symptomatic chronic 
phase characterized by a progressive and debilitating Chagasic cardiomyopathy and 
sometimes mega syndromes. Arrhythmias increasing severely lead to congestive cardiac 
failure and death of the patients usually 10–30 years after the initial infection [2, 3].
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phase is followed by a chronic phase, which remains asymptomatic for many years. The 
parasites are then difficult to observe in the blood, and the other symptoms are also less 
severe. Most patients remain in this indeterminate stage for life (absence of any symp-
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their esophagus and their colon, while 20–40% starts presenting a symptomatic chronic 
phase characterized by a progressive and debilitating Chagasic cardiomyopathy and 
sometimes mega syndromes. Arrhythmias increasing severely lead to congestive cardiac 
failure and death of the patients usually 10–30 years after the initial infection [2, 3].
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The recognition of T. cruzi by the immune system relies on the activation of 
innate immunity and adaptative immunity. In this activation process, the recogni-
tion of pathogen-associated molecular patterns (PAMP) by Toll-like receptors of B 
and T cells is very important as a bridge between both types of immunity [4]. The 
innate and acquired immune responses are characterized by the recruitment of den-
dritic cells, macrophages, natural killer (NK), and B and T lymphocytes, as well as 
their secretion of soluble factors (cytokines and chemokines) [5]. IFN-γ plays a key 
role during T. cruzi infection, increasing the production of nitric oxide by macro-
phages, which inhibits the development of the intracellular from T. cruzi [6]. CD4+ 
Th1 lymphocyte that produces the cytokines interleukin-2 (IL-2) and IFN-γ can 
stimulate the expansion of cytotoxic CD8+ T lymphocytes, a central mechanism for 
systemic protection against T. cruzi infection [5, 7]. Recent studies have confirmed 
that CD8+ T cells act both indirectly by secreting IFN-γ to activate macrophages and 
directly through the production of perforin and their concomitant cytotoxic activ-
ity [8]. Thus, there is now a growing consensus that protective immune response 
against T. cruzi requires the activation of a Th1 immune profile, with the stimulation 
of CD8+ T cells, while antibodies may play a rather secondary role [9].
Although the immune response generated with Trypanosoma cruzi infection is 
potent and active, it fails to clear parasite infection, leading to the chronic phase 
of the Chagas disease. The parasite has developed sophisticated strategies to evade 
host immune responses. The Trypanosoma cruzi immune evasion is mainly based 
on altering the complement system and inhibitory effects on the mononuclear 
phagocyte system lifestyle [10–12], and therefore, this chapter summarizes the 
mechanism employed by Trypanosoma cruzi to escape the host’s deleterious immune 
responses and enter into the host cells and establish persistent infection.
2. Immune evasion during the acute phase
2.1 Escape of the parasitophorous vacuole
Invading the host cell is a complex process that starts with parasite attachment 
to plasmatic membrane and then the compartment is formed called parasitopho-
rous vacuole (VP), which fuses to lysosomes forming the phagolysosome (PLM). 
Acidification of the VP allows trypomastigotes escape from PLM to the cytoplasm, 
where it differentiates into amastigote forms. In the cytoplasm of infected cells, the 
amastigotes multiply by binary fission, they accumulate and transform to blood-
form trypomastigotes, which are released in the bloodstream through the rupture of 
the host cell membrane to find new cells to invade [13–17].
Parasite escape from PLM occurs because the growth and development of 
T. cruzi cannot be maintained within it. Therefore, the trypomastigotes exit to the 
cytoplasm, and after a short period of time, they differentiate into amastigotes, and 
the rupture of this structure is activated by acidic pH generated by the fusion of the 
lysosomes [18].
To survive the acid medium into the phagolysosome, the trypomastigotes 
activate trans-sialidases/neuraminidase, and these enzymes transfer sialic acid 
from the sialyl-glycoconjugates in the membrane of the PLM to the β-galactoses of 
acceptor molecules (GPI-mucins) on the surface of the parasite [19, 20]. More spe-
cifically, the membrane of the phagolysosome is covered on the inner side with two 
important proteins known as lysosomes-associated membrane proteins (LAMP1 Y 
LAMP2), and these proteins are highly sialylated [21, 22]. The terminal sialylation 
of these proteins contributes to maintaining parasitophorous vacuole membrane 
integrity, whereby the removal of sialic acid residues sensitizes the membrane to the 
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action of a transmembrane protein forming pore secreted by the parasite (Tc-TOX) 
[23, 24]. When the phagolysosome is broken, the trypomastigotes are released into 
the cytoplasm.
2.2 Evasion of the oxidative response
Previously, it was mentioned that T. cruzi not only invades phagocytic cells 
via classic phagocytosis but also can actively invade mammalian nonprofessional 
phagocytic cells by induced phagocytosis [25]. The main host cells targeted by  
T. cruzi are resident macrophages at the site of infection and dendritic cells, both of 
which play a main role in the response of the immune system as they are specialized 
antigen presenting cells [11].
Macrophages have two roles; on the one hand, they are important effector cells 
for the control and killing of the intracellular form of the parasite by oxidative and 
nonoxidative mechanism. On the other hand, macrophages may also serve as long-
term host cells that facilitate the replication and survival of the pathogens [26]. 
Macrophage membrane-associated NADPH oxidase is activated during phagocyto-
sis of trypomastigotes, resulting in a stable superoxide radical anion (O2˙−) which 
can be transformed to H2O2 by superoxide dismutase (SOD) [6, 27, 28].
IFN-γ and TNF synthesized during T. cruzi acute infection stimulate infected 
macrophages to produce high amounts of nitric oxide (˙NO) derived by the enzy-
matic activity of inducible nitric oxide synthase (iNOS). The nitric oxide generated 
reacts with O2˙− and produces peroxynitrite (ONOO−), a potent oxidant and cyto-
toxic effector molecule against T. cruzi [29–33]. Trypanosoma cruzi has five antioxi-
dant enzymes such as peroxidases and four iron superoxide dismutases (FeSODs) 
that are located at different subcellular compartments of the parasite, which reduce 
equivalents from NADPH and defend the parasite against host oxidative stress of 
the host (Tables 1 and 2) [27, 34].
2.3 Complement evasion
Trypomastigotes after being released in the bloodstream become a targeted of 
the preexisting soluble factors that potentially recognize and destroy them by dif-
ferent effectors [11]. Serum components, such as the complement system, consist 
of 35 or more soluble protein and cell surface receptors/regulators that interact with 
pathogen structures and activate a cascade of proteases that eliminate invading 
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The recognition of T. cruzi by the immune system relies on the activation of 
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phages, which inhibits the development of the intracellular from T. cruzi [6]. CD4+ 
Th1 lymphocyte that produces the cytokines interleukin-2 (IL-2) and IFN-γ can 
stimulate the expansion of cytotoxic CD8+ T lymphocytes, a central mechanism for 
systemic protection against T. cruzi infection [5, 7]. Recent studies have confirmed 
that CD8+ T cells act both indirectly by secreting IFN-γ to activate macrophages and 
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lysosomes [18].
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acceptor molecules (GPI-mucins) on the surface of the parasite [19, 20]. More spe-
cifically, the membrane of the phagolysosome is covered on the inner side with two 
important proteins known as lysosomes-associated membrane proteins (LAMP1 Y 
LAMP2), and these proteins are highly sialylated [21, 22]. The terminal sialylation 
of these proteins contributes to maintaining parasitophorous vacuole membrane 
integrity, whereby the removal of sialic acid residues sensitizes the membrane to the 
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action of a transmembrane protein forming pore secreted by the parasite (Tc-TOX) 
[23, 24]. When the phagolysosome is broken, the trypomastigotes are released into 
the cytoplasm.
2.2 Evasion of the oxidative response
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via classic phagocytosis but also can actively invade mammalian nonprofessional 
phagocytic cells by induced phagocytosis [25]. The main host cells targeted by  
T. cruzi are resident macrophages at the site of infection and dendritic cells, both of 
which play a main role in the response of the immune system as they are specialized 
antigen presenting cells [11].
Macrophages have two roles; on the one hand, they are important effector cells 
for the control and killing of the intracellular form of the parasite by oxidative and 
nonoxidative mechanism. On the other hand, macrophages may also serve as long-
term host cells that facilitate the replication and survival of the pathogens [26]. 
Macrophage membrane-associated NADPH oxidase is activated during phagocyto-
sis of trypomastigotes, resulting in a stable superoxide radical anion (O2˙−) which 
can be transformed to H2O2 by superoxide dismutase (SOD) [6, 27, 28].
IFN-γ and TNF synthesized during T. cruzi acute infection stimulate infected 
macrophages to produce high amounts of nitric oxide (˙NO) derived by the enzy-
matic activity of inducible nitric oxide synthase (iNOS). The nitric oxide generated 
reacts with O2˙− and produces peroxynitrite (ONOO−), a potent oxidant and cyto-
toxic effector molecule against T. cruzi [29–33]. Trypanosoma cruzi has five antioxi-
dant enzymes such as peroxidases and four iron superoxide dismutases (FeSODs) 
that are located at different subcellular compartments of the parasite, which reduce 
equivalents from NADPH and defend the parasite against host oxidative stress of 
the host (Tables 1 and 2) [27, 34].
2.3 Complement evasion
Trypomastigotes after being released in the bloodstream become a targeted of 
the preexisting soluble factors that potentially recognize and destroy them by dif-
ferent effectors [11]. Serum components, such as the complement system, consist 
of 35 or more soluble protein and cell surface receptors/regulators that interact with 
pathogen structures and activate a cascade of proteases that eliminate invading 
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Briefly, the action of the classical pathway is mediated by the antibodies 
binding to pathogen antigens, then the antibodies interact with the complement 
C1 protein, and it cleaves C2 and C4 to generate C2a and C4b, which join to the 
pathogen surface and form the C3 convertase C4b2a [16, 46]. Lectin complement 
pathway is the first to recognize T. cruzi; this is active by the binding of ficolins to 
the carbohydrates on the parasite surface and also mannan-binding lectins (MBLs) 
to the mannan on the surface of the parasite; then cysteine proteases bound to these 
molecules and cleave C2 and C4 and; this event also generates the C3 convertase 
C4b2a [47–49]. Finally, the alternative pathway is activated by the spontaneously 
hydrolyzed C3 or C3b originating from the other complement pathways; C3b 
interacts with factor B, and the latter in then cut into Bb by factor D, forming the C3 
convertase C3bBb [50]. The three pathways differ in the initial steps of activation, 
but all three converge to produce a C3 convertase and then a C5 convertase, allow-
ing the formation of the membrane attack complex (MAC) which is responsible for 
membrane lysis and subsequent pathogen elimination [16].
Trypanosoma cruzi trypomastigotes are normally resistant to the lytic effects of 
complement from vertebrate hosts susceptible to infection. This resistance of the 
trypomastigotes to direct lysis by the complement system facilitates parasite survival 
and infectivity but during the course of chronic infections; however, the vertebrate 
hosts produce antibodies that render the trypomastigotes sensitive to lysis, primarily 
via the alternative complement cascade and amplified by the classical pathway, and 
this resistance is a developmentally regulated phenomenon because the parasite is 
susceptible to complement lysis when it is in epimastigote form [51].
Complement activity present in normal human serum has been reported to lyse 
circulating forms of T. cruzi following activation by specific host antibodies bound 
to the surface of the parasites [52]. Incubation of trypomastigotes with human 
complement does not lead to lysis when the trypomastigotes do not have immu-
noglobulins on their surfaces. However, if such trypomastigotes are preincubates 
with sera obtained from chronically infected hosts, IgG immunoglobulins bind to 
their surface, and the parasites become sensitive to lysis by fresh human sera as a 
source of C5, thus lysis required antibodies and complement in mammals [53, 54], 
and on the other hand, birds, amphibians, and reptiles are naturally refractory to 
T. cruzi infection, due to complement-mediated lysis and macrophage-induced 
killing of the parasites [52, 55, 56]. Sera of the birds is capable of lysing infective 
forms of the parasite which as mentioned above are resistant to lysis by human 
serum, and this normal lytic activity of chicken serum seems to be independent 
of antibody, because it has been observed that the lytic activity of serum in vitro 
was not impaired in chickens that had been immunosuppressed by four different 
procedures, and the lysis occurs even in the absence of antibodies (e.g., bursecto-
mized chickens are refractory to T. cruzi infections) in which chicken complement 
is probably activated through the alternative pathway [52, 57–59]. The details of the 
mechanisms of resistance of birds to T. cruzi infection need further investigation, 
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since it could improve our understanding of the host-parasite interactions and favor 
the establishment of the innate mechanism of resistance and/or susceptibility of 
vertebrate hosts to T. cruzi.
2.3.1 Molecules of Trypanosoma cruzi that interfere with complement pathways
T. cruzi relies a variety of molecules that block or disrupt different steps of the 
complement pathways to evade complement lysis [44, 60, 61]. Below are some 
molecules of T. cruzi that it uses to get rid the action of the complement pathways.
a. Calreticulin (TcCRT): This protein is expressed in trypomastigotes, and it is 
mainly located in the endoplasmic reticulum (RE), but it has also been found 
in the Golgi, reservosomes, flagellar pocket, cell surface, cytosol, nucleus, and 
kinetoplast. After the infection, calreticulin moves from RE to the emerging 
area of the flagellum on the plasma membrane surface [62–64]. Calreticulin is 
a 45 kDa calcium-binding protein that binds to host mannose-binding lectin 
collagenous tails, preventing their interaction with parasite mannan and also 
interacts directly with L-ficolin preventing C4 conversion to C4b. TcCRT also 
interacts with C1q collagen-like domain, and therefore TcCRT inhibits both the 
classical and lectin pathway activation [65–67].
b. Trypanosoma cruzi complement regulatory protein (TcCRP) Gp160: The 
protein TcCRP, also called Gp160, which is GPI-anchored on the surface of 
trypomastigotes, can bind to C3b and C4b, thus inhibiting the formation of the 
classical and alternative complement C3 convertase [10, 68, 69].
c. Trypanosoma cruzi complement C2 receptor inhibition trispanning (TcCRIT): 
TcCRIT is a 32 kDa transmembrane protein mainly expressed in trypomastig-
otes. TcCRIT has amino acid sequence homology with the C4 beta-chain, the 
binding site of C2. Thus, it blocks C2 cleavage by C1s or MASP-2 into C2a and 
prevents C3 convertase formation, thus regulating the activation of the lectin 
and classical complement pathway [70–72].
d. Trypomastigote decay-accelerating factor (T-DAF): T-DAF is an 87–93 kDa 
glycoprotein expressed on the surface of metacyclic, bloodstream, and tissue-
culture-derived trypomastigotes of T. cruzi. T-DAF mimics the activity of 
the complement regulatory protein DAF and regulates the activation of the 
alternative, classical, and probably the lectins pathways of the complement. 
In summary, T-DAF activity either accelerates the dissociation or assembly 
efficiency of C3 convertases [73, 74].
e. Glycoprotein 58/68: Gp58/68 is a glycoprotein expressed on the surface or 
released by trypomastigotes. This protein is part of a fibronectin/collagen 
receptor of T. cruzi, and for this reason, it plays an important role in the 
interaction of T. cruzi with mammalian cells. Gp58/68 allows the parasite to 
evade alternative pathway complement activation because it is able to inhibit 
the formation of cell-bound C3 convertase (decay-accelerating activity) by 
preventing the initial association of FB to surface fixed C3b [44, 75, 76].
On the other hand, it has been reported that T. cruzi metacyclic trypo-
mastigote induces the release of membrane-derived vesicles (microvesicles) 
from host cells, such as lymphocytes, monocytes, and macrophages, in a Ca2+ 
dependent process. These vesicles inhibit the classical and lectin pathways of 
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glycoprotein expressed on the surface of metacyclic, bloodstream, and tissue-
culture-derived trypomastigotes of T. cruzi. T-DAF mimics the activity of 
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alternative, classical, and probably the lectins pathways of the complement. 
In summary, T-DAF activity either accelerates the dissociation or assembly 
efficiency of C3 convertases [73, 74].
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released by trypomastigotes. This protein is part of a fibronectin/collagen 
receptor of T. cruzi, and for this reason, it plays an important role in the 
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On the other hand, it has been reported that T. cruzi metacyclic trypo-
mastigote induces the release of membrane-derived vesicles (microvesicles) 
from host cells, such as lymphocytes, monocytes, and macrophages, in a Ca2+ 
dependent process. These vesicles inhibit the classical and lectin pathways of 
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the complement by binding to C3 convertase C4b2a on the T. cruzi surface and 
inhibit its catalytic activity [44, 77].
3. Immunoregulatory effects by Trypanosoma cruzi
In the early stages of T. cruzi invasion, the host’s resistance to the infection is medi-
ated by innate immunity, which acts as the first immunological barrier. Macrophages, 
NK cells, and dendritic cells are the cells from the innate immune system and produce 
cytokines (IL-12, TNF-α, and IFN-γ) and effector molecules that control parasite 
replication. Dendritic cells are the connecting cells between the innate and acquired 
immunity, generating cytokines (IL-12) necessary for the differentiation and clonal 
expansion of T helper 1 (Th1) CD4+ as well as CD8+ T cells and plasma B cells. 
CD4+ Th1 or CD8+ T cells synthesize IFN-γ, which activates effector mechanisms in 
macrophages to eliminate both amastigotes and phagocytosed trypomastigotes, while 
cytotoxic activity by B cells lyse the extracellular trypomastigote form or facilitate 
the phagocytosis of parasites opsonized with IgG [3, 78, 79]. However, T. cruzi uses 
different mechanisms to modulate this action of the host immune response and then 
the parasite spreads to many tissues during the acute phase to finally reach the chronic 
stage of the Chagas disease [16]. In the acute phase, T. cruzi infection can induce 
immunosuppression [80], involving the decrease and clonal deletion of the T cells, 
together with strong polyclonal B cell stimulation, which ultimately restricts the 
development of antigen-specific lymphocytes [78, 81].
In the early steps of a primary T. cruzi infection, there is no activation of various 
host defense mechanisms, leading to silent entry [82]. There are three events that 
could contribute to this silent entry: the relatively slow kinetics of T. cruzi intracel-
lular cycle, the parasite escape from the phagolysosome (which was previously 
explained), and the immunoregulatory response mediated by toll-like receptor 
(TLR) activation in dendritic cells [83]. A TLR-dependent activation of dendritic 
cells is required to induce their maturation and migration to regional lymph nodes 
and to activate naïve T cells [84].
Toll-like receptors (TLRs), members of a family of pattern recognition recep-
tors, are responsible for the recognition of pathogens because they can distinguish 
between host molecules and molecules of the pathogens referred to as pathogen-
associated molecular patterns (PAMPs). These receptors are expressed on the cell 
surface or in the lumen of intracellular vesicles (endosomes or lysosomes) of the 
antigen presenting cells (macrophages and dendritic cells), cells of the adaptive 
immunity (T y B lymphocytes), and nonimmune cells (epithelial and endothelial 
cells and fibroblasts) [84–88]. Twelve TLRs family members have been identified in 
mice and 10 in humans. The TLRs 1–9 are conserved in both species, whereas TLRs 
11–13 is only expressed in mice and TLR10 in humans [87, 89]. TLR4 and TLR9 are 
homodimers, whereas TLR2 and TLR6 form heterodimers [90, 91]. Activation of 
the TLRs induces production of proinflammatory cytokines (MyD88-dependent 
signaling cascade, except TLR3) and chemokines, and therefore, these receptors 
are important because that activate innate immunity and molding the subsequent 
acquired immune responses [3, 92–94].
Infection with T. cruzi activates the synthesis of several inflammatory genes 
by different TLR pathways [87]. The parasite has molecules that can activate TLRs 
such as the surface molecules, glycoinositolphospholipids (GIPLs), and anchor 
glycoproteins and polysaccharides that contain identical GPI structures [95]. 
Glycosylphosphatidylinositol anchors derived from mucin-like glycoproteins (GPI-
mucin) are TLR2/6 activators in dendritic cells and macrophages, and this leads to the 
production of the TNF-α, IL-12, and NO. On the other hand, GIPLs activate TLR4 of 
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macrophages to increase IL-2 production. The IL-2 increase activates NK cells and B 
cells to secrete immunoglobulins during infection [3, 96]. T. cruzi genomic DNA (CpG 
DNA motifs) active TLR9 and TLR7 is involved in parasite RNA recognition, and this 
activation results in the production of IL-12 [97, 98]. CpG DNA motifs are concen-
trated in genomic regions encoding large gene families of surface proteins, such as 
mucins, trans-sialidases, and mucin-associated surface proteins (MASPs) [98]. These 
genes are involved in parasite immune evasion mechanisms [4].
TLR7 and TLR9 are expressed in the membrane of phagolysosome, and they are 
active when the parasite is lysed, but as mentioned above, parasite escapes from 
the lysosome, thus the activation of these receptors is reduced. On the other hand, 
TLR2 appeared to act as immunoregulator in the early stage of infection [99].
T. cruzi in addition to evade its destruction also has the capacity to modulate the pat-
tern of secreted cytokines, and examples of this are T. cruzi membrane GPI-anchored 
mucin (AgC10), which can bind to the macrophage surface and induce the secretion of 
IL-1Β but not of IL-12 or TNF-α, which are essential in a protective response. Inhibition 
of TNF-α and IL-12 by T. cruzi could be involved in the evasion of the immune response 
by this parasite [12, 100]. The parasite also promotes the production of IL-10 and TGF-β 
in infected macrophages, which inhibit the induction and effects of IL-12. A cysteine 
protease (cruzain) prevents macrophage activation by blocking the NF-κB P65 pathway 
and downregulated the expression of the proinflammatory cytokine, IL-12. Therefore, 
the infection of the macrophages favors the secretion of anti-inflammatory cytokines 
such as IL-10 and TGF-β that affect the development of protective immune response 
and favors the spread of infection [101, 102].
Trypanosoma cruzi induces the production of both Th1 and Th2 cytokines in 
infected individuals, and high expression levels have been reported for Th1 cyto-
kines IFN-γ and IL-2, as well as for Th2 cytokines IL-4 and IL-10 [103]. The ability 
of T. cruzi to infect a host and to survive and develop and cause Chagas´ disease 
depends on a complex balance Th1 and Th2 cytokine production, as the display 
antagonistic effects, the former being protective for the host and the latter for the 
parasite [11].
In addition to the TLR’s roles in the modulation of innate immunity, TLRs 
participate in the induction of the adaptive immune response [89]. This happens 
mainly by their action on antigen-presenting cells (APCs), either by promoting 
cross-presentation for CD8+ T-cell activation or by increasing the levels of costimu-
latory molecules and by stimulating the secretion of lineage-specific cytokines such 
as IL-12, IL-16, IL-1β, IL-18, and IL-23 by APCs and thus promoting Th1 and Th17 
differentiation [86].
More specifically, the activation of dendritic cells by T. cruzi PAMPs (DNA and 
RNA) will lead to their maturation and production of IL-12, favoring the differentia-
tion of Th cell precursors toward the Th1 phenotype and IFN-γ production [98, 104].
4. Polyclonal activation of B cells
During early stages of the T. cruzi infection, B cells are fundamental to trig-
ger T-cell functions related to the Th1 pathway that favors the control of parasite 
growth [105]. B cells are known to play a key role in the humoral adaptive immune 
response by producing and secreting antibodies [106]. The majority B cells acti-
vated by T. cruzi infection are not specific for parasite antigens [107]. The infection 
with T. cruzi induces polyclonal B cell activation and hypergammaglobulinemia 
based on parasite-derived B cell mitogen. These antibodies are parasite-specific and 
bind to the trypomastigote surface interfering with the binding of IgG inhibitory 
antibodies and consequently preventing the elimination of the parasite [12, 108].
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11–13 is only expressed in mice and TLR10 in humans [87, 89]. TLR4 and TLR9 are 
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by different TLR pathways [87]. The parasite has molecules that can activate TLRs 
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Glycosylphosphatidylinositol anchors derived from mucin-like glycoproteins (GPI-
mucin) are TLR2/6 activators in dendritic cells and macrophages, and this leads to the 
production of the TNF-α, IL-12, and NO. On the other hand, GIPLs activate TLR4 of 
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macrophages to increase IL-2 production. The IL-2 increase activates NK cells and B 
cells to secrete immunoglobulins during infection [3, 96]. T. cruzi genomic DNA (CpG 
DNA motifs) active TLR9 and TLR7 is involved in parasite RNA recognition, and this 
activation results in the production of IL-12 [97, 98]. CpG DNA motifs are concen-
trated in genomic regions encoding large gene families of surface proteins, such as 
mucins, trans-sialidases, and mucin-associated surface proteins (MASPs) [98]. These 
genes are involved in parasite immune evasion mechanisms [4].
TLR7 and TLR9 are expressed in the membrane of phagolysosome, and they are 
active when the parasite is lysed, but as mentioned above, parasite escapes from 
the lysosome, thus the activation of these receptors is reduced. On the other hand, 
TLR2 appeared to act as immunoregulator in the early stage of infection [99].
T. cruzi in addition to evade its destruction also has the capacity to modulate the pat-
tern of secreted cytokines, and examples of this are T. cruzi membrane GPI-anchored 
mucin (AgC10), which can bind to the macrophage surface and induce the secretion of 
IL-1Β but not of IL-12 or TNF-α, which are essential in a protective response. Inhibition 
of TNF-α and IL-12 by T. cruzi could be involved in the evasion of the immune response 
by this parasite [12, 100]. The parasite also promotes the production of IL-10 and TGF-β 
in infected macrophages, which inhibit the induction and effects of IL-12. A cysteine 
protease (cruzain) prevents macrophage activation by blocking the NF-κB P65 pathway 
and downregulated the expression of the proinflammatory cytokine, IL-12. Therefore, 
the infection of the macrophages favors the secretion of anti-inflammatory cytokines 
such as IL-10 and TGF-β that affect the development of protective immune response 
and favors the spread of infection [101, 102].
Trypanosoma cruzi induces the production of both Th1 and Th2 cytokines in 
infected individuals, and high expression levels have been reported for Th1 cyto-
kines IFN-γ and IL-2, as well as for Th2 cytokines IL-4 and IL-10 [103]. The ability 
of T. cruzi to infect a host and to survive and develop and cause Chagas´ disease 
depends on a complex balance Th1 and Th2 cytokine production, as the display 
antagonistic effects, the former being protective for the host and the latter for the 
parasite [11].
In addition to the TLR’s roles in the modulation of innate immunity, TLRs 
participate in the induction of the adaptive immune response [89]. This happens 
mainly by their action on antigen-presenting cells (APCs), either by promoting 
cross-presentation for CD8+ T-cell activation or by increasing the levels of costimu-
latory molecules and by stimulating the secretion of lineage-specific cytokines such 
as IL-12, IL-16, IL-1β, IL-18, and IL-23 by APCs and thus promoting Th1 and Th17 
differentiation [86].
More specifically, the activation of dendritic cells by T. cruzi PAMPs (DNA and 
RNA) will lead to their maturation and production of IL-12, favoring the differentia-
tion of Th cell precursors toward the Th1 phenotype and IFN-γ production [98, 104].
4. Polyclonal activation of B cells
During early stages of the T. cruzi infection, B cells are fundamental to trig-
ger T-cell functions related to the Th1 pathway that favors the control of parasite 
growth [105]. B cells are known to play a key role in the humoral adaptive immune 
response by producing and secreting antibodies [106]. The majority B cells acti-
vated by T. cruzi infection are not specific for parasite antigens [107]. The infection 
with T. cruzi induces polyclonal B cell activation and hypergammaglobulinemia 
based on parasite-derived B cell mitogen. These antibodies are parasite-specific and 
bind to the trypomastigote surface interfering with the binding of IgG inhibitory 
antibodies and consequently preventing the elimination of the parasite [12, 108].
Biology of Trypanosoma cruzi
160
4.1 Factors causing antibody deficiency
4.1.1 Antigenic variability
T. cruzi expresses a variety of antigens on its surface such as mucins, trans-
sialidases, and MASPs, all of them are encoded by highly polymorphic multigene 
families. This high variety of molecules with coordinate expression delays the 
activation of specific B cells and also consequently delays the production and 
maturation of high-affinity antibodies with neutralizing capacity and the priming 
of effective T-CD8+ cells, and this mechanism is known as a smoke screen [16, 19, 
109, 110]. Another important point to mention is that the presence of a broad range 
of antigenic motifs may also be a mechanism to drive the antibody response away 
from catalytic sites of key parasite surface proteins which causes a weak antibody 
response [111].
4.1.2 Reduction of immature B cells in the bone marrow
Immature B cells are reduced because of an increase in the rate of apoptosis. 
Apoptosis is a common process caused by pathogens on host cells, and it probably 
happens as a consequence of the host immune response or by a direct effect of the 
pathogen [112]. Apoptosis of lymphocytes is necessary to preserve a healthy and 
balanced immune system, but if this occurs prior to pathogen elimination, it could 
reduce the effectiveness of the effector mechanisms [113, 114]. This effect may be 
more important if apoptosis happens in the early stages of lymphocyte development 
[115]. Thus, the effect of the infection with T. cruzi is the induction of a marked loss 
of immature B cells in the bone marrow and also compromises recently emigrated B 
cells in the periphery [116]. It has been shown that the apoptosis caused by T. cruzi 
infection occurs in addition to Fas/FasL pathway by the participation of CD11b+ 
myeloid cells that secrete a product of the cyclooxygenase pathway, and this event 
depletes immature B cells in the bone marrow [116, 117]. It is possible that the 
parasite takes advantage of the host cell apoptosis; moreover, it has been shown 
that cell apoptosis may have an additional negative effect because the elimination 
of apoptotic bodies by T. cruzi infected macrophages promotes parasite replication, 
favoring the chronic establishment of the parasite in the host [118], so the induction 
of the host cell apoptosis is another mechanisms to evade the immune response.
4.1.3 Polyclonal activation of non-specific B cells
Polyclonal activation of B cells that normally contributes to the generation of 
specific antibodies for conserved structures presents in pathogens but in the case 
of T. cruzi infection can be a mechanism by which parasite-specific antibodies are 
reduced and irrelevant antibody are increased [115]. Presentation of multiple-
related sequences on the surface of the trypomastigotes or extracellular amastigotes 
could alter the B-cell response by inducing anergy in specific CD4+ lymphocytes 
and/or reduction of affinity of antibodies [109, 119]. Another consequence of 
polyclonal activation can be the generation of antibodies specific of the self-and/
or non-related antigens [107]. Some parasite molecules such as glycoinositol-
phospholipids (GIPLs) generate hypergammaglobulinemia [16, 108, 120]. In the 
acute infection, expansion of total antibodies is slow and starts with IgM and IgA, 
followed by IgG (IgG1, IgG2a, IgG2b, and IgG3) with specificities not related to T. 
cruzi antigens, while the humoral response in the chronic stage shows preferential 
IgG2a production [121–123]. In addition to the high variability of parasite surface 
antigens, parasite-derived B cell mitogens also cause polyclonal B cell activation 
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and hypergammaglobulinemia which results in a delayed parasite-specific anti-
body response [108, 124, 125]. Glutamate dehydrogenase (TcGDH) [126], proline 
racemase [127], and trans-sialidase (TcTS) [128] are among the parasitic proteins 
identifying as polyclonal B cell mitogens [129].
5. Immunomodulation of T cell
Expression of identical antigenic variants on the surface of the majority of 
parasite population is the characteristic of the antigenic variation, with only a small 
subgroup expressing different variants [130, 131].
Trypanosoma cruzi releases antigen in the intracellular host cell environ-
ment, and they are accessible for presentation by the major histocompatibility 
complex class I [3]. The presentation of the antigens promotes the priming of a 
robust but delayes T. cruzi-specific CD8+ T-cell responses. This event is evident 
5–6 days postinfection, after the first round of intracellular replication of the 
parasite [110]. The early immunosuppression of the CD8+ T-cell response may be 
associated with the density of parasites in the cytosol, because during the initial 
infection, previous to the first cycle of replication, low concentration of antigens 
is produced by amastigotes, and on the other hand, because a large repertoire of 
highly polymorphic and immunogenic surface protein that are coexpressed by 
the parasite [110, 132–134].
The parasite has developed strategies to interfere with antigen presentation, and 
this strategy is related with hyperpolarization of the presented antigen repertoire, 
which means that the repertory of CD8+ T-cells is dramatically restricted, and this 
phenomenon is known as immunodominance and prevents complete pathogen 
elimination by host cells by antigen-specific cytotoxic T-cell response [135, 136].
GPI-anchored surface proteins particularly trans-sialidase proteins are among the 
major known CD8+ T cell immunodominant targets in T. cruzi infection [110, 137], due 
to high expression in the infective forms and repetitive/antigenic content [137, 138].
Trans-sialidases are a polymorphic protein subfamily of the GPI-mucin super-
family and are expressed on the parasite surface and released into the extracellular 
medium. These proteins are coded by a multi-copy gene family, comprised by more 
than 1400 genes [19, 139, 140]. These enzymes remove and efficiently transfer 
sialic acid from host-derived glycoconjugates to parasite mucin-like glycoproteins, 
which are the most abundant surface components of infective forms [141]. TcTS has 
several potential immunogenic candidates that can generate an unfocused response. 
The trans-sialidase immune response is focused on a relatively small number of 
epitopes encoded by multiple genes, and this protein is a prominent target of T. 
cruzi-specific CD8+ T cells [19, 110, 142].
Immunodominance may occur by different mechanisms including the forma-
tion of stable MHC-I peptide complexes on the surface of APCs, higher amounts or 
higher affinity T cell precursors or competition of T cells for APCs [135]. CD8+ T 
cells that recognize TS-derived epitopes remain highly competent throughout the 
chronic infection, despite persistent antigen exposure [137, 143, 144].
The immunodominance of TS-derived epitopes predictably results in the out-
competition of other epitope-specific CD8+ T cell populations. However, the sig-
nificance of the tight focusing of the CD8+ T cell response on only a few vast arrays 
of possible parasite-derived epitopes is not known [138]. The immune response 
targets the parasites expressing the common TcTS variants, whereas failing to 
identify parasites that express rare variants of the antigen [145]; thus the immuno-
dominance seems to be an important way by which the parasite escapes from the 
effector mechanisms of the CD8+ T cells and persists until the chronic stage.
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6. Conclusions
Trypanosoma cruzi is a parasite that has a complex life cycle that goes from the 
passage through an invertebrate host to different mammals displaying different devel-
opmental stages during its life cycle. Furthermore, T. cruzi includes several lineages 
that have distinct morphology, infectivity, virulence, and pathogenicity [146]. The 
disease reaches the symptomatic chronic stage in only 30% of patients who acquire 
the infection, whereas 70% shown no clinical symptoms [147]. The above charac-
teristics suggest that during infection may occur a complex interaction between the 
host and the parasite, and although for more than 100 years, since the Chagas disease 
was described, the immunological mechanisms of resistance or susceptibility to the 
parasite have been studied, and it has not been possible to determine exactly which are 
those that effectively can eliminate the parasite. Recently, there is a growing consensus 
that the protective immune response against T. cruzi requires the activation of a Th1 
immune profile, with the stimulation of CD8+ T cells, but as it is detailed in the present 
review, the mechanisms of evasion to the immune response by T. cruzi are diverse and 
quite effective. So not withstanding this large amount of information available, it still 
impossible to predict what will happen in an individual infected with this pathogen. 
Considering the importance of Chagas disease in the world in which there are an 
estimated to be around 8–10 million of infected people and that currently there are no 
vaccines which prevent the parasite infection, it is necessary to look for a better and 
complete understanding of the mechanisms of immune evasion of Trypanosoma cruzi.
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1. Introduction
Chagas disease, also known as American trypanosomiasis, is caused by infection 
with the hemoflagellate protozoa Trypanosoma cruzi. This disease was first described 
in 1909, by the epidemiologist Carlos Justiniano Chagas. In this pioneering work, not 
only the etiological agent Trypanosoma cruzi was described, but also its evolutionary 
forms, life cycle, epidemiology and clinical manifestations of the disease was fully 
reported [1]. More than a century after this discovery, it is estimated that Chagas dis-
ease still affects around 6–7 million people worldwide, especially in Latin America, 
with more than 10,000 deaths annually [2]. Currently, Chagas Disease is considered 
as a neglected tropical disease by the World Health Organization [3].
The progression of Chagas disease is characterized by the occurrence of three 
phases: acute, indeterminate and chronic. Survival during the acute phase of infec-
tion requires an inflammatory response involving cells of innate immunity, such as 
macrophages, dendritic cells and natural killers whereas in the chronic phase the 
T-lymphocyte-mediated immunity maintains parasite replication under control [4]. 
However, evidence suggests that the exacerbated inflammatory response of the host 
is one of the most determinant factors in the progression of Chagas disease, along 
with the virulence and tropism of the strain [5, 6].
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During T. cruzi infection—as in other infections—the immune system acts to 
protect the host from infectious agents and the nutrient status is an important 
factor contributing to immune response [7]. Between the components from the 
diet, fatty acids found in oils and oily food have an important role not only in the 
structure of cell membranes, energy source or as hormones precursors [8], but acts 
directly as modulators of the immune response [9]. Specifically, the consumption 
of fatty acids from the family of omega-3 polyunsaturated fatty acids (n-3 PUFAs), 
found in large amounts in fish oil, has been associated with anti-inflammatory and 
immunomodulatory effects [10]. Taking this into account, an important issue to be 
raised is the effect of n-3 PUFAs supplementation on infectious diseases, such as 
Chagas disease, where an efficient—but controlled inflammation—is necessary and 
important for host defense [11].
Currently, daily oral supplementation with n-3 PUFAs is recommended by the 
American College of Cardiology and American Heart Association as an impor-
tant adjuvant in the treatment of heart failure [12]. In the same sense, daily oral 
supplementation with n-3 PUFAs is recommended by the Brazilian Directive on 
Dyslipidemias and Prevention of Atherosclerosis, updated in 2017 by the Brazilian 
Society of Cardiology (2–4 g daily), as an important complement in the prevention 
of atherosclerosis and its cardioprotective benefits [13]. Despite the recognized 
relevance of n-3 PUFA supplementation in the supplementary treatment of car-
diovascular diseases, and considering the important cardiac compromises that 
may occur during the chronic phase of Chagas disease, supplementation with n-3 
PUFAs may in fact represent a perspective for the additional treatment of patients 
affected by Chagas disease. However, the immunomodulatory effects of the dietary 
supplementation with n-3 PUFAs and the relationship with the host response and 
resistance to T. cruzi infection should be carefully considered.
2. Polyunsaturated fatty acids
Polyunsaturated fatty acids (PUFAs) are a class of fatty acids with 18–22 car-
bons (C18–C22) containing two or more double bonds in the carbon chain. The 
most important PUFAs for human health and nutrition are the omega-6 (n-6) and 
omega-3 (n-3) families. The classification of the fatty acids between this families is 
made considering the position of the first double bond counting from the methyl 
end of the fatty acid chain [14]. Linoleic acid (LA) is considered the parent fatty 
acid of the n–6 PUFAs family, while α-linolenic acid (ALA) is considered the parent 
fatty acid of the n–3 PUFAs family. Both LA and ALA cannot be made by humans 
or other mammals, thus they are considered essential fatty acids and have to be 
supplied in the diet [15].
The n-6 PUFA LA (18:2n-6) could be found naturally the seeds of most plants 
except for cocoa, coconut, and palm. On its turn, the n-3 PUFA ALA (18:3n-3) 
is found in the seeds of flax, rape, chia, perilla, walnuts (and their vegetable 
oils) or even chloroplast of green leafy vegetables. In the body, both LA and ALA 
are metabolized to longer-chain fatty acids of 20 or 22 carbons [15, 16]. LA is 
metabolized to arachidonic acid (AA), a long chain n-6 PUFA (LC n-6 PUFA) 
whereas ALA is metabolized to eicosapentaenoic acid (EPA, 20:5n-3) and doco-
sahexaenoic acid (DHA, 22:6n-3), a long chain n-3 PUFAs (LC n-3 PUFA). This 
reaction occurs through the actions of elongases enzymes, that increase the chain 
length; and desaturases enzymes, which add extra double bonds to the carboxyl 
end of the fatty acid, increasing the degree of unsaturation [17]. Humans and 
others mammalians could convert LA in AA; and ALA in EPA and DHA, however 
this process is slow.
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Although there is a competition between n-6 PUFAs and n-3 PUFAs for the 
desaturation enzymes, which prefer the ALA instead the LA, the Western diet 
provides higher amounts of LA than ALA, being the AA the main unsaturated 
long-chain fatty acid produced [18]. Therefore, the most efficient way to increase 
the amount of LC n-3 PUFAs in the body is through directly ingestion of primary 
sources EPA and DHA, as the seafood. The LC n-3 PUFAs are found in high 
amounts in most seafood, especially in oily fish, in the blubber and tissues of sea 
mammals like seals and whales or even in supplements like fish oils, cod liver oil, 
krill oil, algal oils and in pharmaceutical grade preparations [10].
3.  Immunomodulatory effects of long chain n-3 polyunsaturated fatty 
acids
Experimental assays have shown that diet supplementation with LC n-3 PUFAs 
results in powerful anti-inflammatory and immunomodulatory activities in a range 
of diseases, such as autoimmune [19], inflammatory bowel disease [20], rheumatoid 
arthritis [21] and even infectious diseases [22–25]. There are also clinical trials in human 
patients associating the use of supplements rich in LC n-3 PUFAs with the evolution of 
inflammatory diseases [26] and infections, such as sepsis [27]. Studies in patients with 
rheumatoid arthritis are those that present better results, with several tests showing 
reduction of symptoms, such as morning swelling, pain and stiffness [28].
Inflammation is a fundamental component of the body response to infections 
or injuries that involves the interactions among many different cell types. The 
leucocytes are cells from immune system found in the peripheral blood and lymph 
tissue that actively participate in the inflammation, being specially involved in 
body defense and protection [29]. Typically, inflammation is transient, exerting a 
protective role in the body. However, when the inflammation does not end and the 
acute response become chronic, this uncontrolled response leads to more injury 
[29]. Therefore, inflammation is the pathological mechanism behind many chronic 
diseases, and that is why the immunomodulatory effects of LC n-3 PUFAs are 
considered to be potentially beneficial.
Some mechanisms of the immune response modulation by LC n-3 PUFAs are 
already known, such as modification of function and composition of immune 
system cell membranes, change in the pattern of eicosanoids produced and in the 
cytokine profile, regulation of gene expression and proliferation of T lymphocytes 
[30]. The leukocyte membrane phospholipids from humans consuming a Western 
diet typically have 15–20% of AA, 0.5–1% of EPA and 2–3% of DHA. When fish oil 
rich in LC n-3 PUFAs are incorporated to the diet, increased amounts of EPA and 
DHA are incorporated in these phospholipids in a time and dose dependent fashion, 
and it is occurs at the expense of AA [31, 32]. These changes in membrane fatty 
acid composition subsequently modify the cell-membrane fluidity, production of 
eicosanoids and the formation of lipid rafts [17, 33].
4. Long chain n-3 PUFAs and Trypanosoma cruzi infection
Infection with T. cruzi causes a strong inflammatory reaction at the inoculation 
site and, later, in the myocardium [34]. Approximately one-third to one-half of 
patients with indeterminate disease will eventually develop chronic Chagas cardio-
myopathy (CCC). CCC results from the combined effects of persistent parasitism, 
parasite-driven tissue inflammation, micro-vascular and neurogenic dysfunction, 
and autoimmune responses triggered by the T. cruzi-infection [34, 35].
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There are few studies on the effects of increased consumption of LC n-3 PUFAs 
rich foods as well as the long-term effects of LC n-3 PUFAs on inflammatory profile 
and clinical outcomes in CCC. Recently, a group of Brazilian researchers reported that 
patients aging >18 years, with a diagnosis of CCC, that received LC n-3 PUFAs cap-
sules (1.8 g EPA and 1.2 g DHA) during an 8-week period, presented modifications in 
the lipid and inflammatory profile, demonstrated by a decrease in triglycerides and 
improvements on IL-10 concentration [36]. The same group had already supposed in 
2013 that the anti-inflammatory action of LC n-3 PUFAs may have beneficial effects 
on chronic chagasic cardiomyopathy, and could be translate into a less severe progres-
sion of cardiomyopathy, with subsequent reduction in morbidity [37].
In mice, the resistance to acute infection has been shown to be dependent on 
interferon IFN-γ that activates macrophages to produce nitric oxide (NO) and kill 
the obligate intracellular amastigote form of the parasite [38–40]. In addition, 
TNF-α provides a second signal stimulating NO production and anti-T. cruzi activ-
ity in IFN-γ-activated macrophages.
TNF-α is a cytokine that appears rapidly after infections or lesions, playing a 
key role in fighting invasive pathogens. However, excessive TNF-α production is 
related to mortality and morbidity in sepsis [41], meningitis [42] and malaria [43]. 
Although many of the studies about TNF-α modulation by treatment with LC n-3 
PUFAs indicate a suppressive effect on this cytokine production, there are studies 
reporting an increase in cytokines production by treatment with LC n-3 PUFAs. 
Increased TNF-α production was reported by macrophages stimulated in vitro 
with LPS [25]. Dietary supplementation with fish oil on experimental Klebsiella 
pneumoniae infection and in brain-infection by Plasmodium berghei led to increased 
ex vivo production of TNF-α and IL-1α by in vitro LPS-stimulated macrophages 
[24]. Also, the in vivo treatment with fish oil increased TNF-α plasma levels in mice 
infected with Listeria monocytogenes in the first 24 hours of infection, being lower in 
later times [44]. In addition, specifically in T. cruzi infected-mice that were supple-
mented with fish oil rich in LC n-3 PUFAs it was related increased TNF-α produc-
tion by the spleen cells [22].
The first work on the in vivo effects of PUFAs supplementation on T. cruzi 
infection was published in 1958 by Godfrey and coworkers. They showed that oral 
supplementation with cod liver oil, rich in LC n-3 PUFA, associated with vitamins 
A and D, suppressed mice infections with T. congolense and T. vivax, but showed 
no effect on mice infected with T. cruzi or T. brucei [45]. However, when vitamin E 
was used together with cod liver oil, these adverse effects on host resistance on T. 
congolense and T. vivax infection were reversed, suggesting that diet-induced oxida-
tive stress and vitamin E deficiency were central to this particular diet-infection 
relationship.
In 1995, Takeda and collaborators reported that daily oral administration of the 
LC n-3 PUFA EPA, present in great amounts in fish oil, greatly diminished host 
survival following an experimental infection with T. cruzi [46]. As in the work of 
1958, they included vitamin E in EPA treatment, in order to try to avoid the oxida-
tive stress problem. The authors reported that their EPA-treatment failed to impact 
tissue parasitism, but was associated with elevated capacity to produce the inflam-
matory cytokine TNF-α.
In contrast, more recently our research group has described that oral supple-
mentation with fish oil on T. cruzi infected-mice did not change the mortality 
rate, but it did alter the course of parasitemia, as well as other important host 
responses, such the increased TNF-α production [22]. In T. cruzi infected-mice 
that were supplemented with fish oil rich in LC n-3 PUFAs we observed a tran-
sient, but substantial, increase in peak circulating parasitic load at the 7th day post 
infection. At the 12th day post infection, these fish oil-treated mice had similar 
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levels of parasitemia in the blood compared to controls groups (mice treated with 
saline or corn oil). Surprisingly, besides de high peak of parasitemia, the mice 
that were treated with fish oil rich in LC n-3 PUFAs showed significantly fewer 
parasites in their cardiac tissue at the 12th day post infection (Figure 1) compared 
to mice treated with saline or corn oil. The oral supplementation with corn oil was 
used an alternative fat source rich in the n-6 PUFA linoleic acid but poor in LC n-3 
PUFAs [22].
Figure 1. 
Effects of FO supplementation on cardiac parasitism. From 15 days before T. cruzi infection until the 12th day 
post infection, C57BL/6 mice were supplemented by gavage with 0.6% (v/w) saline, corn oil, or menhaden 
fish oil. C57BL/6 mice were infected with 5 × 103 blood trypomastigotes T. cruzi (Y strain). Cardiac parasitism 
(A): three heart sections were counted for each animal, and the results are expressed as means ± SEM of three 
sections from five animals per group and are representative of two independent experiments. Cardiac tissues 
(B) were examined by hematoxylin and eosin staining from uninfected mice (1) on day 12 after T. cruzi 
infection (2 and 3). Original magnifications were 400× (1 and 2) and 1000× (3). Original publication [22].
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In humans, as in some experimental animals, T. cruzi infection is associ-
ated with anemia, thrombocytopenia, leukopenia and bone marrow hypoplasia 
[47–50]. Dietary supplementation with fish oil had no effect on the anemia of T. 
cruzi-infected mice [22], a finding that contrasts with the improvement in malaria-
induced anemia reported by the treatment with LC n-3 PUFAs [46]. However, 
thrombocytopenia and leukopenia were less severe in T. cruzi-infected mice orally 
treated with fish oil [22].
The production of eicosanoids represents an important role in the regulation 
between the host’s immune response and the establishment of T. cruzi infection 
(Figure 2A). Eicosanoids are lipid mediators of inflammation which include prosta-
glandins (PG), thromboxanes (TX), leukotrienes (LT) and lipoxins (LX). The 
initial substrate for the synthesis of eicosanoids is the lipids present in the mem-
brane phospholipids of cells involved with inflammatory processes. In individuals 
with a regular western diet, AA is the most prevalent fatty acid in the inflammatory 
cell membrane, and it is usually the main substrate for the synthesis of eicosanoids, 
giving rise to series 2-series prostaglandins and thromboxanes and 4-series leukotri-
enes and lipoxins [30].
Acute T. cruzi infection in murine models is characterized by cardiac lesions 
associated by high levels of PGE2 [51]. During acute T. cruzi infection, both PGE2 
and its EP-2 receptor are involved in inflammation and cardiac inflammatory 
infiltrate [52], as leukotrienes, that is important for the local production of NO and 
cardiac parasitism control [53, 54]. Additionally, plasma PGE2, TBX2 e 6-oxo-PGF1α 
levels are increased in murine models of acute infection [55, 56]. In addition to 
cardiac effects, PG are associated with immunosuppression of infected animals, 
with reduction in lymphocyte proliferation, on TNF-α levels, and in the microbici-
dal functions of macrophages [57, 58].
In vitro assays have shown that the phagocytosis of apoptotic cells by macro-
phages during T. cruzi infection potentiates the release of PGE2 and transforming 
growth factor-beta (TGF-β) by these cells. These macrophages become refractory 
to inflammatory cytokines, consequently decreasing NO production and allowing 
parasite survival and growth even in an immune response environment [59]. Also, 
the pharmacological inhibition of the COX enzyme with aspirin in macrophages 
decreased the trypomastigotes internalization in these cells, with increase of 
interleukin-1 (IL1-β), NO and lipoxins [60]. In addition, PGE2 elicits signaling 
pathways capable of instantaneously inhibiting NLRP3 inflammation activation 
[61]. This may be relevant in the context of T. cruzi infection, since the activation of 
the inflammatory complex NLPR3 and caspase-1 is important for parasite control 
during the acute phase of infection, leading to activation of trypanocidal activities 
in macrophages, as NO production [62].
Although PGE2 is important for the parasite survival at the beginning of infec-
tion, the in vivo pharmacological blockade of COX enzymes during the acute 
phase of T. cruzi infection leads to higher levels of parasitemia, lower survival rates 
of experimental mice and increased cardiac parasitism [63–65]. However, COX 
blockade with aspirin already in the chronic phase (60 days after infection) does not 
cause an increase in parasitemia or mortality, but is associated with an improvement 
in the cardiac ejection fraction [64].
Confirming the relevance of inflammatory-lipid mediators during T. cruzi 
infection is the fact that the parasite itself synthesizes prostaglandins and throm-
boxanes (TX) [66]. Infective stages of T. cruzi have the enzyme phospholipase A-1, 
important for the release of fatty acids (such as AA) from the membranes and for 
eicosanoid synthesis, as represented in Figure 2A. From AA, T. cruzi preferentially 
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Figure 2. 
Mechanism and effects of PUFAs n-3 PUFAs supplementation on Trypanosoma cruzi infection. 1—The 
traditional western diet provides to immune cells great amounts of n-6 PUFAs arachidonic acid and linoleic 
acid, while a diet supplementation with LC n-3 PUFAs results in eicosapentaenoic acid and docosahexaenoic 
acid incorporation into immune cells plasma membrane phospholipids [31, 32]. 2—T. cruzi infection trigger 
inflammatory stimulus, as the expression of cyclooxygenase (COX) and Lipoxygenase (LOX) enzymes 
[53, 55]. The enzyme phospholipase A2 (PLA2) removes fatty acids from the membrane phospholipids, 
mainly arachidonic acid (AA) in cells from western diet and mainly eicosapentaenoic acid (EPA) or 
docosahexaenoic acid (DHA) from n-3 diet. 3—The enzymes COX and LOX uses the free fatty acids for 
eicosanoids synthesis. When AA is used as substrate 2-series prostaglandins/thromboxanes and 4-series 
leukotrienes/lipoxins are formed. When the substrate is EPA or DHA, a switch in the class of eicosanoids 
produced occurs, being produced 3-series prostaglandins/thromboxanes and 5-series leukotrienes/lipoxins 
[30], as well mediators that act in the resolution of inflammation: E-series resolvins generated from EPA, 
D-series resolvins from DHA, and protectins and maresins from DHA [72, 73]. 4—In the acute phase of 
infection, the high production of prostaglandin E2 (PGE2) leads to a transient immunosuppression, with 
decreased TNF-α production by the host [57]. The immune cells from n-3 diet produce lower amounts of 
PGE2, and consequently more TNF-α [22]. 5—The thromboxane A2 (TXA2) produced during T. cruzi 
infection is associated with a control mechanism of parasite proliferation and less exposure to immune system 
[67]. The decreased TXA2 production that occurs in cells from n-3 PUFAs diet could explain the increased 
parasitemia that were previously observed in vivo, leading to more T. cruzi exposition to immune system 
[22]. 6—Effects of in vivo supplementation of experimental mice during acute T. cruzi infection [22]. 7—
Effects of in vivo supplementation of human patients with chronic Chagas cardiomyopathy [37]. Original 
publication [22].
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synthesizes TXA2, in addition to small amounts of PGE2α [67]. During acute infec-
tion, TXA2 produced by the parasite acts on the vascular endothelium creating an 
inflammatory phenotype, increasing the expression of adhesion molecules and 
directly participating in the parasitemia control and host survival. The absence of 
TXA2 receptor in infected-host cells leads to large cellular parasitism, when com-
pared to cells that have the receptor. This indicates that T. cruzi has a self-regulated 
mechanism that controls its proliferation trough TXA2 [67]. The effects of both 
TXA2 produced by the parasite and the PGE2 produced by the host create an immu-
nomodulatory environment that favors the survival of the host, an indispensable 
factor for the survival of the parasite and maintenance of the chronic phase of the 
infection [63, 67].
When incorporated into cell plasma membrane, LC n-3 PUFAs competitively 
inhibit the formation of eicosanoids from AA by the enzymes cyclooxygenase 
(COX) and lipoxygenase (LOX), being produced, from the fatty acids EPA and 
DHA, 3-series prostaglandins and thromboxanes and 5-series leukotrienes and 
lipoxins. These eicosanoids produced from the EPA and DHA have less inflamma-
tory activity [68, 69]. This effect occurs in part due to the reduction of AA available, 
but also due to a direct action of the EPA decreasing the activity and expression of 
the COX-2 enzyme, that is responsible for the synthesis of prostaglandins after an 
inflammatory stimulus [70].
We have shown that fish oil supplementation decreased the production of PGE2 
in mice uninfected (Figure 3A) and infected with T. cruzi (Figure 3B) [22], as 
also represented in Figure 2B. In addition, as discussed above, it is reported in the 
scientific literature that LC n-3 PUFA supplementation promotes the production 
of 3-series thromboxanes, rather than the production of 2-series thromboxanes, 
a lipid mediator described as important for the regulation and continuity of 
infection by T. cruzi [67]. The use of LC n-3 PUFAs to modulate the production of 
eicosanoids exhibit relevant differences when compared to the use of pharmaco-
logical inhibitors of COX isoforms. While pharmacological COX blockade results 
in a marked decrease in eicosanoid production, the LC n-3 PUFAs acts promot-
ing a change in the class of eicosanoids produced, without, however, completely 
abolishing those produced from AA. In addition, the inflammatory pro-resolution 
lipid mediators resolvins, maresins and protectins produced from the LC n-3 
PUFAs DHA and EPA could control the tissue injury resulting from the exacer-
bated activation of the immune response [30]. Pro-resolvins are a class of lipid 
mediators that act in the resolution of inflammation [71]. E-series resolvins (RvE) 
are generated from EPA, D-series resolvins (RvD) from DHA, and protectins and 
maresins from DHA. The synthesis of these pro-resolvins also involves the COX 
and LOX pathway [72, 73].
Recently was demonstrated that trypomastigotes and amastigotes of T. cruzi 
produce the pro-resolving lipids RvD1, RvD5, and RvE2. It has been reported that 
plasma RvD1 levels are elevated in T. cruzi infected mice and, at least in part, it is 
possible that this RVD1 is from the parasite itself. This mechanism suggests another 
way of how the parasite can modulate the environment in its favor. This modulation 
of the immune response by the parasite may be important and contribute to the 
perpetuation of the infection into the chronic phase [74].
Therefore, the elucidation of the more specific mechanisms involved with the 
protective effects of n-3 PUFAs on T. cruzi infection (Figure 2C) are important 
aspects to be investigated. Considering the discussion presented here, as well as 
all points raised in the scientific literature, it is a reasonable to consider that the 
immune modulation exerted by LC n-3 PUFAs supplementation actually favors the 
host and may represent a perspective for the supplementary treatment of patients 
affected by Chagas disease.
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5. Conclusion
The immunomodulatory effects of long-chain omega-3 polyunsaturated fatty 
acids (LC n-3 PUFA) are currently widely known. Dietary supplementation with 
LC n-3 PUFAs has been used as a complementary treatment in inflammatory 
diseases. However, the effects of daily supplementation with LC n-3 PUFAS on 
host resistance to infectious disease, such as the T. cruzi infection, are still poorly 
understood. Studies using a well-established mouse model of this human disease 
showed that fish oil supplementation improves de clinical course T. cruzi infection 
during the acute phase of infection. In fact, the potential benefits of LC n-3 PUFAs 
supplementation in humans have been the subject of recent clinical trials. The 
Figure 3. 
Effects of fish oil supplementation on production of PGE2 by spleen cells from mice infected with T. cruzi. 
From 15 days before T. cruzi infection to the 7th dpi, C57BL/6 mice were supplemented by gavage with 0.6% 
(v/w) PBS, corn oil, or fish oil. C57BL/6 mice were infected with 5 × 103 blood trypomastigotes T. cruzi (Y 
strain). Splenocytes (5 × 106 cells/well) from uninfected (A) or T. cruzi-infected mice (B) were cultured with 
and without T. cruzi antigen (Tc-Ag). Supernatants were harvested after 8 hours, and PGE2 was quantified 
in supernatants by EIA. The results are expressed as means ± SEM from four animals per group and are 
representative of two independent experiments. Means not sharing letter are significantly different (P<0.05, 
2-way ANOVA with Bonferroni post-test). Original publication [22].
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modulation of the immune response by LC n-3 PUFAs, mainly through the change 
in eicosanoids patterns produced during T. cruzi infection, could be one mechanism 
that results in improvement of the host response. However, more studies are neces-
sary to determine whether or not oral supplementation with LC n-3 PUFA could 
benefit humans diagnosed with Chagas disease.
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modulation of the immune response by LC n-3 PUFAs, mainly through the change 
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that results in improvement of the host response. However, more studies are neces-
sary to determine whether or not oral supplementation with LC n-3 PUFA could 
benefit humans diagnosed with Chagas disease.
Acknowledgements
Funding: This study was financed in part by the Coordenação de 
Aperfeiçoamento de Pessoal de Nível Superior-Brasil (CAPES) Finance Code 
001, CNPq (grant Edital Universal 14-2014, research fellowships for PP-F (CNPq 
307787/2015-0), MM-P (CNPq 307544/2016-8) and MILM (PNPD-Capes 
22921091) and Fundação Araucária (grant 419-2009).
Conflict of interest
The authors declare that there are no conflicts of interest.
Notes/thanks/other declarations
This study would have been impossible without the aid and support of Dr. Kevin 
Fritsche Department of Nutrition and Exercise Physiology, University of Missouri, 
Columbia, 65,211, Missouri, USA.
187
Fish Oil and Inflammation: A Perspective on the Challenges of Evaluating Efficacy…
DOI: http://dx.doi.org/10.5772/intechopen.84792
References
[1] Chagas C. Nova tripanozomiaze 
humana: estudos sobre a morfolojia e 
o ciclo evolutivo do Schizotrypanum 
cruzi n. gen., n. sp., ajente etiolojico 
de nova entidade morbida do homem. 
Memórias do Instituto Oswaldo Cruz. 
1909;1:159-218
[2] WHO. Chagas Disease (American 
Trypanosomiasis); 2017. Available from: 
http://www.who.int/mediacentre/
factsheets/fs340/en/
[3] WHO. Why are Some Tropical 
Diseases called “neglected”? 2012. 
Available from: http://www.who.int/
features/qa/58/en/
[4] Machado FS, Dutra WO, Esper 
L, Gollob KJ, Teixeira MM, Factor 
SM, et al. Current understanding 
of immunity to Trypanosoma cruzi 
infection and pathogenesis of Chagas 
disease. Seminars in Immunopathology. 
2012;34(6):753-770. DOI: 10.1007/
s00281-012-0351-7
[5] Marin-Neto JA, Cunha-Neto E, 
Maciel BC, Simoes MV. Pathogenesis 
of chronic Chagas heart disease. 
Circulation. 2007;115(9):1109-1123. 
DOI: 10.1161/circulationaha.106.624296
[6] Dutra WO, Menezes CA, Magalhaes 
LM, Gollob KJ. Immunoregulatory 
networks in human Chagas disease. 
Parasite Immunology. 2014;36(8): 
377-387. DOI: 10.1111/pim.12107
[7] Calder PC, Kew S. The immune 
system: A target for functional foods? 
The British Journal of Nutrition. 
2002;88(Suppl 2):S165-S177. DOI: 
10.1079/bjn2002682
[8] Turchini GM, Nichols PD, Barrow 
C, Sinclair AJ. Jumping on the 
omega-3 bandwagon: Distinguishing 
the role of long-chain and short-
chain omega-3 fatty acids. Critical 
Reviews in Food Science and 
Nutrition. 2012;52(9):795-803. DOI: 
10.1080/10408398.2010.509553
[9] Fritsche K. Fatty acids as modulators 
of the immune response. Annual Review 
of Nutrition. 2006;26:45-73. DOI: 
10.1146/annurev.nutr.25.050304.092610
[10] Calder PC. Very long-chain n-3 fatty 
acids and human health: Fact, fiction 
and the future. The Proceedings of the 
Nutrition Society. 2018;77(1):52-72. 
DOI: 10.1017/s0029665117003950
[11] Anderson M, Fritsche KL. (n-3) 
Fatty acids and infectious disease 
resistance. The Journal of Nutrition. 
2002;132(12):3566-3576
[12] Yancy CW, Jessup M, Bozkurt B, 
Butler J, Casey DE Jr, Drazner MH, 
et al. 2013 ACCF/AHA guideline for 
the management of heart failure: A 
report of the American College of 
Cardiology Foundation/American Heart 
Association Task Force on Practice 
Guidelines. Journal of the American 
College of Cardiology 2013;62(16):e147–
e239. DOI: 10.1016/j.jacc.2013.05.019
[13] Faludi AA, Izar MCO, Saraiva 
JFK, Chacra APM, Bianco HT, Afiune 
AN, et al. Atualização da Diretriz 
Brasileira de Dislipidemias e Prevenção 
da Aterosclerose—2017. Arquivos 
Brasileiros de Cardiologia. 2017;109 
(2 Supl 1):1-76. DOI: 10.5935/abc. 
20170121
[14] Ratnayake WM, Galli C. Fat and 
fatty acid terminology, methods 
of analysis and fat digestion and 
metabolism: A background review 
paper. Annals of Nutrition & 
Metabolism. 2009;55(1-3):8-43. DOI: 
10.1159/000228994
[15] Simopoulos AP. An increase in 
the omega-6/omega-3 fatty acid ratio 
increases the risk for obesity. Nutrients. 
2016;8(3):128. DOI: 10.3390/nu8030128
Biology of Trypanosoma cruzi
188
[16] Simopoulos AP. Omega-3 fatty acids 
in health and disease and in growth and 
development. The American Journal of 
Clinical Nutrition. 1991;54(3):438-463. 
DOI: 10.1093/ajcn/54.3.438
[17] Kaur KK, Allahbadia G, Singh 
M. Synthesis and functional significance 
of poly unsaturated fatty acids (PUFA’s) 
in body. Acta Scientific Nutritional 
Health. 2018;2(4):8. DOI: 10.15226/jnhfs
[18] Blasbalg TL, Hibbeln JR, 
Ramsden CE, Majchrzak SF, Rawlings 
RR. Changes in consumption of 
omega-3 and omega-6 fatty acids in the 
United States during the 20th century. 
The American Journal of Clinical 
Nutrition. 2011;93(5):950-962. DOI: 
10.3945/ajcn.110.006643
[19] Maalouly G, Ward C, Smayra V, 
Saliba Y, Aftimos G, Haddad F, et al. 
Fish oil attenuates neurologic severity 
of antiphospholipid syndrome in a 
mice experimental model. Nutritional 
Neuroscience. 2016;20:1-8. DOI: 
10.1080/1028415x.2016.1206165
[20] Hokari R, Matsunaga H, Miura 
S. Effect of dietary fat on intestinal 
inflammatory diseases. Journal of 
Gastroenterology and Hepatology. 
2013;28(Suppl 4):33-36. DOI: 10.1111/
jgh.12252
[21] Woo SJ, Lim K, Park SY, Jung 
MY, Lim HS, Jeon MG, et al. 
Endogenous conversion of n-6 to n-3 
polyunsaturated fatty acids attenuates 
K/BxN serum-transfer arthritis in 
fat-1 mice. The Journal of Nutritional 
Biochemistry. 2015;26(7):713-720. DOI: 
10.1016/j.jnutbio.2015.01.011
[22] Lovo-Martins MI, Malvezi AD, 
da Silva RV, Zanluqui NG, VLH T, 
NOS C, et al. Fish oil supplementation 
benefits the murine host during the 
acute phase of a parasitic infection 
from Trypanosoma cruzi. Nutrition 
Research. 2017;41:73-85. DOI: 10.1016/j.
nutres.2017.04.007
[23] Irons R, Anderson MJ, Zhang 
M, Fritsche KL. Dietary fish oil 
impairs primary host resistance 
against Listeria monocytogenes more 
than the immunological memory 
response. The Journal of Nutrition. 
2003;133(4):1163-1169
[24] Blok WL, Vogels MT, Curfs JH, 
Eling WM, Buurman WA, van der Meer 
JW. Dietary fish-oil supplementation in 
experimental gram-negative infection 
and in cerebral malaria in mice. 
The Journal of Infectious Diseases. 
1992;165(5):898-903
[25] Blok WL, Rabinovitch M, Zilberfarb 
V, Netea MG, Buurman WA, van der 
Meer JW. The influence of dietary 
fish-oil supplementation on cutaneous 
Leishmania amazonensis infection in 
mice. Cytokine. 2002;19(5):213-217
[26] Rajaei E, Mowla K, Ghorbani A, 
Bahadoram S, Bahadoram M, Dargahi-
Malamir M. The effect of omega-3 fatty 
acids in patients with active rheumatoid 
arthritis receiving DMARDs therapy: 
Double-blind randomized controlled 
trial. Global Journal of Health Science. 
2015;8(7):18-25. DOI: 10.5539/gjhs.
v8n7p18
[27] Ferguson JF, Mulvey CK, Patel PN, 
Shah RY, Doveikis J, Zhang W, et al. 
Omega-3 PUFA supplementation and 
the response to evoked endotoxemia in 
healthy volunteers. Molecular Nutrition 
& Food Research. 2014;58(3):601-613. 
DOI: 10.1002/mnfr.201300368
[28] Miles EA, Calder PC. Influence of 
marine n-3 polyunsaturated fatty acids 
on immune function and a systematic 
review of their effects on clinical 
outcomes in rheumatoid arthritis. 
The British Journal of Nutrition. 
2012;107(Suppl 2):S171-S184. DOI: 
10.1017/S0007114512001560
[29] Fritsche KL. The science of fatty 
acids and inflammation. Advances 
in Nutrition (Bethesda, Md). 
189




[30] Calder PC. Marine omega-3 fatty 
acids and inflammatory processes: 
Effects, mechanisms and clinical 
relevance. Biochimica et Biophysica 
Acta. 2015;1851(4):469-484. DOI: 
10.1016/j.bbalip.2014.08.010
[31] Faber J, Berkhout M, Vos AP, 
Sijben JW, Calder PC, Garssen J, et al. 
Supplementation with a fish oil-enriched, 
high-protein medical food leads to rapid 
incorporation of EPA into white blood cells 
and modulates immune responses within 
one week in healthy men and women. The 
Journal of Nutrition. 2011;141(5):964-970. 
DOI: 10.3945/jn.110.132985
[32] Yaqoob P, Pala HS, Cortina-
Borja M, Newsholme EA, Calder 
PC. Encapsulated fish oil enriched 
in alpha-tocopherol alters plasma 
phospholipid and mononuclear 
cell fatty acid compositions but not 
mononuclear cell functions. European 
Journal of Clinical Investigation. 
2000;30(3):260-274
[33] Calder PC, Yaqoob P, Harvey DJ, 
Watts A, Newsholme EA. Incorporation 
of fatty acids by concanavalin 
A-stimulated lymphocytes and the 
effect on fatty acid composition and 
membrane fluidity. Biochemical Journal. 
1994;300(Pt 2):509-518
[34] Groom ZC, Protopapas AD, Zochios 
V. Tropical diseases of the myocardium: 
A review. International Journal of 
General Medicine. 2017;10:101-111. 
DOI: 10.2147/IJGM.S130828
[35] Ribeiro AL, Nunes MP, Teixeira 
MM, Rocha MO. Diagnosis and 
management of Chagas disease and 
cardiomyopathy. Nature Reviews. 
Cardiology. 2012;9(10):576-589. DOI: 
10.1038/nrcardio.2012.109
[36] Silva PSD, Mediano MFF, Silva G, 
Brito PD, Cardoso CSA, Almeida CF,  
et al. Omega-3 supplementation on 
inflammatory markers in patients with 
chronic Chagas cardiomyopathy: A 
randomized clinical study. Nutrition 
Journal. 2017;16(1):36. DOI: 10.1186/
s12937-017-0259-0
[37] Silva PS, Sperandio da Silva 
GM, de Souza AP, Cardoso CS, 
Fonseca CA, Brito PD, et al. Effects 
of omega-3 polyunsaturated fatty 
acid supplementation in patients with 
chronic chagasic cardiomyopathy: Study 
protocol for a randomized controlled 
trial. Trials. 2013;14:379. DOI: 
10.1186/1745-6215-14-379
[38] Gazzinelli RT, Oswald IP, Hieny 
S, James SL, Sher A. The microbicidal 
activity of interferon-gamma-treated 
macrophages against Trypanosoma 
cruzi involves an L-arginine-dependent, 
nitrogen oxide-mediated mechanism 
inhibitable by interleukin-10 and 
transforming growth factor-beta. 
European Journal of Immunology. 
1992;22(10):2501-2506. DOI: 10.1002/
eji.1830221006
[39] Petray P, Rottenberg ME, Grinstein 
S, Orn A. Release of nitric oxide 
during the experimental infection 
with Trypanosoma cruzi. Parasite 
Immunology. 1994;16(4):193-199
[40] Vespa GN, Cunha FQ , Silva 
JS. Nitric oxide is involved in control 
of Trypanosoma cruzi-induced 
parasitemia and directly kills the 
parasite in vitro. Infection and 
Immunity. 1994;62(11):5177-5182
[41] Kaech C, Bochud PY, Calandra 
T. Cytokines and Escherichia coli Sepsis. 
EcoSal Plus. 2006;2(1):1-20. DOI: 
10.1128/ecosalplus.8.8.15
[42] Armah H, Wired EK, Dodoo AK, 
Adjei AA, Tettey Y, Gyasi R. Cytokines 
and adhesion molecules expression in 
the brain in human cerebral malaria. 
International Journal of Environmental 
Research and Public Health. 
2005;2(1):123-131
Biology of Trypanosoma cruzi
188
[16] Simopoulos AP. Omega-3 fatty acids 
in health and disease and in growth and 
development. The American Journal of 
Clinical Nutrition. 1991;54(3):438-463. 
DOI: 10.1093/ajcn/54.3.438
[17] Kaur KK, Allahbadia G, Singh 
M. Synthesis and functional significance 
of poly unsaturated fatty acids (PUFA’s) 
in body. Acta Scientific Nutritional 
Health. 2018;2(4):8. DOI: 10.15226/jnhfs
[18] Blasbalg TL, Hibbeln JR, 
Ramsden CE, Majchrzak SF, Rawlings 
RR. Changes in consumption of 
omega-3 and omega-6 fatty acids in the 
United States during the 20th century. 
The American Journal of Clinical 
Nutrition. 2011;93(5):950-962. DOI: 
10.3945/ajcn.110.006643
[19] Maalouly G, Ward C, Smayra V, 
Saliba Y, Aftimos G, Haddad F, et al. 
Fish oil attenuates neurologic severity 
of antiphospholipid syndrome in a 
mice experimental model. Nutritional 
Neuroscience. 2016;20:1-8. DOI: 
10.1080/1028415x.2016.1206165
[20] Hokari R, Matsunaga H, Miura 
S. Effect of dietary fat on intestinal 
inflammatory diseases. Journal of 
Gastroenterology and Hepatology. 
2013;28(Suppl 4):33-36. DOI: 10.1111/
jgh.12252
[21] Woo SJ, Lim K, Park SY, Jung 
MY, Lim HS, Jeon MG, et al. 
Endogenous conversion of n-6 to n-3 
polyunsaturated fatty acids attenuates 
K/BxN serum-transfer arthritis in 
fat-1 mice. The Journal of Nutritional 
Biochemistry. 2015;26(7):713-720. DOI: 
10.1016/j.jnutbio.2015.01.011
[22] Lovo-Martins MI, Malvezi AD, 
da Silva RV, Zanluqui NG, VLH T, 
NOS C, et al. Fish oil supplementation 
benefits the murine host during the 
acute phase of a parasitic infection 
from Trypanosoma cruzi. Nutrition 
Research. 2017;41:73-85. DOI: 10.1016/j.
nutres.2017.04.007
[23] Irons R, Anderson MJ, Zhang 
M, Fritsche KL. Dietary fish oil 
impairs primary host resistance 
against Listeria monocytogenes more 
than the immunological memory 
response. The Journal of Nutrition. 
2003;133(4):1163-1169
[24] Blok WL, Vogels MT, Curfs JH, 
Eling WM, Buurman WA, van der Meer 
JW. Dietary fish-oil supplementation in 
experimental gram-negative infection 
and in cerebral malaria in mice. 
The Journal of Infectious Diseases. 
1992;165(5):898-903
[25] Blok WL, Rabinovitch M, Zilberfarb 
V, Netea MG, Buurman WA, van der 
Meer JW. The influence of dietary 
fish-oil supplementation on cutaneous 
Leishmania amazonensis infection in 
mice. Cytokine. 2002;19(5):213-217
[26] Rajaei E, Mowla K, Ghorbani A, 
Bahadoram S, Bahadoram M, Dargahi-
Malamir M. The effect of omega-3 fatty 
acids in patients with active rheumatoid 
arthritis receiving DMARDs therapy: 
Double-blind randomized controlled 
trial. Global Journal of Health Science. 
2015;8(7):18-25. DOI: 10.5539/gjhs.
v8n7p18
[27] Ferguson JF, Mulvey CK, Patel PN, 
Shah RY, Doveikis J, Zhang W, et al. 
Omega-3 PUFA supplementation and 
the response to evoked endotoxemia in 
healthy volunteers. Molecular Nutrition 
& Food Research. 2014;58(3):601-613. 
DOI: 10.1002/mnfr.201300368
[28] Miles EA, Calder PC. Influence of 
marine n-3 polyunsaturated fatty acids 
on immune function and a systematic 
review of their effects on clinical 
outcomes in rheumatoid arthritis. 
The British Journal of Nutrition. 
2012;107(Suppl 2):S171-S184. DOI: 
10.1017/S0007114512001560
[29] Fritsche KL. The science of fatty 
acids and inflammation. Advances 
in Nutrition (Bethesda, Md). 
189




[30] Calder PC. Marine omega-3 fatty 
acids and inflammatory processes: 
Effects, mechanisms and clinical 
relevance. Biochimica et Biophysica 
Acta. 2015;1851(4):469-484. DOI: 
10.1016/j.bbalip.2014.08.010
[31] Faber J, Berkhout M, Vos AP, 
Sijben JW, Calder PC, Garssen J, et al. 
Supplementation with a fish oil-enriched, 
high-protein medical food leads to rapid 
incorporation of EPA into white blood cells 
and modulates immune responses within 
one week in healthy men and women. The 
Journal of Nutrition. 2011;141(5):964-970. 
DOI: 10.3945/jn.110.132985
[32] Yaqoob P, Pala HS, Cortina-
Borja M, Newsholme EA, Calder 
PC. Encapsulated fish oil enriched 
in alpha-tocopherol alters plasma 
phospholipid and mononuclear 
cell fatty acid compositions but not 
mononuclear cell functions. European 
Journal of Clinical Investigation. 
2000;30(3):260-274
[33] Calder PC, Yaqoob P, Harvey DJ, 
Watts A, Newsholme EA. Incorporation 
of fatty acids by concanavalin 
A-stimulated lymphocytes and the 
effect on fatty acid composition and 
membrane fluidity. Biochemical Journal. 
1994;300(Pt 2):509-518
[34] Groom ZC, Protopapas AD, Zochios 
V. Tropical diseases of the myocardium: 
A review. International Journal of 
General Medicine. 2017;10:101-111. 
DOI: 10.2147/IJGM.S130828
[35] Ribeiro AL, Nunes MP, Teixeira 
MM, Rocha MO. Diagnosis and 
management of Chagas disease and 
cardiomyopathy. Nature Reviews. 
Cardiology. 2012;9(10):576-589. DOI: 
10.1038/nrcardio.2012.109
[36] Silva PSD, Mediano MFF, Silva G, 
Brito PD, Cardoso CSA, Almeida CF,  
et al. Omega-3 supplementation on 
inflammatory markers in patients with 
chronic Chagas cardiomyopathy: A 
randomized clinical study. Nutrition 
Journal. 2017;16(1):36. DOI: 10.1186/
s12937-017-0259-0
[37] Silva PS, Sperandio da Silva 
GM, de Souza AP, Cardoso CS, 
Fonseca CA, Brito PD, et al. Effects 
of omega-3 polyunsaturated fatty 
acid supplementation in patients with 
chronic chagasic cardiomyopathy: Study 
protocol for a randomized controlled 
trial. Trials. 2013;14:379. DOI: 
10.1186/1745-6215-14-379
[38] Gazzinelli RT, Oswald IP, Hieny 
S, James SL, Sher A. The microbicidal 
activity of interferon-gamma-treated 
macrophages against Trypanosoma 
cruzi involves an L-arginine-dependent, 
nitrogen oxide-mediated mechanism 
inhibitable by interleukin-10 and 
transforming growth factor-beta. 
European Journal of Immunology. 
1992;22(10):2501-2506. DOI: 10.1002/
eji.1830221006
[39] Petray P, Rottenberg ME, Grinstein 
S, Orn A. Release of nitric oxide 
during the experimental infection 
with Trypanosoma cruzi. Parasite 
Immunology. 1994;16(4):193-199
[40] Vespa GN, Cunha FQ , Silva 
JS. Nitric oxide is involved in control 
of Trypanosoma cruzi-induced 
parasitemia and directly kills the 
parasite in vitro. Infection and 
Immunity. 1994;62(11):5177-5182
[41] Kaech C, Bochud PY, Calandra 
T. Cytokines and Escherichia coli Sepsis. 
EcoSal Plus. 2006;2(1):1-20. DOI: 
10.1128/ecosalplus.8.8.15
[42] Armah H, Wired EK, Dodoo AK, 
Adjei AA, Tettey Y, Gyasi R. Cytokines 
and adhesion molecules expression in 
the brain in human cerebral malaria. 
International Journal of Environmental 
Research and Public Health. 
2005;2(1):123-131
Biology of Trypanosoma cruzi
190
[43] Perlmann P, Troye-Blomberg 
M. Malaria blood-stage infection and 
its control by the immune system. Folia 
Biologica. 2000;46(6):210-218
[44] Puertollano MA, Cruz-Chamorro 
L, Puertollano E, Perez-Toscano MT, 
Alvarez de Cienfuegos G, de Pablo 
MA. Assessment of interleukin-12, 
gamma interferon, and tumor 
necrosis factor alpha secretion in sera 
from mice fed with dietary lipids 
during different stages of Listeria 
monocytogenes infection. Clinical and 
Diagnostic Laboratory Immunology. 
2005;12(9):1098-1103. DOI: 10.1128/
cdli.12.9.1098-1103.2005
[45] Godfrey DG. Influence of dietary 
cod liver oil upon Trypanosoma 
congolense, T. cruzi, T. vivax and T. 
brucei. Experimental Parasitology. 
1958;7(3):255-268
[46] Takeda GK, Starobinas N, 
Marcondes MC, Mello EA, Russo M, 
Stolf AM. Oral administration of fish-
oil induces high levels of seric TNF in 
Trypanosoma cruzi infected C57BL/6 
mice. Acta Tropica. 1995;60(3): 
215-219
[47] Cardoso JE, Brener Z. Hematological 
changes in mice experimentally 
infected with Trypanosoma cruzi. 
Memórias do Instituto Oswaldo Cruz. 
1980;75(3-4):97-104
[48] Repka D, Rangel HA, Atta 
AM, Gavino VA, Piedrabuena 
AE. Experimental Chagas’ disease 
in mice infected with one LD50 of 
parasite. Revista Brasileira de Biologia. 
1985;45(3):309-316
[49] Marcondes MC, Borelli P, Yoshida 
N, Russo M. Acute Trypanosoma cruzi 
infection is associated with anemia, 
thrombocytopenia, leukopenia, and 
bone marrow hypoplasia: Reversal by 
nifurtimox treatment. Microbes and 
Infection. 2000;2(4):347-352
[50] Malvezi AD, Cecchini R, de Souza 
F, Tadokoro CE, Rizzo LV, Pinge-Filho 
P. Involvement of nitric oxide (NO) 
and TNF-alpha in the oxidative stress 
associated with anemia in experimental 
Trypanosoma cruzi infection. FEMS 
Immunology and Medical Microbiology. 
2004;41(1):69-77. DOI: 10.1016/j.
femsim.2004.01.005
[51] Abdalla GK, Faria GE, Silva 
KT, Castro EC, Reis MA, Michelin 
MA. Trypanosoma cruzi: The role 
of PGE2 in immune response during 
the acute phase of experimental 
infection. Experimental Parasitology. 
2008;118(4):514-521. DOI: 10.1016/j.
exppara.2007.11.003
[52] Guerrero NA, Camacho M, Vila 
L, Iniguez MA, Chillon-Marinas C, 
Cuervo H, et al. Cyclooxygenase-2 and 
Prostaglandin E2 Signaling through 
Prostaglandin Receptor EP-2 Favor the 
Development of Myocarditis during 
Acute Trypanosoma cruzi Infection. 
PLoS Neglected Tropical Diseases. 
2015;9(8):e0004025. DOI: 10.1371/
journal.pntd.0004025
[53] Pavanelli WR, Gutierrez FR, 
Mariano FS, Prado CM, Ferreira BR, 
Teixeira MM, et al. 5-lipoxygenase is a 
key determinant of acute myocardial 
inflammation and mortality during 
Trypanosoma cruzi infection. Microbes 
and Infection. 2010;12(8-9):587-597. 
DOI: 10.1016/j.micinf.2010.03.016
[54] Panis C, Mazzuco TL, Costa CZ, 
Victorino VJ, Tatakihara VL, Yamauchi 
LM, et al. Trypanosoma cruzi: Effect 
of the absence of 5-lipoxygenase 
(5-LO)-derived leukotrienes on levels 
of cytokines, nitric oxide and iNOS 
expression in cardiac tissue in the acute 
phase of infection in mice. Experimental 
Parasitology. 2011;127(1):58-65. DOI: 
10.1016/j.exppara.2010.06.030
[55] Celentano AM, Gorelik G, Solana 
ME, Sterin-Borda L, Borda E, Gonzalez 
Cappa SM. PGE2 involvement 
191
Fish Oil and Inflammation: A Perspective on the Challenges of Evaluating Efficacy…
DOI: http://dx.doi.org/10.5772/intechopen.84792
in experimental infection with 
Trypanosoma cruzi subpopulations. 
Prostaglandins. 1995;49(3):141-153
[56] Cardoni RL, Antunez MI. 
Circulating levels of cyclooxygenase 
metabolites in experimental 
Trypanosoma cruzi infections. 
Mediators of Inflammation. 
2004;13(4):235-240. DOI: 
10.1080/09637480400003022
[57] Pinge-Filho P, Tadokoro CE, 
Abrahamsohn IA. Prostaglandins 
mediate suppression of lymphocyte 
proliferation and cytokine synthesis 
in acute Trypanosoma cruzi 
infection. Cellular Immunology. 
1999;193(1):90-98
[58] Michelin MA, Silva JS, Cunha 
FQ. Inducible cyclooxygenase 
released prostaglandin mediates 
immunosuppression in acute phase 
of experimental Trypanosoma cruzi 
infection. Experimental Parasitology. 
2005;111(2):71-79. DOI: 10.1016/j.
exppara.2005.05.001
[59] Freire-de-Lima CG, Nascimento 
DO, Soares MB, Bozza PT, Castro-
Faria-Neto HC, de Mello FG, 
et al. Uptake of apoptotic cells 
drives the growth of a pathogenic 
trypanosome in macrophages. Nature. 
2000;403(6766):199-203. DOI: 
10.1038/35003208
[60] Malvezi AD, Panis C, da Silva 
RV, de Freitas RC, Lovo-Martins MI, 
Tatakihara VL, et al. Inhibition of 
cyclooxygenase-1 and cyclooxygenase-2 
impairs Trypanosoma cruzi entry into 
cardiac cells and promotes differential 
modulation of the inflammatory 
response. Antimicrobial Agents and 
Chemotherapy. 2014;58(10):6157-6164. 
DOI: 10.1128/aac.02752-14
[61] Sokolowska M, Chen LY, Liu Y, 
Martinez-Anton A, Qi HY, Logun C, 
et al. Prostaglandin E2 inhibits NLRP3 
inflammasome activation through EP4 
receptor and intracellular cyclic AMP 
in human macrophages. Journal of 
Immunology. 2015;194(11):5472-5487. 
DOI: 10.4049/jimmunol.1401343
[62] Goncalves VM, Matteucci KC, Buzzo 
CL, Miollo BH, Ferrante D, Torrecilhas 
AC, et al. NLRP3 controls Trypanosoma 
cruzi infection through a caspase-1-
dependent IL-1R-independent NO 
production. PLoS Neglected Tropical 
Diseases. 2013;7(10):e2469. DOI: 
10.1371/journal.pntd.0002469
[63] Sterin-Borda L, Gorelik G, Goren 
N, Cappa SG, Celentano AM, Borda 
E. Lymphocyte muscarinic cholinergic 
activity and PGE2 involvement in 
experimental Trypanosoma cruzi 
infection. Clinical Immunology and 
Immunopathology. 1996;81(2):122-128
[64] Mukherjee S, Sadekar N, Ashton 
AW, Huang H, Spray DC, Lisanti MP, 
et al. Identification of a functional 
prostanoid-like receptor in the 
protozoan parasite, Trypanosoma 
cruzi. Parasitology Research. 
2013;112(4):1417-1425. DOI: 10.1007/
s00436-012-3271-5
[65] Hideko Tatakihara VL, Cecchini R, 
Borges CL, Malvezi AD, Graca-de Souza 
VK, Yamada-Ogatta SF, et al. Effects of 
cyclooxygenase inhibitors on parasite 
burden, anemia and oxidative stress in 
murine Trypanosoma cruzi infection. 
FEMS Immunology and Medical 
Microbiology. 2008;52(1):47-58. DOI: 
10.1111/j.1574-695X.2007.00340.x
[66] Machado FS, Mukherjee S, 
Weiss LM, Tanowitz HB, Ashton 
AW. Bioactive lipids in Trypanosoma 
cruzi infection. Advances in 
Parasitology. 2011;76:1-31. DOI: 
10.1016/b978-0-12-385895-5.00001-3
[67] Ashton AW, Mukherjee S, 
Nagajyothi FN, Huang H, Braunstein 
VL, Desruisseaux MS, et al. 
Thromboxane A2 is a key regulator of 
pathogenesis during Trypanosoma cruzi 
Biology of Trypanosoma cruzi
190
[43] Perlmann P, Troye-Blomberg 
M. Malaria blood-stage infection and 
its control by the immune system. Folia 
Biologica. 2000;46(6):210-218
[44] Puertollano MA, Cruz-Chamorro 
L, Puertollano E, Perez-Toscano MT, 
Alvarez de Cienfuegos G, de Pablo 
MA. Assessment of interleukin-12, 
gamma interferon, and tumor 
necrosis factor alpha secretion in sera 
from mice fed with dietary lipids 
during different stages of Listeria 
monocytogenes infection. Clinical and 
Diagnostic Laboratory Immunology. 
2005;12(9):1098-1103. DOI: 10.1128/
cdli.12.9.1098-1103.2005
[45] Godfrey DG. Influence of dietary 
cod liver oil upon Trypanosoma 
congolense, T. cruzi, T. vivax and T. 
brucei. Experimental Parasitology. 
1958;7(3):255-268
[46] Takeda GK, Starobinas N, 
Marcondes MC, Mello EA, Russo M, 
Stolf AM. Oral administration of fish-
oil induces high levels of seric TNF in 
Trypanosoma cruzi infected C57BL/6 
mice. Acta Tropica. 1995;60(3): 
215-219
[47] Cardoso JE, Brener Z. Hematological 
changes in mice experimentally 
infected with Trypanosoma cruzi. 
Memórias do Instituto Oswaldo Cruz. 
1980;75(3-4):97-104
[48] Repka D, Rangel HA, Atta 
AM, Gavino VA, Piedrabuena 
AE. Experimental Chagas’ disease 
in mice infected with one LD50 of 
parasite. Revista Brasileira de Biologia. 
1985;45(3):309-316
[49] Marcondes MC, Borelli P, Yoshida 
N, Russo M. Acute Trypanosoma cruzi 
infection is associated with anemia, 
thrombocytopenia, leukopenia, and 
bone marrow hypoplasia: Reversal by 
nifurtimox treatment. Microbes and 
Infection. 2000;2(4):347-352
[50] Malvezi AD, Cecchini R, de Souza 
F, Tadokoro CE, Rizzo LV, Pinge-Filho 
P. Involvement of nitric oxide (NO) 
and TNF-alpha in the oxidative stress 
associated with anemia in experimental 
Trypanosoma cruzi infection. FEMS 
Immunology and Medical Microbiology. 
2004;41(1):69-77. DOI: 10.1016/j.
femsim.2004.01.005
[51] Abdalla GK, Faria GE, Silva 
KT, Castro EC, Reis MA, Michelin 
MA. Trypanosoma cruzi: The role 
of PGE2 in immune response during 
the acute phase of experimental 
infection. Experimental Parasitology. 
2008;118(4):514-521. DOI: 10.1016/j.
exppara.2007.11.003
[52] Guerrero NA, Camacho M, Vila 
L, Iniguez MA, Chillon-Marinas C, 
Cuervo H, et al. Cyclooxygenase-2 and 
Prostaglandin E2 Signaling through 
Prostaglandin Receptor EP-2 Favor the 
Development of Myocarditis during 
Acute Trypanosoma cruzi Infection. 
PLoS Neglected Tropical Diseases. 
2015;9(8):e0004025. DOI: 10.1371/
journal.pntd.0004025
[53] Pavanelli WR, Gutierrez FR, 
Mariano FS, Prado CM, Ferreira BR, 
Teixeira MM, et al. 5-lipoxygenase is a 
key determinant of acute myocardial 
inflammation and mortality during 
Trypanosoma cruzi infection. Microbes 
and Infection. 2010;12(8-9):587-597. 
DOI: 10.1016/j.micinf.2010.03.016
[54] Panis C, Mazzuco TL, Costa CZ, 
Victorino VJ, Tatakihara VL, Yamauchi 
LM, et al. Trypanosoma cruzi: Effect 
of the absence of 5-lipoxygenase 
(5-LO)-derived leukotrienes on levels 
of cytokines, nitric oxide and iNOS 
expression in cardiac tissue in the acute 
phase of infection in mice. Experimental 
Parasitology. 2011;127(1):58-65. DOI: 
10.1016/j.exppara.2010.06.030
[55] Celentano AM, Gorelik G, Solana 
ME, Sterin-Borda L, Borda E, Gonzalez 
Cappa SM. PGE2 involvement 
191
Fish Oil and Inflammation: A Perspective on the Challenges of Evaluating Efficacy…
DOI: http://dx.doi.org/10.5772/intechopen.84792
in experimental infection with 
Trypanosoma cruzi subpopulations. 
Prostaglandins. 1995;49(3):141-153
[56] Cardoni RL, Antunez MI. 
Circulating levels of cyclooxygenase 
metabolites in experimental 
Trypanosoma cruzi infections. 
Mediators of Inflammation. 
2004;13(4):235-240. DOI: 
10.1080/09637480400003022
[57] Pinge-Filho P, Tadokoro CE, 
Abrahamsohn IA. Prostaglandins 
mediate suppression of lymphocyte 
proliferation and cytokine synthesis 
in acute Trypanosoma cruzi 
infection. Cellular Immunology. 
1999;193(1):90-98
[58] Michelin MA, Silva JS, Cunha 
FQ. Inducible cyclooxygenase 
released prostaglandin mediates 
immunosuppression in acute phase 
of experimental Trypanosoma cruzi 
infection. Experimental Parasitology. 
2005;111(2):71-79. DOI: 10.1016/j.
exppara.2005.05.001
[59] Freire-de-Lima CG, Nascimento 
DO, Soares MB, Bozza PT, Castro-
Faria-Neto HC, de Mello FG, 
et al. Uptake of apoptotic cells 
drives the growth of a pathogenic 
trypanosome in macrophages. Nature. 
2000;403(6766):199-203. DOI: 
10.1038/35003208
[60] Malvezi AD, Panis C, da Silva 
RV, de Freitas RC, Lovo-Martins MI, 
Tatakihara VL, et al. Inhibition of 
cyclooxygenase-1 and cyclooxygenase-2 
impairs Trypanosoma cruzi entry into 
cardiac cells and promotes differential 
modulation of the inflammatory 
response. Antimicrobial Agents and 
Chemotherapy. 2014;58(10):6157-6164. 
DOI: 10.1128/aac.02752-14
[61] Sokolowska M, Chen LY, Liu Y, 
Martinez-Anton A, Qi HY, Logun C, 
et al. Prostaglandin E2 inhibits NLRP3 
inflammasome activation through EP4 
receptor and intracellular cyclic AMP 
in human macrophages. Journal of 
Immunology. 2015;194(11):5472-5487. 
DOI: 10.4049/jimmunol.1401343
[62] Goncalves VM, Matteucci KC, Buzzo 
CL, Miollo BH, Ferrante D, Torrecilhas 
AC, et al. NLRP3 controls Trypanosoma 
cruzi infection through a caspase-1-
dependent IL-1R-independent NO 
production. PLoS Neglected Tropical 
Diseases. 2013;7(10):e2469. DOI: 
10.1371/journal.pntd.0002469
[63] Sterin-Borda L, Gorelik G, Goren 
N, Cappa SG, Celentano AM, Borda 
E. Lymphocyte muscarinic cholinergic 
activity and PGE2 involvement in 
experimental Trypanosoma cruzi 
infection. Clinical Immunology and 
Immunopathology. 1996;81(2):122-128
[64] Mukherjee S, Sadekar N, Ashton 
AW, Huang H, Spray DC, Lisanti MP, 
et al. Identification of a functional 
prostanoid-like receptor in the 
protozoan parasite, Trypanosoma 
cruzi. Parasitology Research. 
2013;112(4):1417-1425. DOI: 10.1007/
s00436-012-3271-5
[65] Hideko Tatakihara VL, Cecchini R, 
Borges CL, Malvezi AD, Graca-de Souza 
VK, Yamada-Ogatta SF, et al. Effects of 
cyclooxygenase inhibitors on parasite 
burden, anemia and oxidative stress in 
murine Trypanosoma cruzi infection. 
FEMS Immunology and Medical 
Microbiology. 2008;52(1):47-58. DOI: 
10.1111/j.1574-695X.2007.00340.x
[66] Machado FS, Mukherjee S, 
Weiss LM, Tanowitz HB, Ashton 
AW. Bioactive lipids in Trypanosoma 
cruzi infection. Advances in 
Parasitology. 2011;76:1-31. DOI: 
10.1016/b978-0-12-385895-5.00001-3
[67] Ashton AW, Mukherjee S, 
Nagajyothi FN, Huang H, Braunstein 
VL, Desruisseaux MS, et al. 
Thromboxane A2 is a key regulator of 
pathogenesis during Trypanosoma cruzi 
Biology of Trypanosoma cruzi
192
infection. The Journal of Experimental 
Medicine. 2007;204(4):929-940. DOI: 
10.1084/jem.20062432
[68] Chapkin RS, Akoh CC, Miller 
CC. Influence of dietary n-3 fatty acids 
on macrophage glycerophospholipid 
molecular species and peptidoleukotriene 
synthesis. Journal of Lipid Research. 
1991;32(7):1205-1213
[69] Trebble TM, Wootton SA, 
Miles EA, Mullee M, Arden NK, 
Ballinger AB, et al. Prostaglandin E2 
production and T cell function after 
fish-oil supplementation: Response to 
antioxidant cosupplementation. The 
American Journal of Clinical Nutrition. 
2003;78(3):376-382
[70] Bagga D, Wang L, Farias-Eisner R, 
Glaspy JA, Reddy ST. Differential effects 
of prostaglandin derived from omega-6 
and omega-3 polyunsaturated fatty 
acids on COX-2 expression and IL-6 
secretion. Proceedings of the National 
Academy of Sciences of the United 
States of America. 2003;100(4):1751-
1756. DOI: 10.1073/pnas.0334211100
[71] Serhan CN. Pro-resolving lipid 
mediators are leads for resolution 
physiology. Nature. 2014;510(7503): 
92-101. DOI: 10.1038/nature13479
[72] Hong S, Gronert K, Devchand PR, 
Moussignac RL, Serhan CN. Novel 
docosatrienes and 17S-resolvins 
generated from docosahexaenoic acid in 
murine brain, human blood, and glial 
cells. Autacoids in anti-inflammation. 
The Journal of Biological Chemistry. 
2003;278(17):14677-14687. DOI: 
10.1074/jbc.M300218200
[73] Mas E, Croft KD, Zahra P, Barden 
A, Mori TA. Resolvins D1, D2, and other 
mediators of self-limited resolution of 
inflammation in human blood following 
n-3 fatty acid supplementation. Clinical 
Chemistry. 2012;58(10):1476-1484. DOI: 
10.1373/clinchem.2012.190199
[74] Colas RA, Ashton AW. 
Trypanosoma cruzi produces the 
specialized proresolving mediators 
resolvin D1, resolvin D5, and 





Parasite, Compartments, and 
Molecules: Trick versus Treatment 
on Chagas Disease
Marcos André Vannier-Santos, Giselle V. Brunoro,  
Maria de Nazaré C. Soeiro, Solange L. DeCastro  
and Rubem F.S. Menna-Barreto
Abstract
Chagas disease, caused by the protozoan Trypanosoma cruzi, is endemic to 
Latin America, standing out as a socio-economic problem for low-income tropi-
cal populations. Such disease affects millions of people worldwide and emerges in 
nonendemic areas due to migration and climate changes. The current chemotherapy 
is restricted to two nitroderivatives (benznidazole and nifurtimox), which is unsat-
isfactory due to limited efficacy (particularly in chronic phase) and adverse side 
effects. T. cruzi life cycle is complex, including invertebrate and vertebrate hosts 
and three developmental forms (epimastigotes, trypomastigotes, and amastigotes). 
In this chapter, we will discuss promising cellular and molecular targets present in 
the vertebrate-dwelling forms of the parasite (trypomastigotes and amastigotes). 
Among the cellular targets, the mitochondrion is the most frequently studied; while 
among the molecular ones, we highlight squalene synthase, C14α-sterol demeth-
ylase, and cysteine proteases. In this scenario, proteomics becomes a valuable tool 
for the identification of other molecular targets, and some previously identified 
candidates will be also discussed. Multidisciplinary studies are needed to identify 
novel key molecules in T. cruzi in order to increase trypanocidal activity and reduce 
mammalian toxicity, ensuring the development of novel drugs for Chagas disease.
Keywords: Trypanosoma cruzi, Chagas disease, chemotherapy, drug targets, 
organelles, proteomics, oxidative metabolism
1. Introduction
Chagas disease, or American trypanosomiasis, was described in 1909 by the 
Brazilian physician Carlos Chagas, who identified the causative agent—Trypanosoma 
cruzi—the transmission vector, major reservoirs, mechanism of human infection, 
as well as some clinical manifestations [1]. This disease is primarily transmitted to 
humans by the feces of hematophagous insects, of the family Reduviidae, subfamily 
Triatominae. The impressive decrease in Chagas disease prevalence from 16–18 mil-
lion people by 1990 to 6–8 million people by 2010 was essentially the consequence 
of the launching of transnational programs in Latin America focused on the elimi-
nation of domestic vectors and blood donors screening supported by Pan American 
Biology of Trypanosoma cruzi
192
infection. The Journal of Experimental 
Medicine. 2007;204(4):929-940. DOI: 
10.1084/jem.20062432
[68] Chapkin RS, Akoh CC, Miller 
CC. Influence of dietary n-3 fatty acids 
on macrophage glycerophospholipid 
molecular species and peptidoleukotriene 
synthesis. Journal of Lipid Research. 
1991;32(7):1205-1213
[69] Trebble TM, Wootton SA, 
Miles EA, Mullee M, Arden NK, 
Ballinger AB, et al. Prostaglandin E2 
production and T cell function after 
fish-oil supplementation: Response to 
antioxidant cosupplementation. The 
American Journal of Clinical Nutrition. 
2003;78(3):376-382
[70] Bagga D, Wang L, Farias-Eisner R, 
Glaspy JA, Reddy ST. Differential effects 
of prostaglandin derived from omega-6 
and omega-3 polyunsaturated fatty 
acids on COX-2 expression and IL-6 
secretion. Proceedings of the National 
Academy of Sciences of the United 
States of America. 2003;100(4):1751-
1756. DOI: 10.1073/pnas.0334211100
[71] Serhan CN. Pro-resolving lipid 
mediators are leads for resolution 
physiology. Nature. 2014;510(7503): 
92-101. DOI: 10.1038/nature13479
[72] Hong S, Gronert K, Devchand PR, 
Moussignac RL, Serhan CN. Novel 
docosatrienes and 17S-resolvins 
generated from docosahexaenoic acid in 
murine brain, human blood, and glial 
cells. Autacoids in anti-inflammation. 
The Journal of Biological Chemistry. 
2003;278(17):14677-14687. DOI: 
10.1074/jbc.M300218200
[73] Mas E, Croft KD, Zahra P, Barden 
A, Mori TA. Resolvins D1, D2, and other 
mediators of self-limited resolution of 
inflammation in human blood following 
n-3 fatty acid supplementation. Clinical 
Chemistry. 2012;58(10):1476-1484. DOI: 
10.1373/clinchem.2012.190199
[74] Colas RA, Ashton AW. 
Trypanosoma cruzi produces the 
specialized proresolving mediators 
resolvin D1, resolvin D5, and 





Parasite, Compartments, and 
Molecules: Trick versus Treatment 
on Chagas Disease
Marcos André Vannier-Santos, Giselle V. Brunoro,  
Maria de Nazaré C. Soeiro, Solange L. DeCastro  
and Rubem F.S. Menna-Barreto
Abstract
Chagas disease, caused by the protozoan Trypanosoma cruzi, is endemic to 
Latin America, standing out as a socio-economic problem for low-income tropi-
cal populations. Such disease affects millions of people worldwide and emerges in 
nonendemic areas due to migration and climate changes. The current chemotherapy 
is restricted to two nitroderivatives (benznidazole and nifurtimox), which is unsat-
isfactory due to limited efficacy (particularly in chronic phase) and adverse side 
effects. T. cruzi life cycle is complex, including invertebrate and vertebrate hosts 
and three developmental forms (epimastigotes, trypomastigotes, and amastigotes). 
In this chapter, we will discuss promising cellular and molecular targets present in 
the vertebrate-dwelling forms of the parasite (trypomastigotes and amastigotes). 
Among the cellular targets, the mitochondrion is the most frequently studied; while 
among the molecular ones, we highlight squalene synthase, C14α-sterol demeth-
ylase, and cysteine proteases. In this scenario, proteomics becomes a valuable tool 
for the identification of other molecular targets, and some previously identified 
candidates will be also discussed. Multidisciplinary studies are needed to identify 
novel key molecules in T. cruzi in order to increase trypanocidal activity and reduce 
mammalian toxicity, ensuring the development of novel drugs for Chagas disease.
Keywords: Trypanosoma cruzi, Chagas disease, chemotherapy, drug targets, 
organelles, proteomics, oxidative metabolism
1. Introduction
Chagas disease, or American trypanosomiasis, was described in 1909 by the 
Brazilian physician Carlos Chagas, who identified the causative agent—Trypanosoma 
cruzi—the transmission vector, major reservoirs, mechanism of human infection, 
as well as some clinical manifestations [1]. This disease is primarily transmitted to 
humans by the feces of hematophagous insects, of the family Reduviidae, subfamily 
Triatominae. The impressive decrease in Chagas disease prevalence from 16–18 mil-
lion people by 1990 to 6–8 million people by 2010 was essentially the consequence 
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Biology of Trypanosoma cruzi
194
Health Organization/World Health Organization (PAHO/WHO) [2]. Despite these 
successful control interventions, the Chagas disease prevalence was estimated to 
reach 1.0–2.4% of the Brazilian population [1]. This disease, classically associated 
with poor and rural populations, underwent an urbanization process in the 1970s 
and 1980s to Latin American cities and later on beyond endemic countries, creating 
new epidemiological, social, and political challenges [3–5].
With the success of vector and blood bank control programs, congenital [6, 7], 
and oral [8, 9] transmissions have become important sources of new cases of Chagas 
disease. Congenital infections represent an estimated 22% of new cases in Latin 
America [2], occurring also in nonendemic countries [10, 11]. The oral route, which 
is probably the most frequent mechanism among vectors and wild mammals, has 
recently become relevant, due to environmental changes caused by deforestation 
[12]. T. cruzi DNA was recently shown in 10% among 140 samples of açai-based 
products marketed in Rio de Janeiro and Pará States in Brazil [13].
Chagas disease results from the establishment of T. cruzi in host tissues, involv-
ing an initial acute phase followed by a chronic phase, classified as indeterminate, 
cardiac, and/or digestive syndromes. The acute phase is characterized by detectable 
parasitemia and is commonly asymptomatic [14]. Without treatment, approxi-
mately 5–10% of symptomatic patients die during this phase due to encephalomyeli-
tis or severe cardiac failure and rarely due to cardiac arrest [15]. After 2–3 months, 
the infection enters the chronic phase, and without successful treatment, it is 
lifelong. Approximately, two-thirds of infected individuals have the indeterminate 
form of the chronic phase, which is asymptomatic and defined by the presence 
of T. cruzi antibodies and normal electrocardiographic and radiologic exams. The 
remaining infected individuals, due to an unbalanced inflammatory response and 
persistent low parasitism, will develop years or even decades later symptomatic 
chronic disease with cardiac (20–30%) and/or digestive (15–20%) disorders.
The current etiological treatment for Chagas disease is restricted to two nitro-
heterocyclic drugs: benznidazole (Bz/LAFEPE, Abarax®, ELEA and Bz/Chemo 
Research, Exeltis) and nifurtimox (Nif, LAMPIT®, Bayer) (Figure 1). Bz has been 
recently FDA-approved for use in children aged 2–12 years, being the first treat-
ment approved in the United States for Chagas disease [16]. The results obtained 
with these two nitroderivatives vary according to the phase of Chagas disease, the 
period, and dose of treatment, as well as the age and geographical origin of the 
patients [17]. Both drugs have often shown successful results with high parasitologi-
cal cure rates during the acute phase, but the effectiveness decreases with advance 
of the infection; therefore, early detection and intervention are crucial for reaching 
high cure rates [18]. The high incidence of collateral effects, especially for adults, 
leads to treatment abandonment rates reaching over 30% of the patients [19–21]. In 
contrast, children have a markedly higher tolerance for treatment [1, 14].
There are significant drawbacks on the use of these drugs, mostly related to 
the limited efficacy in the chronic phase [22], and so, new alternative therapies 
Figure 1. 
Clinical drugs for Chagas disease treatment: (A) benznidazole and (B) nifurtimox.
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are urgently required. In the last decades, many chemical diversity libraries from 
several pharmaceutical companies have been screened in the search of novel anti-T. 
cruzi candidates. In these programs, different approaches have been used including 
target-oriented studies, combination therapies, new formulations for drugs in use, 
and drug repurposing, and thus, in the present review, some of these points will be 
addressed.
2. Trypanosoma cruzi and drug targets
One important point to be addressed in the search of alternative molecular 
targets in T. cruzi is their presence in parasite forms dwelling in vertebrates. Once 
the parasite stages present different metabolic profiles [23, 24], the most promising 
targets are involved in crucial metabolic pathways, such as key enzymes related to 
antioxidant metabolism or sterol biosynthesis. In this section, we revised some of 
the most studied targets for drug intervention.
2.1 Mitochondrion, glycosomes, and oxidative metabolism
Mitochondrion plays a pivotal role in the oxidative stress, since the electron 
leakage from the electron transport chain (ETC particularly from complexes I, III 
and coenzyme Q ) leads to the partial reduction of oxygen, being the main source of 
reactive oxygen species (ROS) in the cells [25]. During electron leakage, ROS were 
produced that interfere with different biological processes [26]. Such production 
leads to the increase in the expression of antioxidant enzymes such as superoxide 
dismutase (SOD), trypanothione reductase (TR), and peroxidases in response to the 
oxidative burst, and TR is considered one of the most promising chemotherapy tar-
gets in Chagas disease [27]. In trypanosomatids, mitochondrial metabolism is quite 
similar to that of other eukaryotes. Complex I (NADH: ubiquinone oxidoreductase) 
is expressed (almost 19 subunits were detected) but its functionality is still contro-
versial [26]. In this way, glucose metabolism results mostly in succinate (complex II 
substrate) in trypanosomatids, derived from glycosomal and mitochondrial NADH-
dependent fumarate reductase activities [28, 29]. Since complex I is not functional, 
oxidative phosphorylation is exclusively dependent of complex II in these protozoa. 
On the other hand, complexes III (ubiquinol:cytochrome c oxidoreductase) and IV 
(cytochrome c oxidase) of high eukaryotes and trypanosomatids display no differ-
ences, being complex III considered the major mitochondrial source of ROS pro-
duction [30]. Many studies pointed to the susceptibility of T. cruzi mitochondrion 
to a great variety of compounds, and such mitochondrial damage (ultrastructural 
swelling, decreased mitochondrial membrane potential, etc.) may comprise early or 
late events in trypanocidal agent activity (Figure 2) [31].
Glycosomes are organelles crucial for the energetic and antioxidant metabolisms 
of the parasite, and the compartmentalization of their enzymes (including the 
majority of the enzymes of the glycolytic pathway) has also been reported to be 
directly involved in the maintenance of T. cruzi viability, indicating this organelle as 
a potential drug target [32]. Among the glycosomal oxidative, scavengers are SOD 
isoforms, tryparedoxin, and peroxidases [26]. Up to now, no specific inhibitors of 
glycosomal enzymes showed promising trypanocidal activity [33].
2.1.1 Mitochondrial ETC
T. cruzi mitochondrion is the most recurrent cellular drug target described 
in mechanistic studies; however, the exact molecular machinery involved in the 
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Figure 1. 
Clinical drugs for Chagas disease treatment: (A) benznidazole and (B) nifurtimox.
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are urgently required. In the last decades, many chemical diversity libraries from 
several pharmaceutical companies have been screened in the search of novel anti-T. 
cruzi candidates. In these programs, different approaches have been used including 
target-oriented studies, combination therapies, new formulations for drugs in use, 
and drug repurposing, and thus, in the present review, some of these points will be 
addressed.
2. Trypanosoma cruzi and drug targets
One important point to be addressed in the search of alternative molecular 
targets in T. cruzi is their presence in parasite forms dwelling in vertebrates. Once 
the parasite stages present different metabolic profiles [23, 24], the most promising 
targets are involved in crucial metabolic pathways, such as key enzymes related to 
antioxidant metabolism or sterol biosynthesis. In this section, we revised some of 
the most studied targets for drug intervention.
2.1 Mitochondrion, glycosomes, and oxidative metabolism
Mitochondrion plays a pivotal role in the oxidative stress, since the electron 
leakage from the electron transport chain (ETC particularly from complexes I, III 
and coenzyme Q ) leads to the partial reduction of oxygen, being the main source of 
reactive oxygen species (ROS) in the cells [25]. During electron leakage, ROS were 
produced that interfere with different biological processes [26]. Such production 
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dismutase (SOD), trypanothione reductase (TR), and peroxidases in response to the 
oxidative burst, and TR is considered one of the most promising chemotherapy tar-
gets in Chagas disease [27]. In trypanosomatids, mitochondrial metabolism is quite 
similar to that of other eukaryotes. Complex I (NADH: ubiquinone oxidoreductase) 
is expressed (almost 19 subunits were detected) but its functionality is still contro-
versial [26]. In this way, glucose metabolism results mostly in succinate (complex II 
substrate) in trypanosomatids, derived from glycosomal and mitochondrial NADH-
dependent fumarate reductase activities [28, 29]. Since complex I is not functional, 
oxidative phosphorylation is exclusively dependent of complex II in these protozoa. 
On the other hand, complexes III (ubiquinol:cytochrome c oxidoreductase) and IV 
(cytochrome c oxidase) of high eukaryotes and trypanosomatids display no differ-
ences, being complex III considered the major mitochondrial source of ROS pro-
duction [30]. Many studies pointed to the susceptibility of T. cruzi mitochondrion 
to a great variety of compounds, and such mitochondrial damage (ultrastructural 
swelling, decreased mitochondrial membrane potential, etc.) may comprise early or 
late events in trypanocidal agent activity (Figure 2) [31].
Glycosomes are organelles crucial for the energetic and antioxidant metabolisms 
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directly involved in the maintenance of T. cruzi viability, indicating this organelle as 
a potential drug target [32]. Among the glycosomal oxidative, scavengers are SOD 
isoforms, tryparedoxin, and peroxidases [26]. Up to now, no specific inhibitors of 
glycosomal enzymes showed promising trypanocidal activity [33].
2.1.1 Mitochondrial ETC
T. cruzi mitochondrion is the most recurrent cellular drug target described 
in mechanistic studies; however, the exact molecular machinery involved in the 
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susceptibility of this organelle to different classes of compounds is still unclear 
[31]. No hypothesis about the molecular mechanism involved in the mitochon-
drial effect of the great majority of trypanocidal drugs was postulated hitherto, 
and the damage specificity in this organelle is very debatable. Some specific 
inhibitors of ETC complexes have already been tested on T. cruzi. Rotenone, 
a well-known complex I inhibitor, has a controversial activity in the parasite. 
However, rotenone at high doses inhibited the activity of T. cruzi NADH-
dependent enzymes [34]. The existence of complex I activity was not strongly 
supported by such inhibition and could be caused by nonspecific binding to other 
electron carriers. On the other hand, depolarization of mitochondrial membrane, 
ROS production, and apoptotic-like phenotype was detected in parasites after the 
treatment with inhibitors of complexes III and IV, antimycin A, and potassium 
cyanide, respectively [24]. Structural and functional similarities between mam-
malian and trypanosomatidae complexes are suggestive of high toxicity.
2.1.2 Trypanothione reductase
The presence of some antioxidant components that are absent in mammalian 
cells makes this pathway a promising target of drug intervention in trypanosoma-
tids. The unusual spermidine-glutathione adduct named trypanothione or N1,N8-
bis(glutathionyl)spermidine found solely in these parasites functions as an electron 
donor in many pathways by neutralizing diverse reactive species through redox 
reactions, also providing reducing equivalents to intermediate molecules in other 
antioxidant pathways and in biosynthetic pathways such as DNA synthesis [35, 36]. 
The catalysis of NADPH-dependent reduction of trypanothione disulfide to T(SH)2 
is performed by trypanothione reductase (TR), enzyme that has been proposed as 
a molecular target, based on the specific inhibition of antioxidant defenses of the 
parasite [37, 38]. The central role of trypanothione makes other enzymes that influ-
ence its production also interesting drug targets such as trypanothione synthetase, 
ornithine decarboxylase (ODC), S-adenosylmethionine (AdoMet) decarboxylase, 
γ-glutamylcysteine synthetase as well as polyamine transporters [39, 40].
In the last decades, many TR inhibitors were developed, but only a few had a 
positive correlation between trypanocidal activity and binding to the enzyme dem-
onstrated [41–43]. Recently, a high-throughput screening of 1.8 million compounds 
Figure 2. 
Most recurrent cellular drug targets in T. cruzi mammalian stages. M: mitochondrion; K: kinetoplast; N: nucleus; 
F: flagellum; Gl: glycosomes; G: golgi; Ac: acidocalcisomes; ER: endoplasmic reticulum; and Ap: autophagosomes.
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was performed, and specific inhibitors of Leishmania TR were identified. Since this 
enzyme is considered well-conserved among trypanosomatids, this study could 
represent a critical step for the identification of inhibitors also for T. cruzi TR [44]. 
Up to the moment, the inhibition of trypanothione metabolism of this parasite was 
poorly assessed in animal models, and no clinical trial has been reported involving 
this target (Figure 3).
2.1.3 ROS inducers
Varying the dose or the time of drug treatment, injury to the mitochondrion 
usually leads to ROS production [45]. Despite many compounds having induced 
mitochondrial alterations, generating ROS, the molecular mechanistic action 
was not elucidated in most studies. In this section, we will discuss only qui-
nones and nitrocompounds, compounds with oxidative mechanisms of action 
well-characterized.
Quinones: Chemical properties of quinoidal carbonyls lead to the direct ROS 
generation [46], and trypanocidal effect of natural quinones and derivatives have 
been assessed [47–50]. In epimastigotes, the oxidative activity of β-lapachone was 
first reported almost 40 years ago [51, 52], and increase in ROS levels has also been 
related to the treatment of T. cruzi with other naphthoquinones [53, 54]. In 2009, 
we proposed the trypanocidal mechanism of action of naphthofuranquinones. 
Such quinones strongly impaired the parasite mitochondrion by the deviation 
of the electrons from ubiquinone, culminating in this organelle  depolarization, 
loss of respiratory rates, inhibition of complexes I–III activities, and ROS 
 production [54]. Increased levels of ROS were also detected in parasites after the 
 treatment with other classes of compounds such as pyrazyl/pyridylhydrazones and 
 thiosemicarbazones [55–57].
Nitrocompounds: These compounds are usually avoided in medicinal chemistry 
approaches because the presence of a nitro group creates concerns regarding toxic-
ity issues associated with DNA damage [58]. Regarding Chagas disease, fexinidazole 
evaluated in vivo, led to high cure rates and reduced myocarditis [59]. Subsequently, 
a phase II clinical trial was performed in chronic chagasic patients in Bolivia using 
fexinidazole treatment (NCT02498782), and it was observed that parasitemia was 
cleared; however, after recruiting 47 participants, some safety and tolerability 
issues arose, and it was decided to conclude the trial without the inclusion of new 
participants. After a 12 month follow-up, a high efficacy rate was evidenced, with-
out relapses [60]. Therefore, a new proof of concept study was initiated in Spain in 
2017, with the results expected in 2019 (EudraCT Number 2016-004905-15).
Figure 3. 
Landmarks in the investigation of TR as a drug target. Despite many efforts up to now, specific inhibitors of 
this enzyme presented neither important trypanocidal activity in vitro nor in vivo. TR DPB ID: 1BZL.
Biology of Trypanosoma cruzi
196
susceptibility of this organelle to different classes of compounds is still unclear 
[31]. No hypothesis about the molecular mechanism involved in the mitochon-
drial effect of the great majority of trypanocidal drugs was postulated hitherto, 
and the damage specificity in this organelle is very debatable. Some specific 
inhibitors of ETC complexes have already been tested on T. cruzi. Rotenone, 
a well-known complex I inhibitor, has a controversial activity in the parasite. 
However, rotenone at high doses inhibited the activity of T. cruzi NADH-
dependent enzymes [34]. The existence of complex I activity was not strongly 
supported by such inhibition and could be caused by nonspecific binding to other 
electron carriers. On the other hand, depolarization of mitochondrial membrane, 
ROS production, and apoptotic-like phenotype was detected in parasites after the 
treatment with inhibitors of complexes III and IV, antimycin A, and potassium 
cyanide, respectively [24]. Structural and functional similarities between mam-
malian and trypanosomatidae complexes are suggestive of high toxicity.
2.1.2 Trypanothione reductase
The presence of some antioxidant components that are absent in mammalian 
cells makes this pathway a promising target of drug intervention in trypanosoma-
tids. The unusual spermidine-glutathione adduct named trypanothione or N1,N8-
bis(glutathionyl)spermidine found solely in these parasites functions as an electron 
donor in many pathways by neutralizing diverse reactive species through redox 
reactions, also providing reducing equivalents to intermediate molecules in other 
antioxidant pathways and in biosynthetic pathways such as DNA synthesis [35, 36]. 
The catalysis of NADPH-dependent reduction of trypanothione disulfide to T(SH)2 
is performed by trypanothione reductase (TR), enzyme that has been proposed as 
a molecular target, based on the specific inhibition of antioxidant defenses of the 
parasite [37, 38]. The central role of trypanothione makes other enzymes that influ-
ence its production also interesting drug targets such as trypanothione synthetase, 
ornithine decarboxylase (ODC), S-adenosylmethionine (AdoMet) decarboxylase, 
γ-glutamylcysteine synthetase as well as polyamine transporters [39, 40].
In the last decades, many TR inhibitors were developed, but only a few had a 
positive correlation between trypanocidal activity and binding to the enzyme dem-
onstrated [41–43]. Recently, a high-throughput screening of 1.8 million compounds 
Figure 2. 
Most recurrent cellular drug targets in T. cruzi mammalian stages. M: mitochondrion; K: kinetoplast; N: nucleus; 
F: flagellum; Gl: glycosomes; G: golgi; Ac: acidocalcisomes; ER: endoplasmic reticulum; and Ap: autophagosomes.
197
Parasite, Compartments, and Molecules: Trick versus Treatment on Chagas Disease
DOI: http://dx.doi.org/10.5772/intechopen.84472
was performed, and specific inhibitors of Leishmania TR were identified. Since this 
enzyme is considered well-conserved among trypanosomatids, this study could 
represent a critical step for the identification of inhibitors also for T. cruzi TR [44]. 
Up to the moment, the inhibition of trypanothione metabolism of this parasite was 
poorly assessed in animal models, and no clinical trial has been reported involving 
this target (Figure 3).
2.1.3 ROS inducers
Varying the dose or the time of drug treatment, injury to the mitochondrion 
usually leads to ROS production [45]. Despite many compounds having induced 
mitochondrial alterations, generating ROS, the molecular mechanistic action 
was not elucidated in most studies. In this section, we will discuss only qui-
nones and nitrocompounds, compounds with oxidative mechanisms of action 
well-characterized.
Quinones: Chemical properties of quinoidal carbonyls lead to the direct ROS 
generation [46], and trypanocidal effect of natural quinones and derivatives have 
been assessed [47–50]. In epimastigotes, the oxidative activity of β-lapachone was 
first reported almost 40 years ago [51, 52], and increase in ROS levels has also been 
related to the treatment of T. cruzi with other naphthoquinones [53, 54]. In 2009, 
we proposed the trypanocidal mechanism of action of naphthofuranquinones. 
Such quinones strongly impaired the parasite mitochondrion by the deviation 
of the electrons from ubiquinone, culminating in this organelle  depolarization, 
loss of respiratory rates, inhibition of complexes I–III activities, and ROS 
 production [54]. Increased levels of ROS were also detected in parasites after the 
 treatment with other classes of compounds such as pyrazyl/pyridylhydrazones and 
 thiosemicarbazones [55–57].
Nitrocompounds: These compounds are usually avoided in medicinal chemistry 
approaches because the presence of a nitro group creates concerns regarding toxic-
ity issues associated with DNA damage [58]. Regarding Chagas disease, fexinidazole 
evaluated in vivo, led to high cure rates and reduced myocarditis [59]. Subsequently, 
a phase II clinical trial was performed in chronic chagasic patients in Bolivia using 
fexinidazole treatment (NCT02498782), and it was observed that parasitemia was 
cleared; however, after recruiting 47 participants, some safety and tolerability 
issues arose, and it was decided to conclude the trial without the inclusion of new 
participants. After a 12 month follow-up, a high efficacy rate was evidenced, with-
out relapses [60]. Therefore, a new proof of concept study was initiated in Spain in 
2017, with the results expected in 2019 (EudraCT Number 2016-004905-15).
Figure 3. 
Landmarks in the investigation of TR as a drug target. Despite many efforts up to now, specific inhibitors of 
this enzyme presented neither important trypanocidal activity in vitro nor in vivo. TR DPB ID: 1BZL.
Biology of Trypanosoma cruzi
198
Surprisingly, trypanocidal action of Nif and Bz is still controversial. Nif has the 
oxidative activity demonstrated in the early 1980s, being hydrogen peroxide and 
superoxide anion production detected, while no reactive species was found after the 
treatment with Bz [61]. Bz and Nif are considered prodrugs that require activation 
by nitroreductases—NTR-I, an oxygen insensitive class catalyzing the two-electron 
reduction of the nitro group and NTR-II, an oxygen-sensitive class catalyzing 
one-electron reduction [62]. The mechanistic proposal of Nif involves nitroanion 
radical metabolization by NTR-II, followed by reoxidation by molecular oxygen 
to form superoxide anion (∙O2−), which is converted to hydrogen peroxide (H2O2) 
under catalysis by SOD (Figure 4) [63]. On the other hand, low molecular weight 
thiol reduction together with no redox cycling in trypanocidal doses supported the 
hypothesis that oxidative effect was not involved in the parasite killing by Nif [64]. 
Additionally, NTR-I activity has been related to the trypanocidal effect of Nif and 
Bz through a two-electron reduction in the nitro group. In an oxygen-independent 
way, the production of nitroso and hydroxylamine intermediates led to amine 
generation, using NADH as a cofactor. The cleavage of the Nif furane ring produces 
a highly reactive unsaturated open chain nitrile [65].
Recently, some highly potent 3-nitro-1H-1,2,4-triazole derivatives emerged 
as excellent substrates for NTR-I, but the enzymatic activity was not required for 
the trypanocidal activity [66]. Alternative enzymes have been associated with the 
reduction of nitro compounds in T. cruzi, indicative of a secondary action for these 
drugs, and further studies about the molecular mechanisms involved must be per-
formed. The high trypanocidal activity together with the identification of exclusive 
nitroreductases in trypanosomatids supports the hypothesis of selectivity [63].
2.1.4 Polyamines
Polyamines (PA) are ubiquitous organic polycations that play a plethora of 
ubiquitous biological roles in most cell types, including bacteria, protozoa, and 
higher organisms [67], with significant metabolic differences, therefore compris-
ing promising drug targets for protozoal diseases [68]. PA metabolism among 
parasitic protozoa is defective in a number of pathways as compared to mammalian 
cells. T. cruzi parasites lack ODC and so are auxotrophic for the diamine putrescine 
[69]. Therefore, the protozoan relies on the diamine uptake from the extracel-
lular milieu via surface transporters or permeases [70], and so, these mechanisms 
comprise targets for chemotherapy agent development [71], and pentamidine was 
shown to inhibit polyamine transport by T. cruzi [72]. Putrescine uptake is required 
for the massive infection [73] and scape from stress conditions [74]. Spermidine 
is synthesized by the transfer of an aminopropyl group from decarboxylated 
S-adenosyl-l-methionine to putrescine and takes part in the biogenesis of T[SH]2 
a pivotal adduct in oxidative stress endurance and involved in anti-T. cruzi drug 
Figure 4. 
Metobolization of nitrocompounds by NTR-1 and NTR-II. ROS is generated by reoxidation (one electron 
route). Two-electron reduction produces hydroxylamine intermediates and reactive nitroso [63].
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resistance [75]. In this regard, the putrescine analog DAB (1,4-diamino-2-buta-
none) promotes oxidative stress in T. cruzi [76] and leads to T. cruzi mitochondrial 
destruction [77]. It is noteworthy that DAB not only is involved on reactive species 
production but also inhibit putrescine synthesis [78] and incorporation [79].
Polyamines may play multiple functions in parasite endurance under oxidative 
stress conditions, not only for TSH is a spermidine adduct but also because these 
polycations per se may be antioxidant, protecting T. cruzi from oxidative stress [80]. 
Polyamines are also relevant for controlling differentiation, including T. cruzi meta-
cyclogenesis [81]. Thus, the enzymes involved in polyamine and TSH metabolism 
provide important drug targets for potential anti-T. cruzi therapy [40].
2.2 Biosynthesis of sterols
Sterols are essential lipid molecules, performing numerous cellular roles associ-
ated with membrane and signal functions [82]. Cholesterol is biosynthesized in 
humans, whereas ergosterol or other 24-alkylated sterols are biosynthesized in 
opportunistic fungi and parasitic protozoa and such difference is exploited in the 
drug development [83]. T. cruzi and related trypanosomatids have a strict require-
ment for endogenous sterols (ergosterol and analogs) for survival that cannot be 
replaced by cholesterol found in the host. Thus, the biosynthesis of sterols is a major 
target in the drug development for Chagas disease [84]. Among enzymes of the 
sterol metabolism, squalene synthase (SQS) and C14α-sterol demethylase (CYP51) 
have been intensively investigated as drug targets (Figure 5).
2.2.1 Squalene synthase (SQS)
This enzyme catalyzes the dimerization of two molecules of farnesyl pyrophos-
phate (FPP) to produce squalene. This enzyme is under study as a possible target 
for cholesterol-lowering agents in humans [85]. SQS is a membrane-bound enzyme 
Figure 5. 
Ergosterol biosynthesis is an important drug target in T. cruzi. In red, the enzymes described as molecular 
targets and in blue, the classes of the speciffic inhibitors. Inside gray boxes, the intermediary steps of the 
conversion of lanosterol into 4,4-dimethyl-5a-cholesta-8,1,4,24-3b-ol by sterol 14-α-demethylase (CYP51).
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in T. cruzi epimastigotes, being distributed between glycosome and mitochondrial/
microsomal vesicles [86]. FPP is a branching point in isoprenoid biosynthesis: 
conversion to squalene and sterols by SQS or synthesis of other essential isopren-
oids. The quinuclidine-based inhibitors of mammalian SQS, 3-(biphenyl-4-yl)-
3-hydroxyquinuclidine (BPQ-OH) ER27856, E5700, and ER-119884 were assayed 
against T. cruzi, leading to the in vitro inhibition of epimastigote and intracellular 
amastigote proliferation, depletion of endogenous squalene and sterols, and marked 
ultrastructural alterations [86, 87] and in vivo E5700 led to 100% survival and 
parasitemia negativation [88]. However, E5700 and ER-119884 have no selectivity 
toward the parasite enzyme in comparative assays with the recombinant human 
enzyme [89]. In 2014, the X-ray crystallographic structure of SQS from T. cruzi was 
reported, confirming the binding of the enzyme to distinct classes of inhibitors 
such as the quinuclidines E5700 and ER119884 and the thiocyanate WC-9 opening 
possibilities to the development of alternative inhibitors [90].
In a screening of compounds containing the 4-phenoxyphenoxy skeleton, 
4-phenoxyphenoxyethyl thiocyanate (WC-9) was highlighted due to the high activ-
ity against the proliferative form epimastigotes (low micromolar) and intracellular 
amastigotes (nanomolar) and a potent inhibitor of the enzymatic activity of both 
glycosomal and mitochondrial isoforms of SQS [91, 92]. Since then, different series 
of WC-9 analogs have been developed [91, 93], including seleno-containing analogs 
resulting in compounds, such as 4-phenoxyphenoxyethyl selenocyanate, with EC50 
values at low nanomolar level and selectivity index (SI) higher than 900 [94].
2.2.2 C14α-sterol demethylase (CYP51)
This enzyme catalyzes the oxidative removal of the 14α-methyl group from of 
catalyzing the oxidative removal of the 14α-methyl group from sterol precursors 
such as lanosterol or eburicol, via a repetitive three-step process that uses NADPH 
and oxygen to produce 4,4-dimethyl-5α-cholesta-8,14,24-trien-3β-ol [83]. CYP51s 
are the most conserved cytochrome P450 enzymes [84]. Series of azoles originally 
developed for the treatment of fungal infections targets this enzyme leading to accu-
mulation of lanosterol and other sterol intermediates and displaying activity in vitro 
and in vivo against T. cruzi [95–97]. This line of investigation led to the selection of 
the triazole posaconazole [98, 99] and E1224 (fosravuconazole) [100, 101] for Phase 
II clinical trials with chronic patients, which, however, led to therapeutic failure as 
compared to benznidazole, with parasitemia relapses: NCT01162967 (Chagazol) 
[102], NCT01377480 (Stopchagas) [103], and NCT01489228 (E1224 trial) [104].
VNI, a carboxamide-containing β-phenyl-imidazole, identified from a Novartis 
collection of azoles, was active in acute and chronic mouse models using Tulahuen 
strain [105]; whereas in experiments with other parasite strains, no complete para-
sitological clearance was achieved [106]. In subsequent work, VFV, a fluoro analog 
of VNI, designed to fill the deepest portion of the CYP51 substrate-binding cavity 
demonstrated 100% efficacy in experimental infection, displaying favorable oral 
bioavailability and pharmacokinetics [107]. Comparison between VNI and VFV, 
in murine models of infection, revealed that regardless of the treatment scheme or 
delivery vehicle, VFV was more potent in both genders [108]. VT-1161, a 1-tetra-
zole-based drug undergoing phase II antifungal clinical trials, is active in vitro and 
in vivo against T. cruzi. It was structurally characterized in a complex with TcCYP51, 
allowing for the optimization of new tetrazole-based analogs and presents good 
pharmacokinetic properties and an excellent safety profile [109]. Friggeri et al. 
[110] synthesized imidazolyl-2-phenylethanol derivatives, and several of them were 
active against intracellular amastigotes and inhibited TcCYP51. In sequence, eight 
new derivatives were prepared and assayed against the parasite, and the most active 
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was a piperazinyl-carbamate derivative at nanomolar range, low cytotoxicity, and 
good chemical and metabolic stability [111]. Recently, a series of pyrazolo[3,4-e]
[1,4]thiazepin analogs, novel CYP51 inhibitors, were investigated revealing in vitro 
and in vivo activity against T. cruzi, with several analogs displaying effect at low 
micromolar dosis and low host toxicity [112].
2.3 Cysteine proteases
Cysteine proteases are intensively used as molecular targets in trypanosomatid 
disease drug discovery efforts. Target-based screening, structure-based drug 
design, and medicinal chemistry approaches targeting cysteine proteases are strate-
gies intensively used in the development of drugs for diseases caused by pathogenic 
trypanosomatids. T. cruzi cysteine protease named cruzipain (or cruzain) is a 
cathepsin-L-like protease of the papain family and is essential for the intracellular 
replication, differentiation, and immune evasion of the parasite [113, 114]. Three-
dimensional structures of cruzain with different ligands have been reported, allow-
ing the design and synthesis of new hit compounds [115]. Based on the interaction 
with its active site, enzyme inhibitors have been classified as irreversible, forming 
covalent bonds with cysteine sulfur, or as reversible, forming 1,2-adducts with 
cysteine that are generally unstable [116]. Among irreversible peptidyl inhibitors 
of cruzipain, we highlight diazomethyl ketones, allyl sulfones, vinyl sulfonamides, 
and vinyl sulfones, including K777 and its arginine variant WRR-483 [117–119]. 
Among nonpeptidyl inhibitors of cruzipain, we found thiosemicarbazones, thiazo-
lylhydrazones, thiazoles, and oxadiazoles (Figure 6) [120].
Another group of compounds that has been studied as cruzipain reversible 
inhibitors are those containing a nitrile head: purine nitriles [121], nitrile analogs 
of odanacatib [122, 123], and nonpeptidic nitriles [124]. Salas-Sarduy et al. [125] 
identified two new cruzipain inhibitory scaffolds from GlaxoSmithKline HAT and 
Chagas chemical boxes, both containing a nitrile moiety, with major structural dif-
ferences between them. Benzimidazoles and oxidiazoles have also been explored as 
noncovalent cruzain inhibitors, using an approach combining high throughput and 
virtual screenings [126, 127].
Development of cruzipain inhibitors by structure activity relationship (SAR) 
studies, combinatorial chemistry, HTS, and virtual screening are also employed 
in repositioning strategies [128]. Bromocriptine (antiparkinson and antidiabetic 
Figure 6. 
Cruzipain as a molecular target in T. cruzi. Irreversible and reversible inhibition was demonstrated by 
different classes of compounds. Cruzipain PDB ID: 3Io6.
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in T. cruzi epimastigotes, being distributed between glycosome and mitochondrial/
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oids. The quinuclidine-based inhibitors of mammalian SQS, 3-(biphenyl-4-yl)-
3-hydroxyquinuclidine (BPQ-OH) ER27856, E5700, and ER-119884 were assayed 
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enzyme [89]. In 2014, the X-ray crystallographic structure of SQS from T. cruzi was 
reported, confirming the binding of the enzyme to distinct classes of inhibitors 
such as the quinuclidines E5700 and ER119884 and the thiocyanate WC-9 opening 
possibilities to the development of alternative inhibitors [90].
In a screening of compounds containing the 4-phenoxyphenoxy skeleton, 
4-phenoxyphenoxyethyl thiocyanate (WC-9) was highlighted due to the high activ-
ity against the proliferative form epimastigotes (low micromolar) and intracellular 
amastigotes (nanomolar) and a potent inhibitor of the enzymatic activity of both 
glycosomal and mitochondrial isoforms of SQS [91, 92]. Since then, different series 
of WC-9 analogs have been developed [91, 93], including seleno-containing analogs 
resulting in compounds, such as 4-phenoxyphenoxyethyl selenocyanate, with EC50 
values at low nanomolar level and selectivity index (SI) higher than 900 [94].
2.2.2 C14α-sterol demethylase (CYP51)
This enzyme catalyzes the oxidative removal of the 14α-methyl group from of 
catalyzing the oxidative removal of the 14α-methyl group from sterol precursors 
such as lanosterol or eburicol, via a repetitive three-step process that uses NADPH 
and oxygen to produce 4,4-dimethyl-5α-cholesta-8,14,24-trien-3β-ol [83]. CYP51s 
are the most conserved cytochrome P450 enzymes [84]. Series of azoles originally 
developed for the treatment of fungal infections targets this enzyme leading to accu-
mulation of lanosterol and other sterol intermediates and displaying activity in vitro 
and in vivo against T. cruzi [95–97]. This line of investigation led to the selection of 
the triazole posaconazole [98, 99] and E1224 (fosravuconazole) [100, 101] for Phase 
II clinical trials with chronic patients, which, however, led to therapeutic failure as 
compared to benznidazole, with parasitemia relapses: NCT01162967 (Chagazol) 
[102], NCT01377480 (Stopchagas) [103], and NCT01489228 (E1224 trial) [104].
VNI, a carboxamide-containing β-phenyl-imidazole, identified from a Novartis 
collection of azoles, was active in acute and chronic mouse models using Tulahuen 
strain [105]; whereas in experiments with other parasite strains, no complete para-
sitological clearance was achieved [106]. In subsequent work, VFV, a fluoro analog 
of VNI, designed to fill the deepest portion of the CYP51 substrate-binding cavity 
demonstrated 100% efficacy in experimental infection, displaying favorable oral 
bioavailability and pharmacokinetics [107]. Comparison between VNI and VFV, 
in murine models of infection, revealed that regardless of the treatment scheme or 
delivery vehicle, VFV was more potent in both genders [108]. VT-1161, a 1-tetra-
zole-based drug undergoing phase II antifungal clinical trials, is active in vitro and 
in vivo against T. cruzi. It was structurally characterized in a complex with TcCYP51, 
allowing for the optimization of new tetrazole-based analogs and presents good 
pharmacokinetic properties and an excellent safety profile [109]. Friggeri et al. 
[110] synthesized imidazolyl-2-phenylethanol derivatives, and several of them were 
active against intracellular amastigotes and inhibited TcCYP51. In sequence, eight 
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drug), amiodarone (antiarrhythmic drug), and levothyroxine (hypothyroidism 
drug) were selected in a screening campaign for cruzain inhibitors of the DrugBank 
database [129], clofazimine (antileprosy drug) and benidipine (antihypertensive) 
from the Merck Index 12th database [130, 131], and etofyllin clofibrate (antilipemic 
drug) and piperacillin, cefoperazone, and flucloxacillin (β-lactam antibiotics) from 
a collection of 3180 FDA drugs [132].
Calpains are calcium-dependent nonlysosomal cysteine peptidases highly 
conserved among eukaryotes, but their precise biological function is not completely 
clear. In mammalian cells, calpains participate in many different calcium processes 
including proliferation, differentiation, cytoskeletal assembly, cellular signaling, 
among many others; however, T. cruzi calpains do not present a mapped active 
catalytic site up to now [133]. In man, uncontrolled activity of calpains has been 
associated with muscular and neurological disorders such as Alzheimer, Parkinson, 
multiple sclerosis, and arthritis, and the terapeutic effect of specific calpain inhibi-
tors was suggested [134, 135]. Recently, the repurposing of calpain inhibitors was 
also postulated for neglected tropical diseases, including Chagas disease [133]. In 
T. cruzi, only the inhibitor MDL28170 was tested, and the trypanocidal activity at low 
micromolar range was shown on all three parasite forms, impairing the ultrastruc-
tural architecture of Golgi and reservosomes [136, 137]. Despite the study’s scarcity, 
calpains inhibition has been suggested as an attractive antitrypanosomatid approach 
even without the confirmation of their proteolytic activity in these parasites.
2.4 Nuclear and kinetoplast DNA
Both T. cruzi kinetoplast and nucleus may be targeted by different classes of 
compounds with antiparasitic activity [138, 139]. Early studies [140] revealed 
that hydroxystilbamidine led to the disorganization of kinetoplast DNA (kDNA). 
Later other compounds such as vinblastine, geranylgeraniol, diaminobenzidine, 
and aromatic diamidines were reported to affect kDNA arrangement causing its 
fragmentation [138, 141, 142]. Trypanosomatid nucleus and kinetoplast display 
topoisomerases that show significant structural differences from host orthologs 
advocating their potential as drug targets [143]. Interestingly, T. cruzi topoisomer-
ase I is inactivated by ROS [144], so the oxidative stress induced by both immune 
response and trypanocidal agents may also affect parasite chromatin organization.
Classic aromatic diamidines have been shown to bind noncovalently and 
through a nonintercalative manner to the minor groove of DNA; several hypotheses 
regarding their mode of action were proposed. They could act by complexation with 
DNA and subsequently lead to a selective inhibition of DNA-dependent enzymes 
and/or through the direct inhibition of transcription [145]. Thus, evidences suggest 
that diamidines interfere in the kinetoplast function of trypanosomatids through 
a selective association to the unique AT-rich regions of kDNA minicircles, perhaps 
involving DNA-processing enzymes [146]. Medicinal chemistry studies pointed 
to arylimidamides (AIAs) as the most promising antimicrobial diamidines [106]. 
DB702, DB786, DB811, and DB889 presented anti-T. cruzi activity in the low-
micromolar range and led to ultrastructural alterations mainly associated with the 
nucleus and mitochondrion [147, 148]. On the other hand, recent study with novel 
bis-AIAs revealed their higher potency and in silico analysis showed DNA as the 
main target, but no DNA ultrastructural alterations were found [149].
On the other hand, enzymes involved in nucleic acid metabolism could be also 
promising targets. Topoisomerases play a crucial role for the DNA dynamics during 
the transcription, replication, or even in the repair. Due to their participation in 
essential cellular processes, interfering with DNA topology, and consequently lead-
ing to physiological implications, topoisomerases have been described as molecular 
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targets for cancer and also parasitic illnesses such as Chagas disease. Up to now, 
innumerous topoisomerase inhibitors presented antitrypanosomatidae activi-
ties such as camptothecin, doxorubicin, etoposide, suramin, among many others 
[150]. Recently, voacamine and an isobenzofuranone derivative induced important 
morphological alterations in different trypanosomatids, including T. cruzi. In 
Leishmania parasites, the most affected organelle was mitochondrion (severely 
swelled presenting membrane depolarization), where the derivative led to kineto-
plast network disorganization [151, 152].
3. Proteomic insights for the target identification in the parasite
The evaluation of the proteomic profile in trypanosomatids is particularly inter-
esting because these protozoa exhibit open reading frames in long polycistronic 
regions, and the regulation of gene expression occurs only post-transcriptionally, 
justifying the importance on monitoring the protein expression by proteomic 
approach [153]. This section will focus on proteomic analysis of parasite forms 
dwelling in mammalian hosts. The first large-scale analysis was performed by 
Atwood and colleagues in 2005 [23], identifying 1486 proteins of culture-derived 
trypomastigotes, and 30 trans-sialidases, enzymes that play an important role 
in parasite host cell invasion, were among the top-scoring proteins exclusively 
detected in this developmental form. T. cruzi surface subproteome and basic 
proteins analysis confirmed the high distribution of trans-sialidases in this life 
form [154, 155]. Specific trypomastigote surface analysis also revealed membrane-
associated enzymes that are involved in biosynthetic pathway of phospholipid 
and glycolysis [155]. The evaluation of chromatin fraction of this stage revealed 
RNA-binding proteins and histones, representing 29% of chromatin protein content 
[156], providing new insights into gene expression and histone modifications 
involved in the parasite cycle regulation. Likewise, T. cruzi glycoproteome was 
assessed, and trypomastigote-specific glycoproteins were identified, including 
mucin family members [157, 158].
In metacyclic trypomastigotes, Atwood and co-workers [23] identified 2339 
proteins, and different antioxidant enzymes were among the main proteins 
detected. The presence of these enzymes in this stage could be related to the para-
site adaptation to the oxidative environment inside the vertebrate host circulation 
and particularly inside the phagocytes. The analysis of metacyclogenesis revealed 
increased expression of cytoskeletal proteins as well as proteins related to energetic 
and oxidative metabolisms, suggestive of the morphological and metabolic reor-
ganization [159]. Plasma membrane subproteome pointed to a large repertoire of 
surface proteins in this parasite stage, including trans-sialidases, mucins, and GP63 
protease [160]. Such glycoprotein diversity confers adaptation of the parasite to 
distinct environmental conditions. Morever, secretome of metacyclic trypomasti-
gotes also demonstrated trans-sialidases and other surface molecules, playing a role 
in parasite invasion during acute and chronic infections [161, 162]. The blockage of 
this process could be an interesting strategy in novel drug development.
The first proteomic analysis of bloodstream trypomastigotes was performed by 
our group in 2015, identifying a total 5901 proteins [163]. In this work, a compari-
son among the proteomic maps of trypomastigotes (bloodstream, cultured-derived, 
and metacyclic forms) was also assessed, and 2202 proteins related to the parasite 
surface, cytoskeleton, redox metabolism, cell signaling, and energetic metabolism 
were exclusively detected in bloodstream forms. Overall, the proteomic profile 
of bloodstream form comprises an important tool to discover potential new drug 
targets and novel antigens for vaccines or diagnostics. The differences in the 
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trypomastigote proteomic profiles were expected due to their environment, and 
huge number of stage-specific proteins in bloodstream forms, probably triggered by 
the exposure to the host immune system reinforces the necessity for drug validation 
on this developmental form. In relation to proteomic evaluation of trypanocidal 
action of drugs, β-lapachone-derived naphthoimidazoles induced the increase in 
the abundance of 27 proteins, involved in stress response, cell structure, energetic 
metabolism, nucleic and amino acid metabolisms, oxidative metabolism, among 
other pathways [164]. This large-scale study revealed an important set of proteins 
belonging to metabolic pathways that play pivotal functions for this parasite form, 
providing new insights for the understanding of the parasite biology and of poten-
tial drugable molecules for the treatment of Chagas disease.
In 2005, 1871 proteins of culture-derived amastigotes were identified, prefer-
ably involved in endoplasmic reticulum to Golgi trafficking, suggesting an intense 
traffic at this stage [23]. The analysis of amastigogenesis evidenced high abundance 
of glycolytic enzymes in amastigotes as well as the lower abundance of flagellar 
components, compatible with the morphology of this stage [165]. Later, the surface 
subproteome of vertebrate-dwelling parasite forms was characterized, displaying 
molecules involved in cell division, signal transduction, and lipid metabolism, 
crucial for the parasite intracellular self-maintenance [155].
Another interesting target is the posttranslational modification of parasite 
proteins. Acetylation at lysine residues exerts important role in both vertebrates 
and microbial cells. The NAD+-dependent lysine deacetylases are termed sirtuins. 
Humans present seven different sirtuins, whereas T. cruzi, solely two. TcSIR2RP1 
andTcSIR2RP3 are found in the cytosolic and mitochondrial compartments, respec-
tively. Parasites overexpressing TcSIR2RP1 display enhanced metacyclogenesis and 
host cell infection [166]. The sirtuin antagonist salermide diminishes intracellular 
parasite proliferation and parasitemia in murine infection [167]. Thus, acetylation 
of T. cruzi proteins may provide useful targets for the development of antiparasitic 
agents [167, 168]. In addition, mammalian sirtuin targeting may be beneficial in 
chronic chagasic cardiomyopathy [169].
4. Conclusions
The clinical chemotherapy for Chagas disease (Nif and Bz) led to a parasitologi-
cal cure in the great number of congenital, adult acute, or early chronic cases [170]. 
However, undesirable side effects and the resistance of some parasite strains [171], 
together with the limited efficacy in symptomatic chronic cases, drive the continu-
ous search for novel chemotherapeutic agents [33]. Drug repurposing or even 
combinations with the current drugs could be options to minimize this problem [59, 
120]. In this direction, phenotypic strategy has been considered the most valuable 
approach for the screening of antiparasitic compounds [172].
High throughput screening complemented by whole-cell phenotypic assays 
represents the more feasible option in the search for novel anti-T. cruzi compounds, 
also leading to an increment in sensitivity [173]. Preclinical in silico combined to in 
vitro assays represents an essential step for the recognition of T. cruzi drug targets, 
generating knowledge about the metabolism, biochemical pathways, or biological 
processes allowing the target validation. In this way, the identification of selective 
targets comprises a logical startpoint to the reduction of the side effects in the hosts 
[153, 163]. Ultrastructural observations can predict the potential primary cellular 
targets due to their earlier alterations triggered by pharmacologic stimuli, helping 
the prospection of molecular modes of action of antiparasitic agents [141, 174].
205
Parasite, Compartments, and Molecules: Trick versus Treatment on Chagas Disease
DOI: http://dx.doi.org/10.5772/intechopen.84472
Large-scale proteomics represents an alternative approach for the assessment 
of molecular mechanisms of trypanocidal drugs. Indeed, despite its potential, such 
technique is poorly employed in this context. The importance of the use of clinical 
relevant T. cruzi stages in drug screening was evidenced by the remarkable differ-
ences found among the proteomic profile of parasite forms [23, 163]. The proteomic 
analysis of bloodstream trypomastigotes identified a huge variety of proteins from 
distinct biological processes, pointed to more than 2000 proteins present only in 
bloodstream forms (not in trypomastigotes from other sources), reinforcing the 
importance of the chemotherapeutic tests using recent isolated parasites from 
animals’ blood [163].
In the current scenario, the CYP51 still represents one the most promising 
alternatives. Large-scale screening pointed to the high activity of CYP51 inhibitors 
in vitro (even higher than Bz), but not producing T. cruzi elimination [175, 176]. 
Unfortunately, the clinical trial with posaconazole and E1224 was also unsatisfac-
tory [102]. In Argentina, a drug–drug interaction analysis of the combination Bz 
and E1224 in healthy volunteers demonstrated no improvement in tolerability or 
safety parameters [177], and a clinical study using this combination is planned 
[178]. Also, the use of new scaffolds with the design of inhibitors much more selec-
tive toward CYP51 has demonstrated its high trypanocidal activity in association or 
not with other licensed drugs [108, 179].
Among the parasite antioxidant defenses, the most promising drug target is TR, 
and the specific inhibitor development has been proposed in the last three decades 
[36]. However, no active inhibitors of this enzyme were described up to now 
[180]. The hypothesis that T. cruzi is more susceptible to oxidative species than the 
vertebrate hosts is an old misleading concept, due to the highly efficient scavengers 
described in the parasite [51, 181]. Another aspect to be considered is the central 
role of ROS production and the mitochondrion for the trypanocial action of a great 
variety of preclinical compounds [31]. The mitochondrial swelling is frequently 
observed in T. cruzi after the treatment with different drugs, but this phenotype is 
rarely associated with a specific molecular mechanism, except for DNA ligands such 
as aromatic amidines [106]. The molecular mechanistic proposal opens the possibil-
ity of the mitochondrial dysfunction to be as a random consequences of indirect 
effect triggered by the impaired homeostasis, resulting in redox imbalance [31].
Bioinformatic, proteomic, and ultrastructural analyses are pivotal tools in the 
identification of drug targets; however, the use of specific inhibitors must be vali-
dated before the following studies. The absence of the predicted biological activity 
or even the specific binding to the respective molecular target is not uncommon 
[178, 182]. To improve the safety, mechanisms of action characterization should be 
performed in parallel to the high-throughput screening of the trypanocidal activity 
[183]. In case of obligatory intracellular parasites as T. cruzi, the direct analysis in a 
phenotypic assay is also essential, considering permeability of the host cells besides 
the therapeutic window related to the mammalian host toxicity aspects [182]. The 
adequate choice of the experimental design is also crucial. Animal models, parasite 
strains, and treatment protocols for preclinical assays (in vitro and in vivo) must be 
standardized, in order to reach better translation to humans [184].
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trypomastigote proteomic profiles were expected due to their environment, and 
huge number of stage-specific proteins in bloodstream forms, probably triggered by 
the exposure to the host immune system reinforces the necessity for drug validation 
on this developmental form. In relation to proteomic evaluation of trypanocidal 
action of drugs, β-lapachone-derived naphthoimidazoles induced the increase in 
the abundance of 27 proteins, involved in stress response, cell structure, energetic 
metabolism, nucleic and amino acid metabolisms, oxidative metabolism, among 
other pathways [164]. This large-scale study revealed an important set of proteins 
belonging to metabolic pathways that play pivotal functions for this parasite form, 
providing new insights for the understanding of the parasite biology and of poten-
tial drugable molecules for the treatment of Chagas disease.
In 2005, 1871 proteins of culture-derived amastigotes were identified, prefer-
ably involved in endoplasmic reticulum to Golgi trafficking, suggesting an intense 
traffic at this stage [23]. The analysis of amastigogenesis evidenced high abundance 
of glycolytic enzymes in amastigotes as well as the lower abundance of flagellar 
components, compatible with the morphology of this stage [165]. Later, the surface 
subproteome of vertebrate-dwelling parasite forms was characterized, displaying 
molecules involved in cell division, signal transduction, and lipid metabolism, 
crucial for the parasite intracellular self-maintenance [155].
Another interesting target is the posttranslational modification of parasite 
proteins. Acetylation at lysine residues exerts important role in both vertebrates 
and microbial cells. The NAD+-dependent lysine deacetylases are termed sirtuins. 
Humans present seven different sirtuins, whereas T. cruzi, solely two. TcSIR2RP1 
andTcSIR2RP3 are found in the cytosolic and mitochondrial compartments, respec-
tively. Parasites overexpressing TcSIR2RP1 display enhanced metacyclogenesis and 
host cell infection [166]. The sirtuin antagonist salermide diminishes intracellular 
parasite proliferation and parasitemia in murine infection [167]. Thus, acetylation 
of T. cruzi proteins may provide useful targets for the development of antiparasitic 
agents [167, 168]. In addition, mammalian sirtuin targeting may be beneficial in 
chronic chagasic cardiomyopathy [169].
4. Conclusions
The clinical chemotherapy for Chagas disease (Nif and Bz) led to a parasitologi-
cal cure in the great number of congenital, adult acute, or early chronic cases [170]. 
However, undesirable side effects and the resistance of some parasite strains [171], 
together with the limited efficacy in symptomatic chronic cases, drive the continu-
ous search for novel chemotherapeutic agents [33]. Drug repurposing or even 
combinations with the current drugs could be options to minimize this problem [59, 
120]. In this direction, phenotypic strategy has been considered the most valuable 
approach for the screening of antiparasitic compounds [172].
High throughput screening complemented by whole-cell phenotypic assays 
represents the more feasible option in the search for novel anti-T. cruzi compounds, 
also leading to an increment in sensitivity [173]. Preclinical in silico combined to in 
vitro assays represents an essential step for the recognition of T. cruzi drug targets, 
generating knowledge about the metabolism, biochemical pathways, or biological 
processes allowing the target validation. In this way, the identification of selective 
targets comprises a logical startpoint to the reduction of the side effects in the hosts 
[153, 163]. Ultrastructural observations can predict the potential primary cellular 
targets due to their earlier alterations triggered by pharmacologic stimuli, helping 
the prospection of molecular modes of action of antiparasitic agents [141, 174].
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Large-scale proteomics represents an alternative approach for the assessment 
of molecular mechanisms of trypanocidal drugs. Indeed, despite its potential, such 
technique is poorly employed in this context. The importance of the use of clinical 
relevant T. cruzi stages in drug screening was evidenced by the remarkable differ-
ences found among the proteomic profile of parasite forms [23, 163]. The proteomic 
analysis of bloodstream trypomastigotes identified a huge variety of proteins from 
distinct biological processes, pointed to more than 2000 proteins present only in 
bloodstream forms (not in trypomastigotes from other sources), reinforcing the 
importance of the chemotherapeutic tests using recent isolated parasites from 
animals’ blood [163].
In the current scenario, the CYP51 still represents one the most promising 
alternatives. Large-scale screening pointed to the high activity of CYP51 inhibitors 
in vitro (even higher than Bz), but not producing T. cruzi elimination [175, 176]. 
Unfortunately, the clinical trial with posaconazole and E1224 was also unsatisfac-
tory [102]. In Argentina, a drug–drug interaction analysis of the combination Bz 
and E1224 in healthy volunteers demonstrated no improvement in tolerability or 
safety parameters [177], and a clinical study using this combination is planned 
[178]. Also, the use of new scaffolds with the design of inhibitors much more selec-
tive toward CYP51 has demonstrated its high trypanocidal activity in association or 
not with other licensed drugs [108, 179].
Among the parasite antioxidant defenses, the most promising drug target is TR, 
and the specific inhibitor development has been proposed in the last three decades 
[36]. However, no active inhibitors of this enzyme were described up to now 
[180]. The hypothesis that T. cruzi is more susceptible to oxidative species than the 
vertebrate hosts is an old misleading concept, due to the highly efficient scavengers 
described in the parasite [51, 181]. Another aspect to be considered is the central 
role of ROS production and the mitochondrion for the trypanocial action of a great 
variety of preclinical compounds [31]. The mitochondrial swelling is frequently 
observed in T. cruzi after the treatment with different drugs, but this phenotype is 
rarely associated with a specific molecular mechanism, except for DNA ligands such 
as aromatic amidines [106]. The molecular mechanistic proposal opens the possibil-
ity of the mitochondrial dysfunction to be as a random consequences of indirect 
effect triggered by the impaired homeostasis, resulting in redox imbalance [31].
Bioinformatic, proteomic, and ultrastructural analyses are pivotal tools in the 
identification of drug targets; however, the use of specific inhibitors must be vali-
dated before the following studies. The absence of the predicted biological activity 
or even the specific binding to the respective molecular target is not uncommon 
[178, 182]. To improve the safety, mechanisms of action characterization should be 
performed in parallel to the high-throughput screening of the trypanocidal activity 
[183]. In case of obligatory intracellular parasites as T. cruzi, the direct analysis in a 
phenotypic assay is also essential, considering permeability of the host cells besides 
the therapeutic window related to the mammalian host toxicity aspects [182]. The 
adequate choice of the experimental design is also crucial. Animal models, parasite 
strains, and treatment protocols for preclinical assays (in vitro and in vivo) must be 
standardized, in order to reach better translation to humans [184].
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